{
    "id": "dc46f271-5e1c-4635-b836-44ad5150acd1",
    "userId": "1034911",
    "fileName": "Protocol - Protocol - 06-Mar-2019_202018.pdf",
    "documentFilePath": "\\\\quintiles.net\\enterprise\\Services\\protdigtest\\pilot_iqvxml\\dc46f271-5e1c-4635-b836-44ad5150acd1",
    "iqvdataToc": "\"{\\\"index\\\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479, 1480, 1481, 1482, 1483, 1484, 1485, 1486, 1487, 1488, 1489, 1490, 1491, 1492, 1493, 1494, 1495, 1496, 1497, 1498, 1499, 1500, 1501, 1502, 1503, 1504, 1505, 1506, 1507, 1508, 1509, 1510, 1511, 1512, 1513, 1514, 1515, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1523, 1524, 1525, 1526, 1527, 1528, 1529, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, 1539, 1540, 1541, 1542, 1543, 1544, 1545, 1546, 1547, 1548, 1549, 1550, 1551, 1552, 1553, 1554, 1555, 1556, 1557, 1558, 1559, 1560, 1561, 1562, 1563, 1564, 1565, 1566, 1567, 1568, 1569, 1570, 1571, 1572, 1573, 1574, 1575, 1576, 1577, 1578, 1579, 1580, 1581, 1582, 1583, 1584, 1585, 1586, 1587, 1588, 1589, 1590, 1591, 1592, 1593, 1594, 1595, 1596, 1597, 1598, 1599, 1600, 1601, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1613, 1614, 1615, 1616, 1617, 1618, 1619, 1620, 1621, 1622, 1623, 1624, 1625, 1626, 1627, 1628, 1629, 1630, 1631, 1632, 1633, 1634, 1635, 1636, 1637, 1638, 1639, 1640, 1641, 1642, 1643, 1644, 1645, 1646, 1647, 1648, 1649, 1650, 1651, 1652, 1653, 1654, 1655, 1656, 1657, 1658, 1659, 1660, 1661, 1662, 1663, 1664, 1665, 1666, 1667, 1668, 1669, 1670, 1671, 1672, 1673, 1674, 1675, 1676, 1677, 1678, 1679, 1680, 1681, 1682, 1683, 1684, 1685, 1686, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, 1706, 1707, 1708, 1709, 1710, 1711, 1712, 1713, 1714, 1715, 1716, 1717, 1718, 1719, 1720, 1721, 1722, 1723, 1724, 1725, 1726, 1727, 1728, 1729, 1730, 1731, 1732, 1733, 1734, 1735, 1736, 1737, 1738, 1739, 1740, 1741, 1742, 1743, 1744, 1745, 1746, 1747, 1748, 1749, 1750, 1751, 1752, 1753, 1754, 1755, 1756, 1757, 1758, 1759, 1760, 1761, 1762, 1763, 1764, 1765, 1766, 1767, 1768, 1769, 1770, 1771, 1772, 1773, 1774, 1775, 1776, 1777, 1778, 1779, 1780, 1781, 1782, 1783, 1784, 1785, 1786, 1787, 1788, 1789, 1790, 1791, 1792, 1793, 1794, 1795, 1796, 1797, 1798, 1799, 1800, 1801, 1802, 1803, 1804, 1805, 1806, 1807, 1808, 1809, 1810, 1811, 1812, 1813, 1814, 1815, 1816, 1817, 1818, 1819, 1820, 1821, 1822, 1823, 1824, 1825, 1826, 1827, 1828, 1829, 1830, 1831, 1832, 1833, 1834, 1835, 1836, 1837, 1838, 1839, 1840, 1841, 1842, 1843, 1844, 1845, 1846, 1847, 1848, 1849, 1850, 1851, 1852, 1853, 1854, 1855, 1856, 1857, 1858, 1859, 1860, 1861, 1862, 1863, 1864, 1865, 1866, 1867, 1868, 1869, 1870, 1871, 1872, 1873, 1874, 1875, 1876, 1877, 1878, 1879, 1880, 1881, 1882, 1883, 1884, 1885, 1886, 1887, 1888, 1889, 1890, 1891, 1892, 1893, 1894, 1895, 1896, 1897, 1898, 1899, 1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908, 1909, 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1918, 1919, 1920, 1921, 1922, 1923, 1924, 1925, 1926, 1927, 1928, 1929, 1930, 1931, 1932, 1933, 1934, 1935, 1936, 1937, 1938, 1939, 1940, 1941, 1942, 1943, 1944, 1945, 1946, 1947, 1948, 1949, 1950, 1951, 1952, 1953, 1954, 1955, 1956, 1957, 1958, 1959, 1960, 1961, 1962, 1963, 1964, 1965, 1966, 1967, 1968, 1969, 1970, 1971, 1972, 1973, 1974, 1975, 1976, 1977, 1978, 1979, 1980, 1981, 1982, 1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990], \\\"columns\\\": [\\\"section_level\\\", \\\"CPT_section\\\", \\\"type\\\", \\\"content\\\", \\\"font_info\\\", \\\"level_1_CPT_section\\\", \\\"file_section\\\", \\\"file_section_num\\\", \\\"file_section_level\\\", \\\"seq_num\\\", \\\"qc_change_type\\\"], \\\"data\\\": [[\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Protocol Title:</td>\\\\n      <td>An ~REDACTED~ Open Label, Single-Arm, Multicenter, Phase 3 Study to Evaluate Safety and Tolerability of Diroximel Fumarate (BIIB098) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Protocol Number:</td>\\\\n      <td>272MS303</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Name of Study Treatment:</td>\\\\n      <td>Research Name:  BIIB098 (also known as ALKS 8700) Generic Name:  Diroximel Fumarate (DRF) Trade Names:   Vumerity</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Study Phase:</td>\\\\n      <td>3</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Study Indication:</td>\\\\n      <td>Relapsing Forms of Multiple Sclerosis (RMS)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Study Rationale:</td>\\\\n      <td>The main goal of the current ~REDACTED~ study is to assess the safety and tolerability profile of DRF administered orally in adult East Asian participants with RMS. DRF was developed as a modified-release oral treatment for RMS. In October 2019, DRF under the trade name VUMERITY <sup>\\\\u00ae</sup> was approved by the US FDA for the treatment of adult patients ~REDACTED~ with RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. In participants with RRMS, DRF demonstrated safety and tolerability in 2 global Phase 3 studies, Study ALK8700-A301 (A301, EVOLVE-MS-1; currently ongoing) and Study\\\\u00a0ALK8700-A302 (A302, EVOLVE-MS-2; completed). In both studies, DRF at a dose of 231 mg twice daily for 1 week followed by 462 mg twice daily for 96-weeks (in Study A301) and 462 mg twice daily for 4 weeks (in Study A302), had an acceptable safety profile and was well tolerated. Although the complex and multifactorial pathogenesis of MS is considered to be generally similar across Caucasian and Asian populations, currently there are limited safety and tolerability and efficacy data on DRF in the Asian population, including the East Asian MS populations therefore, additional data is warranted in this population. This Phase 3 study is designed to collect data in East Asian participants with RMS who are treated with DRF. DRF is an aminoethyl ester of MMF that undergoes rapid hydrolysis through esterases to produce MMF. MMF is also the active metabolite of the approved drug product, DMF. An oral form of DMF under the trade name Tecfidera <sup>\\\\u00ae</sup> has been approved by the US FDA since 2013 for the treatment of patients with RMS. The 462\\\\u00a0mg dose of DRF and the 240mg dose of DMF administered orally provide bioequivalent exposure of MMF. The safety and efficacy profile of DRF is expected to be similar to that of DMF based on the bioequivalence of MMF. Of note, DMF\\\\u2019s efficacy and safety in the East Asian population was explored in a randomized, double-blind, placebo-controlled Phase 3 DMF study (Study 109MS305 [APEX]). The results from Study 109MS305 demonstrated that DMF was well tolerated and showed sustained efficacy in East Asian participants with RRMS. These results were consistent with results reported previously in studies with Caucasians.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Rationale for Dose and Schedule Selection:</td>\\\\n      <td>The DRF dosage selected for this study (231 mg twice daily for the first 7 days and 462\\\\u00a0mg twice daily thereafter) is the approved dose regimen in the US for the treatment of patients with RMS and has been selected as the recommended dose in marketing applications to other health authorities. The doses of DRF to be used for initial dose titration (231 mg) and for treatment maintenance (462 mg) in this study are within the range of doses evaluated in completed Phase 1 studies. As noted above, DRF shares the common active metabolite MMF with DMF. In the Phase 1 study of DRF and DMF in healthy volunteers (ALK8700-A103), at different strengths, DRF (462 mg) and DMF (240\\\\u00a0mg) have shown bioequivalent exposures of MMF and are therefore expected to have similar efficacy and safety profiles. Results of the DMF PK, safety, and tolerability study in Japanese, Chinese, and Caucasian adult healthy volunteers (Study 109HV108) indicate that the PK behavior of DMF across the 3ethnic groups is similar and consistent with the observed exposure in mixed-race populations in previous studies with either healthy volunteers or MS patients. These observations further support the implementation of a 462 mg twice daily dosing regimen of DRF in the current study.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Risk-Benefit Analysis</td>\\\\n      <td>The potential benefits of participation in this study are expected to outweigh the risks. The safety profile of DRF relies on the well-known safety profile of the reference drug, DMF. The safety of DMF has been established in 2 randomized, placebo-controlled, double-blind, pivotal Phase 3 studies (DEFINE and CONFIRM) and further in extensive postmarketing experience. Flushing and GI events (abdominal pain, nausea, diarrhea, and vomiting) were among the most commonly experienced AEs with DMF in the 2\\\\u00a0pivotal Phase\\\\u00a03 studies    [ Phillips 2017 Phillips 2017 ]  . Study 109MS305 showed that DMF had an acceptable safety profile in East Asian participants that was consistent with the profile established in the studies with global participants. Important identified risks for DMF and hence DRF include decreases in lymphocyte counts and progressive multifocal leukoencephalopathy. Data from DRF studies have shown comparability to the DMF safety profile with no new safety issues identified to date. The frequency and severity of the GI-related side effects are an important issue for patients taking DMF and are a barrier to treatment adherence. This highlights the need for an efficacious agent with improved GI tolerability to optimize patient satisfaction and treatment outcomes    [ Phillips and Fox 2013 Phillips and Fox 2013 ]  . In Study A302, which was a 5-week prospective, randomized, blinded control study in participants with RRMS that formally explored differences in GI tolerability between DRF (N=253) and DMF (N=251), the duration, incidence and severity of participant-reported GI symptoms were significantly lower across a multitude of endpoints (including the primary endpoint) in the group of participants treated with DRF compared with the group of participants treated with DMF. The incidence of GI AEs in the DRF group was lower compared with the DMF group (34.8% and 49.0%, respectively), and discontinuations during the Treatment Period due to GI events were also notably less in the DRF group compared with the DMF group (0.8% and 4.8%, respectively)    [ Naismith 2020 Naismith 2020 ]  . In Study A301 (N\\\\u00a0=\\\\u00a01057), interim results showed that DRF is generally well tolerated for up to 96\\\\u00a0weeks, and no new safety signals have been identified. The incidence of GI AEs in de\\\\u00a0novo recruited participants at Week 24 was 27.5%. Treatment effect was assessed using exploratory efficacy clinical and MRI endpoints and results were consistent with the ones seen in Phase 3 studies with DMF. These results from the Phase 3 DRF studies support a favorable safety and efficacy profile in patients with RRMS. Accordingly, DRF has the potential to address an unmet need for patients with RMS who are unable to tolerate DMF. It is anticipated that the above favorable results reported in global Phase 3 studies with DRF will also benefit participants who receive DRF treatment in this study.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Study Objectives and Endpoints</td>\\\\n      <td>See    Table\\\\u00a02  .</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>PASS</td>\\\\n      <td>This study meets the criteria of a Post-Authorization Safety Study. Category:     This study does NOT meet the criteria of a Post-Authorization Safety Study.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Study Design:</td>\\\\n      <td>See    Figure\\\\u00a01  for a schematic of the study design. This is a multicenter, open-label, single-arm, Phase 3 study to evaluate the safety and tolerability of DRF administered orally to East Asian participants with RMS. This study will be conducted in 2 parts: Part 1 is designed to evaluate PK, safety and tolerability of DRF administered orally. Part 2 is designed as a 24-week safety extension period in participants from Part 1. Results from Part 2 will be reported separately as a safety extension of Part 1. Study assessments conducted at each visit are listed in    Table\\\\u00a04  . After eligibility for the study has been confirmed during Screening, all eligible, consenting participants will begin open-label treatment at the Baseline Visit (Day 1). Participants will initiate treatment with DRF 231 mg twice daily on Day\\\\u00a01 through Day 7 followed by 462\\\\u00a0mg twice daily from Day 8 onwards with allowable dose reduction for tolerability from Day\\\\u00a08 onwards. Study staff will administer the first dose of DRF at the Baseline Visit (Day1). Starting on Day 8 of treatment, dose reduction to DRF 231 mg twice daily is permitted at the Investigator\\\\u2019s discretion for participants who are unable to tolerate DRF 462mg twice daily. Once a participant has stabilized after dose reduction, attempts should again be made to achieve and maintain the target maintenance dose of DRF 462\\\\u00a0mg twice daily. If a participant remains unable to tolerate DRF 462 mg twice daily after 1\\\\u00a0month on treatment (i.e., by Visit 3), further dose reduction will not be permitted, and the participant will be discontinued from the study. Participants will undergo periodic safety assessments that are scheduled every 2 weeks up to Week 4 and then every 4 weeks until the end of the Treatment Period at Week 48 (Visit 14) and a Safety Follow-Up Visit 2 weeks later at Week 50 (Visit\\\\u00a015). Any participant who prematurely discontinues study treatment or withdraw from the study will be asked to return to clinical to complete all study assessments for Visit 14/ET Visit as well as Safety Follow-Up Visit 2 weeks later (Visit 15). Participants who complete the study or who terminate the study early and have last measured lymphocyte count <\\\\u00a00.8 \\\\u00d7 10 <sup>3</sup> /\\\\u00b5L will return to the clinic for additional lymphocyte count monitoring visits every 2 months starting from Visit\\\\u00a015 (or from the ET visit for participants who who terminate the study early) for a period of 6 months (i.e., a maximum of 3 visits) or until lymphocyte counts reach normal limits (\\\\u2265\\\\u00a00.91 \\\\u00d7 10 <sup>3</sup> /\\\\u00b5L), whichever occurs first (    Table\\\\u00a06  ). At every visit, the study staff will dispense DRF for participants\\\\u2019 self-administration. Participants will be instructed to take study treatment with or without food. However, participants will be instructed to avoid taking study treatment with a high-fat, high-calorie meal. Serial blood samples will be collected predose and at various timepoints postdose on Day\\\\u00a01 (Visit 1) and Day 29 (Visit 3) to estimate PK parameters (in a PK population subset) from the concentration data for metabolites MMF and HES. Sparse blood samples will be collected 2 to 3 hours postdose on Day 29 (Visit 4) and Day 57 (Visit 5) for all participants that could potentially be used for PK analysis.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Study Location:</td>\\\\n      <td>Sites in Japan and China are planned .</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>Study Population:</td>\\\\n      <td>This study will be conducted in adult male and female East Asian participants with RMS aged 18 to 65 years, inclusive. See    Table\\\\u00a03  for specific study eligibility criteria.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Number of planned participants and Treatment Cohorts:</td>\\\\n      <td>Approximately 50 Japanese and 50 Chinese participants are planned to be included in this study providing a total of 100 participants with RMS. Participants who withdraw from the study or discontinue study treatment will not be replaced. The study will consist of 2 treatment cohorts as follows: Cohort 1: approximately 50 Japanese participants with RMS Cohort 2: approximately 50 Chinese participants with RMS The PK population will consist of a subset of 14 participants each in both cohorts (14 out of 50 per cohort). If a participant in the PK subset (14 out of 50 per cohort) discontinues the study prior to or on Day\\\\u00a029 of the PK sampling period, the participant should be replaced with one of the enrolled participants. Study treatment includes DRF 231 mg administered as one capsule twice daily and DRF 462\\\\u00a0mg administered as two 231 mg capsules twice daily. Participants will titrate from DRF 231 mg twice daily for the first week on treatment to 462 mg twice daily from Day\\\\u00a08 onwards.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>Sample Size Determination:</td>\\\\n      <td>A sample size of 50\\\\u00a0participants per cohort is based on feasibility considerations and is deemed sufficient to characterize the safety and tolerability profile. With this sample size, the probability of observing at least 1 SAE with a background incidence of 4% would be 87% based on data from the 24-week Treatment Period in Study A301 (DRF global Phase3 study) in RRMS participants who were na\\\\u00efve to DRF treatment. In addition, assuming the incidence of GI AEs at 24 weeks of 27.5% as observed in de\\\\u00a0novo participants recruited in Study A301, the sample size of 50\\\\u00a0participants per cohort will provide a 96% probability of observing a point estimate of GI AE incidence rate <\\\\u00a039% in Part 1 of the study (at 24 weeks). The 24-week incidence rate of 39% was observed in East Asian participants who received DMF twice daily in Study 109MS305. PK parameters of MMF and HES will be evaluated in a subset of 14 participants per cohort with RMS. These PK parameters will also be assessed by comparing their values to non-Japanese participants in Study A301. Based on observed MMF PK parameters in healthy volunteers (Study ALK8700-A110), a sample size of 14 participants per cohort will provide reasonable precision of PK parameters of MMF and HES.  The subset of 14 participants per cohort with RMS for the PK study must be in the overnight fasted state prior to administration of the first dose of DRF on Days 1 and 29. Ethnic sensitivity on HES PK between Japanese and non-Japanese participants will be assessed by using the combined pre-dose trough values and plasma concentration data at 2-3 hours post-dose in all 50 Japanese patients.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Visit Schedule:</td>\\\\n      <td>Study assessments conducted at each visit are listed in    Table\\\\u00a04  . During the Part 1, participants will have up to 8 visits during the Treatment Period (i.e., Baseline [Day 1], Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week\\\\u00a024) and will be contacted via telephone twice. Participants will have up to 1 additional visit during the Screening Period. During Part 2, participants will report to the study site every 4 weeks up to Week 48 during the Treatment Period and will have the Safety Follow-Up Visit 2 weeks later (Week\\\\u00a050) after the end of the Treatment-Period. All visits should be performed within the time frame from the nominal visit day as shown in    Table\\\\u00a04  . Visit days are calculated with respect to Day 1 (the date of first dose).</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>Duration of Study Participation:</td>\\\\n      <td>Study duration for participants who complete the study will be up to 54 weeks: 4-week Screening Period 24-week Treatment Period in Part 1 24-week extension Treatment Period in Part 2 2-week safety Follow-Up period</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>Discontinuation of Treatment:</td>\\\\n      <td>A participant must permanently discontinue study treatment for any of the following reasons: The participant becomes pregnant. Study treatment must be discontinued immediately (Note: Instructions for reporting the pregnancy will be provided in the full protocol). The participant withdraws consent to continue study treatment. The participant experiences an AE that requires permanent discontinuation of study treatment. The participant is unwilling or unable to comply with the protocol. At the discretion of the Investigator for medical reasons. At the discretion of the Sponsor or upon request of a regulatory authority. The reason for discontinuation of study treatment must be recorded in the case report form. In addition to the reasons provided above for permanent discontinuation of study treatment, study treatment must also be temporarily withheld if any of the following laboratory parameters meet the following threshold limits: AST or ALT >\\\\u00a03\\\\u00a0\\\\u00d7\\\\u00a0ULN; confirmed by repeat testing. If the value remains >\\\\u00a03\\\\u00a0\\\\u00d7\\\\u00a0ULN for \\\\u2265\\\\u00a04 weeks after discontinuation of study treatment, the participant must permanently discontinue study treatment. Lymphocyte count <\\\\u00a00.5\\\\u00a0\\\\u00d7\\\\u00a010 <sup>3</sup> /\\\\u00b5L, confirmed by repeat testing as soon as possible. If the value remains <\\\\u00a00.5\\\\u00a0\\\\u00d7\\\\u00a010 <sup>3</sup> /\\\\u00b5L for \\\\u2265\\\\u00a04 weeks after treatment interruption, the participant must permanently discontinue study treatment. Participants who permanently discontinue the study with a last measured lymphocyte count <\\\\u00a00.8\\\\u00a0\\\\u00d7\\\\u00a010 <sup>3</sup> /\\\\u00b5L will require additional follow-up to monitor their lymphocyte counts, see    Table\\\\u00a06  . eGFR <\\\\u00a060 mL/min/1.73\\\\u00a0m <sup>2</sup> ; confirmed by repeat testing as soon as possible. If the eGFR remains <\\\\u00a060 mL/min/1.73\\\\u00a0m <sup>2</sup> for \\\\u2265\\\\u00a04\\\\u00a0weeks after discontinuation of study treatment, the participant must permanently discontinue study treatment. Urine albumin to urine creatinine ratio >\\\\u00a0200\\\\u00a0mg/g; confirmed by repeat testing as soon as possible. If the urine albumin to urine creatinine ratio remains >\\\\u00a0200\\\\u00a0mg/g for \\\\u2265\\\\u00a04\\\\u00a0weeks after discontinuation of study treatment, the participant must permanently discontinue study treatment.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>Safety Assessments</td>\\\\n      <td>The following assessments will be performed to evaluate the safety profile of DRF: SAEs and non-serious AEs monitoring (which will include GI AEs) Medical history Physical examination Vital sign measurements 12-lead ECGs C-SSRS administered by the clinician Concomitant therapy and procedure recording Clinical laboratory assessments (    Table\\\\u00a01  ) Pregnancy testing</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Study Treatment Pharmacokinetic Assessments:</td>\\\\n      <td>For the subset of participants included in the PK substudy (n = 14 in each cohort, PK population), serial blood sample collection for PK analysis of metabolites MMF and HES will be taken at the following timepoints on Days 1 and 29: Day 1: -30 minutes, 0 (first dose administered), and postdose at 1, 2, 3, 4, 6, 8, and 12\\\\u00a0hours (predose prior to administration of second dose) Day 29: -30 minutes, 0 (first dose administered) and postdose at 1, 2, 3, 4, 6, 8, and 12\\\\u00a0hours (predose prior to administration of second dose) The following PK parameters will be calculated for MMF and HES in plasma (when possible) using noncompartmental methods: AUC tau C max T max t \\\\u00bd T lag CL/F V Z /F R ac In addition, sparse blood samples will be collected for PK analysis of metabolites MMF and HES as following: On Day 29, blood sample will be collected 2 to 3 hours postdose for non-PK population participants (n= approximately 36 in each cohort), On Day 57, blood samples will be collected 2 to 3 hours postdose for all participants (n = approximately 50 in each cohort)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>Efficacy Assessments:</td>\\\\n      <td>The following efficacy parameters will be evaluated: Brain MRI assessments with and without Gd+: Gd+ lesion count (number of Gd+ lesions) new/newly enlarging T2 lesion count new T1 hypointense lesion count Relapse assessment EDSS Health-related quality of life assessments EQ-5D SF-36</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>Pharmacodynamic Assessments:</td>\\\\n      <td>NA</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>Other Assessments:</td>\\\\n      <td>NA</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>Biomarker Samples</td>\\\\n      <td>DNA:     Mandatory      Optional      No RNA:     Mandatory      Optional      No Protein:     Mandatory      Optional      No Other (specify):     Mandatory      Optional      No</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>Samples for Laboratory Assessments</td>\\\\n      <td>The following laboratory assessments will be performed to evaluate the safety profile of DRF and eligibility of participants: Table1:  Clinical Laboratory Assessments Hematology    1  Biochemistry Urinalysis Hematocrit Hemoglobin Red blood cell count Total and differential (absolute) white blood cell count Platelets Sodium Potassium Chloride Bicarbonate Glucose Calcium Uric Acid Creatinine Total protein Blood urea nitrogen Albumin Total bilirubin ALT AST LDH Alkaline phosphatase GGT Creatine phosphokinase Lipid profile: blood cholesterol, high-density lipoprotein, low\\\\u00a0density lipoprotein, and triglycerides Serum FSH (to confirm postmenopausal status) Color pH Specific gravity Ketones Protein Glucose Bilirubin Nitrite Urobilinogen Occult blood Microscopic examination of sediment only if urinalysis dipstick results are abnormal Urine albumin Urine beta-2-microglobulin Urine creatinine 1  Additional hematology assessments will be collected for participants requiring follow-up for lymphopenia at the time of study completion or early termination</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>Statistical Statement and Analytical Plan:</td>\\\\n      <td>All enrolled participants who receive at least 1 dose of DRF will be part of the safety population that will be used in the safety analyses. Summary statistics will be provided for all demographic variables and baseline characteristics. Medical history will be summarized for the safety population using the number of observations and percentage of participants reporting each category. Reported AE terms will be coded using MedDRA. Safety assessments will be summarized using descriptive statistics along with supportive listings. The incidence and incidence rate of all reported treatment\\\\u2011emergent SAEs and AEs will be summarized by system organ class, and preferred terms within each system organ class. SAEs and AEs resulting in treatment discontinuation will be summarized. Observed values and change from baseline in laboratory parameters, vital signs, ECG parameters, and scores on the C-SSRS will be summarized by study visit. The number and percentage of subjects who have met potentially clinically significant criteria at any postbaseline visit will be summarized. Listings will be provided for all safety assessments. The population for PK analysis is defined as all participants who receive at least 1\\\\u00a0dose of DRF and who have at least 1 postdose plasma PK parameters of MMF or HES. MMF and HES plasma concentrations will be summarized using descriptive statistics (mean, standard deviation, median, minimum, and maximum) and the mean values with standard errors will be plotted over time both on a linear and a logarithmic scale. The MMF and HES concentrations will also be used to calculate the following PK parameters using noncompartmental methods: The following PK parameters will be calculated on Days 1 and 29: C max AUC tau Other PK parameters: T max CL/F and CL/F/body weight in L/hr and L/hr/kg, respectively, for each participant V z /F and V z /F/body weight in L and L/kg, respectively, for each participant t \\\\u00bd  T lag R ac Each of these PK parameters will be summarized using descriptive statistics (mean, standard deviation, geometric mean, 95% CI, coefficient of variation, median, minimum and maximum for AUC tau C max V z /F, t \\\\u00bd R ac CL/F; median, minimum, and maximum for T max and T lag ). All efficacy analyses will be carried out using the FAS population defined as all participants who receive at least one dose of DRF and have had at least one post-baseline efficacy assessment. All efficacy endpoints will be summarized by study timepoint and by change from baseline using descriptive statistics as appropriate.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>Interim Analysis:</td>\\\\n      <td>No interim analysis will be performed. Separate analyses will be conducted for Part 1 and Part 2 of the study</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td>Study Stopping Rules:</td>\\\\n      <td>The Sponsor can terminate this study at any time after informing the Investigator. The Sponsor will notify Investigators (and its partners [if appropriate]) when the study is to be placed on hold, completed, or terminated.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>28</th>\\\\n      <td>Special Requirements:  (Check all that apply)</td>\\\\n      <td>None     Committee(s), specify:     Other, specify:</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"0\\\", \\\"TableIndex\\\": \\\"1\\\", \\\"TableName\\\": \\\"Protocol Concept: Phase 3 study to evaluate the safety and TOLERABILITY of diroximEL fumarate (biib098) in adult participants From the ASIA-PACIFIC region with relapsing FORMS OF multiple sclerosis\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"C-TableText\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"October 2020\\\", \\\"29\\\", \\\"1\\\", 3], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\" \\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"C-TableText\\\"}, \\\"Unmapped\\\", \\\"Trade Names:    Vumerity\\\", \\\"\\\", \\\"0\\\", 4], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Urinalysis</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Color pH Specific gravity Ketones Protein Glucose Bilirubin Nitrite Urobilinogen Occult blood Microscopic examination of sediment only if urinalysis dipstick results are abnormal Urine albumin Urine beta-2-microglobulin Urine creatinine</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"0\\\", \\\"TableIndex\\\": \\\"2\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Trade Names:    Vumerity\\\", \\\"\\\", \\\"0\\\", 5],[\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GlaxoSmithKline group of companies\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 14, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"~REDACTED~\\\"}, {\\\"start_idx\\\": 0, \\\"end_idx\\\": 14, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"66b599b7-de27-4839-a905-115c918771de\\\", \\\"childbox\\\": \\\"fb6d9f72-1fb4-4449-9300-c1bef2abfaba\\\", \\\"subtext\\\": \\\"e951362d-044f-49a5-bd33-0c200b52c9f2\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 1, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TITLE PAGE\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 28, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0cc66598-c628-4925-925c-49a50d9faaf7\\\", \\\"childbox\\\": \\\"c7915f54-9882-4e89-8e37-b69ad1be234a\\\", \\\"subtext\\\": \\\"12e1e5f9-9503-4031-a8ac-57b8063bac89\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 28, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 2, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Protocol Title:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"579e5370-63eb-41a3-b8a9-9f2f13bf3415\\\", \\\"childbox\\\": \\\"8a9b394f-4dbe-417a-9ec9-4f067b5dc312\\\", \\\"subtext\\\": \\\"82ee8c3d-92cb-4402-a325-18d80a2d90dd\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 3, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing ~REDACTED~ with placebo and with ~REDACTED~, in combination with conventional synthetic DMARDs, in participants with moderately to severely active ~REDACTED~ who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 96, \\\"end_idx\\\": 105, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 129, \\\"end_idx\\\": 137, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"579e5370-63eb-41a3-b8a9-9f2f13bf3415\\\", \\\"childbox\\\": \\\"8a9b394f-4dbe-417a-9ec9-4f067b5dc312\\\", \\\"subtext\\\": \\\"49af3b7e-a0c1-4378-8644-6ad40fe999ad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 4, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Protocol Number\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3875efce-98ea-4b51-a1ba-16c0f1400f0c\\\", \\\"childbox\\\": \\\"76723107-5643-4d5b-ac9c-33b062d2e3d1\\\", \\\"subtext\\\": \\\"2f12a4e2-1d01-4589-bda6-c5741ba1b68e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 5, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\": 202018\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3875efce-98ea-4b51-a1ba-16c0f1400f0c\\\", \\\"childbox\\\": \\\"76723107-5643-4d5b-ac9c-33b062d2e3d1\\\", \\\"subtext\\\": \\\"1dfa1159-9d53-48b0-9135-b5fbe44c2578\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 6, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Compound Number:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"31c0fa52-bfd7-45d8-983a-4dea4a36bfb5\\\", \\\"childbox\\\": \\\"b4e1b6a1-213c-45b1-8c24-defa371a05bd\\\", \\\"subtext\\\": \\\"14e2e6b6-47c6-4879-8949-e5febcef966e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 7, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"31c0fa52-bfd7-45d8-983a-4dea4a36bfb5\\\", \\\"childbox\\\": \\\"dcde73c8-37b7-4fb0-a322-f95d42caa011\\\", \\\"subtext\\\": \\\"8f73b068-f969-4849-97ea-406e6b586426\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 8, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GSK3196165\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"31c0fa52-bfd7-45d8-983a-4dea4a36bfb5\\\", \\\"childbox\\\": \\\"2b80ddd8-f327-470a-8fb9-3171aff96217\\\", \\\"subtext\\\": \\\"9906b13f-0974-413f-8370-e85e93574c29\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 9, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study Phase:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8cfe466c-609e-471c-96f5-2cacf62089d1\\\", \\\"childbox\\\": \\\"fd5c9ad7-2762-4f68-af36-81f40b808d97\\\", \\\"subtext\\\": \\\"92296eb1-f98e-4e47-a9df-e20fd083bee5\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 10, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Phase 3\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8cfe466c-609e-471c-96f5-2cacf62089d1\\\", \\\"childbox\\\": \\\"fd5c9ad7-2762-4f68-af36-81f40b808d97\\\", \\\"subtext\\\": \\\"aba63a9c-1928-4a95-bfe9-fd340bc2e11b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 11, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Short Title\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f7341733-6cbd-46e7-92b1-2d1e9659eb93\\\", \\\"childbox\\\": \\\"51a8e8cd-250f-42dd-8ee2-3688b4bf1fb2\\\", \\\"subtext\\\": \\\"a39440fe-1fd2-46f9-b19a-436b5107ff64\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 12, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\": Efficacy and safety of GSK3196165 versus placebo and sarilumab in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 25, \\\"end_idx\\\": 34, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 55, \\\"end_idx\\\": 63, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f7341733-6cbd-46e7-92b1-2d1e9659eb93\\\", \\\"childbox\\\": \\\"51a8e8cd-250f-42dd-8ee2-3688b4bf1fb2\\\", \\\"subtext\\\": \\\"2146cbdc-9fe0-45b5-8a2d-221585e30840\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 13, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study Name:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a0e42b4-b854-4bce-8489-b9f9d655fa52\\\", \\\"childbox\\\": \\\"a5bd8007-73ca-4e0d-ba85-74f6810e63af\\\", \\\"subtext\\\": \\\"e496f340-880e-49cc-9513-bb8ac2f67f95\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 14, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"contRAst-3\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a0e42b4-b854-4bce-8489-b9f9d655fa52\\\", \\\"childbox\\\": \\\"a5bd8007-73ca-4e0d-ba85-74f6810e63af\\\", \\\"subtext\\\": \\\"186e021f-5739-4021-a6ac-b8d5ce97056e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 15, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sponsor Name and Legal Registered Address:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5116f50f-0bf0-4613-bb42-f3c00f47cf23\\\", \\\"childbox\\\": \\\"8ec97d9e-6238-4743-9a10-bf6f43392c4b\\\", \\\"subtext\\\": \\\"8aeafccd-4a56-4841-919e-5a56e47068bf\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 16, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GlaxoSmithKline Research & Development Limited\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 45, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline Research & Development Limited\\\"}, {\\\"start_idx\\\": 0, \\\"end_idx\\\": 45, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline Research & Development Limited\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"d25371b4-bbe2-4e3c-9f35-2be6e3446361\\\", \\\"childbox\\\": \\\"3d48c7bb-acc5-43ff-afcc-a108e7804a8d\\\", \\\"subtext\\\": \\\"917c5e75-7154-4706-b34d-a8345fa3fa59\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 17, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"980 Great West Road\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 18, \\\"standard_entity_name\\\": \\\"ANY: Address\\\", \\\"subcategory\\\": \\\"ANY: Address\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"980 Great West Road\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"7604221c-07b5-469e-a773-de232954b084\\\", \\\"childbox\\\": \\\"b413c54f-37bc-4c94-9006-7c33dd3374dc\\\", \\\"subtext\\\": \\\"a4cada6b-b9c0-4eb8-b50d-066c49e26791\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 18, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Brentford\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 8, \\\"standard_entity_name\\\": \\\"ANY: Address\\\", \\\"subcategory\\\": \\\"ANY: Address\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Brentford\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f048a4d1-22e5-435b-aff1-37f62f2613ac\\\", \\\"childbox\\\": \\\"b46084f6-2844-42f4-bb80-6432c3561dec\\\", \\\"subtext\\\": \\\"60d0065e-f465-491f-a2b7-bb5e77a2dbaa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 19, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Middlesex, TW8 9GS UK\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 20, \\\"standard_entity_name\\\": \\\"ANY: Address\\\", \\\"subcategory\\\": \\\"ANY: Address\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Middlesex, TW8 9GS UK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"acec9663-d0db-431a-9da0-20ed816d96bf\\\", \\\"childbox\\\": \\\"06a82679-520c-4c63-a3cd-ea51a88fdd89\\\", \\\"subtext\\\": \\\"1c70391e-a461-4d5e-a1f3-dca82cd21175\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 20, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Medical Monitor Name and Contact Information\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bd077a82-afd6-413b-bd34-de5a1ddba180\\\", \\\"childbox\\\": \\\"7f5c1331-9fa7-43dd-8bde-d61e8b325a21\\\", \\\"subtext\\\": \\\"2be94d8f-4e45-4d1c-9f0a-21015b05f185\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 21, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"can be found in the Study Reference Manual\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bd077a82-afd6-413b-bd34-de5a1ddba180\\\", \\\"childbox\\\": \\\"7f5c1331-9fa7-43dd-8bde-d61e8b325a21\\\", \\\"subtext\\\": \\\"3cbdf4dc-b5b2-457d-a4be-f63404628165\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 22, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Regulatory Agency Identifying Number(s):\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae793f79-6aec-4e45-bd0c-051e86548db0\\\", \\\"childbox\\\": \\\"6da9868c-23da-45e7-8192-b5c15cc0c02e\\\", \\\"subtext\\\": \\\"cfa1de06-373b-451b-a339-b0d54bf20db0\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 23, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"IND:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8d79d911-2fdd-4b5c-b5da-6f4237db4440\\\", \\\"childbox\\\": \\\"80970542-bc27-485e-bbab-5467a7948621\\\", \\\"subtext\\\": \\\"6efb6955-88b3-4dd9-87f2-d76185f5a156\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 24, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"121958\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8d79d911-2fdd-4b5c-b5da-6f4237db4440\\\", \\\"childbox\\\": \\\"80970542-bc27-485e-bbab-5467a7948621\\\", \\\"subtext\\\": \\\"edc850ff-8166-480e-9c43-ca2872de4de9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 25, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"EudraCT:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"afdab759-a2ec-4cbd-ada2-6c6fe1eb483b\\\", \\\"childbox\\\": \\\"92a663e5-5bc1-4b59-961d-f22b57261bdd\\\", \\\"subtext\\\": \\\"7f8894e4-b791-4e89-97df-241d6eb6cc9e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 26, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2019-000868-18\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"afdab759-a2ec-4cbd-ada2-6c6fe1eb483b\\\", \\\"childbox\\\": \\\"92a663e5-5bc1-4b59-961d-f22b57261bdd\\\", \\\"subtext\\\": \\\"32d6d456-8500-4b8e-b24a-139821043089\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 27, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Approval Date: 06-MAR-2019\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9e4d039f-0f03-4a88-89d8-e2d3b78c932b\\\", \\\"childbox\\\": \\\"c994ee71-8a96-4927-88af-b007317a860c\\\", \\\"subtext\\\": \\\"68bebe79-ed72-41a5-bcf9-f62628476351\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 28, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Copyright 2019 the GlaxoSmithKline group of companies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 19, \\\"end_idx\\\": 33, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline\\\"}, {\\\"start_idx\\\": 19, \\\"end_idx\\\": 33, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"9f36eb8f-2cf6-4ba5-9122-fb48e3b59dfe\\\", \\\"childbox\\\": \\\"f9c822b1-b91b-4203-826d-368617518b93\\\", \\\"subtext\\\": \\\"0f7bdf80-9a8c-4a31-9ce2-0bf0d79022a3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 29, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All rights reserved.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9f36eb8f-2cf6-4ba5-9122-fb48e3b59dfe\\\", \\\"childbox\\\": \\\"3923eb80-82c5-4a01-9baa-2fb88900043e\\\", \\\"subtext\\\": \\\"0f7bdf80-9a8c-4a31-9ce2-0bf0d79022a3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 30, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Unauthorised copying or use of this information is prohibited.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4c2387bc-96e1-4a37-89fd-c2e6c2e72fb5\\\", \\\"childbox\\\": \\\"d6608fbf-35f5-44e6-a936-2988b05b1c89\\\", \\\"subtext\\\": \\\"7e5d77b6-637d-49b4-8615-7e8ff1fcde83\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 31, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Mark Layton\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 99, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 10, \\\"standard_entity_name\\\": \\\"OTHER: Person Name\\\", \\\"subcategory\\\": \\\"OTHER: Person Name\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Mark Layton\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"8337924c-c5ec-4158-a6f7-7d9d3321810a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 99, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 32, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Digitally signed by Mark Layton Date:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 20, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"OTHER: Person Name\\\", \\\"subcategory\\\": \\\"OTHER: Person Name\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Mark Layton\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"5a8792b2-2ad5-4e68-800c-a8158137476c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 33, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"b4da5d7b-1bc5-464d-a695-1fb379aba8cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 34, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"019.03.06 12:46:47 Z\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"dc46ae36-641a-4b16-8699-d69c570b32b7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 35, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Mark Layton\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 99, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 10, \\\"standard_entity_name\\\": \\\"OTHER: Person Name\\\", \\\"subcategory\\\": \\\"OTHER: Person Name\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Mark Layton\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"80f83ebb-2407-46a4-adda-9de743602c92\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 99, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 36, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Digitally signed by Mark Layton Date:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 20, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"OTHER: Person Name\\\", \\\"subcategory\\\": \\\"OTHER: Person Name\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Mark Layton\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"df3eff34-29ad-4140-8f67-9176b806614d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 37, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"aaed3478-083b-42b6-b9ef-448c3fe0eba7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 38, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"019.03.06 12:46:47 Z\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"b14a35fc-077d-4ab8-804d-2530d2cc9eb4\\\", \\\"subtext\\\": \\\"4ae7a1d6-18a7-4540-b107-5c3f42451c73\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 39, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e6d4a77-b3b2-480e-bc55-c6edc3c4d30d\\\", \\\"childbox\\\": \\\"44f798af-0615-44eb-80d1-198c894de738\\\", \\\"subtext\\\": \\\"b48e4337-4dea-4fba-af21-3ec8e2c4f600\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 40, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Mark\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 99, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1c6919c4-8b51-4224-be47-e26109a4b514\\\", \\\"childbox\\\": \\\"75cee828-53bd-4c81-a550-e47abfa7eebe\\\", \\\"subtext\\\": \\\"8337924c-c5ec-4158-a6f7-7d9d3321810a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 99, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 41, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Layton\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 99, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"48cc2b22-d417-40b1-ac44-75c7e3b73923\\\", \\\"childbox\\\": \\\"21c23c47-c8c5-45be-a30d-c52febc2d08e\\\", \\\"subtext\\\": \\\"3a0fc2fd-6e20-44d0-9063-7e4f1a5416b3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 99, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 42, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Digitally signed\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e12bb8f-2a58-41a4-918b-af26e4a91767\\\", \\\"childbox\\\": \\\"55123457-a27f-4d05-9b13-ae2c0a3d633d\\\", \\\"subtext\\\": \\\"5a8792b2-2ad5-4e68-800c-a8158137476c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 43, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"by Mark Layton\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 3, \\\"end_idx\\\": 13, \\\"standard_entity_name\\\": \\\"OTHER: Person Name\\\", \\\"subcategory\\\": \\\"OTHER: Person Name\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Mark Layton\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"2e9b48d0-f457-40aa-825e-0feb82571291\\\", \\\"childbox\\\": \\\"88a8ecd2-f0a2-4065-9202-b115bc308147\\\", \\\"subtext\\\": \\\"d7613b87-95d1-462d-9f0d-229e8b5727fc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 44, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Date:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"615cd357-d895-4cad-81d0-202639c352e8\\\", \\\"childbox\\\": \\\"68785bba-9bf0-4259-8de0-2ca78ea88c24\\\", \\\"subtext\\\": \\\"566e6023-9690-49f1-a3e5-686d9ce7d075\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 45, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45163981-d76f-44bd-913a-665de69486fd\\\", \\\"childbox\\\": \\\"1d044155-4cd3-4ad3-8e8a-a9f56622eebb\\\", \\\"subtext\\\": \\\"b4da5d7b-1bc5-464d-a695-1fb379aba8cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 46, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"019.03.06\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1100f1ab-9e5f-4005-a426-867bd4b20160\\\", \\\"childbox\\\": \\\"5f4e1ff2-2415-4b80-ac0d-0303641db753\\\", \\\"subtext\\\": \\\"dc46ae36-641a-4b16-8699-d69c570b32b7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 47, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12:46:47\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"80debed4-d26b-4a52-9003-bbb5e880f9fe\\\", \\\"childbox\\\": \\\"0b88ef2c-7725-4f86-bce0-41f37c7207a8\\\", \\\"subtext\\\": \\\"e0cbace5-688c-4308-be87-8695953c9519\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 48, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Z\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 42, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ba48f36c-0768-4086-a216-70e350d4c275\\\", \\\"childbox\\\": \\\"92db99ee-458c-4a3c-980d-8d64c5fa7654\\\", \\\"subtext\\\": \\\"a9b747d7-8077-49bb-92ed-3d43350c75e9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 42, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 49, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dfbc9b92-023c-40ac-bb50-78129574ce37\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 50, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"96e85924-ecb6-40c8-9e63-b63e9e7ad31f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 51, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"33301908-9b66-45e3-9c6a-6296b26b3976\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 52, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9ceca11-9fb4-4a3a-b509-32725592d9f4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 53, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7537d540-690d-4d8b-b506-9815c7f6017f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 54, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dc0ae6f9-459a-4c60-98a5-fb3c23763df1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 55, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b657ea8c-73d4-4761-8453-264e00b659eb\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 56, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ef8a517e-442a-4889-bbb6-33be9146c064\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 57, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cc44eb69-ad32-4129-8de9-860e998a5419\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"TITLE PAGE\\\", \\\"\\\", \\\"1\\\", 58, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TABLE OF CONTENTS\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1b1587d8-19a7-4940-9d4f-97ccc6e0a9b6\\\", \\\"childbox\\\": \\\"f59a47e5-9d1b-454b-bf0e-fdcd54c05c10\\\", \\\"subtext\\\": \\\"3934e3a0-7812-4512-a57a-f3db5dad1009\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 59, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PAGE\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d0444df-a36b-416f-927a-ec1bf91d1c74\\\", \\\"childbox\\\": \\\"f773b43e-2170-4c5b-bc61-3d0a49fedd8e\\\", \\\"subtext\\\": \\\"e0de8810-3cc7-44cd-9b9e-8ec5d609f24c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 60, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. PROTOCOL SUMMARY 7\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb4533d5-f4c1-476c-9e00-a01968008c97\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 61, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1.1. Synopsis 7\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"53600c69-100d-4205-9d73-e76f71c3ad27\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 62, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1.2. Schema 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"db2d607b-31cd-4b75-8393-98d44b70fc53\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 63, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1.3. Schedule of Activities (SoA) 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"151aa046-63fb-41e9-8906-1a880cf76e2c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 64, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. INTRODUCTION 14\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"51c33eb2-7850-45d3-8565-c9dd9f5216c2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 65, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.1. Study Rationale 14\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c1f37256-f5bc-4919-b928-71ae41bbcb38\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 66, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.2. Background 14\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aff84794-567a-4358-8287-4f2ce42d716c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 67, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.3. Benefit/Risk Assessment 15\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5faa67f5-1c58-4b94-a1c7-d86a5d2ed818\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 68, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.3.1. Risk Assessment 16\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"66a8b6be-ae32-4e44-87a8-11369db7c026\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 69, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.3.2. Benefit Assessment 27\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8fc7000d-786f-4212-9f14-3599715fe7b2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 70, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.3.3. Overall Benefit: Risk Conclusion 27\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0a5d4771-af9e-4f98-a3d9-309ee15361dc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 71, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. OBJECTIVES AND ENDPOINTS 28\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b87d52a5-7212-4011-a0c6-08acad204b26\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 72, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. STUDY DESIGN 30\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9c5a65ad-955a-48bc-a856-0cc1ebc44733\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 73, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.1. Overall Design 30\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fe380df9-69fa-46bd-aa01-636c6f85aa6e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 74, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.2. Scientific Rationale for Study Design 31\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"43f6922f-0204-413e-be3e-250bbcb1c7dc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 75, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.3. Justification for Dose 31\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3b263aa4-07bd-485b-b127-e286256caedb\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 76, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.4. End of Study Definition 33\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"49409a4f-5c4d-4e9b-af1c-8382ffec3626\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 77, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5. STUDY POPULATION 33\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"13bb7ace-9a3e-4e2d-baf0-6a388c4ac6f3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 78, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.1. Inclusion Criteria 34\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"efc895a3-4534-43c3-b130-9ac539f07454\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 79, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.2. Exclusion Criteria 35\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a980741f-366a-4dab-94e4-14dd507e724e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 80, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.3. Lifestyle Considerations 38\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"78bcfe0a-8fe5-4304-81e1-097542b85744\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 81, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.4. Screen Failures 38\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0425d11f-035f-411b-b38e-67ab3fc9ad10\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 82, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6. STUDY INTERVENTION 39\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"32ba15b9-3b4a-4bfa-8af0-7749c72fe82a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 83, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1. Study Interv ention(s) Administered 39\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"049552f2-3894-4e12-b961-585be7ee9786\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 84, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.2. Preparation/Handling/Storage/Accountability 42\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"567b1a88-0897-4590-96ab-4ef3544e9b45\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 85, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3. Measures to Minimise Bias: Randomisation and Blinding 43\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a7a78eda-dbea-4baa-affa-3ff48ab713c2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 86, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.4. Study Interv ention Compliance 44\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"50a61ac9-270d-48d4-8352-6719376b56cc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 87, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5. Prior and Concomitant Therapies 45\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"514c466d-e3be-4631-b936-349eeefca7e3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 88, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.1. Permitted Therapies 45\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c6fddbf0-de8c-4a9c-accd-aaf8e49775ca\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 89, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.2. Prohibited Therapies 47\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0de105dd-0a5d-480a-9590-2b05dca8b9eb\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 90, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.3. Rescue Medicine 49\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e819b32b-9a09-4d45-a10d-84c5c7c3d245\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 91, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.6. Dose Modific ation 49\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0011a061-fcce-4850-8675-b4eb84304905\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 92, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.6.1. Dose Modification of Study Intervention 49\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e4d1775-092e-4c23-91c7-634f4dbd7b8c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 93, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.6.2. Dose Modification of Background Therapy 50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e359a3b6-4758-4fc6-b718-fa69d6a6ed01\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 94, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.7. Intervention after the End of the Study 50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3ed0c5c8-f417-44e9-bda8-6ccf13111406\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 95, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL 50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2d4ec6a5-a599-4e06-992a-2addf9e0bdb7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 96, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1. Discontinuation of Study Intervention 50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52299f63-bc33-40ab-b958-4431cfebb3ea\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 97, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.1. Liver Chemistry Stopping Criteria 50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"104a9dfd-0e79-4906-b119-90a96992421d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 98, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.1.1. Study Intervention Restart or Rechallenge after liver stopping criteria met 51\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cac80dce-9d61-4862-be6d-dded3f69221c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 99, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.2. Other Stopping Criteria 51\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3cd6f29e-b662-4d6a-88a2-72ec51df42be\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 100, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.3. Temporary Discontinuation 52\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9ddf1a42-168c-4da6-8b2e-3c1f62bf6e4d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 101, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.3.1. Respiratory Symptoms 52\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3e217a32-bf58-4a66-97b6-7d149fe7e581\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 102, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.3.2. Serious and Opportunistic Infections 52\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"79aa1997-8da2-4eaa-9354-5a887d233106\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 103, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.3.3. Hematologic Abnormalities 52\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4b58739-44f7-4a30-9453-28f1bbccd036\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 104, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1.3.4. TB Reactivation 53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ea27fecb-0dd9-42e3-83f6-fa1142357320\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 105, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.2. Participant Discontinuation/Withdrawal from the Study 53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af7ecaf5-1217-4a91-934f-c9fa39adc953\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 106, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3. Lost to Follow Up 53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6ac4865f-4efc-4fa0-bc94-fe7b9bea9dfd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 107, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8. STUDY ASSESSME NTS AND PROCEDURES 55\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4918de46-5b08-4ac6-8e0f-582cc6e562d9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 108, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1. Efficacy Assessments 55\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e0b62c3b-af56-422a-9c3e-70aa276ebd41\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 109, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.1. Joint Assessments 55\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64df3f59-a7ab-468b-b269-4b2d285a6b5b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 110, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.2. Physician\\\\u2019s Global Assessment of Arthritis 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65c718c2-3e12-4935-a382-d5db4bae038a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 111, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3. Patient Reported Outcomes 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9e73cfef-33e1-4790-9b60-bcaa87ecac67\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 112, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.1 . Patient\\\\u2019s Assessment of Arthritis Pain 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"afa93e8a-8062-4e48-b68f-a0ad5538eb9d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 113, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.2. Patient\\\\u2019s Global Assessment of Arthritis 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"653dfdd4-cdcf-4ab9-86b6-76feb6df4097\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 114, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.3. Health Assessment Questionnaire \\\\u2013 Disability Index (HAQ-DI) 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7bafc9b0-19c4-4826-8de9-72398f8c6694\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 115, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.4. Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9d1ac760-6ac9-49bf-a63f-57ff0b4972ca\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 116, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.5. PROM IS Sleep Disturbance 57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d238175b-d52b-4954-be93-d13710b52f30\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 117, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.6. Rheumatoid Arthritis Symptom and Impact Questionnaire 57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bb5d4e65-8b36-4050-81d7-54b0c743595c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 118, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.7. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue 57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c56a93a9-8679-4dd5-be9f-8b9a8233523c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 119, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.8. SF-36 Short Form Health Survey 57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7c303bda-dea7-434a-b45e-5ad974ed0f1b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 120, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.9. PainDETECT Questionnaire 57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"28d8ffd9-e203-4bf4-9681-9584981e8927\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 121, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.10. Participant Feedback Questionnaire 57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1fac194a-4e85-47ee-9c7c-e2c54c442447\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 122, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2. Safety Assessments 58\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"92990eee-615b-47cb-a351-c78ddaf476a5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 123, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.1. Dyspnoea Assessments 58\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d7a21d2-7701-4355-8008-5f76ee64c7e5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 124, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.2. Physical Examinations 58\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3634707a-e583-4bb5-85ad-b2705ad1b935\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 125, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.3. Electrocardiograms 58\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f2c3b0a9-c6e5-44ae-9bb3-61c095777c0a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 126, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.4. Vital Signs 58\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bfa05c3d-153a-402b-b680-00ee1ef83fb2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 127, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.5. Clinical Safety Laboratory Assessments 59\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 7, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Clinical Safety Laboratory\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"c71a727c-6d79-4d7e-a5be-4539b957c8e5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 128, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.6. Pulmonary Assessment s 60\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d5f170a5-88fc-4100-a1e6-3b4da9ee5d35\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 129, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.7. Tuberculosis Monitoring 61\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9edaec4-78cd-422e-bb03-aaf30c6191c7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 130, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.7.1. Tuberculosis Status Definitions 61\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"10060dc7-c186-4ead-a257-8f605c8533fa\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 131, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.7.2. Tuberculosis Testing 62\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"98ca70d4-742b-4fe1-ae85-1670aaff41f6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 132, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.7.3. Treatment of Latent TB During the Study 62\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e5bab82c-1e1e-4a5e-91cb-743468b102fd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 133, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.7.4. Monitoring for TB Infection and Re-activation During the Study 62\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8a04fa85-a679-4fc2-8955-19ca8b1d9db3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 134, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.8. Hepatitis B Monitoring 63\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e0e75bd8-e952-4ec1-acac-c637681e8757\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 135, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.8.1. Risk of Reactivation in Participants Positive for Hepatitis B Core Antibody (HBcAb) 64\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ef7705c2-d9bc-47af-bbcb-786decd0b4b3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 136, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.8.2. Treatment of Participants Who Are HBcAb Positive and Who Develop Detectable HBV DNA Requiring Initiation of Antiviral Therapy 64\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"601e16e3-26c5-4862-87c5-9e226ec35478\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 137, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.8.3. Follow Up of Participants Treated With Anti-viral Therapy 64\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"11959bb4-3d9f-468e-84ea-6bad816a13a5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 138, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.2.9. Markers of drug-drug interactions 64\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e3df3312-72a6-46da-b6a9-8c1fd54dd92d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 139, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3. Adverse Events and Serious Adverse Events 64\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e10cbc14-bcad-4ad6-b401-b9884e88f979\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 140, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3.1. Time Period and Frequency for Collecting AE and SAE\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fad57688-9798-4e97-9588-736abbe1e527\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 141, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Information 65\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1a38b30b-43f9-4c95-b343-9adaad61fc62\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 142, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3.2. Method of Detecting AEs and SAEs 65\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f3616ddf-3b9d-40cb-ad70-e88e31420588\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 143, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3.3. Follow-up of AEs and SAEs 65\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5bf4582d-36e1-4215-b98f-a19b68a14d45\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 144, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3.4. Regulatory Reporting Requirements for SAEs 66\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d87dfbd3-c9af-4eef-8c1d-266dc8c95db7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 145, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3.5. Pregnancy 66\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c6e87ec7-2fb6-44d7-a1c7-1fadc2da0d9a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 146, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3.6. Cardiovascular and Death Events 66\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d2b7f849-2816-4b28-aa19-e0bfb4de6576\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 147, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.3.7. AEs of Special Interest 67\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eccadeaa-c1d5-462f-bc4a-642f07c4ecf0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 148, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.4. Treatment of Overdose 68\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e634f5c6-1da6-4124-b625-2f67028f83f2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 149, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.5. Pharmacokinetics 68\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e1eeb9a-93fa-4bb5-ae35-441b020db33e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 150, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.6. Pharmacodynamics 69\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"afdde771-79fd-4aff-8811-29fdb0d873d5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 151, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.6.1. Target engagement 69\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c43aeafd-d803-4688-a027-8fba876e9802\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 152, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.7 . Genetics 69\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"df56f504-8e93-4e09-ba4c-8e034d23100e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 153, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.8. Biomarkers 69\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b8b92aef-ab4e-4de3-b4c5-9dfa5da61e05\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 154, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.8.1. Pharmacodynamic (PD) Biomarkers 70\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1356bc7d-cb1b-4742-a872-4d6144d994c4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 155, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8 .8.2. RNA Transcriptome Research 70\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b8b1a8f9-77ad-46cd-8677-69cc36dd54d9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 156, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.8.3. RNA Expression Research of a Subset of RNA Species 70\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"07514ea5-cc76-461f-95aa-0e00183e779b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 157, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.9. Immunogenicity Assessments 71\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2f7dc78-a0cf-4566-be7c-44958dd5c883\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 158, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.10. Medical Resource Utilisation and Health Economics 71\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dfe6b197-cd2f-4612-9bf6-fc414b040e51\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 159, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9. STATISTICAL CONSIDERATIONS 72\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9ab7e011-910c-41a9-9b55-bf1feb66e262\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 160, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1. Statistical Hypotheses 72\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7de4a633-90ee-4bd7-a83a-17206ed687a8\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 161, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2. Sample Size Determination 72\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2273a5b7-3909-46ca-bca1-2a78fb1a751b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 162, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.1. Sample Size Sensitivity 72\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1abf7f75-8097-47b3-9dbd-ac558af86853\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 163, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3. Populations for Analyses 73\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7d2e6ab5-e087-47e9-a516-03b5b6829335\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 164, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.4. Statistical Analyses 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f3e1f18c-8426-415b-8524-1ca4b4af3640\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 165, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.4.1. Efficacy Analyses 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f4e88132-7229-4fc6-a4d5-5377aba17d0b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 166, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.4.1.1. Estimand strategy 75\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"86792f4f-26ca-4a65-bac4-e6268c9b8b87\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 167, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.4.2. Safety Analyses 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"becd8a04-4847-4457-85df-a012b1887fdf\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 168, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.4.3. Other Analyses 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"345456b3-d668-43c2-a176-7dc31bf10de6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 169, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.5. Interim Analyses 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"da62f5fe-9d9c-43e8-b467-e31eff9e1831\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 170, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.5.1. Data Monitoring Committee (DMC) 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e7492e9-b058-4561-ba44-69ed5c78ab51\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 171, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1 0. SUPPORTING DOCUMENTATION AND OPERATIONAL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4be7f69c-47b7-4b1e-95e2-8bc27d0dea4a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 172, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CONSIDERATIONS 77\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65ce67e0-a630-4156-b786-0f12a9c511f6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 173, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1. Appendix 1: Regulatory, Ethical, and Study Oversight\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"623c5ac0-a33d-4595-8111-af52f1758768\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 174, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Considerations 77\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b9819f29-91b8-4cfb-8574-3ef2adf0703a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 175, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.1. Regulatory and Et hical Considerations 77\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d5439fee-b00d-4d3f-a6c8-d88780c8afb1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 176, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.2. Financial Disclosure 77\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a437a6ce-15b2-4f50-8ec6-3f16450aea8d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 177, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.3. Informed Consent Process 78\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2bf1dfe-4c27-4d9b-ad7a-e464e8c67c18\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 178, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.4. Data Protection 78\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dbe52b13-f979-4f26-b360-027a2414f6d4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 179, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.5. Committ ees Structure 78\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d8129fed-2a1b-4ac3-be26-dad337a83363\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 180, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.6. Publication Policy 79\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"604eade5-3540-4543-b220-9b17f019a433\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 181, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.7. Dissemination of Clinical Study Data 79\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1a6c7b38-6d58-4b24-9fa1-816d22b12dac\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 182, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.8. Data Quality Assurance 80\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f67a2ece-c45e-4119-a07a-58ab13848ecc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 183, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.9. Source Documents 80\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"218daeb9-93c4-4241-a143-6efcd8c1200a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 184, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.10. Study and Si te Closure 81\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3ff59316-4020-40d6-a391-e3b565f3de49\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 185, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2. Appendix 2: Clinical Laboratory Tests 82\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"83580861-71ca-4c80-a05b-8fd72c268039\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 186, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.3. Appendix 3: Adverse Events: Definitions and Procedures for\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"70f5c543-8c04-43af-9726-a88daa693387\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 187, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Recording, Evaluating, Follow-up, and Reporting 84\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8976a742-b3b0-42cf-bcec-51d99828510c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 188, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.3.1. Definition of AE 84\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3c73fb77-7408-4c9c-8a33-9198471858c0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 189, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.3.2. Definition of SAE 85\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c4bece01-9fe8-44e9-aff7-06234a23b17e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 190, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.3.3. Definition of Car diovascular Events 86\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"49b74e11-35ac-41b1-aa67-8914c3c0ba4e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 191, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.3.4. Recording and Follow-Up of AE and SAE 86\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"80a1c354-060b-43b4-b5e7-d80a2a15a382\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 192, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.3.5. Reporting of SAE to GSK 88\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 28, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 28, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"76de3662-6f73-4387-a0b1-04a071fb5b00\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 193, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"33b8bb57-74d1-4eb9-801b-b4c4316852d4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 194, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Information 90\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a0a7e1fd-27a4-47a2-ac2e-d4aa71e3791f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 195, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4.1. Definitions: 90\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"28a2260f-741d-4cb3-b85c-386c4fb2a97e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 196, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4.1.1. Woman of Childbearing Potential (WOCBP) 90\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e988482b-f325-4205-a967-a16e597c3e42\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 197, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4.1.2. Women in the following categories are not considered WOCBP 90\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f986f983-4059-4774-8dd2-7ccb0eefa99f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 198, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4.2. Contraception Guidance: 91\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1dbdb38c-0d7a-4b48-a0de-8fa0b930b065\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 199, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4.3. Collection of Pregnancy Information: 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cc8bb112-d0fb-49f4-9cf2-82db438868e0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 200, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4.4. Contraception Eligibility Criteria for Female and Male Participants 93\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3b020a1c-6aa6-491b-8ae1-3fd54d941132\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 201, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.5. Appendix 5: Genetics 95\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3a639a2e-9483-40ca-b049-14ac8de89c49\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 202, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.6. Appendix 6: Liver chemistry stopping and monitoring criteria and required actions and follow up assessments (study specific for 202018) 96\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5fbae94b-9acf-48c8-8451-4b70e5db91f5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 203, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.6.1. Liver chemistry stopping criteria and required follow up\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d10343d9-45dd-45c4-bf78-f28e3acbda74\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 204, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"assessments 96\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1f3b1f53-2b65-4a05-bac4-ed1d17ad5353\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 205, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.6.2. Liver chemistry increased monitoring criteria with\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5ea4884e-6b1f-4e6b-9494-1df4b24e4e40\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 206, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"temporary discontinuation of study intervention 97\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"63403412-869c-46e8-abce-926df00c79d6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 207, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.7. Appendix 7: Summary of composite endpoints 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"faa3601c-6158-4f2b-97c8-476924cf8ac1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 208, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.7.1. ACR 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0e13b062-97e9-4a74-922a-bc563ea7187c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 209, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.7.2. Disease Activity Score 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c4ddb6b0-bc01-4f4f-a578-55bd8bbd31bc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 210, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.7.3. Clinical Disease Activity Index (CDAI) 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7eec2429-3f82-4b31-952c-e158947bff3f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 211, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.8. Appendix 8: Hierarchy Options to Demonstrate Superiority of Each Dose of GSK3196165 Versus Placebo or Sarilumab 101\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 79, \\\"end_idx\\\": 88, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 108, \\\"end_idx\\\": 116, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"Sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"7d6d0aaa-473e-4a12-a336-fd931890909b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 212, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.9. App endix 9: Country-specific requirements 102\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"50f3281f-7160-4c69-8fce-789e91a7c7d8\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 213, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.10. Appendix 10: Abbreviations and Trademarks 103\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6d17037a-83f6-46c2-939b-b2288103ff28\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 214, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11. REFERENCES 107\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3bd469cb-bda4-41eb-89d2-aad685bc7274\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 215, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ee51650f-ce7f-4c0f-becf-2d200f856a7d\\\", \\\"childbox\\\": \\\"b9ec2660-c1c0-4708-a55e-f4e3b75b2f09\\\", \\\"subtext\\\": \\\"bf9fb3d4-e046-4efd-be48-bb0ef70a82a3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 216, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"18f62f9a-5652-4822-93a4-9af8df1fee13\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 217, \\\"\\\"], [\\\"1\\\", \\\"Protocol Summary\\\", \\\"header\\\", \\\"1. PROTOCOL SUMMARY\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c8699b91-e580-4d7b-b09a-2cbd9f6225fc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"PROTOCOL SUMMARY\\\", \\\"1.\\\", \\\"1\\\", 218, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"header\\\", \\\"1.1. Synopsis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7db874fe-80c8-4032-bcd3-6f48fa426e93\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 219, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Protocol Title:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ea4ceef2-61ab-4cba-9775-b96a6b2336b9\\\", \\\"childbox\\\": \\\"58bf9311-7567-4f47-980d-a2cf539e4612\\\", \\\"subtext\\\": \\\"6e2017b9-d043-4668-8a55-5dfc1622ef51\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 220, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 96, \\\"end_idx\\\": 105, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 129, \\\"end_idx\\\": 137, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ea4ceef2-61ab-4cba-9775-b96a6b2336b9\\\", \\\"childbox\\\": \\\"58bf9311-7567-4f47-980d-a2cf539e4612\\\", \\\"subtext\\\": \\\"b2cd7ec7-79ee-42e5-81e2-31d873dba928\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 221, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Short Title:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fa831dbc-2705-42b9-a944-d493d6d68044\\\", \\\"childbox\\\": \\\"e19137d5-1dfe-4534-9612-1abdb2408054\\\", \\\"subtext\\\": \\\"9ff6d0e8-9f15-4e5a-82c8-84bdb264ed46\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 222, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Efficacy and safety of GSK3196165 versus placebo and sarilumab in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 23, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 53, \\\"end_idx\\\": 61, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"fa831dbc-2705-42b9-a944-d493d6d68044\\\", \\\"childbox\\\": \\\"e19137d5-1dfe-4534-9612-1abdb2408054\\\", \\\"subtext\\\": \\\"5cab77ad-f352-46e3-a9f4-7c4b0dcd25ba\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 223, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Rationale:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"918c49cf-b5da-4853-99ca-15a290820585\\\", \\\"childbox\\\": \\\"06659b1f-52cf-4b4f-86a1-5c0b20e8c102\\\", \\\"subtext\\\": \\\"8e028e53-fde3-4942-a3f8-3d5df72aeb9d\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 224, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"The aim of this study is to determine the efficacy and safety of GSK3196165, in combination with conventional synthetic disease-modifying antirheumatic drug(s) (csDMARD)(s), for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to biologic DMARD(s)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 65, \\\"end_idx\\\": 74, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 302, \\\"end_idx\\\": 318, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"biologic DMARD(s)\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"918c49cf-b5da-4853-99ca-15a290820585\\\", \\\"childbox\\\": \\\"06659b1f-52cf-4b4f-86a1-5c0b20e8c102\\\", \\\"subtext\\\": \\\"0769ce01-1a93-4d09-bbae-3bc0824977f6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 225, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"(bDMARD)(s) and/or JAK inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"92b68e8a-16f0-4d51-859b-4597c5ffaa94\\\", \\\"childbox\\\": \\\"24a0e1cf-9827-4115-b5f3-32747c70b429\\\", \\\"subtext\\\": \\\"0aeadeec-ae90-4430-b1ef-374a547aad25\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 226, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Two doses of GSK3196165 (90 mg subcutaneous [SC] weekly and 150 mg SC weekly) will be compared with placebo (to Week 12) and with sarilumab (200 mg SC every other week), an inhibitor of IL-6 that is approved in many countries for the treatment of adults with moderately to severely active RA who have an inadequate response to bDMARD(s) and/or JAK inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 13, \\\"end_idx\\\": 22, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 130, \\\"end_idx\\\": 138, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 186, \\\"end_idx\\\": 189, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"IL-6\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"92b68e8a-16f0-4d51-859b-4597c5ffaa94\\\", \\\"childbox\\\": \\\"d84c76dc-ed57-48d2-9d19-63071b943a17\\\", \\\"subtext\\\": \\\"0aeadeec-ae90-4430-b1ef-374a547aad25\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 227, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Objectives and Endpoints:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"633ec63f-bbec-4151-b4a3-c1117a4061a5\\\", \\\"childbox\\\": \\\"1c1ad929-0a5e-4a46-9d2b-20da94363b4d\\\", \\\"subtext\\\": \\\"684f7260-f073-4be5-a25d-1bb55cd407ac\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 228, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c32b6762-9d2a-4b72-879d-fc968f5b7883\\\", \\\"childbox\\\": \\\"c81a22bf-7e2f-4618-9c1b-07c2e5334759\\\", \\\"subtext\\\": \\\"44fa71e5-a098-4851-b98b-f669dc0fb6d1\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 229, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5aa70e97-339d-4f41-bc66-b19be467f217\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 230, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65eb176b-5eaa-4938-922e-6de1daf9701d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 231, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"76bdb931-d54d-4849-b2e0-b7629f516178\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 232, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"csDMARD = conventional synthetic disease modifying antirheumatic drug; ACR20/50/70 = 20%/50%/70% improvement in American College of Rheumatology criteria; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire disability index; VAS = visual analogue scale; LDA = low disease activity; DAS28 = disease activity score including 28 different joints; CRP = C-reactive protein; EULAR = European league against rheumatism; ESR = erythrocyte sedimentation rate; AEs = adverse events; SAEs = serious adverse events; AESIs = adverse events of special interest; NCI-CTCAE = National Cancer Institute-common terminology criteria for adverse events; GM-CSF = granulocyte-macrophage colony stimulating factor; SF-36 = short form-36;\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 112, \\\"end_idx\\\": 143, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"American College of Rheumatology\\\"}, {\\\"start_idx\\\": 578, \\\"end_idx\\\": 586, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"NCI-CTCAE\\\"}, {\\\"start_idx\\\": 590, \\\"end_idx\\\": 621, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"National Cancer Institute-common\\\"}, {\\\"start_idx\\\": 664, \\\"end_idx\\\": 669, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}, {\\\"start_idx\\\": 673, \\\"end_idx\\\": 720, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"granulocyte-macrophage colony stimulating factor\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"615cfe25-68ee-4cf8-b005-6ffc16e0894d\\\", \\\"childbox\\\": \\\"24310027-291b-4a02-a651-93c579764d7a\\\", \\\"subtext\\\": \\\"cf2f8090-dde1-438b-9cce-d10ee53ed5dc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 233, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"FACIT = functional assessment of chronic illness therapy; RA = rheumatoid arthritis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c68b6e60-a8a0-425d-9d7e-98796f0929f6\\\", \\\"childbox\\\": \\\"91e7dd14-7170-410f-9199-66300ea82712\\\", \\\"subtext\\\": \\\"fb7e0bce-9124-4912-b296-acebd4bee6ee\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 234, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Overall Design:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbb141c8-01ce-42cd-8858-beb7b6667318\\\", \\\"childbox\\\": \\\"7e3fac02-74ae-4ab9-9b32-3257e9f0d521\\\", \\\"subtext\\\": \\\"cbd6daba-deff-4c1d-862e-c957ef5df3c5\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 235, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"This is a double-blind, parallel group, multicentre, placebo and active comparator-controlled study of the efficacy and safety of GSK3196165 in participants with moderately to severely active RA, who have had an inadequate response to treatment with bDMARDs and/or JAK inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 130, \\\"end_idx\\\": 139, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"cbb141c8-01ce-42cd-8858-beb7b6667318\\\", \\\"childbox\\\": \\\"7e3fac02-74ae-4ab9-9b32-3257e9f0d521\\\", \\\"subtext\\\": \\\"72c44511-c574-424e-a8ee-538e4b1f23c2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 236, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"The study consists of a screening phase of up to 6 weeks, a 24-week treatment phase and a safety follow-up visit at Week 34.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbb141c8-01ce-42cd-8858-beb7b6667318\\\", \\\"childbox\\\": \\\"f3d03c0f-463e-42f5-b8ec-1c2f9aff9a17\\\", \\\"subtext\\\": \\\"da6dba67-ddcf-46c7-acb3-7742a7076582\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 237, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Upon successful screening, participants will be randomised to one of six intervention arms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbb141c8-01ce-42cd-8858-beb7b6667318\\\", \\\"childbox\\\": \\\"0737c361-e4e7-4ce6-b7b4-4f447695e9fb\\\", \\\"subtext\\\": \\\"da6dba67-ddcf-46c7-acb3-7742a7076582\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 238, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Participants who complete the treatment period of this study may be eligible to participate in a long-term extension study to further evaluate the efficacy and safety of GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 170, \\\"end_idx\\\": 179, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"cbb141c8-01ce-42cd-8858-beb7b6667318\\\", \\\"childbox\\\": \\\"3c96cc00-ac4d-4aee-8e69-7d94cb44d92b\\\", \\\"subtext\\\": \\\"e8974bd1-eee2-48dc-8fdf-f75604d1596d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 239, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Disclosure Statement\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c486cc0a-ad94-4fec-a265-7fe38e2ed9d0\\\", \\\"childbox\\\": \\\"b244fdd7-1647-482a-a26f-fbbc874ce07f\\\", \\\"subtext\\\": \\\"7933c51f-4f00-4528-a8a6-3a900642eda9\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 240, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\": This is a parallel group treatment study with 6 arms that is participant, investigator and outcomes assessor blinded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c486cc0a-ad94-4fec-a265-7fe38e2ed9d0\\\", \\\"childbox\\\": \\\"b244fdd7-1647-482a-a26f-fbbc874ce07f\\\", \\\"subtext\\\": \\\"fb8afb64-5b46-4aae-915a-6c8fab4968ba\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 241, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Number of Participants:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f00b8e6b-1285-4472-ba70-b888a4e96a3b\\\", \\\"childbox\\\": \\\"3ed7fb74-6763-42f8-a3ae-394e7a95beda\\\", \\\"subtext\\\": \\\"80b3c3db-d8e8-4c77-bc17-7f36d653efec\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 242, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Approximately 1050-1200 participants will be screened to achieve between 525 and 600 randomly assigned to study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f00b8e6b-1285-4472-ba70-b888a4e96a3b\\\", \\\"childbox\\\": \\\"3ed7fb74-6763-42f8-a3ae-394e7a95beda\\\", \\\"subtext\\\": \\\"92bce124-4594-4c32-9860-48601a4fabce\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 243, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Approximately 525 evaluable participants are expected to be included in the primary analysis, of whom approximately 473 are expected to complete the Week 12 visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f00b8e6b-1285-4472-ba70-b888a4e96a3b\\\", \\\"childbox\\\": \\\"bfb63004-126b-48fb-bd01-088e27594fc8\\\", \\\"subtext\\\": \\\"91975df3-6914-4bd9-98e0-eae948496b26\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 244, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"The maximum of 600 participants may be recruited if necessary to ensure sufficient numbers in key Asian country subgroups.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f00b8e6b-1285-4472-ba70-b888a4e96a3b\\\", \\\"childbox\\\": \\\"fea05cee-7806-4c1c-85a7-0721050911b5\\\", \\\"subtext\\\": \\\"91975df3-6914-4bd9-98e0-eae948496b26\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 245, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"The sample size calculation is provided in Section 9.2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"95ac3af9-9f93-4879-a40c-e8391151afd4\\\", \\\"childbox\\\": \\\"e918c2a4-8b89-4e0c-98d3-e282c22feecf\\\", \\\"subtext\\\": \\\"d100f364-1fa4-4567-af33-d8e0dba134a6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 246, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Intervention Groups and Duration:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9a64e3ea-aefa-41ad-8851-24b606ae81e7\\\", \\\"childbox\\\": \\\"d3a63b3c-5603-4110-ab86-746fe3eba563\\\", \\\"subtext\\\": \\\"1fd69347-d532-4d11-9d31-a020496e2380\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 247, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Participants will be randomised to one of six intervention arms, in a ratio of 6:6:6:1:1:1 to GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, sarilumab 200 mg SC every other week or placebo (3 arms) respectively, all in combination with background csDMARD(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 94, \\\"end_idx\\\": 103, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 123, \\\"end_idx\\\": 132, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 151, \\\"end_idx\\\": 159, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e1986c7a-9b45-4a8e-821e-067bf2e85005\\\", \\\"childbox\\\": \\\"146226af-ea55-435b-8756-afe1ecfa6117\\\", \\\"subtext\\\": \\\"07ab8325-62a5-44c3-a0ca-3292be0b3320\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 248, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"At Week 12, the 3 placebo arms will switch from placebo to active intervention (either GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, or sarilumab 200 mg SC every other week).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 87, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 116, \\\"end_idx\\\": 125, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 147, \\\"end_idx\\\": 155, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e1986c7a-9b45-4a8e-821e-067bf2e85005\\\", \\\"childbox\\\": \\\"5b69fa7d-3f8e-4c8c-bbaf-73b227b00187\\\", \\\"subtext\\\": \\\"f82f955e-8989-4ebc-a225-28f4f1a642d7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 249, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Randomisation will be stratified by previously failed medication (1 bDMARD, >1 bDMARD or \\\\u22651 JAK inhibitor [regardless of whether bDMARD received in past]).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e1986c7a-9b45-4a8e-821e-067bf2e85005\\\", \\\"childbox\\\": \\\"9c88bac5-b4ae-4fd7-aadd-f3fcd225e513\\\", \\\"subtext\\\": \\\"f82f955e-8989-4ebc-a225-28f4f1a642d7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 250, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"A separate randomisation cohort in addition to the main randomisation may be utilised for key Asian country subgroups, in order to allow separate analyses for these countries if required.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c1426195-5482-4a7c-bde0-fd4e0ad31e3f\\\", \\\"childbox\\\": \\\"1a344d85-9cea-49bd-b7f7-af97e0b4578c\\\", \\\"subtext\\\": \\\"a1c72c03-b4bd-422c-9988-a7ee2e8b81e5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 251, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"The total treatment period is 24 weeks, with a safety follow-up visit at Week 34, for those participants who do not continue into the long term-extension study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"00c43c56-f4ad-45a6-aa65-71f00678bb08\\\", \\\"childbox\\\": \\\"799573bb-2509-4f8f-be88-b26fef9a5894\\\", \\\"subtext\\\": \\\"7ebb91fc-d034-4b03-86f8-df6104a74a53\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 252, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Independent Data Monitoring Committee:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4392b34-9954-4d7b-bbab-e03cd040a54f\\\", \\\"childbox\\\": \\\"7ee06336-ea94-4173-9964-d4a09781b4ed\\\", \\\"subtext\\\": \\\"b26e0c6a-3109-4af8-83b0-6a85d6d9eaac\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 253, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Yes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4392b34-9954-4d7b-bbab-e03cd040a54f\\\", \\\"childbox\\\": \\\"7ee06336-ea94-4173-9964-d4a09781b4ed\\\", \\\"subtext\\\": \\\"60e66ad8-ca58-47ee-afc1-d0e553f8d148\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 254, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Major Adverse Cardiac Event Adjudication Committee:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f8d971f5-ef1a-48c4-b808-a23764a25bdb\\\", \\\"childbox\\\": \\\"0c3d9f1b-bf63-4881-9498-be3dea32d34b\\\", \\\"subtext\\\": \\\"4bb295c0-df29-4fda-9281-25697bbd3482\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 255, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Yes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f8d971f5-ef1a-48c4-b808-a23764a25bdb\\\", \\\"childbox\\\": \\\"0c3d9f1b-bf63-4881-9498-be3dea32d34b\\\", \\\"subtext\\\": \\\"30a16675-d586-4401-a02d-21d9a7fcb1ac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 256, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Pulmonary Adjudication Committee:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1a819fb-7d04-40ee-a29d-cc6b408295a9\\\", \\\"childbox\\\": \\\"8fad9bc1-463a-41c9-a119-3b20660572fe\\\", \\\"subtext\\\": \\\"67b78106-be2b-48ca-af3e-70b38b35453a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 257, \\\"\\\"], [\\\"2\\\", \\\"Synopsis\\\", \\\"text\\\", \\\"Yes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1a819fb-7d04-40ee-a29d-cc6b408295a9\\\", \\\"childbox\\\": \\\"8fad9bc1-463a-41c9-a119-3b20660572fe\\\", \\\"subtext\\\": \\\"9e9f8d4e-5d3a-4356-a80b-67fa47225e69\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Synopsis\\\", \\\"1.1.\\\", \\\"2\\\", 258, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"header\\\", \\\"1.2. Schema\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9d1888a0-0188-4a51-8fcb-ab0cd3daf43b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 259, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W12\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"48d38b36-3d24-4edf-9f66-4ed6aea83f47\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 260, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W24 end of study assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"ab0d3052-c93b-4f00-8096-ee7c2ada1a1b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 261, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W24\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"b226128a-c55a-419b-9bd2-46dfc0874612\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 262, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W12 endpoint visit& switch all bDMARD-IRSarilumab200mg every other week (EoW) + csDMARDGSK3196165 90mg weekly + csDMARDGSK3196165 150mg weekly + csDMARDPlacebo + csDMARDSarilumab200mg EoW csDMARD+Placebo + csDMARDGSK3196165 90mg weekly+csDMARDPlacebo + csDMARDGSK3196165 150 mg weekly+csDMARDOption to transition to LTE study 209564 or exit after safety follow-up at Week 34.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"9b1ee35f-3456-4457-996f-3708d731b795\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 263, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W 0\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"b6b32399-f8ff-4b5a-8c31-33989676311a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 264, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Screening\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"b3209cd3-0b41-4cf4-9171-9a40d3816f24\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 265, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W-6W12\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"88312cd6-c0ed-4113-aece-91db748c055e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 266, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W24 end of study assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"c0f8e073-0c94-4a66-9301-b5a05b396f98\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 267, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W24\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"5f38a156-0254-40ae-96a6-0d56b47047bc\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 268, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W12 endpoint visit& switch all bDMARD-IRSarilumab200mg every other week (EoW) + csDMARDGSK3196165 90mg weekly + csDMARDGSK3196165 150mg weekly + csDMARDPlacebo + csDMARDSarilumab200mg EoW csDMARD+Placebo + csDMARDGSK3196165 90mg weekly+csDMARDPlacebo + csDMARDGSK3196165 150 mg weekly+csDMARDOption to transition to LTE study 209564 or exit after safety follow-up at Week 34.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"cff53d0a-1449-4cbc-9dd7-58a9c67d82f4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 269, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W 0\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"99992561-fdff-45d9-88e6-228f03684bb7\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 270, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Screening\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"b962cb8f-1296-4ec2-89ff-e75c1af48ee7\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 271, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W-6\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37a25f86-b6ea-4f73-88e4-434fe79818c4\\\", \\\"childbox\\\": \\\"77113923-8220-4ad1-b90e-b95c97a35fa6\\\", \\\"subtext\\\": \\\"e2acd903-47cc-44f0-b6a3-151aa6b747a7\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 272, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W12\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"063864f7-3b46-4e53-baef-d579ee047f0c\\\", \\\"childbox\\\": \\\"cd4f3ff2-ed13-4f72-b61d-eb2010788f9a\\\", \\\"subtext\\\": \\\"48d38b36-3d24-4edf-9f66-4ed6aea83f47\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 273, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W24 end of study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c93002a3-859f-434e-9d82-34d6ddcf1ff6\\\", \\\"childbox\\\": \\\"09c3cb62-b81d-4245-a40f-8df32938306d\\\", \\\"subtext\\\": \\\"ab0d3052-c93b-4f00-8096-ee7c2ada1a1b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 274, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45bb7f27-cd39-4aec-aa7b-8dd277ff4560\\\", \\\"childbox\\\": \\\"65d616f8-69e8-4696-9a6c-bc2387db1f0e\\\", \\\"subtext\\\": \\\"877dae48-801b-4f92-ba9a-98768a35cb4b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 275, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W24\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8a77ef7b-7726-45b1-a952-4542147eea7d\\\", \\\"childbox\\\": \\\"77d5b718-5193-434f-81b0-80100193c2cc\\\", \\\"subtext\\\": \\\"b226128a-c55a-419b-9bd2-46dfc0874612\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 276, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W12 endpoint visit\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9a3d336a-1b4a-4453-9660-2d7ab1cada1d\\\", \\\"childbox\\\": \\\"ec80849f-f15b-4854-9a96-e956d4b1dbfd\\\", \\\"subtext\\\": \\\"9b1ee35f-3456-4457-996f-3708d731b795\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 277, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"& switch all\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3de630aa-5b9e-4036-96b2-285d54a681fd\\\", \\\"childbox\\\": \\\"5969c149-83e1-46b3-b398-810348135539\\\", \\\"subtext\\\": \\\"61735ef9-9faa-4a4c-87e1-96f6559b2f47\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 278, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"bDMARD-IR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cd24bcc6-2d1a-4618-96ab-de896e49d0b3\\\", \\\"childbox\\\": \\\"e05b40b7-e2c7-4868-84aa-33d9c787a4c8\\\", \\\"subtext\\\": \\\"121ee72a-9851-4be2-b748-ba7bd0c8fb3f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 279, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Sarilumab\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 8, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"Sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"324a37e3-4ccd-43af-96e2-a9fcdf33f032\\\", \\\"childbox\\\": \\\"315d85c2-4017-4be9-86d4-4817bf0470f6\\\", \\\"subtext\\\": \\\"aedba3cb-eefa-4c6a-ac26-f57dd54fd409\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 280, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"200\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fcdd13a2-515e-4d75-8f5a-c316305beed9\\\", \\\"childbox\\\": \\\"993a62a2-8b78-4adc-bf95-e81648c5e1ba\\\", \\\"subtext\\\": \\\"a354dee4-ab2e-4e0b-a6d5-0ab4f6d71822\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 281, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"mg every other week (EoW) + csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"986120ca-4aee-4d47-a4e5-76bca52c800a\\\", \\\"childbox\\\": \\\"b94b76d7-fbf7-4715-b293-9ec4097516ff\\\", \\\"subtext\\\": \\\"99c67736-6dec-4282-8125-e8de7860734e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 282, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"GSK3196165 90mg weekly + csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"8f9a18e0-a89c-4abf-a8b9-71e00c34d93e\\\", \\\"childbox\\\": \\\"4d94562e-e53a-4023-afde-3466688a2bc6\\\", \\\"subtext\\\": \\\"e2beab08-131d-4a32-868e-7e7dfbe0cbee\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 283, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"GSK3196165 150mg weekly + csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"25b25366-f080-49ec-8be5-5c91d0cd5846\\\", \\\"childbox\\\": \\\"821ad15d-f1aa-403a-addc-cdf92d33f6b0\\\", \\\"subtext\\\": \\\"6b843742-4eb2-4965-a9f8-1715a9279e2d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 284, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Placebo + csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bc10f905-a34e-4586-8eab-cbeea730a9d7\\\", \\\"childbox\\\": \\\"3e01bf3b-90ab-410f-817e-5d3f830408b9\\\", \\\"subtext\\\": \\\"6532b583-bc24-4191-bacf-55dfa93c0245\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 285, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Sarilumab\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 8, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"Sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4cb5ffc8-6cda-4114-9462-1a2df6beb3f0\\\", \\\"childbox\\\": \\\"9df4ae10-6755-42a0-8624-73ec33a4f4e3\\\", \\\"subtext\\\": \\\"3cdce5d6-74ff-49fb-96be-25b66610947a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 286, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"200\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"385372aa-1afd-44e9-8135-b2f32923069f\\\", \\\"childbox\\\": \\\"5d9dcf58-0b21-4fde-9c06-7457fbbb739a\\\", \\\"subtext\\\": \\\"981d7fa9-bafb-4f98-9e7e-4052cbb165c2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 287, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"mg EoW\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9d54d866-377c-411b-9e19-17079250c933\\\", \\\"childbox\\\": \\\"ba4ece80-36d6-4a27-838f-de7e8d4cf28e\\\", \\\"subtext\\\": \\\"abc48c04-dfc1-492e-9f29-6bac72e25aa1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 288, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4c70f0d7-c501-4460-8b21-4d6403a04d2e\\\", \\\"childbox\\\": \\\"60ce1546-5eba-4f35-ac03-47227cab026e\\\", \\\"subtext\\\": \\\"1f8d0a0e-5ed7-4387-9114-30cdd636c7a6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 289, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"+\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"476f3194-7b3c-4e5e-9bf2-510131f64822\\\", \\\"childbox\\\": \\\"45388474-0ca4-459c-8adc-66016257f6f4\\\", \\\"subtext\\\": \\\"ba493a9a-ad59-489d-af91-57246ad9039c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 290, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Placebo + csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8b3d21a5-9faa-4cd9-b6c9-e812730f4156\\\", \\\"childbox\\\": \\\"6e114005-a538-4db5-9350-3e8027d17dd8\\\", \\\"subtext\\\": \\\"99f014b4-7297-43a7-a788-f4134e3d7a33\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 291, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"GSK3196165 90mg weekly+csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"904ebd43-c905-40f5-9c4d-d44fb883efa0\\\", \\\"childbox\\\": \\\"e2804d5b-0390-4d8a-8e74-e12c1d59478f\\\", \\\"subtext\\\": \\\"c1db88d0-4656-41d8-8d2a-be27fce53fe6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 292, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Placebo + csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2226110c-0cfa-4ec6-b9da-0d36e73ed3b1\\\", \\\"childbox\\\": \\\"a2659f41-a938-41d9-a041-366ee25cda28\\\", \\\"subtext\\\": \\\"b8dc3acc-8df9-4859-a8fe-ee99d56fae85\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 293, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"GSK3196165 150 mg weekly+csDMARD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"093d54a0-fa94-43be-9ef9-7e2457534a23\\\", \\\"childbox\\\": \\\"3a4ae74a-7fd4-4756-9bf0-08ebd3b3c468\\\", \\\"subtext\\\": \\\"b49187e9-0c6c-4df0-8b38-ad10ef450062\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 294, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Option to transition to\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"361aa20f-726c-49b3-bfd6-48722556615e\\\", \\\"childbox\\\": \\\"86f3afff-43cd-4d37-9b4f-b356af178b84\\\", \\\"subtext\\\": \\\"ee38834b-2384-4b9c-8b30-4f417d46b24e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 295, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"LTE study 209564 or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"80735e46-4563-4dff-97de-b36ca217e547\\\", \\\"childbox\\\": \\\"e11fab1e-14cd-4233-9a3f-0c5e823d627e\\\", \\\"subtext\\\": \\\"0c706002-ef78-44a8-9454-f9db8ade3041\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 296, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"exit after safety\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3ca37cf7-1756-4d3e-9281-86601177150a\\\", \\\"childbox\\\": \\\"0b0f1607-48c6-4803-a88f-05d4c090a970\\\", \\\"subtext\\\": \\\"a4e83f34-cf50-40b3-a2b8-3d0585abeed2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 297, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"follow-up at Week 34.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e3030ee9-05da-4514-9f80-83b0bd606110\\\", \\\"childbox\\\": \\\"9abc5f7a-4223-4e82-bb2c-3434b00fc71b\\\", \\\"subtext\\\": \\\"303c55a6-e845-4cdd-9daa-9c8e7eff45f1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 298, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W 0\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5aab29ef-032c-4569-bcdd-149e7b76c22d\\\", \\\"childbox\\\": \\\"5fac442e-c50a-4ced-a3d0-dd4d19420504\\\", \\\"subtext\\\": \\\"b6b32399-f8ff-4b5a-8c31-33989676311a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 299, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Screening\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dec790e0-3082-48a1-895f-73b6e3f16b72\\\", \\\"childbox\\\": \\\"29af2434-e2d2-49af-9d25-8c04f4c7d62b\\\", \\\"subtext\\\": \\\"b3209cd3-0b41-4cf4-9171-9a40d3816f24\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 300, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"W-6\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"00e8c63a-1d5c-465b-b2a8-31a4b46ebfd3\\\", \\\"childbox\\\": \\\"5005bf2a-f6c6-4020-91a4-27ad0dd4dcf2\\\", \\\"subtext\\\": \\\"88312cd6-c0ed-4113-aece-91db748c055e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 301, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cebaa0ba-b566-4f4d-8408-39267b41ecf0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 302, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c6cd44f5-ad99-480c-bb07-65d8e6a40112\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 303, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a7979dc5-1d7a-4bd1-839e-b2a0ae50d3b2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 304, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"83356a4e-dada-453d-b391-eb8ac7525ffb\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 305, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c8d6d860-e563-4f95-93c0-634de35445bd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 306, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a0068494-2b0a-4b9a-a3ac-0eea12d2573b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 307, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7d6651d3-52aa-4d83-a821-f0c807ef07ef\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 308, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0b58551e-20fa-43f8-a725-b078435c0caf\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 309, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"742e7d71-ec69-4069-9700-6c701b722cb5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 310, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e9827523-4534-441a-a884-708b144389dd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 311, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2de85ed2-f4f7-4789-9599-e3dafab9c92c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 312, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b86b30ab-70ec-4f50-a362-d2481e20b799\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 313, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1dce072e-fcdb-4360-ab42-1bc058ebcd6a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 314, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64e55ab8-e699-4eec-bc18-15c9513b4b04\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 315, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9ed0894e-f6c1-4e84-920c-6fcd14fee381\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 316, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"04a02993-8b00-4325-a578-a42bc72a2e03\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 317, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2e1aaf7-8542-467e-8754-9e2677c1efdd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 318, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fce1ea29-fa97-4a3c-9722-8c463261a43c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 319, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ac5296ca-5f18-49ea-b496-d418ef138714\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 320, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4b0da7de-f357-4e1a-b3e0-9566e7d3a254\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 321, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9100bb32-4203-4541-b8b7-5c2c33c57a02\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 322, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"df74ffb0-92ec-4a12-a8d8-6a25e70fa8f1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 323, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"51481050-1073-442b-b980-ece922a507e6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 324, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e771581a-9dcd-4fe5-8da6-75771c0a863b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 325, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5ae979cc-0690-431c-9ee3-62383e31ef5d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 326, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f993b19e-38bf-4880-abcd-58c4e3e5f08f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 327, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8922a86c-1b25-4e82-a678-19658ce01b23\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 328, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ede1976c-7e6e-4cc8-a85b-c57e980327fc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 329, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"27143edc-90e5-4959-b39b-4336dc6eaf2d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 330, \\\"\\\"], [\\\"2\\\", \\\"Schema\\\", \\\"text\\\", \\\"Placebo to active\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b5439f42-c036-4e0d-99b1-4abd784f65d0\\\", \\\"childbox\\\": \\\"e53796c8-afe0-46ee-9d45-3f23f45dd27a\\\", \\\"subtext\\\": \\\"6c31de5f-3633-46b3-99f4-4bfad84762a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schema\\\", \\\"1.2.\\\", \\\"2\\\", 331, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"header\\\", \\\"1.3. Schedule of Activities (SoA)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bc8ce446-f562-47bc-97ac-6190a90da26c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 332, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"59e2b14d-3faa-4a82-8de8-3591f897279c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 333, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"X\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b00ca882-b0d5-4c28-9b99-ba5ec0fd43c8\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 334, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"See Section 8 for further details of study procedures listed in the SoA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b728c08b-8efc-457f-a1fa-496a5d0a523d\\\", \\\"childbox\\\": \\\"92c56e1a-5018-443e-afa4-863201e5d0e3\\\", \\\"subtext\\\": \\\"b3c491e4-243a-4271-a63b-c1b6eaade5c8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 335, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"Order of Assessments:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d1a18f06-fb73-4696-b2dd-d0a792823925\\\", \\\"childbox\\\": \\\"f92366c1-a22c-4a48-b12f-3b94d10af3aa\\\", \\\"subtext\\\": \\\"4f7e9955-514f-4f77-9d77-244fc5a76648\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 336, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\\u2022 PROs should be completed first, before any other assessments, procedures or consultations, to avoid influencing participants\\\\u2019 perception.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4af53a50-9a34-4363-8d02-b674b62ea98f\\\", \\\"childbox\\\": \\\"e76a577e-a263-41b7-be49-dd63c8bf4194\\\", \\\"subtext\\\": \\\"53014db9-c2d7-4d6e-b7ff-edd77c61b740\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 337, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\\u2022 Where possible, joint counts should follow PRO completion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"de42c32d-e1f3-475e-84e5-417a458dd204\\\", \\\"childbox\\\": \\\"0ed1645c-3a5d-48af-bb10-fbddf4720d2b\\\", \\\"subtext\\\": \\\"e49bd042-7370-49a0-834f-18a6a9f9d89d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 338, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"PhGA should then take place, followed by other assessments (including safety), ECGs, vital signs and blood draws, before dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"de42c32d-e1f3-475e-84e5-417a458dd204\\\", \\\"childbox\\\": \\\"baf10212-f50d-42d1-b0c4-3d92fe875803\\\", \\\"subtext\\\": \\\"89efa994-f451-45a6-8430-3a155aaad1ff\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 339, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\\u2022 PK sampling and blood draws\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d8250fa5-d6f7-4d9e-8915-4ff89f9714fd\\\", \\\"childbox\\\": \\\"b4179a79-7ee2-498f-8056-9112854db0bc\\\", \\\"subtext\\\": \\\"24287e78-735e-4b3d-9b45-b57e84a7a902\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 340, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"must\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d8250fa5-d6f7-4d9e-8915-4ff89f9714fd\\\", \\\"childbox\\\": \\\"b4179a79-7ee2-498f-8056-9112854db0bc\\\", \\\"subtext\\\": \\\"9a7ba48b-251f-4f7c-9a54-26169c6eeeac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 341, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"always take place before dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d8250fa5-d6f7-4d9e-8915-4ff89f9714fd\\\", \\\"childbox\\\": \\\"b4179a79-7ee2-498f-8056-9112854db0bc\\\", \\\"subtext\\\": \\\"e060fdc9-9f31-4f8e-92f9-418a8f17bc39\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 342, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"Study Dosing and Visit Schedule:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f816bebc-0d82-4c36-9724-04cf98092687\\\", \\\"childbox\\\": \\\"59761b8b-cc9a-4c0b-87b1-856e8fd9b29d\\\", \\\"subtext\\\": \\\"904e9104-c92b-4b06-927e-1e1c20fc4c10\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 343, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\\u2022 Study SC injection should be administered weekly, on the same day each week.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"19265a47-3c32-4915-a095-11ceb9c4ecda\\\", \\\"childbox\\\": \\\"10507718-58aa-40f3-8c90-82a049cee99b\\\", \\\"subtext\\\": \\\"d6d1ee33-73e1-481a-b09a-186651dc37a8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 344, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\\u2022 A window of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ecaebfc1-0ffd-48be-81b9-dfe163ce57e8\\\", \\\"childbox\\\": \\\"b6991c8c-0755-4d05-81b3-b7d66d9ff066\\\", \\\"subtext\\\": \\\"40f86d61-f3a5-4ebc-b766-9de984fdab45\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 345, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ecaebfc1-0ffd-48be-81b9-dfe163ce57e8\\\", \\\"childbox\\\": \\\"b6991c8c-0755-4d05-81b3-b7d66d9ff066\\\", \\\"subtext\\\": \\\"981d9240-6984-4222-9b28-f2399e91eb96\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 346, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"2 days is acceptable for the SC injection (minimum gap of 5 days between each dose, for no more than 2 consecutive doses).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ecaebfc1-0ffd-48be-81b9-dfe163ce57e8\\\", \\\"childbox\\\": \\\"b6991c8c-0755-4d05-81b3-b7d66d9ff066\\\", \\\"subtext\\\": \\\"3dee1d70-389d-4914-a59b-583ab5e04d47\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 347, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"Participants should return to their 7 day dosing schedule as soon as possible thereafter.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ecaebfc1-0ffd-48be-81b9-dfe163ce57e8\\\", \\\"childbox\\\": \\\"54c2009f-12f0-443a-94f5-317a64e4a1da\\\", \\\"subtext\\\": \\\"3dee1d70-389d-4914-a59b-583ab5e04d47\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 348, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"See Section 6.1 for further information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ecaebfc1-0ffd-48be-81b9-dfe163ce57e8\\\", \\\"childbox\\\": \\\"0408bd14-b4a5-47a7-bad1-0199102d7bff\\\", \\\"subtext\\\": \\\"e1faa371-3839-4809-a30c-12b84514453d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 349, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\\u2022 Where possible, assessment visits should be scheduled to coincide with the weekly administration of study intervention,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ca936187-c712-4d37-af0c-5758dde55a2e\\\", \\\"childbox\\\": \\\"68598af3-27cc-491d-9b6a-db99c873e6ef\\\", \\\"subtext\\\": \\\"e2c4bee0-0e3f-4c83-81fe-94a73a0332cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 350, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"the injection will then be performed at the site, after completion of PK sampling\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ca936187-c712-4d37-af0c-5758dde55a2e\\\", \\\"childbox\\\": \\\"68598af3-27cc-491d-9b6a-db99c873e6ef\\\", \\\"subtext\\\": \\\"d69bc48c-fb6c-4cad-9fb7-fa2eade73aa1\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 351, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ca936187-c712-4d37-af0c-5758dde55a2e\\\", \\\"childbox\\\": \\\"68598af3-27cc-491d-9b6a-db99c873e6ef\\\", \\\"subtext\\\": \\\"1de6564e-77a4-401c-8266-d89ed1be8270\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 352, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\\u2022 Dosing must always be performed by an unblinded administrator on weeks 0, 2, 4,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22b07654-4851-4b7a-8a0c-ba31542ffbeb\\\", \\\"childbox\\\": \\\"830a271f-a060-48b3-98e2-943e4fb25153\\\", \\\"subtext\\\": \\\"da08c234-f0fa-4213-b4e9-9b3bcdb59e76\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 353, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"6, 8, 10, 12, 14, 16, 18, 20, 22, even if PFS are available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fa2055bf-fcd9-4452-9771-316c9c4bb633\\\", \\\"childbox\\\": \\\"fc0b2f06-9f6d-4b3f-b164-b142cbb6c912\\\", \\\"subtext\\\": \\\"3be8fc6e-00d8-4f89-9376-45d27b96e5ca\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 354, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"On Weeks 0, 1, 12 and 13, participants must be dosed\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fa2055bf-fcd9-4452-9771-316c9c4bb633\\\", \\\"childbox\\\": \\\"baa61131-3fb1-4578-9252-b47e4b3d2be0\\\", \\\"subtext\\\": \\\"3be8fc6e-00d8-4f89-9376-45d27b96e5ca\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 355, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"at site\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fa2055bf-fcd9-4452-9771-316c9c4bb633\\\", \\\"childbox\\\": \\\"baa61131-3fb1-4578-9252-b47e4b3d2be0\\\", \\\"subtext\\\": \\\"8c1f72f0-02fd-4eaa-adcd-8f7a423f723d\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 356, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"(after completion of study assessments) and monitored for 1 hour post dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fa2055bf-fcd9-4452-9771-316c9c4bb633\\\", \\\"childbox\\\": \\\"baa61131-3fb1-4578-9252-b47e4b3d2be0\\\", \\\"subtext\\\": \\\"96eed665-3881-4d85-a686-a20b41cacb98\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 357, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"SoA \\\\u2013 Screening Period\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"33d50a29-d44b-4df5-94a4-c9980c011c58\\\", \\\"childbox\\\": \\\"ae29af58-fee8-4da9-8775-c17f3047bbdf\\\", \\\"subtext\\\": \\\"c2766039-2793-4e59-a9c0-03d1816951aa\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 358, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4827b349-47bc-412b-9d64-bb538cac8600\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 359, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"63fb7934-d54d-4b21-8f01-15ec6e32150e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 360, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cc921010-7d22-47a7-8120-c3e68c0b6034\\\", \\\"childbox\\\": \\\"afe8446a-8489-4002-a091-df0114a44f4a\\\", \\\"subtext\\\": \\\"2750e900-9bc5-461b-b617-c82dc6868919\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 361, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"84bccc6c-b781-49c8-b60a-b9dc5ec8d9b2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 362, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5c0fbe9c-f57b-42e2-afd9-f178ed1c36bd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 363, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b649d3d3-4032-40fc-881b-54b2f3e2aa55\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 364, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6c081b54-bb87-49b3-9f4f-f5bf770f4cc8\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 365, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2998ead7-cae5-4658-8d43-064df014babf\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 366, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ca452486-514e-4d75-9acf-3916481c3c93\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 367, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2caa6fb0-b458-446c-bbfc-25c7be0e6ea7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 368, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b8c1321f-e144-46f6-8f6b-a8a8b2b2776f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 369, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"da85d7eb-a834-405a-904e-d5fe06248a19\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 370, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"611ed7cb-22d2-4bbf-bfcd-c2371aa563f9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 371, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"820db14e-fcf2-4309-944d-a3e5bf5a85d6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 372, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6bca9294-0c39-409a-8806-bee23a6466a4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 373, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"49b45a3e-96bf-46af-ac8c-27ef193d96fc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 374, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0e008d0d-9ee1-46a1-9dbf-e60dcaeb2557\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 375, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fec857e5-ee24-4041-8666-968a01b01973\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 376, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a4b0408e-9607-44c4-b6c1-894f92c6250d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 377, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2d9a7dd-8a86-4406-b99f-97a6b0e3fe71\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 378, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"99e6e0f4-6926-4c19-94af-c0aca205871e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 379, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"de146e47-d8ef-4163-8a27-4b583617402e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 380, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bbd5152e-e36c-4e74-92e6-cb3246df39e4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 381, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"03c17b9d-baac-493d-a66b-36f7241887b1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 382, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7978fdf8-8cd6-44a8-bb67-97bdcf7fcf4e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 383, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"16a70769-c9c6-4dda-a87e-f7996eac672f\\\", \\\"childbox\\\": \\\"19c49ff2-753b-46e3-ba7b-fd11e4b50ec2\\\", \\\"subtext\\\": \\\"c481057f-3c83-4080-ac95-ee1c1cf9046e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 384, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d0cd7145-827f-46e9-b944-51d32c3139f2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 385, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cba91004-2f98-48dd-9c36-d077e7b797e0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 386, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"2018N385816_00\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c35be4a5-cd97-4b79-bf9e-b8cb34725b2c\\\", \\\"childbox\\\": \\\"e9e21fba-4aed-4f71-bcc8-efd90debe464\\\", \\\"subtext\\\": \\\"808b4897-ca7a-4350-ad76-5dccd33614db\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 387, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c35be4a5-cd97-4b79-bf9e-b8cb34725b2c\\\", \\\"childbox\\\": \\\"2d2bb94b-3026-4653-a891-f447eaa97a45\\\", \\\"subtext\\\": \\\"4d4c0c1c-aa35-457e-93cc-23c071601717\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 388, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"CONFIDENTIAL\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c35be4a5-cd97-4b79-bf9e-b8cb34725b2c\\\", \\\"childbox\\\": \\\"4ebe1b51-0121-4a28-ae94-668bb4c7bc99\\\", \\\"subtext\\\": \\\"78d3bc1a-6677-44c7-9961-a4a73f5a6dfa\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 389, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c35be4a5-cd97-4b79-bf9e-b8cb34725b2c\\\", \\\"childbox\\\": \\\"7b12d00b-ad02-42dd-b93b-a0f8ef4879cc\\\", \\\"subtext\\\": \\\"ebc727a3-3c1a-402c-a545-e5947ad59757\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 390, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"202018\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c35be4a5-cd97-4b79-bf9e-b8cb34725b2c\\\", \\\"childbox\\\": \\\"97e4e087-e364-4cbf-aec4-5a43f5b2b2c8\\\", \\\"subtext\\\": \\\"7925a4aa-afc1-461f-ba15-042fefcc451e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 391, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"SoA \\\\u2013 Treatment Period\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dd3697fe-2f16-4582-b331-f8345749744d\\\", \\\"childbox\\\": \\\"0db5bad5-05f7-47c3-b0c6-ffa9ae3037da\\\", \\\"subtext\\\": \\\"c6f8fa1b-7ad4-49ea-beb2-2650c4abd9b8\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 392, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b85cdf72-c8fa-453b-ad81-3ab35c32f4f3\\\", \\\"childbox\\\": \\\"df672cf5-8dad-401f-90b4-e1e9b9095413\\\", \\\"subtext\\\": \\\"0ffd6e98-135d-4dd8-9475-74bb7da6e23b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 393, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"123d921c-f2bb-4d5e-90ad-55c8df38e74e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 394, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"SoA \\\\u2013 Safety follow-up visit\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"63ee5f7b-1ad9-45de-b35f-3b5242a513d5\\\", \\\"childbox\\\": \\\"c3c5adff-3e6b-42eb-89af-85f2632cf52c\\\", \\\"subtext\\\": \\\"e59335a6-f285-49cc-8d2c-b017f9e939cb\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 395, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8b0a7b57-1f61-40b4-83a2-c4d5a642880e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 396, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"49a76de9-9208-4c96-98c6-0889f1a01422\\\", \\\"childbox\\\": \\\"dd1aa5d0-3d48-47ce-b4d6-17cd3d96ab2c\\\", \\\"subtext\\\": \\\"09ba798e-d747-4091-96ea-3d917790f352\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 397, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1eccfa5e-f8b2-4dd7-a68d-c1f86ff5dec7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 398, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d7fce391-a7c6-41f0-a00b-31fadcb5cff3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 399, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7869234c-e341-4e13-af00-2e8fac6be9aa\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 400, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4e961d57-e883-4ff7-88fa-1e83b66e4841\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 401, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"082237b8-2106-476e-98b3-d43f26cf4280\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 402, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bc20d3b2-a940-4ca5-b1ec-5cb2f707bb8d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 403, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6b73bc0a-61fe-48a1-917c-ebe180a6492c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 404, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1c85ea80-30f0-4773-b824-4c0fb678a9e6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 405, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"Assessments for Early withdrawal from study\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a16e61fb-8c69-4b15-aebe-4017f2af49dc\\\", \\\"childbox\\\": \\\"860de8c7-7ceb-4fd5-a8cc-dfee0fd79c8e\\\", \\\"subtext\\\": \\\"b534c997-1c51-44f1-a84f-4627b241c364\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 406, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"Follow Week 24 procedures at the time of withdrawal, or within 1 week, then schedule a safety follow-up visit 12 weeks post last dose of study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a5930a7-99c7-48de-88c7-51ed97edd7f4\\\", \\\"childbox\\\": \\\"e548a8ba-dc9b-4f46-a763-5dc408337c6b\\\", \\\"subtext\\\": \\\"7dcb1e85-e5a6-4183-ba60-92e56f7a28b3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 407, \\\"\\\"], [\\\"2\\\", \\\"Schedule of Activities (SoA)\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a5930a7-99c7-48de-88c7-51ed97edd7f4\\\", \\\"childbox\\\": \\\"ee53b649-ed12-4a82-b89b-672313fc6d29\\\", \\\"subtext\\\": \\\"424c8085-59eb-45e8-b0c7-14b1543ac94c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Protocol Summary\\\", \\\"Schedule of Activities (SoA)\\\", \\\"1.3.\\\", \\\"2\\\", 408, \\\"\\\"], [\\\"1\\\", \\\"Introduction\\\", \\\"header\\\", \\\"2. INTRODUCTION\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e2fe3da8-d5da-4cc5-8515-bdb8040b1b42\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"INTRODUCTION\\\", \\\"2.\\\", \\\"1\\\", 409, \\\"\\\"], [\\\"1\\\", \\\"Introduction\\\", \\\"text\\\", \\\"GSK3196165 is a novel human monoclonal anti-granulocyte-macrophage colony stimulating factor (GM-CSF) antibody that is being developed for once-weekly treatment of rheumatoid arthritis (RA).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 39, \\\"end_idx\\\": 91, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"anti-granulocyte-macrophage colony stimulating factor\\\"}, {\\\"start_idx\\\": 94, \\\"end_idx\\\": 99, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b8df3bd5-5794-4959-bd5d-4ac0b83c9c9a\\\", \\\"childbox\\\": \\\"2a3f3c59-1032-4b3f-9a86-fcf2a0425b36\\\", \\\"subtext\\\": \\\"bfe52e38-b89f-4e32-9c1d-2056899e3e12\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"INTRODUCTION\\\", \\\"2.\\\", \\\"1\\\", 410, \\\"\\\"], [\\\"2\\\", \\\"Study Rationale\\\", \\\"header\\\", \\\"2.1. Study Rationale\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f6b0bf07-9b53-4eb1-a30e-f535f3ff71bd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Rationale\\\", \\\"2.1.\\\", \\\"2\\\", 411, \\\"\\\"], [\\\"2\\\", \\\"Study Rationale\\\", \\\"text\\\", \\\"The aim of this study is to determine the efficacy and safety of GSK3196165, in combination with conventional synthetic disease-modifying antirheumatic drug(s) (csDMARD)(s), for the treatment of adults with moderately to severely active RA who have had an inadequate response to biologic DMARD(s) (bDMARD)(s) and/or JAK inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 65, \\\"end_idx\\\": 74, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 279, \\\"end_idx\\\": 295, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"biologic DMARD(s)\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"40c7ee8d-2c6a-4362-bb0a-1ab82097de2c\\\", \\\"childbox\\\": \\\"b38f183c-d31d-4f28-a466-1daf9da37b37\\\", \\\"subtext\\\": \\\"c7ad5d4c-d8d7-45bf-a452-d45216be9ad7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Rationale\\\", \\\"2.1.\\\", \\\"2\\\", 412, \\\"\\\"], [\\\"2\\\", \\\"Study Rationale\\\", \\\"text\\\", \\\"Two doses of GSK3196165 (90 mg subcutaneous [SC] weekly and 150 mg SC weekly) will be compared with placebo (to Week 12) and with sarilumab 200 mg SC every other week, an inhibitor of IL-6 that is approved for the treatment of adults with moderately to severely active RA who have had an inadequate response to bDMARD(s) and/or JAK inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 13, \\\"end_idx\\\": 22, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 130, \\\"end_idx\\\": 138, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 184, \\\"end_idx\\\": 187, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"IL-6\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"40c7ee8d-2c6a-4362-bb0a-1ab82097de2c\\\", \\\"childbox\\\": \\\"1a11c61d-1b1f-4517-95b8-faa36afa1724\\\", \\\"subtext\\\": \\\"5b3d1d32-cc3e-4699-9266-f9f9a61c3b10\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Rationale\\\", \\\"2.1.\\\", \\\"2\\\", 413, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"header\\\", \\\"2.2. Background\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"290d66e7-eb2f-47f0-86c3-cd288a409463\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 414, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"RA is a chronic, systemic inflammatory autoimmune disease, characterised by a symmetrical polyarthritis that is associated with substantial disability and morbidity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2d8bf35d-af76-48af-920a-bea7987cb437\\\", \\\"childbox\\\": \\\"19fb6458-dd47-4f27-be68-833a8014a2b3\\\", \\\"subtext\\\": \\\"b37344ca-cac5-4d53-8295-caf101f37470\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 415, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"RA affects approximately 0.5-1.0% of the worldwide population, primarily women, with a peak incidence of onset between 40 and 60 years of age.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2d8bf35d-af76-48af-920a-bea7987cb437\\\", \\\"childbox\\\": \\\"8c93f804-0d47-4330-aacb-e9acb99982aa\\\", \\\"subtext\\\": \\\"b37344ca-cac5-4d53-8295-caf101f37470\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 416, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"A substantial proportion of patients either fail to respond, or have inadequate response, to currently available RA therapies [Gaujoux-Viala, 2014; Nam, 2014].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"75647b09-6362-44a4-ab79-50d9cef2695b\\\", \\\"childbox\\\": \\\"a83d70e9-4974-4dc9-8a8b-69b215f0cb5c\\\", \\\"subtext\\\": \\\"7671de3a-3f47-4abc-8428-c5775f5157a2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 417, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Therefore, there is still a medical need for more effective treatments for RA with alternative mechanisms of action.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"75647b09-6362-44a4-ab79-50d9cef2695b\\\", \\\"childbox\\\": \\\"74564d9c-f3ea-4c93-b18a-99356b14e9c5\\\", \\\"subtext\\\": \\\"c6ba024a-8fb1-4047-91d6-754e8168dad6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 418, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"GM-CSF is a pro-inflammatory cytokine that regulates the functions of myeloid lineage cells that are considered to play key roles in the pathology of RA including macrophages and neutrophils [Avci, 2016; Hamilton, 2016; Wicks, 2016].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 5, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4f6b4ed8-9462-4bef-ad28-50d20e5bece2\\\", \\\"childbox\\\": \\\"698ade5e-7ce9-4592-9e79-fd1fedcda61a\\\", \\\"subtext\\\": \\\"27bd9f9b-e6a8-4207-be8f-9043f598124f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 419, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Increased levels of GMCSF are found in the synovial fluid from RA patients and its receptor is expressed in synovial tissue [Avci, 2016; Wicks, 2016].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4f6b4ed8-9462-4bef-ad28-50d20e5bece2\\\", \\\"childbox\\\": \\\"16bc7c39-61c7-47fa-9e17-c83907c1d633\\\", \\\"subtext\\\": \\\"8df7b499-ab55-4bfe-a8ba-0dfa2fb4742f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 420, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Preclinical studies using various inflammatory arthritis models have shown that GM-CSF removal or neutralisation improved pain, function and joint histologic structure [Cook, 2001; Plater-Zyberk, 2007; Cook, 2013; Cook 2018a] and inhibited matrix metalloproteinase (MMP)-mediated cartilage degradation in experimental arthritis induced by joint instability [Cook, 2012].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 80, \\\"end_idx\\\": 85, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4f6b4ed8-9462-4bef-ad28-50d20e5bece2\\\", \\\"childbox\\\": \\\"6a380d07-0849-47e2-b389-2c841d0f2642\\\", \\\"subtext\\\": \\\"1db1b91b-d1f5-486e-9ef1-c26f897e1fbc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 421, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"GSK3196165 is a high-affinity recombinant human monoclonal antibody (mAb) that binds specifically to human GM-CSF and prevents its interaction with its cell surface receptor [Steidl, 2008].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 48, \\\"end_idx\\\": 66, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"monoclonal antibody\\\"}, {\\\"start_idx\\\": 69, \\\"end_idx\\\": 71, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"mAb\\\"}, {\\\"start_idx\\\": 107, \\\"end_idx\\\": 112, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"02a8ec4c-7c07-4434-a5a3-67ae24d53509\\\", \\\"childbox\\\": \\\"f6761dfb-ec72-4ac5-8dba-67f50fde00aa\\\", \\\"subtext\\\": \\\"859c8d66-40bb-4d21-aaaa-d973df6293e6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 422, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Clinical studies in patients with RA have shown that GSK3196165 [Behrens, 2015] and mavrilimumab (an anti-GM-CSF receptor\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 53, \\\"end_idx\\\": 62, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 84, \\\"end_idx\\\": 95, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"mavrilimumab\\\"}, {\\\"start_idx\\\": 101, \\\"end_idx\\\": 111, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"anti-GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"02a8ec4c-7c07-4434-a5a3-67ae24d53509\\\", \\\"childbox\\\": \\\"14c3d970-7f10-4feb-b72c-b5ebb96b6e7d\\\", \\\"subtext\\\": \\\"5d07e3a3-2e94-4120-8c4a-5e8c401c9c0f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 423, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"02a8ec4c-7c07-4434-a5a3-67ae24d53509\\\", \\\"childbox\\\": \\\"14c3d970-7f10-4feb-b72c-b5ebb96b6e7d\\\", \\\"subtext\\\": \\\"56deaaf3-8ea4-4a2b-9d35-a420f6596f24\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 424, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"-subunit antibody) [Burmester, 2017; Burmester, 2018; Cook, 2018b] are able to reduce RA disease activity and pain.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"02a8ec4c-7c07-4434-a5a3-67ae24d53509\\\", \\\"childbox\\\": \\\"14c3d970-7f10-4feb-b72c-b5ebb96b6e7d\\\", \\\"subtext\\\": \\\"6f4c740b-82f6-4f61-904b-d1ff15358ba2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 425, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"A Phase IIb dose-ranging study of GSK3196165 with methotrexate (MTX) treatment, in patients with RA and an inadequate response to MTX, has also been completed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 34, \\\"end_idx\\\": 43, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 50, \\\"end_idx\\\": 61, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"methotrexate\\\"}, {\\\"start_idx\\\": 64, \\\"end_idx\\\": 66, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"MTX\\\"}, {\\\"start_idx\\\": 130, \\\"end_idx\\\": 132, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"MTX\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"02a8ec4c-7c07-4434-a5a3-67ae24d53509\\\", \\\"childbox\\\": \\\"af4dd8e8-2fc8-4500-8d4a-5cefc306941e\\\", \\\"subtext\\\": \\\"c3adbdf6-a6d3-49e9-817d-2c641dd00eef\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 426, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"In the BAROQUE Phase IIb study (201755), treatment with GSK3196165 in combination with MTX demonstrated efficacy in the treatment of active RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 56, \\\"end_idx\\\": 65, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 87, \\\"end_idx\\\": 89, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"MTX\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4aaa9f25-14d8-4855-b804-b361dfd67b66\\\", \\\"childbox\\\": \\\"03d9eaba-35b8-47fd-9da3-5d65ff639098\\\", \\\"subtext\\\": \\\"06fbde98-3402-4b9c-83f2-3c9c985a70ce\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 427, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"At Week 12 of the study, all doses above 22.5 mg resulted in a significant reduction in DAS28(CRP) (Disease Activity Score including 28 different joints) and significantly higher ACR20 (20% improvement in American College of Rheumatology criteria) response rates in comparison to placebo.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 205, \\\"end_idx\\\": 236, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"American College of Rheumatology\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4aaa9f25-14d8-4855-b804-b361dfd67b66\\\", \\\"childbox\\\": \\\"1ba6e49f-df40-47ac-a4dc-755a2d9f599a\\\", \\\"subtext\\\": \\\"6bfc2008-2bb1-4dc5-a6b6-54ba561242e7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 428, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Substantial improvements in tender and swollen joint counts, a large effect in CDAI (Clinical Disease Activity Index) and rapid improvements in pain were also identified.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4aaa9f25-14d8-4855-b804-b361dfd67b66\\\", \\\"childbox\\\": \\\"76163ee0-26be-4448-832b-04196a78706a\\\", \\\"subtext\\\": \\\"d4fb4640-2e3b-493a-b428-27d01ac1a91e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 429, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The overall adverse event (AE) and serious adverse event (SAE) profile was unremarkable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4aaa9f25-14d8-4855-b804-b361dfd67b66\\\", \\\"childbox\\\": \\\"f1062e9a-a7f0-45ec-80ef-4202d28f0673\\\", \\\"subtext\\\": \\\"d4fb4640-2e3b-493a-b428-27d01ac1a91e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 430, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The majority of AEs were of mild or moderate intensity and there were no deaths, malignancies or venous thromboembolisms during the trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4aaa9f25-14d8-4855-b804-b361dfd67b66\\\", \\\"childbox\\\": \\\"7484b68c-9e36-4614-9cdf-bd6fca9d9a9f\\\", \\\"subtext\\\": \\\"b930512f-ce18-4840-81f3-e5a781d60d6a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 431, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Additional information is provided in the GSK3196165 Investigator\\\\u2019s Brochure (IB) [GSK Document Number 2014N190256_02].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 42, \\\"end_idx\\\": 44, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 83, \\\"end_idx\\\": 85, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 42, \\\"end_idx\\\": 51, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 42, \\\"end_idx\\\": 44, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 83, \\\"end_idx\\\": 85, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4aaa9f25-14d8-4855-b804-b361dfd67b66\\\", \\\"childbox\\\": \\\"9c178ac8-cd3d-413c-b3ec-1517d73ce8fc\\\", \\\"subtext\\\": \\\"b930512f-ce18-4840-81f3-e5a781d60d6a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 432, \\\"\\\"], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"It is therefore hypothesised that GSK3196165, in combination with csDMARD(s), may provide clinical benefit to patients with RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 34, \\\"end_idx\\\": 43, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4aaa9f25-14d8-4855-b804-b361dfd67b66\\\", \\\"childbox\\\": \\\"3c536ea8-4153-4fe7-a21d-b9ee7e95d19a\\\", \\\"subtext\\\": \\\"f3c877a9-d1e3-4668-817c-80498e113801\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"2.2.\\\", \\\"2\\\", 433, \\\"\\\"], [\\\"2\\\", \\\"Benefit/Risk Assessment\\\", \\\"header\\\", \\\"2.3. Benefit/Risk Assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"39b5d341-fa81-424d-a796-84850bd7f76d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit/Risk Assessment\\\", \\\"2.3.\\\", \\\"2\\\", 434, \\\"\\\"], [\\\"2\\\", \\\"Benefit/Risk Assessment\\\", \\\"text\\\", \\\"More detailed information about the known and expected benefits and risks and reasonably expected adverse events of GSK3196165 may be found in the IB.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 116, \\\"end_idx\\\": 125, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"60ee42c2-c2ac-422e-a633-68173df93c98\\\", \\\"childbox\\\": \\\"225f4072-3978-4c7b-8094-8751083a586b\\\", \\\"subtext\\\": \\\"d9d95d85-ee08-4c44-a528-8745e5ecb2dc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit/Risk Assessment\\\", \\\"2.3.\\\", \\\"2\\\", 435, \\\"\\\"], [\\\"2\\\", \\\"Benefit/Risk Assessment\\\", \\\"text\\\", \\\"The risks associated with the active comparator sarilumab can be found in the approved product label or local prescribing information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 48, \\\"end_idx\\\": 56, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"60ee42c2-c2ac-422e-a633-68173df93c98\\\", \\\"childbox\\\": \\\"1112eb2a-7c68-4513-92c8-3651f2533c3c\\\", \\\"subtext\\\": \\\"d865165a-6670-4596-8142-fd799464ca02\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit/Risk Assessment\\\", \\\"2.3.\\\", \\\"2\\\", 436, \\\"\\\"], [\\\"2\\\", \\\"Benefit/Risk Assessment\\\", \\\"text\\\", \\\"The potential risk assessment and mitigation strategy for the administration of GSK3196165 in this protocol is outlined below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 80, \\\"end_idx\\\": 89, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e88db02d-4e6f-4595-8627-8c29ec2ec4b2\\\", \\\"childbox\\\": \\\"50e82d3a-7520-47ce-8978-10383f1bf253\\\", \\\"subtext\\\": \\\"01535e54-ca2d-4270-ac9e-0156ba150b37\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit/Risk Assessment\\\", \\\"2.3.\\\", \\\"2\\\", 437, \\\"\\\"], [\\\"2\\\", \\\"Benefit/Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0cf5898f-c032-4890-b49d-fcd67191f2e9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Benefit/Risk Assessment\\\", \\\"2.3.\\\", \\\"2\\\", 438, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"header\\\", \\\"2.3.1. Risk Assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5c59abac-12ae-4015-8636-ce8b91a2d33a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 439, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2ad8957c-5d27-4842-b54c-312e3ee26bca\\\", \\\"childbox\\\": \\\"d4e51c24-a4d6-4fbf-839e-396dc46ca970\\\", \\\"subtext\\\": \\\"8bdff93d-b1fa-4cd8-8d6b-edcd66f4f429\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 440, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"735e7128-ba5e-4c12-a6d4-36af60f5b544\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 441, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c73e4392-e460-4350-874f-07d39513bfa7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 442, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ede772f5-e47a-4e83-bbbe-ac3dc9b4e3ff\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 443, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8187e2c3-ed3d-49e3-87c0-a35ee4e5dbf5\\\", \\\"childbox\\\": \\\"fb897fd5-c31a-4354-823e-02c829a760ac\\\", \\\"subtext\\\": \\\"13816bff-6989-41c1-8ed3-e3240ccf6788\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 444, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"50661c6e-bcad-404a-8b51-35ccfe81a927\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 445, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"673f99e1-c237-4b0d-b0a8-f202c82c602b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 446, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e5a5e6dd-b40b-4476-b666-567007d00e00\\\", \\\"childbox\\\": \\\"88590a0e-791f-4390-bade-586632ae819f\\\", \\\"subtext\\\": \\\"68bfd0e2-f95b-45c8-910d-357ab47e16c6\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 447, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"612b0af9-dd16-4cb0-a130-fc92db0f361c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 448, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"60379985-0a2c-4cac-9c45-db4c035b570b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 449, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bd7c1356-86b0-40b0-bed0-f43cd1dd49b6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 450, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e84edb41-5a12-4ac2-b791-1b34a33d8a01\\\", \\\"childbox\\\": \\\"fb41416b-1d97-4b80-ae14-cb9211cd2cf4\\\", \\\"subtext\\\": \\\"5208c599-1e4b-4ac8-9364-050cf6e6214c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 451, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fcd9abba-674f-4a83-ad07-d4475a41128f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 452, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9eaac855-7c17-4f1e-90a4-fe9b684a6a3a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 453, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5019b751-6f3b-44c0-91f7-e35cfd4ac36a\\\", \\\"childbox\\\": \\\"4313e550-895a-4f6e-a59e-1d7f3637d1b3\\\", \\\"subtext\\\": \\\"a5f9d863-2b47-42d2-84c7-2528278a433d\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 454, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5ccc7942-d0c1-480b-a328-1da71322e9ee\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 455, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2c371395-26bc-4b1d-a0e2-ddb3c3d761af\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 456, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e8e8f7c1-acc0-4a0f-8b7e-532e59452825\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 457, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c434708-4ea2-428d-ad01-1929cbf41ab7\\\", \\\"childbox\\\": \\\"9a9c093b-afe9-45ce-a103-b0317653e978\\\", \\\"subtext\\\": \\\"ca842ca5-ffc6-4d77-a788-a1c3a3763cbc\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 458, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"414551e2-0919-42aa-857d-d833d937b6a6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 459, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ebef7bee-6776-433e-ab0d-ce4e7a568036\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 460, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bd4fa902-26f5-487a-af94-efe74c969d5d\\\", \\\"childbox\\\": \\\"427f093d-cfe4-487d-956e-853f67cacd32\\\", \\\"subtext\\\": \\\"21ebae28-b40f-427b-95fa-aa37060c317c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 461, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17e637aa-ec60-4ce5-9cdc-aef1fdc6d0a7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 462, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"36bc8186-5907-4a19-8634-d49469440a9a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 463, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"149f612f-21c6-463a-827d-c516de59153b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 464, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"007ff1cf-8b1c-4e14-a37d-3096970c6855\\\", \\\"childbox\\\": \\\"4c742d4d-0c0b-49a0-b361-3d782d3d8fcc\\\", \\\"subtext\\\": \\\"247af387-cc54-4163-8dd9-4ae145083e5c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 465, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c6ac455e-e6b2-4d58-8ca0-210ff1d9cb94\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 466, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7589a979-4273-46ac-b8f4-af8441241ce7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 467, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22622c48-7cc4-47e1-ab5a-b977cdfe6e0c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 468, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"922538a1-ffd9-4cda-bb36-b780cd4365d9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 469, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c894bc4-36e1-4605-90a1-b2ba73be537b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 470, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f051e187-2d12-4348-80af-6547ba6acf07\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 471, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b3c6d9e5-79aa-4d43-a64d-17b2c8dc1c6c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 472, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6ab34ad6-dc25-495e-804a-369a422084c2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 473, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c4599963-b114-4d1f-822e-e710f9f158fc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 474, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e6973455-2ae1-4f04-8006-2d56d0169336\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 475, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"99d49022-c3a3-4371-84cc-3d974567e3cf\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 476, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"88830d91-8af7-4a56-83aa-c884c14858e4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 477, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9ab5b1ac-6c26-4436-a720-f88711b28ca3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 478, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2249a48-4b34-4a7f-a9e4-1254a0702767\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 479, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d98621db-a3b2-43e6-a892-fea443bde97a\\\", \\\"childbox\\\": \\\"816121cf-663c-4b68-9e7f-9436e0bc226b\\\", \\\"subtext\\\": \\\"2b366db3-ce01-4311-a5dd-fe6f08dbf304\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 480, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"93c4cee5-b4d2-4ab6-a843-91e5b0927391\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 481, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ee22d13f-ffc8-4baf-b690-27f8f6fb6e9b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 482, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbdc1e10-2c0c-4f09-81e9-7588ef5fe0da\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 483, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f17a47f5-fd26-4b13-b71e-d751284e515f\\\", \\\"childbox\\\": \\\"abc8250e-949d-4561-a4df-90e40ce2759a\\\", \\\"subtext\\\": \\\"27d2f7e3-30f2-4157-9b93-8ece19cbc2b0\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 484, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f6185536-1f79-4156-919d-2b470ebe087d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 485, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"241a2374-b065-4e2d-adfc-47d86c919866\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 486, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c0a14431-a0f5-4754-bcf6-07ee55fb5ff9\\\", \\\"childbox\\\": \\\"5cf89e0f-db2f-41d1-985a-c5ec8b0f6d47\\\", \\\"subtext\\\": \\\"c3cf0975-ad75-4d94-84ab-589c4c53b148\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 487, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c83e58c3-b23d-410a-b3cc-6b97b03a6d67\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 488, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ed2c311b-99c7-4727-81ce-1c7ca0d87a4d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 489, \\\"\\\"], [\\\"3\\\", \\\"Risk Assessment\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"83f4b5ee-2c32-40b1-af37-d114c39a16b5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"Risk Assessment\\\", \\\"2.3.1.\\\", \\\"3\\\", 490, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"header\\\", \\\"2.3.2. Benefit Assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6062ba54-7508-4534-907d-d729a434f867\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 491, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"GM-CSF plays a key role in initiation and progression of inflammation in RA and indirectly increases the destruction of the bone and cartilage.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 5, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ad154ef2-db03-4494-861d-5d6723d3088c\\\", \\\"childbox\\\": \\\"49db60b6-f4fa-4840-8bf1-2ef0768c570f\\\", \\\"subtext\\\": \\\"a4ba627a-bf88-4710-a6f3-2903017806f7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 492, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"GSK3196165 binds human GM-CSF and inhibits GM-CSF mediated responses in vitro.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 23, \\\"end_idx\\\": 28, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}, {\\\"start_idx\\\": 43, \\\"end_idx\\\": 48, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ad154ef2-db03-4494-861d-5d6723d3088c\\\", \\\"childbox\\\": \\\"e18c7a29-7b3f-4590-a9a1-8311332547e0\\\", \\\"subtext\\\": \\\"7d51d099-5e4a-462b-b850-45979b5abbed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 493, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"Clinical studies in RA have shown that GSK3196165 [Behrens, 2015] and mavrilimumab (an anti-GM-CSF alphasubunit receptor antibody) [Burmester, 2017, Burmester, 2018; Cook, 2018b] were able to reduce RA disease activity and pain.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 39, \\\"end_idx\\\": 48, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 70, \\\"end_idx\\\": 81, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"mavrilimumab\\\"}, {\\\"start_idx\\\": 87, \\\"end_idx\\\": 97, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"anti-GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ad154ef2-db03-4494-861d-5d6723d3088c\\\", \\\"childbox\\\": \\\"6467cf03-cf5e-467f-a950-791623516f11\\\", \\\"subtext\\\": \\\"7d51d099-5e4a-462b-b850-45979b5abbed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 494, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"In addition, results from BAROQUE showed that all doses of GSK3196165 above 22.5 mg in combination with MTX resulted in a significant reduction in DAS28(CRP), significantly higher ACR20 response rates, substantial improvements in tender and swollen joint counts, a large effect in CDAI and rapid improvements in pain with an acceptable safety profile when compared with placebo.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 59, \\\"end_idx\\\": 68, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 104, \\\"end_idx\\\": 106, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"MTX\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ad154ef2-db03-4494-861d-5d6723d3088c\\\", \\\"childbox\\\": \\\"cbdd3c73-5847-433e-af4f-b474bb0b5e1d\\\", \\\"subtext\\\": \\\"fb479f4e-3388-48fe-8ea0-e3aa2057f3ad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 495, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"These data support further evaluation of GSK3196165 as a treatment option in\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 41, \\\"end_idx\\\": 50, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ad154ef2-db03-4494-861d-5d6723d3088c\\\", \\\"childbox\\\": \\\"75786a07-dce1-4743-bc91-47a6a90a9b7f\\\", \\\"subtext\\\": \\\"cd3f0638-c1d9-493d-bd20-acbebc66669d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 496, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7093df5a-e4a6-4f67-aa50-c832d3536657\\\", \\\"childbox\\\": \\\"11367e47-ecc5-4f4e-9c87-8a80b2cee678\\\", \\\"subtext\\\": \\\"9586d27c-e021-49a5-8d23-5be33b10d345\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 497, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"Participants randomised to the active comparator arm, will receive the marketed drug sarilumab, which is approved in many countries for the treatment of adults with moderately to severely active RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2f441dbd-9c30-4607-a913-7642cde518e5\\\", \\\"childbox\\\": \\\"a563e660-6a61-46dc-b22a-81aa3d635417\\\", \\\"subtext\\\": \\\"cc2c421e-fe9a-433b-8823-34ee7359e814\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 498, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"Participants randomised to one of the placebo arms, will receive placebo intervention only for 12 weeks, and will switch at Week 12 to receiving either GSK3196165 or active comparator for the remainder of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 152, \\\"end_idx\\\": 161, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"2f441dbd-9c30-4607-a913-7642cde518e5\\\", \\\"childbox\\\": \\\"6b67ede3-7ca8-4b8a-9eae-929f7e8410e6\\\", \\\"subtext\\\": \\\"cc2c421e-fe9a-433b-8823-34ee7359e814\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 499, \\\"\\\"], [\\\"3\\\", \\\"Benefit Assessment\\\", \\\"text\\\", \\\"Furthermore, each participant will benefit from extensive monitoring of their disease activity with numerous assessments throughout the study such as physical examinations, X-rays, ECGs, vital signs, pulse oximetry, respiratory function tests, laboratory tests, and swollen/tender joint assessments among others.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e39f013-c240-4c81-9e3a-93e1865b3ec2\\\", \\\"childbox\\\": \\\"6037c724-4545-4310-a25d-a25c796b2dfb\\\", \\\"subtext\\\": \\\"a2d2741e-7159-4cb4-9e4a-b6410cd64af9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit Assessment\\\", \\\"2.3.2.\\\", \\\"3\\\", 500, \\\"\\\"], [\\\"3\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"header\\\", \\\"2.3.3. Overall Benefit: Risk Conclusion\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cac301b1-b0a1-4a03-9fc6-a6b3673b03a7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"2.3.3.\\\", \\\"3\\\", 501, \\\"\\\"], [\\\"3\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"text\\\", \\\"Current preclinical and clinical data with GSK3196165 indicates that it binds and inhibits the function of GM-CSF and that this inhibition may have clinical utility in the treatment of inflammatory and autoimmune diseases, such as RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 43, \\\"end_idx\\\": 52, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 107, \\\"end_idx\\\": 112, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"cc880d45-ace2-41f7-9ca1-7d303efe569a\\\", \\\"childbox\\\": \\\"2fed31d2-e2b3-4c66-9a71-1aa74e0ad6d0\\\", \\\"subtext\\\": \\\"267f4e0b-3375-4f0c-8db6-cc05fcc4192d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"2.3.3.\\\", \\\"3\\\", 502, \\\"\\\"], [\\\"3\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"text\\\", \\\"The main potential risks are those that may be associated with inhibition of GM-CSF, including infection, pulmonary alveolar proteinosis, neutropenia, malignancy and reproductive toxicity, plus those associated with the administration of a therapeutic monoclonal antibody, including hypersensitivity reactions, injection site reactions and immunogenicity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 77, \\\"end_idx\\\": 82, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}, {\\\"start_idx\\\": 252, \\\"end_idx\\\": 270, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"monoclonal antibody\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"da074be7-c76e-4d7f-b789-3a83fff07ef0\\\", \\\"childbox\\\": \\\"737de9f0-43ed-4327-a1b6-809b49256beb\\\", \\\"subtext\\\": \\\"69b87912-4454-4120-9540-5dcfe7279b48\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"2.3.3.\\\", \\\"3\\\", 503, \\\"\\\"], [\\\"3\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"text\\\", \\\"In addition to routine pharmacovigilance, the safety review team (SRT) will review blinded safety data approximately every 4 weeks during the period of study conduct and unblinded safety data will be reviewed by the Independent Data Monitoring Committee (IDMC) at scheduled intervals (see Section 10.1.5).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b956e5df-a72e-4c31-a840-99991e132bab\\\", \\\"childbox\\\": \\\"7967448f-e77b-41d0-ad87-b5d87ef12198\\\", \\\"subtext\\\": \\\"88e6991b-edf8-4828-a848-77a0443484b2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"2.3.3.\\\", \\\"3\\\", 504, \\\"\\\"], [\\\"3\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"text\\\", \\\"Key safety data that meets predefined thresholds will be reviewed by the IDMC allowing ongoing assessment of the overall benefit:risk throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b956e5df-a72e-4c31-a840-99991e132bab\\\", \\\"childbox\\\": \\\"93f6ba9d-1bf8-44ca-b01d-3feebb3385e6\\\", \\\"subtext\\\": \\\"a854b8ef-797d-43aa-ad0f-bc6a15efb563\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"2.3.3.\\\", \\\"3\\\", 505, \\\"\\\"], [\\\"3\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"text\\\", \\\"Full details of safety thresholds will be provided in the IDMC charter.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b956e5df-a72e-4c31-a840-99991e132bab\\\", \\\"childbox\\\": \\\"d2600f88-5e06-4749-9ee2-0ec7ac7f5440\\\", \\\"subtext\\\": \\\"9f774453-3194-4a5b-909c-7a4bd4b8e751\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"2.3.3.\\\", \\\"3\\\", 506, \\\"\\\"], [\\\"3\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"text\\\", \\\"Taking into account the measures taken to minimise risk to participants randomised in this study, the potential risks identified in association with GSK3196165 are justified by the anticipated benefits that may be afforded to participants with RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 149, \\\"end_idx\\\": 158, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"6574f82f-e06e-4d13-b867-ca6cba95f579\\\", \\\"childbox\\\": \\\"08d78130-3a49-4eae-83fe-47ca99f1d5a2\\\", \\\"subtext\\\": \\\"22349ee5-ded4-4cec-bbf1-c5b21de8ef6f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Overall Benefit: Risk Conclusion\\\", \\\"2.3.3.\\\", \\\"3\\\", 507, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"3. OBJECTIVES AND ENDPOINTS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9333559b-55bb-438a-abca-83e05edec527\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"OBJECTIVES AND ENDPOINTS\\\", \\\"3.\\\", \\\"1\\\", 508, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce792825-b875-4523-9c60-d9515fdf15a3\\\", \\\"childbox\\\": \\\"3859166d-73f3-4668-b131-7e4bff9f279a\\\", \\\"subtext\\\": \\\"dbad323c-6e36-4dc8-af3e-86ae6c529de2\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"OBJECTIVES AND ENDPOINTS\\\", \\\"3.\\\", \\\"1\\\", 509, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1b5fa9a7-d91b-45bd-8a79-f433ace0a2fc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"OBJECTIVES AND ENDPOINTS\\\", \\\"3.\\\", \\\"1\\\", 510, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5f6c8212-91ab-47ed-a5ee-fe4b65f105aa\\\", \\\"childbox\\\": \\\"e6f43ff4-f339-4bbd-bdc7-dbe1cec4644a\\\", \\\"subtext\\\": \\\"a1a0e8eb-6872-4783-8281-7f6f74123f9b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"OBJECTIVES AND ENDPOINTS\\\", \\\"3.\\\", \\\"1\\\", 511, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"682a1f7f-ffae-4576-a81a-18e1ca740744\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Introduction\\\", \\\"OBJECTIVES AND ENDPOINTS\\\", \\\"3.\\\", \\\"1\\\", 512, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"csDMARD = conventional synthetic disease modifying antirheumatic drug; ACR20/50/70 = 20%/50%/70% improvement in American College of Rheumatology criteria; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire disability index; VAS = visual analogue scale; LDA = low disease activity; DAS28 = disease activity score including 28 different joints; CRP = C-reactive protein; EULAR = European league against rheumatism; PROMIS = Patient-Reported Outcomes Measurement Information System; ESR = erythrocyte sedimentation rate; AEs = adverse events; SAEs = serious adverse events; AESIs = adverse events of special interest; NCI-CTCAE = National Cancer Institute-common terminology criteria for adverse events; GM-\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 112, \\\"end_idx\\\": 143, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"American College of Rheumatology\\\"}, {\\\"start_idx\\\": 645, \\\"end_idx\\\": 653, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"NCI-CTCAE\\\"}, {\\\"start_idx\\\": 657, \\\"end_idx\\\": 688, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"National Cancer Institute-common\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b5477d35-e7c5-4c9d-b1ca-a82e7fd9d10d\\\", \\\"childbox\\\": \\\"b21f9626-7a89-4c9b-b221-1ffd6f117fe9\\\", \\\"subtext\\\": \\\"771bda65-f05f-4be8-9b2f-87cf7f110c50\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"OBJECTIVES AND ENDPOINTS\\\", \\\"3.\\\", \\\"1\\\", 513, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CSF = granulocyte-macrophage colony stimulating factor; ECM = extracellular matrix; RNA = ribonucleic acid; SF-36 = short form-36; FACIT = functional assessment of chronic illness therapy; RA = rheumatoid arthritis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 2, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"CSF\\\"}, {\\\"start_idx\\\": 6, \\\"end_idx\\\": 53, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"granulocyte-macrophage colony stimulating factor\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"c00902a6-6ee9-41ef-91d8-3ebf1552475d\\\", \\\"childbox\\\": \\\"94b7e942-3966-47ed-b254-ac6ccfaae591\\\", \\\"subtext\\\": \\\"f883afc4-f456-4786-8664-5cb323452371\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"OBJECTIVES AND ENDPOINTS\\\", \\\"3.\\\", \\\"1\\\", 514, \\\"\\\"], [\\\"1\\\", \\\"Study Design\\\", \\\"header\\\", \\\"4. STUDY DESIGN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b8ead73c-c95e-484f-8c55-fe799da0fb9c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"STUDY DESIGN\\\", \\\"4.\\\", \\\"1\\\", 515, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"header\\\", \\\"4.1. Overall Design\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a8f64e60-ce2e-4ef6-bedb-372d3d860dc8\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 516, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"\\\\u2022 This is a Phase 3, randomised, multicentre, double-blind, parallel group, placebo and active comparator (sarilumab) controlled study, with primary objective to assess the efficacy and safety of GSK3196165 in combination with csDMARD(s) in participants with moderately to severely active RA who have an inadequate response to bDMARDs and/or JAK inhibitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 107, \\\"end_idx\\\": 115, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 196, \\\"end_idx\\\": 205, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"264c1bbb-6258-47b2-a2fd-af4cd9743ac7\\\", \\\"childbox\\\": \\\"f69ea670-6a31-4879-a22e-60733475e860\\\", \\\"subtext\\\": \\\"4a8c5647-a8d1-4b32-9815-f428c4f8badb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 517, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"\\\\u2022 This is a 24-week study with primary endpoint at Week 12 to coincide with the duration of placebo intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"94e8a986-aca5-4edc-a844-115da4534a12\\\", \\\"childbox\\\": \\\"ba0a252f-4334-4905-baf8-aa592a1104c9\\\", \\\"subtext\\\": \\\"c3dab0d0-d11b-43b2-85eb-de21e4afa5cf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 518, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"\\\\u2022 Upon successful screening, participants will be randomised to one of six intervention arms, in a ratio of 6:6:6:1:1:1 to GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, sarilumab 200 mg SC every other week or placebo (three arms) respectively, all in combination with background csDMARD(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 123, \\\"end_idx\\\": 132, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 152, \\\"end_idx\\\": 161, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 180, \\\"end_idx\\\": 188, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"15cf5a7b-a29c-4af9-9f22-401797112a72\\\", \\\"childbox\\\": \\\"652ea259-aa03-49b1-aeda-d9a677f93162\\\", \\\"subtext\\\": \\\"fea6c8db-a943-4ab1-b192-18575228f3ed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 519, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"At Week 12, participants in the three placebo arms will switch from placebo to active intervention (either GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, or sarilumab 200 mg SC every other week).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 107, \\\"end_idx\\\": 116, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 136, \\\"end_idx\\\": 145, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 167, \\\"end_idx\\\": 175, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"15cf5a7b-a29c-4af9-9f22-401797112a72\\\", \\\"childbox\\\": \\\"5e91c476-269c-48f3-bce4-def64e58216b\\\", \\\"subtext\\\": \\\"cc804545-7614-468c-8fef-4404fdde3545\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 520, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"Randomisation will be stratified by previously failed medication (1 bDMARD, >1 bDMARD or \\\\u22651 JAK inhibitor [regardless of whether bDMARD received in past]).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"15cf5a7b-a29c-4af9-9f22-401797112a72\\\", \\\"childbox\\\": \\\"8ccb9d44-3cae-4f8f-90b8-289c9ea745c1\\\", \\\"subtext\\\": \\\"cc804545-7614-468c-8fef-4404fdde3545\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 521, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"\\\\u2022 GSK3196165 and placebo will be administered by weekly subcutaneous (SC) injection; participants randomised to sarilumab will receive SC injections of sarilumab every other week, plus a placebo injection in the intervening weeks to maintain the blind.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 2, \\\"end_idx\\\": 11, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 112, \\\"end_idx\\\": 120, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 152, \\\"end_idx\\\": 160, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"05cce6cd-ecdb-4dd4-b010-9496478aa2dc\\\", \\\"childbox\\\": \\\"e8143512-cd7f-4ea7-a88a-c7467e7f16a7\\\", \\\"subtext\\\": \\\"13206527-f3c8-406f-ae9e-d32db27f3881\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 522, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"See Section 6.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"05cce6cd-ecdb-4dd4-b010-9496478aa2dc\\\", \\\"childbox\\\": \\\"5f22af0e-a3fe-474e-8453-669894309634\\\", \\\"subtext\\\": \\\"efa58824-4317-4ebc-9c83-973ab0bbc619\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 523, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"\\\\u2022 Due to ethical considerations, placebo control will only be allowed until Week 12.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a138d925-5ef3-458d-b94a-77509edb5b0a\\\", \\\"childbox\\\": \\\"615da8c0-2394-4f95-957c-6bccb040cff8\\\", \\\"subtext\\\": \\\"c42efe3f-4406-4cc8-847e-b40e7799686c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 524, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"At their Week 12 visit, participants in the three placebo arms will switch to receiving the active intervention specified for that arm.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a138d925-5ef3-458d-b94a-77509edb5b0a\\\", \\\"childbox\\\": \\\"b52a0ecd-2d43-47e6-ba54-7fa209aaf36f\\\", \\\"subtext\\\": \\\"c42efe3f-4406-4cc8-847e-b40e7799686c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 525, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"This will enable placebo participants to receive active intervention from Week 12 onwards and for the study to accrue additional randomised safety data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a138d925-5ef3-458d-b94a-77509edb5b0a\\\", \\\"childbox\\\": \\\"ce792398-9686-4928-a891-2167f73c1983\\\", \\\"subtext\\\": \\\"6817a6da-6386-4db3-befc-54553eeffd5c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 526, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"The intervention switch at Week 12 will be managed automatically by the Interactive Response Technology (IRT) in order to maintain the blind.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a138d925-5ef3-458d-b94a-77509edb5b0a\\\", \\\"childbox\\\": \\\"a550fa78-d715-491a-9d79-9b21077066f7\\\", \\\"subtext\\\": \\\"6817a6da-6386-4db3-befc-54553eeffd5c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 527, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"\\\\u2022 Participants who successfully complete the 24-week treatment period may be eligible to transition into long term extension study 209564.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2ee09949-f8b9-4633-92d2-49654a5fb898\\\", \\\"childbox\\\": \\\"5ad3124a-07a9-445d-9271-476e6f0bc3d5\\\", \\\"subtext\\\": \\\"da3a5ab6-94bc-45a2-8754-4dc12cecd545\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 528, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"Any participant who does not transition into study 209564 will undergo a safety follow-up visit at\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2ee09949-f8b9-4633-92d2-49654a5fb898\\\", \\\"childbox\\\": \\\"429871f4-58c2-4ca0-9e08-ef827b04a03c\\\", \\\"subtext\\\": \\\"939afea2-d359-4ab1-952a-1768cc0be451\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 529, \\\"\\\"], [\\\"2\\\", \\\"Overall Design\\\", \\\"text\\\", \\\"Week 34 (corresponding to 12 weeks after the last potential dose of sarilumab, at Week 22).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 68, \\\"end_idx\\\": 76, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"af3eaa0d-5d06-4dbc-8dca-a7a65d0bb36d\\\", \\\"childbox\\\": \\\"2521e192-7594-4b7c-8379-b8478da46fd2\\\", \\\"subtext\\\": \\\"e4e0d314-dea5-40e6-8508-4a6d79239406\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overall Design\\\", \\\"4.1.\\\", \\\"2\\\", 530, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"header\\\", \\\"4.2. Scientific Rationale for Study Design\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b7c67673-3820-4972-8e8d-0d2a34af8d65\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 531, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"This study is a placebo-controlled, sarilumab-controlled, parallel-dose study of SC doses of GSK3196165 added on to stable dose(s) of csDMARD(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 36, \\\"end_idx\\\": 55, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab-controlled\\\"}, {\\\"start_idx\\\": 93, \\\"end_idx\\\": 102, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"be0650da-4029-4ac9-86c6-a16af1b028e0\\\", \\\"childbox\\\": \\\"bbfc61e0-6ae6-488c-b733-28a5e31a2a7d\\\", \\\"subtext\\\": \\\"81c578cb-5a14-4439-8075-49595206fde9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 532, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"Participants will be allowed to receive a stable dose of \\\\u226410 mg/day oral prednisolone or equivalent and/or a stable dose of NSAID(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 73, \\\"end_idx\\\": 84, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"prednisolone\\\"}, {\\\"start_idx\\\": 124, \\\"end_idx\\\": 131, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"NSAID(s)\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"be0650da-4029-4ac9-86c6-a16af1b028e0\\\", \\\"childbox\\\": \\\"c8f7cdd0-6c91-46a0-b265-86f81d847c8f\\\", \\\"subtext\\\": \\\"78505666-2155-4328-85c1-8167aed5365b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 533, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"The double-blind, placebo-controlled, randomised clinical study is considered the gold standard for the safety and efficacy assessment of a new therapy both by clinicians and regulatory authorities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"54b270a6-29e0-4ee4-8362-ddcf2f7c3e3a\\\", \\\"childbox\\\": \\\"ff24a98a-a131-4a9b-ba04-a750891af1dc\\\", \\\"subtext\\\": \\\"423fbff8-b8d3-4e7b-bf26-1ffd4c7c95da\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 534, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"Control with a comparator, sarilumab, will also comply with recent guidelines from regulatory authorities and help further establish the safety and efficacy in comparison with an established bDMARD.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 27, \\\"end_idx\\\": 35, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"54b270a6-29e0-4ee4-8362-ddcf2f7c3e3a\\\", \\\"childbox\\\": \\\"cc0d6600-fb5b-4845-a169-97cf0acd891c\\\", \\\"subtext\\\": \\\"423fbff8-b8d3-4e7b-bf26-1ffd4c7c95da\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 535, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"In the proposed study, participants will continue to receive stable dose(s) of csDMARD(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"54b270a6-29e0-4ee4-8362-ddcf2f7c3e3a\\\", \\\"childbox\\\": \\\"e5ed1e83-c6d7-41e3-9896-78de5015a4d9\\\", \\\"subtext\\\": \\\"cb129d82-91f9-4d81-b4d5-04b10fb970f0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 536, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"All placebo participants will switch to active intervention (either GSK3196165 150 mg or 90 mg or sarilumab 200 mg) at their Week 12 visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 68, \\\"end_idx\\\": 77, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 98, \\\"end_idx\\\": 106, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"54b270a6-29e0-4ee4-8362-ddcf2f7c3e3a\\\", \\\"childbox\\\": \\\"b485f05e-d33f-458d-b98b-8764a569e80a\\\", \\\"subtext\\\": \\\"cb129d82-91f9-4d81-b4d5-04b10fb970f0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 537, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"Participants are not allowed to receive any additional bDMARDs other than GSK3196165 or sarilumab, or any targeted synthetic DMARD (tsDMARD) (including JAK inhibitors) during the study, to mitigate the potential increased safety risks of administering a combination of bDMARDs or a combination of a bDMARD and a tsDMARD.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 74, \\\"end_idx\\\": 83, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 88, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 56, \\\"end_idx\\\": 60, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"DMARD\\\"}, {\\\"start_idx\\\": 125, \\\"end_idx\\\": 129, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"DMARD\\\"}, {\\\"start_idx\\\": 134, \\\"end_idx\\\": 138, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"DMARD\\\"}, {\\\"start_idx\\\": 270, \\\"end_idx\\\": 274, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"DMARD\\\"}, {\\\"start_idx\\\": 300, \\\"end_idx\\\": 304, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"DMARD\\\"}, {\\\"start_idx\\\": 314, \\\"end_idx\\\": 318, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"DMARD\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"54b270a6-29e0-4ee4-8362-ddcf2f7c3e3a\\\", \\\"childbox\\\": \\\"142ccbec-725d-426e-8b56-ca752c8c0ae3\\\", \\\"subtext\\\": \\\"004dd957-e1c7-43cc-a845-09cb4cd453e3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 538, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"Efficacy and safety of GSK3196165 will be compared with placebo (until Week 12) and an established active comparator (until Week 24), sarilumab which is approved in many countries for the treatment of RA in patients inadequately controlled with DMARDs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 23, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 134, \\\"end_idx\\\": 142, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"bbb79ee2-1602-4f20-8e66-c20fe88fa2cd\\\", \\\"childbox\\\": \\\"9b812985-f3cd-40fe-969b-73c4ea51b5f6\\\", \\\"subtext\\\": \\\"d9eb06c3-f447-461b-a9ce-e4fae6a1eb4d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 539, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"ACR20 is considered an established endpoint which continues to be an acceptable measure to demonstrate reduction in disease activity as recommended in the US regulatory guidelines.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ba2a93c3-694d-4e35-83df-579a17854fed\\\", \\\"childbox\\\": \\\"f79b4edc-1f56-49f8-9301-709ddf264a83\\\", \\\"subtext\\\": \\\"b9c3a62b-a98c-440f-bd03-abe027a433a6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 540, \\\"\\\"], [\\\"2\\\", \\\"Scientific Rationale for Study Design\\\", \\\"text\\\", \\\"Health assessment Questionnaire Disability Index (HAQ-DI) is considered an established endpoint which continues to be an acceptable measure to demonstrate improvement in physical function as recommended in the US and EU regulatory guidelines.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"729d5f79-7475-4ad7-90cb-ff25374a49fa\\\", \\\"childbox\\\": \\\"efd7a16f-d615-4448-a841-1f78d1923b48\\\", \\\"subtext\\\": \\\"ce4975d1-6e4f-4549-9f59-d130e6e660b1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Scientific Rationale for Study Design\\\", \\\"4.2.\\\", \\\"2\\\", 541, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"header\\\", \\\"4.3. Justification for Dose\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d1e11d42-7ebd-4f4e-b7a9-569d1c99b9fa\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 542, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"GSK3196165\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"2c70422b-68e5-419b-b583-b5a9c8edabfb\\\", \\\"childbox\\\": \\\"534ac054-1536-47ac-b69f-f065a42f5309\\\", \\\"subtext\\\": \\\"40b1e629-4ab9-41e1-bcf0-9fc5a37ca44a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 543, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The GSK3196165 doses for this study have been selected based on pharmacokinetics (PK), efficacy, safety data and exposure-response relationship for efficacy endpoints from the phase 2b dose finding study, BAROQUE (201755).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 4, \\\"end_idx\\\": 13, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"85ac03ce-ddeb-49c1-9237-83906aad270d\\\", \\\"childbox\\\": \\\"8747c27c-2f64-49f0-a637-f7de55773ca4\\\", \\\"subtext\\\": \\\"5c93efb2-f387-4294-85d6-6f6366850063\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 544, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The BAROQUE study showed an acceptable safety profile and clinically meaningful efficacy at the highest dose of 180 mg SC weekly for 5 injections, then every other week until Week 50.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d44c648d-5d62-4be6-b1eb-eb335767c014\\\", \\\"childbox\\\": \\\"6a265aab-cd32-4299-9e2e-6d5bfaead8df\\\", \\\"subtext\\\": \\\"e69fe9db-f96e-4f8b-9dc2-5f451bc8d75c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 545, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The efficacy however started to plateau after Week 6 with no further improvement post Week 12.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d44c648d-5d62-4be6-b1eb-eb335767c014\\\", \\\"childbox\\\": \\\"688f0fe2-fd4c-454f-a564-8097ee92587d\\\", \\\"subtext\\\": \\\"08bb1012-25be-4493-98a3-d96242487d6a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 546, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"This effect is likely due to lower trough concentrations achieved in BAROQUE than predicted from PK data from historic studies (MSC-1000, MSC1001 and MOR103C104).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d44c648d-5d62-4be6-b1eb-eb335767c014\\\", \\\"childbox\\\": \\\"9abca85d-2806-4d22-b79e-c026f73453d8\\\", \\\"subtext\\\": \\\"08bb1012-25be-4493-98a3-d96242487d6a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 547, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The reason for the lower than expected exposure to GSK3196165 in RA participants in BAROQUE is not fully understood.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 51, \\\"end_idx\\\": 60, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"d44c648d-5d62-4be6-b1eb-eb335767c014\\\", \\\"childbox\\\": \\\"5b4fb992-03b1-41c0-b90a-01aca63eff32\\\", \\\"subtext\\\": \\\"19f78ffc-6d96-4048-8cd4-ee38f51fe48e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 548, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The PK of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d44c648d-5d62-4be6-b1eb-eb335767c014\\\", \\\"childbox\\\": \\\"8426b0cf-61de-4b29-8cb1-37debfb2fd26\\\", \\\"subtext\\\": \\\"8d6bcd51-b568-490c-a4bd-aedff7335b39\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 549, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"GSK3196165 was linear over the tested dose range (IV; 0.025 \\\\u2013 3 mg/kg and SC; 22.5 \\\\u2013 180 mg), which is consistent with the PK profile of a mAb against soluble cytokine [GSK Document Number 2017N353526_00].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 2, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 169, \\\"end_idx\\\": 171, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 139, \\\"end_idx\\\": 141, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"mAb\\\"}, {\\\"start_idx\\\": 0, \\\"end_idx\\\": 2, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 169, \\\"end_idx\\\": 171, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"e2762119-8e5e-49fd-acf9-bb2c2ac73d2d\\\", \\\"subtext\\\": \\\"97e4fe1d-c154-472b-81d5-f884a86df062\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 550, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"However, GSK3196165 clearance in healthy volunteers (HV) was 3 times higher (0.93, confidence interval [CI]: 0.83 \\\\u2013 1.04 L/day) than generally reported for a mAb (0.3 L/day) and the half-life (t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 9, \\\"end_idx\\\": 18, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 158, \\\"end_idx\\\": 160, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"mAb\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"6c3c4941-1af6-4700-921a-35fbcbf37a0f\\\", \\\"subtext\\\": \\\"85e2c222-9e02-409b-a83a-5dbf2c4ab53d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 551, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"1/2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"6c3c4941-1af6-4700-921a-35fbcbf37a0f\\\", \\\"subtext\\\": \\\"eb47f92b-42cb-460d-a1f1-89ae1aa61578\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 552, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\") of 12 days was shorter than a typical mAb.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 40, \\\"end_idx\\\": 42, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"mAb\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"6c3c4941-1af6-4700-921a-35fbcbf37a0f\\\", \\\"subtext\\\": \\\"e6d41a4e-4c23-4dfa-b2fa-74da086c416e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 553, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"In addition, the SC bioavailability (0.34, CI: 0.26 \\\\u2013 0.44) was lower than expected for a mAb.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 90, \\\"end_idx\\\": 92, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"mAb\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"578c8376-ed89-4b7a-bc91-140a04e50e37\\\", \\\"subtext\\\": \\\"e6d41a4e-4c23-4dfa-b2fa-74da086c416e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 554, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"In RA participants, the apparent clearance (CL/F) after SC administration of GSK3196165 was 2.4 times higher than HV and the estimated t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 77, \\\"end_idx\\\": 86, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"4479e1e2-3775-4431-a4ab-90b9d6621a05\\\", \\\"subtext\\\": \\\"d17e1158-9442-4059-a5e2-9866cec1f41f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 555, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"1/2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"4479e1e2-3775-4431-a4ab-90b9d6621a05\\\", \\\"subtext\\\": \\\"c35e7146-3202-4d69-8ab7-e22a52001338\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 556, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"was 10 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e793149f-87d4-4b67-af8d-6505addc6bc4\\\", \\\"childbox\\\": \\\"4479e1e2-3775-4431-a4ab-90b9d6621a05\\\", \\\"subtext\\\": \\\"e7d52253-2d9b-4e5f-be85-709805fee289\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 557, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"In this study, the dosing frequency will be increased to every week to overcome the higher CL/F and lower t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"056e102d-0676-499f-ac10-d69da3e06c35\\\", \\\"childbox\\\": \\\"9e50ab67-b9e8-4701-8bfb-5f3727f7970a\\\", \\\"subtext\\\": \\\"1f845c4e-3ad4-471c-94d2-a0d84aabf4b4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 558, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"1/2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"056e102d-0676-499f-ac10-d69da3e06c35\\\", \\\"childbox\\\": \\\"9e50ab67-b9e8-4701-8bfb-5f3727f7970a\\\", \\\"subtext\\\": \\\"6704de0a-4e85-4462-b3ef-2cca46460700\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 559, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"of 10 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"056e102d-0676-499f-ac10-d69da3e06c35\\\", \\\"childbox\\\": \\\"9e50ab67-b9e8-4701-8bfb-5f3727f7970a\\\", \\\"subtext\\\": \\\"e241319f-3e9e-4fb2-a683-fdcd2cabf8f7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 560, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The GM-CSF-GSK3196165 complex data from BAROQUE also supports weekly administration as an optimal dosing regimen for GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 4, \\\"end_idx\\\": 20, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GM-CSF-GSK3196165\\\"}, {\\\"start_idx\\\": 11, \\\"end_idx\\\": 20, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 117, \\\"end_idx\\\": 126, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"056e102d-0676-499f-ac10-d69da3e06c35\\\", \\\"childbox\\\": \\\"358d373e-6017-4d9e-9ce8-6667b49f590e\\\", \\\"subtext\\\": \\\"e241319f-3e9e-4fb2-a683-fdcd2cabf8f7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 561, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"This dosing frequency with a 90 and 150 mg dose is predicted to result in steady-state pre-dose concentrations of 1500 and 2500 ng/mL, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"056e102d-0676-499f-ac10-d69da3e06c35\\\", \\\"childbox\\\": \\\"8707af89-3edf-4de6-9db0-a6900e27e832\\\", \\\"subtext\\\": \\\"e241319f-3e9e-4fb2-a683-fdcd2cabf8f7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 562, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Based on a longitudinal exposure-response model of DAS28(CRP), a dose of 90 mg SC every week is predicted to provide clinically meaningful efficacy similar to the 180 mg regimen in the BAROQUE study and in line with other RA targeted DMARDs, whilst 150 mg SC every week dose is predicted to provide greater efficacy to that achieved in BAROQUE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"056e102d-0676-499f-ac10-d69da3e06c35\\\", \\\"childbox\\\": \\\"28a86306-829c-4064-90fe-101f746ba603\\\", \\\"subtext\\\": \\\"4383b10d-6765-4067-92b3-b19cf2994e1a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 563, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Figure 1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d82c5da-d0f2-469d-a715-33d966dcb2f5\\\", \\\"childbox\\\": \\\"31a8f626-07f1-480f-865b-1ab737ee0220\\\", \\\"subtext\\\": \\\"c961c378-07fe-4b88-aa91-a99b6d69231c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 564, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d82c5da-d0f2-469d-a715-33d966dcb2f5\\\", \\\"childbox\\\": \\\"b383c6e9-e1ee-403a-97c3-9f3c6b435632\\\", \\\"subtext\\\": \\\"cf6f1ba0-8069-4e23-8593-987b14da23e1\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 565, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Comparison of PK/PD Model Predicted Median Change from Baseline in DAS28(CRP) given 3 Dose Regimens of GSK3196165:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 103, \\\"end_idx\\\": 112, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5d82c5da-d0f2-469d-a715-33d966dcb2f5\\\", \\\"childbox\\\": \\\"cb452575-e6b2-4d2d-af04-d43eb2725f7d\\\", \\\"subtext\\\": \\\"cf6f1ba0-8069-4e23-8593-987b14da23e1\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 566, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"header\\\", \\\"180 mg Weekly for 5 Weeks Followed by Every Other Week\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c3298d5-92d8-4a06-b531-a5e04afbb5d6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 567, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"(BAROQUE Regimen), 90 mg Weekly and 150 mg Weekly\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6cd71870-3657-49da-b767-eaac190f60ac\\\", \\\"childbox\\\": \\\"69e88f1f-4b6b-446d-ad64-e8b51742c913\\\", \\\"subtext\\\": \\\"db6d0a26-d761-41e7-8d01-4bcba1daf0d0\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 568, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e69a87d4-6ffe-4ade-9611-74b7c61ded4e\\\", \\\"childbox\\\": \\\"a570e1c3-6a1d-4f4f-8fd5-ad31910025ca\\\", \\\"subtext\\\": \\\"cb40b796-d3c8-472e-af19-c66917043893\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 569, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Based on dose-response relationship at Week 4 (matching the weekly dose regimen to be used in this study) the 90 mg and 150 mg doses translate into a ED70 and ED80 respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e936738d-ead0-4350-8949-fb233610b6ce\\\", \\\"childbox\\\": \\\"518c80da-abab-46bd-80a0-0459caed957c\\\", \\\"subtext\\\": \\\"79a00b62-e549-44f9-a60c-1a0f94670371\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 570, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Logistic regression analysis of ACR20 and ACR50 response at Week 12, also indicated higher trough concentrations are associated with response rate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e936738d-ead0-4350-8949-fb233610b6ce\\\", \\\"childbox\\\": \\\"932b1f03-647b-451c-851f-7d9c443fe053\\\", \\\"subtext\\\": \\\"016dcd6a-e4b3-4983-bfe5-966b1bf8a1a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 571, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The predicted ACR20 response rate for the 90 mg and 150 mg weekly doses are 63% and 69%, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e936738d-ead0-4350-8949-fb233610b6ce\\\", \\\"childbox\\\": \\\"59c40464-2143-4d92-90c8-b9f91857f8c5\\\", \\\"subtext\\\": \\\"016dcd6a-e4b3-4983-bfe5-966b1bf8a1a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 572, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Furthermore, the safety profile of GSK3196165 in BAROQUE was acceptable at all doses with no apparent dose response in the incidence of AEs or SAEs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 35, \\\"end_idx\\\": 44, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"cd42b54e-b62b-4566-af7b-17f63a18acd9\\\", \\\"childbox\\\": \\\"9c21a107-f1f9-4d7c-ad98-30827e971a43\\\", \\\"subtext\\\": \\\"0b29d4ce-6144-4bc6-b29b-073191dfd711\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 573, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"More details are provided in the GSK3196165 IB.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 33, \\\"end_idx\\\": 42, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"cd42b54e-b62b-4566-af7b-17f63a18acd9\\\", \\\"childbox\\\": \\\"27475864-efcd-4794-bf28-78e4e0b91aef\\\", \\\"subtext\\\": \\\"0b29d4ce-6144-4bc6-b29b-073191dfd711\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 574, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Given the GSK3196165 half-life of 10 days, steady-state is expected to be reached after 5 weekly doses (as in BAROQUE), therefore GSK3196165 concentrations with the 150 mg every week dosing regimen should not exceed concentrations studied in BAROQUE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 10, \\\"end_idx\\\": 19, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 130, \\\"end_idx\\\": 139, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"79b848b6-720f-4114-8c85-97dc2da5dd6f\\\", \\\"childbox\\\": \\\"eb796e24-20e6-47b9-8d82-ad27a13ffa8d\\\", \\\"subtext\\\": \\\"f153f31c-7227-4c97-951c-71b492b0a8ac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 575, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The highest dose of 150 mg weekly provides a 3 to 5-fold safety margin to the 5 mg/kg dose in the 26-week monkey toxicology study where no foamy alveolar macrophages were observed (NOEL).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"79b848b6-720f-4114-8c85-97dc2da5dd6f\\\", \\\"childbox\\\": \\\"0060d4a7-f158-44ed-8fbb-75b2c445150f\\\", \\\"subtext\\\": \\\"d89dd4e1-bc81-4548-b0f7-8e49009644a5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 576, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"In summary, PK, exposure-response, dose-response and safety data from the BAROQUE study, supported by modelling strongly support the selection of the 90 mg and 150 mg weekly doses, where 90 mg is expected to provide clinically-meaningful efficacy at levels similar to BAROQUE and existing targeted DMARDs, and 150 mg is predicted to provide greater clinical benefit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"77968e77-f1ee-4ccf-81ba-ee347f0eef5a\\\", \\\"childbox\\\": \\\"3520ecb6-16f7-40d5-9389-c5c0ecc8f998\\\", \\\"subtext\\\": \\\"82b332c0-3dd6-4668-8aa4-1552497a90da\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 577, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Both doses are also covered by an appropriate safety margin.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"77968e77-f1ee-4ccf-81ba-ee347f0eef5a\\\", \\\"childbox\\\": \\\"46f71a6c-c66d-42f4-b65a-d2661a78b9cc\\\", \\\"subtext\\\": \\\"924c0290-8cf1-49cc-838f-6dc9079bc3cc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 578, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"Sarilumab\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 8, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"Sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"c76e4c70-3c01-4268-9b9b-327409eef7e3\\\", \\\"childbox\\\": \\\"6e2c1cda-bf4e-4665-8358-b97819f7de8b\\\", \\\"subtext\\\": \\\"6d4a3ad4-14a3-4dd2-99dc-b406488ba7b9\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 579, \\\"\\\"], [\\\"2\\\", \\\"Justification for Dose\\\", \\\"text\\\", \\\"The sarilumab dose has been selected based on the recommended approved dose (200 mg every other week) in the countries where it is commercially available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 4, \\\"end_idx\\\": 12, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"3b942a83-c477-48f0-9a9a-186e6ab7d58b\\\", \\\"childbox\\\": \\\"a11e345c-6b32-4ccb-854b-7cca8da5a80c\\\", \\\"subtext\\\": \\\"0cfd3dd0-e6d3-4dd0-8d28-a25f2db621ef\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Justification for Dose\\\", \\\"4.3.\\\", \\\"2\\\", 580, \\\"\\\"], [\\\"2\\\", \\\"End of Study Definition\\\", \\\"header\\\", \\\"4.4. End of Study Definition\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f7c331b8-f2ff-4681-b9a0-267024a8e0a9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End of Study Definition\\\", \\\"4.4.\\\", \\\"2\\\", 581, \\\"\\\"], [\\\"2\\\", \\\"End of Study Definition\\\", \\\"text\\\", \\\"A participant is considered to have completed the study if he/she has completed all phases of the study including the last visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c350bd8c-0b08-417c-839f-4c5e3b8f6e77\\\", \\\"childbox\\\": \\\"12b2d6ba-93b1-48ca-8f22-d7480c5e3c90\\\", \\\"subtext\\\": \\\"5de9af4d-f60b-4e0a-87ae-540af8b23413\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End of Study Definition\\\", \\\"4.4.\\\", \\\"2\\\", 582, \\\"\\\"], [\\\"2\\\", \\\"End of Study Definition\\\", \\\"text\\\", \\\"This will be the Week 24 visit for those participants who transition into the long-term follow-up study or the safety follow-up visit for all other participants.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c350bd8c-0b08-417c-839f-4c5e3b8f6e77\\\", \\\"childbox\\\": \\\"afd56292-271c-47a9-854a-5f4c0c33560d\\\", \\\"subtext\\\": \\\"89cf204d-eeac-4882-9b8c-1d5e88166ca8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End of Study Definition\\\", \\\"4.4.\\\", \\\"2\\\", 583, \\\"\\\"], [\\\"2\\\", \\\"End of Study Definition\\\", \\\"text\\\", \\\"The end of the study is defined as the date of the last visit of the last participant in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9a06148f-612a-4def-b823-9cc946e21122\\\", \\\"childbox\\\": \\\"83891b02-10ec-4b6c-ac0a-bbfa489a53a5\\\", \\\"subtext\\\": \\\"82975a41-fce5-4de5-a1f9-1db41d7825b3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End of Study Definition\\\", \\\"4.4.\\\", \\\"2\\\", 584, \\\"\\\"], [\\\"1\\\", \\\"Study Population\\\", \\\"header\\\", \\\"5. STUDY POPULATION\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6b428f4a-6fe9-439b-a38f-b7d762458d0f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY POPULATION\\\", \\\"5.\\\", \\\"1\\\", 585, \\\"\\\"], [\\\"1\\\", \\\"Study Population\\\", \\\"text\\\", \\\"Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as protocol waivers or exemptions, is not permitted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fb6958ba-c26d-4e2b-8077-e63193c58bf5\\\", \\\"childbox\\\": \\\"32819490-6455-4fed-aee5-fc0ba3f97c8d\\\", \\\"subtext\\\": \\\"f9002b26-9cf6-4567-99b5-9d722dc8ea0a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY POPULATION\\\", \\\"5.\\\", \\\"1\\\", 586, \\\"\\\"], [\\\"1\\\", \\\"Study Population\\\", \\\"text\\\", \\\"Investigators should review and update the vaccination status of potential participants as per local guidelines for adult vaccination prior to entering them into the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5559f3d6-0cc4-49a7-95c5-ea5fe83c3097\\\", \\\"childbox\\\": \\\"6bd750b5-ce02-4cbd-9e39-bdf20cbec6bf\\\", \\\"subtext\\\": \\\"6133f499-19e7-4dd0-b973-1e46fbba88bf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY POPULATION\\\", \\\"5.\\\", \\\"1\\\", 587, \\\"\\\"], [\\\"1\\\", \\\"Study Population\\\", \\\"text\\\", \\\"All participants who have not received the herpes zoster vaccine at study entry will be recommended to do so >30 days prior to randomisation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 57, \\\"end_idx\\\": 63, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"vaccine\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5559f3d6-0cc4-49a7-95c5-ea5fe83c3097\\\", \\\"childbox\\\": \\\"c68daf33-0d36-4f67-8ba1-acde635c3bd3\\\", \\\"subtext\\\": \\\"178417ea-aebf-4d34-841d-076562510892\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY POPULATION\\\", \\\"5.\\\", \\\"1\\\", 588, \\\"\\\"], [\\\"1\\\", \\\"Study Population\\\", \\\"text\\\", \\\"All participants may receive inactivated flu vaccines during the study at the discretion of the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5559f3d6-0cc4-49a7-95c5-ea5fe83c3097\\\", \\\"childbox\\\": \\\"1774c685-b9bf-4e7f-8cf5-1579165fe8db\\\", \\\"subtext\\\": \\\"b71db21b-99f5-421b-b5ef-40eeefcdd985\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY POPULATION\\\", \\\"5.\\\", \\\"1\\\", 589, \\\"\\\"], [\\\"1\\\", \\\"Study Population\\\", \\\"text\\\", \\\"Note that \\\\u201cInadequate response\\\\u201d to prior treatment in this population, is defined as: In the opinion of the investigator, after at least 3 months of treatment the participant experienced insufficient efficacy or loss of response (e.g.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"07187bfb-26de-401c-b344-e0dba1177458\\\", \\\"childbox\\\": \\\"3e693630-480b-46fa-ae61-f7fd4ff152dc\\\", \\\"subtext\\\": \\\"02743744-3ab0-4590-a89b-be381845cbfc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY POPULATION\\\", \\\"5.\\\", \\\"1\\\", 590, \\\"\\\"], [\\\"1\\\", \\\"Study Population\\\", \\\"text\\\", \\\"no EULAR response; failure to achieve ACR20; any other clinical criteria recommended per local guidelines that would trigger a change of treatment), or the participant discontinued treatment due to intolerability or toxicity irrespective of treatment duration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"07187bfb-26de-401c-b344-e0dba1177458\\\", \\\"childbox\\\": \\\"1ce58469-8e86-4fc7-ac70-3d0b620f9eb1\\\", \\\"subtext\\\": \\\"82dd3fbd-8d4d-428a-aa8e-898d17c7b82b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY POPULATION\\\", \\\"5.\\\", \\\"1\\\", 591, \\\"\\\"], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"header\\\", \\\"5.1. Inclusion Criteria\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ad6bca76-69a5-4034-8d47-52e5bb990e0e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Inclusion Criteria\\\", \\\"5.1.\\\", \\\"2\\\", 592, \\\"\\\"], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Participants are eligible to be included in the study only if all of the following criteria apply:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dafa1678-24fd-4f4f-95fb-792c2682f1aa\\\", \\\"childbox\\\": \\\"7771f015-b5e4-4b45-bc1b-006012614ae3\\\", \\\"subtext\\\": \\\"0459619f-8fc1-4f1c-b7b0-91a4e25079a6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Inclusion Criteria\\\", \\\"5.1.\\\", \\\"2\\\", 593, \\\"\\\"], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5839d68e-88df-4889-a000-32dd0d1299b4\\\", \\\"childbox\\\": \\\"101d8acd-1267-40f3-ac4b-2281aabdcd00\\\", \\\"subtext\\\": \\\"501354f8-f2ea-4017-afc6-e94fcce0f832\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Inclusion Criteria\\\", \\\"5.1.\\\", \\\"2\\\", 594, \\\"\\\"], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8227d355-5ea9-4440-af9a-61c575f895ac\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Inclusion Criteria\\\", \\\"5.1.\\\", \\\"2\\\", 595, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"header\\\", \\\"5.2. Exclusion Criteria\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"14198751-3570-415d-8a0a-7d9202f5f497\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 596, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"A participant will not be eligible for inclusion in this study if any of the following criteria apply:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b3d43fba-139e-4fbd-a0b4-c20b6772f60b\\\", \\\"childbox\\\": \\\"ee986ccb-479a-4cec-b9aa-11836e951e82\\\", \\\"subtext\\\": \\\"02796a0a-04f6-485e-9465-f743b27719a7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 597, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d6ecccf-ca7b-4a85-84d4-6a76f1c56533\\\", \\\"childbox\\\": \\\"856c2a6c-25ad-4581-b90d-4a869c00a2aa\\\", \\\"subtext\\\": \\\"d9b77191-e7fe-4f16-b73c-916e7118873c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 598, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"43f4b585-c5d6-47ce-9df0-a778783d3755\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 599, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6d8cd1b2-f296-4910-a13b-001100a17b58\\\", \\\"childbox\\\": \\\"d547abd0-c619-4621-8e20-cd682947c2cf\\\", \\\"subtext\\\": \\\"621edf88-bd17-4316-93e5-8d4e25bf84da\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 600, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"43cd258c-cfa6-4e69-b1f5-b24b6771be42\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 601, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 111, \\\"end_idx\\\": 119, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"25a8a967-f51a-4173-afe4-4d5a13f9f76b\\\", \\\"childbox\\\": \\\"ba7d9c9f-2302-469d-aabd-4f6919b5796b\\\", \\\"subtext\\\": \\\"fbfc9213-4b3b-4a2e-8434-0ab61b2ce7b4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 602, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"medications/treatments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7cbf7efa-095f-4309-a88f-670e86abf0e0\\\", \\\"childbox\\\": \\\"157f60fb-3527-4f5e-b68d-ecddbce0b3b8\\\", \\\"subtext\\\": \\\"53b09273-f0ce-42f9-9a68-1bec6d4b8449\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 603, \\\"\\\"], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c10ea4ff-ff79-49ef-948b-dd88c8563107\\\", \\\"childbox\\\": \\\"ddf8fa1f-7ad4-412d-a2f2-4900ff16d7df\\\", \\\"subtext\\\": \\\"caa9cc14-4c5f-45c6-9837-1c23ecdc9975\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Exclusion Criteria\\\", \\\"5.2.\\\", \\\"2\\\", 604, \\\"\\\"], [\\\"2\\\", \\\"Lifestyle Considerations\\\", \\\"header\\\", \\\"5.3. Lifestyle Considerations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"495d6eab-7cc7-4554-a6d6-60ece6bcc67f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Lifestyle Considerations\\\", \\\"5.3.\\\", \\\"2\\\", 605, \\\"\\\"], [\\\"2\\\", \\\"Lifestyle Considerations\\\", \\\"text\\\", \\\"There are no lifestyle restrictions in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b2b8b659-d4cb-4cd5-a10d-416c5035ce0b\\\", \\\"childbox\\\": \\\"036fd016-a361-4ef2-9387-67f7847053c8\\\", \\\"subtext\\\": \\\"2fefd00c-0861-4c50-b901-bba886d2a241\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Lifestyle Considerations\\\", \\\"5.3.\\\", \\\"2\\\", 606, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"header\\\", \\\"5.4. Screen Failures\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6cd7bf2c-19a3-48f4-8f04-31b77d5f5858\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 607, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomised.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2d6ecb5-e898-4036-86f5-ee6198c87415\\\", \\\"childbox\\\": \\\"0046012a-a6d2-4a39-9a7d-be5f57982a0a\\\", \\\"subtext\\\": \\\"9625fcc3-dab4-4b5c-a20b-e50ac3cee7f1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 608, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2d6ecb5-e898-4036-86f5-ee6198c87415\\\", \\\"childbox\\\": \\\"1b79e4ef-da28-43e5-8fdb-44c6a24ed7f7\\\", \\\"subtext\\\": \\\"9625fcc3-dab4-4b5c-a20b-e50ac3cee7f1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 609, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse events (SAEs).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2d6ecb5-e898-4036-86f5-ee6198c87415\\\", \\\"childbox\\\": \\\"ed143948-c4ac-4156-8d6b-8b818ac6ea42\\\", \\\"subtext\\\": \\\"26a74988-f50e-4a84-bb76-4f3056a1a9d6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 610, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened once with the agreement of the Medical Monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c0ec5967-ad83-4a46-a4bd-52069280ab31\\\", \\\"childbox\\\": \\\"01102c26-01fd-4b3e-be2c-6cbf7fe95305\\\", \\\"subtext\\\": \\\"44e9300b-3d87-4c56-9220-8deb51b7eff3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 611, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"The entire screening process must be repeated (except for chest X-ray if performed within the previous 12 weeks of the first screening period).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c0ec5967-ad83-4a46-a4bd-52069280ab31\\\", \\\"childbox\\\": \\\"7ae8932a-e593-4e19-a5c5-25a723f01be3\\\", \\\"subtext\\\": \\\"44e9300b-3d87-4c56-9220-8deb51b7eff3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 612, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"A QuantiFERON-TB Gold plus test may be repeated once during screening if the initial result is indeterminate, alternatively a T-SPOT.TB test may be used following an indeterminate result.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c718d4af-60c3-40b8-97e4-483ade442576\\\", \\\"childbox\\\": \\\"0ea54f7d-41ea-4848-b790-1d8346be688c\\\", \\\"subtext\\\": \\\"0be5f8bc-71d9-4386-91cf-f2e98c2e8f8d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 613, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"This is not considered a rescreening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c718d4af-60c3-40b8-97e4-483ade442576\\\", \\\"childbox\\\": \\\"3fbdfa3d-a2d6-4bf3-ae06-a1ac51fc1c9f\\\", \\\"subtext\\\": \\\"0f32c080-60b5-4443-aa6c-b96fa20fa4e5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 614, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"If the repeat test is positive or indeterminate, then the participant is excluded from the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c718d4af-60c3-40b8-97e4-483ade442576\\\", \\\"childbox\\\": \\\"776c06d7-2f8b-4863-8eac-1b2027a68503\\\", \\\"subtext\\\": \\\"0f32c080-60b5-4443-aa6c-b96fa20fa4e5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 615, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"For those participants requiring Isoniazid (INH) therapy for latent TB, LFTs must be assessed following 3 weeks of INH treatment in screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 33, \\\"end_idx\\\": 41, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Isoniazid\\\"}, {\\\"start_idx\\\": 44, \\\"end_idx\\\": 46, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"INH\\\"}, {\\\"start_idx\\\": 115, \\\"end_idx\\\": 117, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"INH\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"14501cc0-8a19-41e0-bd9d-9d297b4b97df\\\", \\\"childbox\\\": \\\"43a6788d-6b64-49f6-81d3-8de6b916e773\\\", \\\"subtext\\\": \\\"5a8f210b-60f3-4dbe-b074-19c5267504e6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 616, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"Participants will fail screening if ALT >1.5 x ULN is identified; these participants may be re-screened if ALT elevation resolves to ALT <x 1.5 ULN during ongoing INH therapy following discussion with the medical monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 163, \\\"end_idx\\\": 165, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"INH\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"14501cc0-8a19-41e0-bd9d-9d297b4b97df\\\", \\\"childbox\\\": \\\"322d44d5-9d9a-491e-860d-40636958fe78\\\", \\\"subtext\\\": \\\"31a4d573-891c-4dc5-ad19-7783428ff24b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 617, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"If a participant fails any of the laboratory exclusion criteria, the test may be repeated once within the screening period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a001a208-595b-4f90-be79-312aefc5f5ca\\\", \\\"childbox\\\": \\\"fae5d92f-df0d-47e2-831d-c6f22f7afcac\\\", \\\"subtext\\\": \\\"45ed1a6f-0639-4467-bbc8-bbab505e32be\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 618, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"If the participant fails the laboratory criteria for a second time, they will be considered a screen failure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a001a208-595b-4f90-be79-312aefc5f5ca\\\", \\\"childbox\\\": \\\"bce1e4a8-fe6e-4e9c-8b79-03704474266f\\\", \\\"subtext\\\": \\\"45ed1a6f-0639-4467-bbc8-bbab505e32be\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 619, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"Retesting within screening window of any blood sample withdrawn due to sample handling problems, breakage or sample integrity is not considered a rescreening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6b888718-05c6-4e86-8b12-9ff20748af24\\\", \\\"childbox\\\": \\\"fa95b2cf-f76d-44a9-9834-bbb54d1708d2\\\", \\\"subtext\\\": \\\"cdf8c319-252c-47d9-bbd6-62f571231910\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 620, \\\"\\\"], [\\\"2\\\", \\\"Screen Failures\\\", \\\"text\\\", \\\"Further details regarding the procedure for re-screening can be found in the SRM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c5ef56fb-1997-4521-95f9-c1a78c1c17fd\\\", \\\"childbox\\\": \\\"af518697-9e81-4643-9a4d-6ae2543a37b5\\\", \\\"subtext\\\": \\\"dba8f1e5-4e92-4901-90ea-7de7bb147537\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Screen Failures\\\", \\\"5.4.\\\", \\\"2\\\", 621, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6. STUDY INTERVENTION\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9cf9152-19ef-49b6-a3a1-c6ffd3bba43c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY INTERVENTION\\\", \\\"6.\\\", \\\"1\\\", 622, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5259e39f-9d98-420e-bc56-efc23c5a748f\\\", \\\"childbox\\\": \\\"d7637cf9-6c0d-4b32-9acf-4243a8b5c088\\\", \\\"subtext\\\": \\\"3f16a22e-7df1-45c5-b577-12fe9f368b30\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"STUDY INTERVENTION\\\", \\\"6.\\\", \\\"1\\\", 623, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"header\\\", \\\"6.1. Study Intervention(s) Administered\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e210729a-379d-49c9-bd68-743816f06f87\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 624, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"An overview of the study interventions is provided in Table 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e5440465-91e5-4268-a42f-59dfec3933c0\\\", \\\"childbox\\\": \\\"55d4dada-0430-4bb0-b0c2-8394f7f071a3\\\", \\\"subtext\\\": \\\"06430269-2d5d-49bc-a995-509d70492189\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 625, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Investigators should note the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e5440465-91e5-4268-a42f-59dfec3933c0\\\", \\\"childbox\\\": \\\"7d0ef56a-18fc-4090-b42f-e42a4b89a0eb\\\", \\\"subtext\\\": \\\"b236a064-c393-4176-beb7-0ef73eca903f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 626, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 GSK3196165 and placebo will be administered by weekly subcutaneous (SC) injection; participants randomised to sarilumab will receive SC injections of sarilumab every other week, plus a placebo injection in the intervening weeks to maintain the blind.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 2, \\\"end_idx\\\": 11, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 112, \\\"end_idx\\\": 120, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 152, \\\"end_idx\\\": 160, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f53a3a2b-8006-410a-b675-2d52c638ea9d\\\", \\\"childbox\\\": \\\"3e34ef5c-7655-42fe-ab14-c155725ff9f2\\\", \\\"subtext\\\": \\\"bb855f83-6c10-40a5-8937-101e2f6c5b70\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 627, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 Study SC injection should be administered weekly, on the same day each week.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"09be31ee-6df5-43f4-a65b-21442b224559\\\", \\\"childbox\\\": \\\"51d19d19-4507-4fe3-b385-be3887d8aa52\\\", \\\"subtext\\\": \\\"4e43dc3b-cbc5-482a-bc6a-d898dd5f2d86\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 628, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"The weekly SC injections of study intervention should rotate between the thighs and abdomen.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"09be31ee-6df5-43f4-a65b-21442b224559\\\", \\\"childbox\\\": \\\"6a612878-4f62-41a6-a339-f3035185be5a\\\", \\\"subtext\\\": \\\"4e43dc3b-cbc5-482a-bc6a-d898dd5f2d86\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 629, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 A window of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"187e7b8c-416d-47d2-9e72-3504202cc867\\\", \\\"childbox\\\": \\\"bbf95a4e-9c91-4a23-a93a-4ea483f9e067\\\", \\\"subtext\\\": \\\"c1e9a1b9-2f15-4d9b-a2ae-349e441a0019\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 630, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"187e7b8c-416d-47d2-9e72-3504202cc867\\\", \\\"childbox\\\": \\\"bbf95a4e-9c91-4a23-a93a-4ea483f9e067\\\", \\\"subtext\\\": \\\"9515b066-da22-47f9-9ecf-ea8a25906f54\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 631, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"2 days is acceptable for the SC injection (minimum gap of 5 days between each dose, for no more than 2 consecutive doses).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"187e7b8c-416d-47d2-9e72-3504202cc867\\\", \\\"childbox\\\": \\\"bbf95a4e-9c91-4a23-a93a-4ea483f9e067\\\", \\\"subtext\\\": \\\"7f57946a-d65d-476e-987a-0ad9e27718d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 632, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Participants should return to their 7 day dosing schedule as soon as possible thereafter.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"187e7b8c-416d-47d2-9e72-3504202cc867\\\", \\\"childbox\\\": \\\"cd9f9182-b39c-4cc2-8631-33964574a86e\\\", \\\"subtext\\\": \\\"7f57946a-d65d-476e-987a-0ad9e27718d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 633, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 Participants must receive their SC injection at the site and be monitored for general safety for 1 hour after the injection at Weeks 0, 1, 12, and 13; the safety monitoring at Weeks 12 and 13 is due to the switch of the placebo participants to active intervention at the Week 12 visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"53a2e0b7-f678-40b3-8050-2792026776c1\\\", \\\"childbox\\\": \\\"475fc148-e789-4625-b83d-0338d20518eb\\\", \\\"subtext\\\": \\\"7ff3b8b9-7c08-4336-86dc-953e91d678e3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 634, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Safety monitoring will include monitoring for systemic hypersensitivity and local injection site reactions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"53a2e0b7-f678-40b3-8050-2792026776c1\\\", \\\"childbox\\\": \\\"a619964d-26a0-4005-856a-cf242fd2c71b\\\", \\\"subtext\\\": \\\"88aea1ef-0b8c-4866-a6f1-3434d000ce72\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 635, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 Until such time as GSK3196165 becomes available in a pre-filled syringe, every SC injection must be delivered by an unblinded administrator and the syringe must be shielded from the participant at all times, to avoid unblinding.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 21, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"30902f33-d1e3-474a-b513-89da7fb9bbce\\\", \\\"childbox\\\": \\\"38c741d4-94cf-482d-a0b4-b62a61e5402c\\\", \\\"subtext\\\": \\\"c89126aa-b211-4e7e-998f-4465cc16b5c1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 636, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 If/when GSK3196165 becomes available in a pre-filled syringe, the SC injection must still be delivered by an unblinded administrator at weeks corresponding to sarilumab dosing (i.e.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 10, \\\"end_idx\\\": 19, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f9405cec-6e99-4ccf-81a2-32eccb064b9b\\\", \\\"childbox\\\": \\\"094a2e2c-54cb-4b03-8a9f-28b5c6d0db17\\\", \\\"subtext\\\": \\\"bb32847f-cd84-4f67-ab68-649c4aba495f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 637, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22), to avoid unblinding.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9405cec-6e99-4ccf-81a2-32eccb064b9b\\\", \\\"childbox\\\": \\\"6f398d91-ae08-42f1-824e-1580694c2a97\\\", \\\"subtext\\\": \\\"6c83d561-d04b-441e-ba0e-a375df9b9651\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 638, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Self-administration of pre-filled syringe may be permitted on intervening weeks.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9405cec-6e99-4ccf-81a2-32eccb064b9b\\\", \\\"childbox\\\": \\\"f75cfecd-3b82-47c2-9570-638b3d1040f7\\\", \\\"subtext\\\": \\\"6c83d561-d04b-441e-ba0e-a375df9b9651\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 639, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Any participant who doses at home must be instructed to contact the site immediately if they experience any symptoms following dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9405cec-6e99-4ccf-81a2-32eccb064b9b\\\", \\\"childbox\\\": \\\"45a9dfc2-239f-4f8b-a93a-30c8d68d1312\\\", \\\"subtext\\\": \\\"6c83d561-d04b-441e-ba0e-a375df9b9651\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 640, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 Where possible, assessment visits should be scheduled to coincide with the weekly administration of study SC injection,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a966d46d-bf2f-46a5-b1c0-6bd635f9cd7b\\\", \\\"childbox\\\": \\\"cd313115-66e4-4554-9aa9-0b51678f9969\\\", \\\"subtext\\\": \\\"ccda40d4-f559-4c4e-9773-b4bc15e2cfe6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 641, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"the injection will then be performed at the site, after completion of PK sampling\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a966d46d-bf2f-46a5-b1c0-6bd635f9cd7b\\\", \\\"childbox\\\": \\\"cd313115-66e4-4554-9aa9-0b51678f9969\\\", \\\"subtext\\\": \\\"191ef3cb-9d09-435f-b172-79ba4c7fecfe\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 642, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"(see Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a966d46d-bf2f-46a5-b1c0-6bd635f9cd7b\\\", \\\"childbox\\\": \\\"cd313115-66e4-4554-9aa9-0b51678f9969\\\", \\\"subtext\\\": \\\"f48d9bc8-0c6b-4ff8-8da6-bbec4295906f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 643, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 Participants who are initially dosed with SC injections of study intervention supplied from vials, should continue to be dosed from the vials until at least Week 12 to coincide with the timing of the primary endpoint unless this is impractical due to supply issues; these participants may be switched to SC injections from the pre-filled syringes after Week 12, if sufficient supply is available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a0ab0acc-c2e6-447f-9059-892403648271\\\", \\\"childbox\\\": \\\"1f4a1db1-e0a2-41fb-b982-fa02631f61f6\\\", \\\"subtext\\\": \\\"719b52a3-b5f2-40fb-a2d2-94b5362148fb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 644, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"\\\\u2022 Participants who are initially dosed with SC injections of study intervention from the pre-filled syringes should continue to be dosed in this manner for the duration of the study providing sufficient supplies are available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b0ca78ee-8a83-4fa7-85a1-64f877e959a5\\\", \\\"childbox\\\": \\\"527f658f-bc5e-422a-be1a-54c4e20abce3\\\", \\\"subtext\\\": \\\"47f07cef-0903-45ab-87d0-c5645a5ddb16\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 645, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"In parallel to receiving study intervention, all participants will receive a stable dose of background csDMARD(s) (refer to Section 6.5).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7b1f2bc3-925e-4fbf-8d37-36ea0d56c61e\\\", \\\"childbox\\\": \\\"95fa4cf1-ba3d-4e7a-b638-28474349fe90\\\", \\\"subtext\\\": \\\"da526369-400f-44e7-ac9a-f5039b4d2077\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 646, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Any participant whose background DMARD is MTX must also receive \\\\u22655 mg/week folic (or folinic) acid orally (dosing regimen at the discretion of the investigator).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 33, \\\"end_idx\\\": 37, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"DMARD\\\"}, {\\\"start_idx\\\": 42, \\\"end_idx\\\": 44, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"MTX\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"7b1f2bc3-925e-4fbf-8d37-36ea0d56c61e\\\", \\\"childbox\\\": \\\"886b1edc-5d30-4946-8e1e-9f40c7585a3b\\\", \\\"subtext\\\": \\\"3df9d828-55e4-4f47-bd18-a24dc0f2f174\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 647, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"Dose modifications to background DMARDs are discussed in Section 6.6.2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7b1f2bc3-925e-4fbf-8d37-36ea0d56c61e\\\", \\\"childbox\\\": \\\"6598ab4b-1ba8-400d-b6ce-b43f2276546e\\\", \\\"subtext\\\": \\\"e11fd955-7562-46f5-b8bc-e4f3a82ba554\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 648, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention(s) Administered\\\", \\\"text\\\", \\\"All local standard-of-care practices for the administration of csDMARD(s), including laboratory testing, follow-up care, contraindications, and (for MTX) folic acid administration, should be performed throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 149, \\\"end_idx\\\": 151, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"MTX\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"479271e2-18dc-46d4-96de-df0b4a9140b4\\\", \\\"childbox\\\": \\\"b88807fd-9088-4fda-8957-09e654861ee6\\\", \\\"subtext\\\": \\\"214babda-a755-40ba-81c7-182f52c3a0e8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention(s) Administered\\\", \\\"6.1.\\\", \\\"2\\\", 649, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Table 1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"43239e3e-4047-4a19-93ef-b3f558b823ee\\\", \\\"childbox\\\": \\\"0cf63243-bc0f-4021-a356-17d712b1132a\\\", \\\"subtext\\\": \\\"fed5a1db-eec1-4ec7-87d4-7990c92a5340\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Overview of Study Intervention\\\", \\\"Table 1\\\", \\\"3\\\", 650, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"43239e3e-4047-4a19-93ef-b3f558b823ee\\\", \\\"childbox\\\": \\\"d1205cd4-55ff-4591-915c-5408f443c878\\\", \\\"subtext\\\": \\\"b702a1ee-368b-43b7-8c35-c61c3ba5b176\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Overview of Study Intervention\\\", \\\"Table 1\\\", \\\"3\\\", 651, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Overview of Study Intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"43239e3e-4047-4a19-93ef-b3f558b823ee\\\", \\\"childbox\\\": \\\"d5a27a62-9216-428e-9437-4dcaf0fb542f\\\", \\\"subtext\\\": \\\"b702a1ee-368b-43b7-8c35-c61c3ba5b176\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Overview of Study Intervention\\\", \\\"Table 1\\\", \\\"3\\\", 652, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6cb4d179-edbc-41b0-be76-3d3da1b37065\\\", \\\"childbox\\\": \\\"eb357dba-c2bc-4217-92f9-2c888b6d0763\\\", \\\"subtext\\\": \\\"a9cfe3fb-350d-4c51-a971-a24c0ef7b48a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Overview of Study Intervention\\\", \\\"Table 1\\\", \\\"3\\\", 653, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fba2d40f-e5ab-42b2-bf1f-df1a649e45b0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"mg\\\", \\\"150\\\", \\\"1\\\", 654, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e0300d48-9975-4f16-905b-e8ce1b6d9743\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"mg\\\", \\\"150\\\", \\\"1\\\", 655, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"* Placebo consists of 3 arms to Week 12, after which participants will be switched to 1 of the 3 active intervention arms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d26c4ff-326f-49a1-bd6d-1417274a88c5\\\", \\\"childbox\\\": \\\"1349d727-47f0-4ba7-8097-de57e367bf0c\\\", \\\"subtext\\\": \\\"3618c4e7-0031-4643-b62b-3102e6a75591\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"mg\\\", \\\"150\\\", \\\"1\\\", 656, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PFS = prefilled syringe; GM-CSF = granulocyte macrophage colony stimulating factor; Ab = antibody.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 25, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}, {\\\"start_idx\\\": 46, \\\"end_idx\\\": 81, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"macrophage colony stimulating factor\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"323a5f4f-5709-46ee-883f-cd90df5d3ec2\\\", \\\"childbox\\\": \\\"057fe157-4952-4d7a-8fbd-cbb2639eece9\\\", \\\"subtext\\\": \\\"17d3d39f-3458-4088-bfca-bdc361a0a28a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"mg\\\", \\\"150\\\", \\\"1\\\", 657, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GSK3196165 in vials and placebo will be administered SC, using syringes and needles commonly used for SC administration (e.g.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"323a5f4f-5709-46ee-883f-cd90df5d3ec2\\\", \\\"childbox\\\": \\\"c8f9dadb-4301-4e9b-a880-c8f7d151a798\\\", \\\"subtext\\\": \\\"17d3d39f-3458-4088-bfca-bdc361a0a28a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"mg\\\", \\\"150\\\", \\\"1\\\", 658, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1 mL syringe, with 25 or 27 gauge needle); compatibility with commonly used syringes and needles has been demonstrated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"323a5f4f-5709-46ee-883f-cd90df5d3ec2\\\", \\\"childbox\\\": \\\"2e6d1904-4099-44e3-8a5b-3e55be2e1f7f\\\", \\\"subtext\\\": \\\"b81a0e72-bd85-4191-95c3-7b10830df19b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"mg\\\", \\\"150\\\", \\\"1\\\", 659, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"header\\\", \\\"6.2. Preparation/Handling/Storage/Accountability\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f1904bc5-4319-4884-bb96-c7d842180ac5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 660, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"\\\\u2022 The site pharmacist or unblind administrator must confirm appropriate temperature conditions have been maintained during transit for all study intervention received and any discrepancies are reported and resolved before use of the study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0e65527c-e05e-4794-a908-451e18c19f5a\\\", \\\"childbox\\\": \\\"26ccfa4c-a32a-4e64-852f-acd3cb522340\\\", \\\"subtext\\\": \\\"fed5c32a-699d-493b-a6c9-d6baff62cc20\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 661, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"\\\\u2022 Only participants enrolled in the study may receive study intervention and only authorised site staff may supply or administer study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e452444-e14c-43ef-959c-eea8d89f4ec0\\\", \\\"childbox\\\": \\\"6e88fd06-184b-4a43-a55c-69069cf0d05c\\\", \\\"subtext\\\": \\\"8b8daaa0-3601-4dea-94f7-2aa1fc09a8ed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 662, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorised site staff.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5e452444-e14c-43ef-959c-eea8d89f4ec0\\\", \\\"childbox\\\": \\\"4374111a-3c45-43c5-8f27-7e610ffe3868\\\", \\\"subtext\\\": \\\"8b8daaa0-3601-4dea-94f7-2aa1fc09a8ed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 663, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"\\\\u2022 The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b6aeac04-a6d3-43a2-a64c-4c57da0967d5\\\", \\\"childbox\\\": \\\"1383a82a-d522-4c99-a2ed-d4d9087f35b0\\\", \\\"subtext\\\": \\\"7b9c4689-316b-4011-b6df-8a3eaf117244\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 664, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"\\\\u2022 Further guidance and information for the final disposition of unused study intervention are provided in the SRM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b45b0140-cada-4a1a-a195-624621c99d0c\\\", \\\"childbox\\\": \\\"438e3695-d7b2-480b-8e02-7311dfab31b4\\\", \\\"subtext\\\": \\\"5e2a78e8-5c35-4489-8f62-0d141068fa26\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 665, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"\\\\u2022 Under normal conditions of handling and administration, study intervention is not expected to pose significant safety risks to site staff.  Take adequate precautions to avoid direct eye or skin contact and the generation of aerosols or mists.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dcc7484d-91bd-4a8d-a542-e6eef9076a76\\\", \\\"childbox\\\": \\\"11b4d30d-ec63-4ff2-9602-9ea7aa9a97ef\\\", \\\"subtext\\\": \\\"41414deb-bc7c-4f17-a079-af4226506bd0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 666, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"In the case of unintentional occupational exposure notify the monitor, Medical Monitor and/or GSK study contact.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 94, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 94, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"dcc7484d-91bd-4a8d-a542-e6eef9076a76\\\", \\\"childbox\\\": \\\"cf2392a3-15f9-4c4a-9762-162d11a018cb\\\", \\\"subtext\\\": \\\"e48797fc-7104-498c-b814-0503c264cd33\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 667, \\\"\\\"], [\\\"2\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"text\\\", \\\"\\\\u2022 A Material Safety Data Sheet (MSDS)/equivalent document describing occupational hazards and recommended handling precautions either will be provided to the investigator, where this is required by local laws, or is available upon request from GSK.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 244, \\\"end_idx\\\": 246, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 244, \\\"end_idx\\\": 246, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"d019d1a6-59d1-4441-8391-1996ddc81122\\\", \\\"childbox\\\": \\\"018ddd56-4b5b-4edf-9bf1-5d0ffb4f7d81\\\", \\\"subtext\\\": \\\"f55ae858-7111-4cf9-85b5-60ab3b6d75e8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Preparation/Handling/Storage/Accountability\\\", \\\"6.2.\\\", \\\"2\\\", 668, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"header\\\", \\\"6.3. Measures to Minimise Bias: Randomisation and Blinding\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"edae5719-9986-42c3-a7a9-4c9bbbd01d59\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 669, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"All participants will be centrally randomised using Interactive Response Technology (IRT).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6ec4c4e1-4753-408b-9b0f-0ec2aadbf661\\\", \\\"childbox\\\": \\\"d250db49-de21-43bd-a34e-feecd7e38e2c\\\", \\\"subtext\\\": \\\"3ad264a6-2b85-406b-8d83-d4cf520c985b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 670, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Before the study is initiated, the log in information and directions for the IRT will be provided to each site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6ec4c4e1-4753-408b-9b0f-0ec2aadbf661\\\", \\\"childbox\\\": \\\"3acd19d1-2346-4652-befc-a0120b0a8048\\\", \\\"subtext\\\": \\\"19fae04e-65ce-44fd-b8f0-0e20c03b17ec\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 671, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Study intervention will be dispensed at the study visits summarised in the SoA for the treatment period (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6ec4c4e1-4753-408b-9b0f-0ec2aadbf661\\\", \\\"childbox\\\": \\\"accb9915-d1aa-4515-a94c-2ef41f8c3b29\\\", \\\"subtext\\\": \\\"19fae04e-65ce-44fd-b8f0-0e20c03b17ec\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 672, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Returned study intervention should not be re-dispensed to the participants.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6ec4c4e1-4753-408b-9b0f-0ec2aadbf661\\\", \\\"childbox\\\": \\\"b2397e95-3cdf-411e-8c40-1ac86ee13b96\\\", \\\"subtext\\\": \\\"8731a409-684a-4516-98c7-9966137a3aa6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 673, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"The IRT will be programmed with blind-breaking instructions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ab825de4-2afd-44ce-ad50-7d6acf574b03\\\", \\\"childbox\\\": \\\"d78817c9-69d6-4f79-9af9-92c045f7bbf2\\\", \\\"subtext\\\": \\\"538b9d19-32c0-4390-ad17-da24c1f5c483\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 674, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"In case of an emergency, the investigator has the sole responsibility for determining if unblinding of a participant\\\\u2019s intervention assignment is warranted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ab825de4-2afd-44ce-ad50-7d6acf574b03\\\", \\\"childbox\\\": \\\"82d1799a-7a6a-42de-9c25-be3fcb590197\\\", \\\"subtext\\\": \\\"538b9d19-32c0-4390-ad17-da24c1f5c483\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 675, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Participant safety must always be the first consideration in making such a determination.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ab825de4-2afd-44ce-ad50-7d6acf574b03\\\", \\\"childbox\\\": \\\"18789206-125a-4dc2-af69-53f2ddc964b0\\\", \\\"subtext\\\": \\\"6af47706-d26c-4e97-9176-891b7c72b235\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 676, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"If the investigator decides that unblinding is warranted, the investigator should make every effort to contact GSK or designee prior to unblinding a participant\\\\u2019s intervention assignment unless this could delay emergency intervention of the participant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 111, \\\"end_idx\\\": 113, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 111, \\\"end_idx\\\": 113, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ab825de4-2afd-44ce-ad50-7d6acf574b03\\\", \\\"childbox\\\": \\\"736528c3-a4d9-44ab-a724-1c7237db14ba\\\", \\\"subtext\\\": \\\"6af47706-d26c-4e97-9176-891b7c72b235\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 677, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"If a participant\\\\u2019s intervention assignment is unblinded GSK must be notified within 24 hours after breaking the blind.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 56, \\\"end_idx\\\": 58, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 56, \\\"end_idx\\\": 58, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ab825de4-2afd-44ce-ad50-7d6acf574b03\\\", \\\"childbox\\\": \\\"e927a79f-c208-4c63-8c5d-35620887eba4\\\", \\\"subtext\\\": \\\"7ac2243c-bd3f-4bdd-a50a-37a3a6737a93\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 678, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"The date and reason that the blind was broken must be recorded in the source documentation and case report form, as applicable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ab825de4-2afd-44ce-ad50-7d6acf574b03\\\", \\\"childbox\\\": \\\"551e9bd4-9ca3-493d-8257-a5a734346ce2\\\", \\\"subtext\\\": \\\"8f16b74e-6a84-4468-9084-736bae179805\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 679, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Participants will be randomised in a ratio of 6:6:6:1:1:1 to receive study intervention (Section 1.2 and Section 6.1).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1fa6410-8e3a-4634-9cdf-09dfad86c766\\\", \\\"childbox\\\": \\\"e98898b8-e9e5-4bcc-82e7-0dfe8db5da82\\\", \\\"subtext\\\": \\\"ebe4282e-0fb9-4bc6-bd80-0156ece3d989\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 680, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Investigators will remain blinded to each participant\\\\u2019s assigned study intervention throughout the course of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1fa6410-8e3a-4634-9cdf-09dfad86c766\\\", \\\"childbox\\\": \\\"f2717c4f-98a7-404f-bd06-f37c0ded7a67\\\", \\\"subtext\\\": \\\"54790017-8fc4-461a-aff1-e6f4896b4c00\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 681, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"To maintain this blind, all participants will receive once-weekly SC injections for the duration of the treatment period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1fa6410-8e3a-4634-9cdf-09dfad86c766\\\", \\\"childbox\\\": \\\"25f3097a-27e6-4ddf-b2a5-e54c3dab600f\\\", \\\"subtext\\\": \\\"54790017-8fc4-461a-aff1-e6f4896b4c00\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 682, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Until such time as a matched placebo becomes available for GSK3196165, every SC injection must be delivered by an unblinded administrator and the syringe must be shielded from the participant to avoid unblinding.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 59, \\\"end_idx\\\": 68, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"a1fa6410-8e3a-4634-9cdf-09dfad86c766\\\", \\\"childbox\\\": \\\"c0639471-fe48-4ff9-ad02-db0cfe0f4e25\\\", \\\"subtext\\\": \\\"31fa3028-9ac3-405c-9b31-3e891019d39c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 683, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"The sarilumab dosing regimen is every other week, therefore participants randomised to sarilumab will receive SC injections of sarilumab every other week, plus a placebo injection in the intervening weeks to maintain the blind.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 4, \\\"end_idx\\\": 12, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 87, \\\"end_idx\\\": 95, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 127, \\\"end_idx\\\": 135, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"1f6fceb9-40f0-4e54-886d-e615d8c39921\\\", \\\"childbox\\\": \\\"6c20f9e7-9760-4028-8910-0035ac5f0fb3\\\", \\\"subtext\\\": \\\"0384d3e0-220d-4bd3-afdc-93cb5565d3c3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 684, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"This will be managed by the IRT.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1f6fceb9-40f0-4e54-886d-e615d8c39921\\\", \\\"childbox\\\": \\\"6e0c5d65-b728-4680-90d1-97ff9c957724\\\", \\\"subtext\\\": \\\"0e14fc01-8d34-43b8-8bd1-5151ac0479e0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 685, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"In addition, regardless of whether PFS are available, on weeks corresponding to sarilumab dosing (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22), all participants must receive their study SC injection from an unblinded administrator, with the injection syringe shielded from the participant, to avoid unblinding.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1f6fceb9-40f0-4e54-886d-e615d8c39921\\\", \\\"childbox\\\": \\\"acd56112-8e12-4fa2-ab78-ddb08981a7b2\\\", \\\"subtext\\\": \\\"0e14fc01-8d34-43b8-8bd1-5151ac0479e0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 686, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"An unblinded pharmacist (or unblinded designee) will be responsible for the dispensation of the study intervention and will endeavour to ensure that there are no differences in time taken to dispense between the different intervention arms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f925a421-6d13-4a89-8727-9839a302748a\\\", \\\"childbox\\\": \\\"0e3c9138-7cab-46b8-8efb-d040317ab517\\\", \\\"subtext\\\": \\\"ff43724a-be3e-4fc6-a4f0-0a224a789f2c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 687, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"While the study drug is supplied in vials, care will be taken to ensure that participants are not able to see the injection volume, syringe size or colour of liquid.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f925a421-6d13-4a89-8727-9839a302748a\\\", \\\"childbox\\\": \\\"c88be7cf-c993-4e32-8993-a6f661229962\\\", \\\"subtext\\\": \\\"da948da1-01a3-4f0b-b53c-cb7bfe7dbbd0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 688, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"The syringe should be prepared away from view of the participant, and appropriate shielding or masking of the syringe applied prior to administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f925a421-6d13-4a89-8727-9839a302748a\\\", \\\"childbox\\\": \\\"4ae3e170-31fe-4dae-8775-2c84c19352bd\\\", \\\"subtext\\\": \\\"da948da1-01a3-4f0b-b53c-cb7bfe7dbbd0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 689, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"In addition, in order to maintain the integrity of the blind, investigators and site staff will not have access to ongoing post-randomisation hsCRP/ESR analyses and should refrain from performing either routine ESR or CRP assessments unless clinically indicated for AE assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8cc19851-b804-49a1-8520-12dcc1d44091\\\", \\\"childbox\\\": \\\"5c0809ac-5bfa-4efe-87a3-c674c4cc859d\\\", \\\"subtext\\\": \\\"b951ffec-609b-4955-9838-9d8fdd809457\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 690, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Furthermore, the results of the PK analyses of GSK3196165 will not be provided to the sites.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 47, \\\"end_idx\\\": 56, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"8cc19851-b804-49a1-8520-12dcc1d44091\\\", \\\"childbox\\\": \\\"9d9a3a11-9b24-4735-9a7c-72eaa912856f\\\", \\\"subtext\\\": \\\"5d128248-e358-4f6d-abbe-53b38f7710b4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 691, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"In order to reduce bias, an independent joint assessor will perform all joint assessments (Section 8.1.1).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c8af090e-2e9a-48cd-80f8-1b5711d88615\\\", \\\"childbox\\\": \\\"4f5f3692-5d8a-4e61-9116-df58526d17dc\\\", \\\"subtext\\\": \\\"1b84e3a0-fff5-4893-becd-b335ec2e1741\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 692, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"Unblinded monitors and in the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded study intervention records at the site(s) to verify that randomisation/dispensing has been done accurately.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bfd9badc-154b-451e-bb4d-764accd1971f\\\", \\\"childbox\\\": \\\"3392ad42-ea44-4a88-bc89-3f8e451db3c4\\\", \\\"subtext\\\": \\\"9b33d781-a468-4506-aa49-5839f3727eb2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 693, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"A participant may continue in the study if that participant\\\\u2019s intervention assignment is unblinded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d062c130-2fea-47b5-9d7b-3279b1475185\\\", \\\"childbox\\\": \\\"c0acc8a2-249a-4919-ad20-ac9bc304e076\\\", \\\"subtext\\\": \\\"7d74c957-ad67-49d6-aa12-186a1ca147fd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 694, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"GSK\\\\u2019s Pharma Safety staff may unblind the intervention assignment for any participant with an SAE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\\u2019s\\\"}, {\\\"start_idx\\\": 0, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\\u2019s\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e597460d-dce2-4951-b586-eccf98867e2c\\\", \\\"childbox\\\": \\\"ff5a05d4-4cb9-48df-aa67-14decbbf16cf\\\", \\\"subtext\\\": \\\"3e1734ed-d4c9-404f-9011-f85aa31bc982\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 695, \\\"\\\"], [\\\"2\\\", \\\"Measures to Minimize Bias: Randomization and Blinding\\\", \\\"text\\\", \\\"If the SAE requires that an expedited regulatory report be sent to one or more regulatory agencies, a copy of the report, identifying the participant\\\\u2019s intervention assignment, may be sent to investigators in accordance with local regulations and/or GSK policy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 250, \\\"end_idx\\\": 252, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 250, \\\"end_idx\\\": 252, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e597460d-dce2-4951-b586-eccf98867e2c\\\", \\\"childbox\\\": \\\"1e6b3cb2-9464-44d1-a726-d7d12872f601\\\", \\\"subtext\\\": \\\"3e1734ed-d4c9-404f-9011-f85aa31bc982\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Measures to Minimise Bias: Randomisation and Blinding\\\", \\\"6.3.\\\", \\\"2\\\", 696, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"header\\\", \\\"6.4. Study Intervention Compliance\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9fbfd500-b788-455d-b702-2b45dd723a66\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 697, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"GSK3196165 or matching placebo will be administered by SC injection at the times indicated in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4a1c06d9-1d97-4904-aa33-8a22211158d7\\\", \\\"childbox\\\": \\\"74671cdb-51ee-401b-a3f9-098db81364ce\\\", \\\"subtext\\\": \\\"298a2e4c-0a9e-413c-97a4-a4ddc5446b8c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 698, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"Participants should receive all doses per schedule, however exceptional circumstances may lead to a dose being missed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a1c06d9-1d97-4904-aa33-8a22211158d7\\\", \\\"childbox\\\": \\\"e260d472-cf32-4a58-b85c-41e7ebf44c3c\\\", \\\"subtext\\\": \\\"708d3571-0754-4772-b524-651c9209fa52\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 699, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"If a dose is missed, the dose may be rescheduled to a new date/time providing the new date is within the SoA window for the missed dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a1c06d9-1d97-4904-aa33-8a22211158d7\\\", \\\"childbox\\\": \\\"993f1660-0ccd-4569-9099-472f315ecbc1\\\", \\\"subtext\\\": \\\"c7c9ac38-3abe-4ced-b40c-cefc963ca057\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 700, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"If the dose cannot be rescheduled within the visit window,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a1c06d9-1d97-4904-aa33-8a22211158d7\\\", \\\"childbox\\\": \\\"41aa3d65-e4a3-40aa-b8e9-b81a26edaeec\\\", \\\"subtext\\\": \\\"c7c9ac38-3abe-4ced-b40c-cefc963ca057\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 701, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"the dose must not be given outside the window\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a1c06d9-1d97-4904-aa33-8a22211158d7\\\", \\\"childbox\\\": \\\"41aa3d65-e4a3-40aa-b8e9-b81a26edaeec\\\", \\\"subtext\\\": \\\"ff02ddb2-4c35-49e9-a241-0b5bd2bc375e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 702, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"and must be marked as missed in the IRT.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a1c06d9-1d97-4904-aa33-8a22211158d7\\\", \\\"childbox\\\": \\\"41aa3d65-e4a3-40aa-b8e9-b81a26edaeec\\\", \\\"subtext\\\": \\\"7ada75f5-abe0-40df-9f3f-c5853f865da2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 703, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"After a missed dosed, further dosing may continue per SoA with the following requirements:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a1c06d9-1d97-4904-aa33-8a22211158d7\\\", \\\"childbox\\\": \\\"c2c80a6c-10ae-450d-bc23-52c66dcdbd76\\\", \\\"subtext\\\": \\\"809d4477-8d8c-4537-a417-a1cd26b9f755\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 704, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"\\\\u2022 Except for doses temporarily interrupted for safety reasons, the investigator must meet to discuss compliance with the study intervention with any participant who appears to be non-compliant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8481910d-5130-4dce-904e-749f3eabc74a\\\", \\\"childbox\\\": \\\"aac7536a-8c07-4485-bff9-005e18b14c0e\\\", \\\"subtext\\\": \\\"c024a7ad-b42f-4a09-9af0-f7cbcf0f4dfc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 705, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"\\\\u2022 If the participant continues to be non-compliant and missed further doses, the investigator may decide to permanently discontinue the participant from study intervention and initiate standard of care.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f723640f-ce45-4cd6-a138-bde9f814bb91\\\", \\\"childbox\\\": \\\"876c48f4-acc3-46bc-aa97-7e1b498fc037\\\", \\\"subtext\\\": \\\"a61814b4-d7eb-4b4d-a26c-f32ca4b4edf1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 706, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"The participant will be encouraged to continue to attend study visits until week 24.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f723640f-ce45-4cd6-a138-bde9f814bb91\\\", \\\"childbox\\\": \\\"b9723783-99f0-47c7-9fac-a596417ca95d\\\", \\\"subtext\\\": \\\"524b8779-2335-40ed-9ada-7d2ee052a5f2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 707, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"A record of the number of study intervention injections dispensed to and taken by each participant must be maintained by the site staff and reconciled with study intervention and compliance records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c20b22b9-2e73-436d-b01b-6e9ebd4e5cab\\\", \\\"childbox\\\": \\\"9129680e-cfbf-4668-ba9f-11ab5fe9a794\\\", \\\"subtext\\\": \\\"63b154fc-2f43-4294-a227-4eba516991c3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 708, \\\"\\\"], [\\\"2\\\", \\\"Study Intervention Compliance\\\", \\\"text\\\", \\\"Intervention start and stop dates, including dates for intervention delays will also be recorded in the CRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c20b22b9-2e73-436d-b01b-6e9ebd4e5cab\\\", \\\"childbox\\\": \\\"51ce3474-d236-4946-8e5e-32b72de66955\\\", \\\"subtext\\\": \\\"0f36ce9f-1114-42b1-8853-fccc7a65297e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Study Intervention Compliance\\\", \\\"6.4.\\\", \\\"2\\\", 709, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5. Prior and Concomitant Therapies\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0a2b980f-4d25-42f2-ae7a-c9e178b5c933\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prior and Concomitant Therapies\\\", \\\"6.5.\\\", \\\"2\\\", 710, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Due to effect of cytokines on the CYP450 enzymes (Section 2.3.1) initiation or discontinuation of study intervention may have clinically relevant effect for CYP substrates with a narrow therapeutic index e.g.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 17, \\\"end_idx\\\": 25, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"cytokines\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f597074e-e3ba-4260-850c-777855d08f5e\\\", \\\"childbox\\\": \\\"90c8eeee-deef-411f-b700-86234e1ebdbe\\\", \\\"subtext\\\": \\\"bea62982-fe70-49e1-9848-ae65f95545a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prior and Concomitant Therapies\\\", \\\"6.5.\\\", \\\"2\\\", 711, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"warfarin and theophylline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 7, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"warfarin\\\"}, {\\\"start_idx\\\": 13, \\\"end_idx\\\": 24, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"theophylline\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f597074e-e3ba-4260-850c-777855d08f5e\\\", \\\"childbox\\\": \\\"9c72cffe-3fb9-424b-9723-63aabffcb280\\\", \\\"subtext\\\": \\\"15c4aa03-079e-43ab-a4b2-d6a105e6e589\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prior and Concomitant Therapies\\\", \\\"6.5.\\\", \\\"2\\\", 712, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Where a CYP3A4 substrate drug is co-administered during the study, in addition to recording the initial dose and any dosage changes over time in the CRF, the results of any therapeutic monitoring (e.g.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f597074e-e3ba-4260-850c-777855d08f5e\\\", \\\"childbox\\\": \\\"bf81a758-862e-45a1-a3c7-f8d7f12cd37f\\\", \\\"subtext\\\": \\\"15c4aa03-079e-43ab-a4b2-d6a105e6e589\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prior and Concomitant Therapies\\\", \\\"6.5.\\\", \\\"2\\\", 713, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"INR results), if available, should also be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f597074e-e3ba-4260-850c-777855d08f5e\\\", \\\"childbox\\\": \\\"63ba977b-cb97-4e0b-a31c-190af3f553f7\\\", \\\"subtext\\\": \\\"15c4aa03-079e-43ab-a4b2-d6a105e6e589\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prior and Concomitant Therapies\\\", \\\"6.5.\\\", \\\"2\\\", 714, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigators should exercise caution when study intervention is co-administered with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 163, \\\"end_idx\\\": 181, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"oral contraceptives\\\"}, {\\\"start_idx\\\": 184, \\\"end_idx\\\": 193, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"lovastatin\\\"}, {\\\"start_idx\\\": 196, \\\"end_idx\\\": 207, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"atorvastatin\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"9001e46f-4924-4ded-a199-cb3ec1353929\\\", \\\"childbox\\\": \\\"09436fb8-1852-43d2-a69f-9cd774f5b2b9\\\", \\\"subtext\\\": \\\"ccd4f582-a7ac-4684-bfba-a6ae20c35729\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prior and Concomitant Therapies\\\", \\\"6.5.\\\", \\\"2\\\", 715, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.1. Permitted Therapies\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"848c2973-fd3b-4641-9bec-c68d5d911bc1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 716, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Medications or treatments deemed necessary by the investigator to provide supportive care will be permitted during the study except when administration would occur during a time of restricted use, as in Table 2, or if the medication is specifically excluded, as in Section 6.5.2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dce93db8-934d-434a-8523-270e19a96288\\\", \\\"childbox\\\": \\\"8c70cfde-8132-4cca-8d59-6a5a2e0dea3c\\\", \\\"subtext\\\": \\\"a6312f49-43f9-45e5-9cf6-192f9478dbef\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 717, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The permitted dose is the usual marketed dose approved in the country in which the study is being conducted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dce93db8-934d-434a-8523-270e19a96288\\\", \\\"childbox\\\": \\\"bc5f1d8b-747d-4b52-860b-c29ee86a3b30\\\", \\\"subtext\\\": \\\"eacb3509-686c-4d67-b283-10a7e12b4eb0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 718, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any use of these medications must be recorded in the eCRF, along with:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dce93db8-934d-434a-8523-270e19a96288\\\", \\\"childbox\\\": \\\"aa6b6afb-21bd-4a23-a58a-9e2447c78a03\\\", \\\"subtext\\\": \\\"eacb3509-686c-4d67-b283-10a7e12b4eb0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 719, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 reason for use\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"96c9cf2c-1329-4674-8479-a9e4830fa3a8\\\", \\\"childbox\\\": \\\"ce64363e-03c6-43d7-b704-69eb1c0dbe55\\\", \\\"subtext\\\": \\\"daf60051-b118-4aac-b1a4-9ea9daaa44f4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 720, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 dates of administration including start and end dates\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3731b408-c4de-48cd-84ea-9582736fd40c\\\", \\\"childbox\\\": \\\"c2c19c4b-70c6-4ffc-a6fa-b61228a40916\\\", \\\"subtext\\\": \\\"6bdedbfe-de72-457d-8b25-d3bbfc66bfda\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 721, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 dosage information including dose and frequency\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c4df08a5-3164-469b-905e-4a31634632f2\\\", \\\"childbox\\\": \\\"5fb0ce99-c08a-4e50-9249-2895ba9e554d\\\", \\\"subtext\\\": \\\"c0c0f0cf-c745-4725-8998-bf5ebb1532e7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 722, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Medical Monitor should be contacted if there are any questions regarding concomitant or prior therapy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f85ba005-929e-43c7-b5e7-3cb91ab4200e\\\", \\\"childbox\\\": \\\"f10cfa5d-4a92-4612-ac46-93ffde3cefe6\\\", \\\"subtext\\\": \\\"fe425f34-8af3-4d29-a569-1dc302a19b87\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 723, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The requirements for use of specific permitted medications/treatments are listed in Table 2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f85ba005-929e-43c7-b5e7-3cb91ab4200e\\\", \\\"childbox\\\": \\\"f0fcf941-22e2-4346-a7b0-3d7df83d6537\\\", \\\"subtext\\\": \\\"fe425f34-8af3-4d29-a569-1dc302a19b87\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Permitted Therapies\\\", \\\"6.5.1.\\\", \\\"3\\\", 724, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 2 Requirements for Use of Specific Permitted Medications/Treatments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b9a0f365-a62e-4528-8105-5120fcaaf175\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 725, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ba3e59e0-0e88-4f5f-ab38-2496c2cd1109\\\", \\\"childbox\\\": \\\"190823f5-556c-4222-abfb-e003527a417a\\\", \\\"subtext\\\": \\\"c25f78ab-b46e-4285-be6d-d0a6d1b4edfa\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 726, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cf68b0a4-011d-499e-b608-d10a96ab4e93\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 727, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d0c2771-f176-463a-8529-034eaeba4105\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 728, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a6c15b86-a9e4-4b94-bfe9-3b4adc8a19dd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 729, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7c09e9d8-90ca-43ad-8768-e5e5db87b420\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 730, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bca9e970-8ef7-4b63-b193-94e7347881dd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 731, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"58fcd8bc-79d8-4fa7-b3d8-6e23ed15f354\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 732, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7eacf214-8fb8-4942-84ab-e0ab90ea9a0c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 733, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c8e67ce1-51c6-4637-a2cf-c04f802bb434\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 734, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b73f0ad4-9c75-430d-a568-60da17a85641\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 735, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1d44b9a9-8158-4640-9f07-a9f7ab47aed5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 736, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4d1a478f-440c-4ef4-9f8c-187368663a03\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 737, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8966d740-8eb1-4f95-9e08-2185d1c656a0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 738, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"39258b1c-adc4-48c0-922a-69156dd242e7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 739, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8ebb6d82-82b7-40dc-9b8d-7ea2c77d537f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 740, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1cbd8792-e53d-45f4-972a-12190a735481\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 741, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d6fc027b-2439-4473-acc6-50c02c4d0ede\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 742, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a92ba35f-ecad-43e9-a3df-dc9c268a1777\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 743, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6c846ef4-9f1f-40f9-bd6f-9cc15ae22cc0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 744, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1d3224cd-f968-47e0-8e0e-a8beeea4505e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 745, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"958c537d-4468-4313-a6c5-359413b81ca0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 746, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b45240cd-27c3-48d7-a481-5344098effcb\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 747, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7b3c4003-599c-49e9-bf28-e4e4954b4dd3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 748, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b272bf23-a11c-49e4-961b-726295910cea\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 749, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Prior to any dose changes in csDMARD(s) or oral corticosteroids, it is recommended that the Investigator contacts the medical monitor to discuss and agree with the dose change.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 48, \\\"end_idx\\\": 62, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"corticosteroids\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"a4c5c2c0-d474-4863-806e-27be3575fccd\\\", \\\"childbox\\\": \\\"3fcf3e6d-496e-44ea-82fd-0af4a15ef6a4\\\", \\\"subtext\\\": \\\"e7b2c185-d7b9-4960-8f56-f4d532e6e5ad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 750, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Use of analgesics is restricted during the first 12 weeks of study intervention and thereafter, investigators should follow routine clinical practice to manage RA pain (see Table 2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 7, \\\"end_idx\\\": 16, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"analgesics\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b1d87b34-fafc-46c6-899d-1f4812685daf\\\", \\\"childbox\\\": \\\"4a43e616-4dc1-4451-9f04-26003f55fccb\\\", \\\"subtext\\\": \\\"98eb9e24-82e2-4b59-b021-7b11c4865f16\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 751, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any new analgesic or change in analgesic use must be recorded in the concomitant medication eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 8, \\\"end_idx\\\": 16, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"analgesic\\\"}, {\\\"start_idx\\\": 31, \\\"end_idx\\\": 39, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"analgesic\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b1d87b34-fafc-46c6-899d-1f4812685daf\\\", \\\"childbox\\\": \\\"e48536e0-9bd6-4237-ad8d-b22d177bf557\\\", \\\"subtext\\\": \\\"79422cde-90f3-44ad-95bc-367f0c6a3f22\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 752, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Other medications (including vitamins, herbal and dietary supplements) will be considered on a case-by-case basis and will be permitted if in the opinion of the Investigator, after consultation with the medical monitor as necessary, the medication will not interfere with the study procedures or compromise participant safety.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"53527742-3858-4e12-a802-bc412b59eaf8\\\", \\\"childbox\\\": \\\"b0b9ef23-69bb-4064-b0d7-7c39ef99c4bb\\\", \\\"subtext\\\": \\\"9a0650b9-9fea-4754-a922-c2d38a89c9eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Requirements for Use of Specific Permitted Medications/Treatments\\\", \\\"Table 2\\\", \\\"4\\\", 753, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.2. Prohibited Therapies\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3ed5ff1e-f4c4-477d-9691-068ff571be24\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prohibited Therapies\\\", \\\"6.5.2.\\\", \\\"3\\\", 754, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Medications prohibited or restricted prior to the study, during the study and/or during the safety follow-up of the study are listed in Table 3, along with any period of exclusion which must be applied.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9b6f11a3-4b5b-4fe2-b0cc-e9c34478a794\\\", \\\"childbox\\\": \\\"bdfa5ced-f600-496c-9868-6862d0921a53\\\", \\\"subtext\\\": \\\"4ee8f207-9394-4bd3-96bd-32f1543480be\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prohibited Therapies\\\", \\\"6.5.2.\\\", \\\"3\\\", 755, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3 Prohibited medications/treatments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52924b85-44d6-4219-bfcf-a42d4c0afbdd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 756, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2970514e-3b67-4133-a358-cee1690e73c7\\\", \\\"childbox\\\": \\\"c3ed3edd-805a-4d61-a89a-26e1dab67012\\\", \\\"subtext\\\": \\\"9b602867-bb7a-44f2-9090-a56b0b9e3b78\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 757, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b322fc61-a2f7-4c5d-bd4f-b655ba95b110\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 758, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f5c82f6b-5606-4314-95a0-b0bf7dd7f061\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 759, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a4d3319-f0d1-4fb2-a536-1f3924b938b2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 760, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"744856a0-5247-40d1-aac8-887db83db420\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 761, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1e421e00-f9f1-498a-854d-95ab4fac85d2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 762, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dfee216c-87e0-4692-a4b9-7e447a7b794e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 763, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c4e4de3a-044a-4fe9-b56d-f413a700541f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 764, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"51b2112e-ee09-46e5-8cb4-cee7d1265f5f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 765, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"144120a7-a0f2-439e-827c-9847cb0736c7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 766, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"983e743e-4e5f-40c6-a84a-74554144b5e0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 767, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8fea79ad-76fb-419d-a574-28b14f5262b0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 768, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6c04f96d-a5ef-458c-9403-e4f2c1727858\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 769, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17904eba-c28f-45dd-927e-e4d983f2e4e5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 770, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"12acc23b-d999-448f-b989-32fa2f20b219\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 771, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fa62a2d0-0857-4462-8fff-5d2bed6e2785\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 772, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"01c2ae37-35ac-447e-9c19-7a4c4f75487f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 773, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b6c01baa-a4a9-4857-bf55-70d70c4bcef4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 774, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4375bda6-6ed9-4080-938a-ea788c9315aa\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 775, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"549ad628-2b57-4e0d-bd17-4e5d46c0c00a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 776, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b7937e9c-fd8a-4e7d-b241-d41c0138ea09\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Population\\\", \\\"Prohibited medications/treatments\\\", \\\"Table 3\\\", \\\"4\\\", 777, \\\"\\\"], [\\\"3\\\", \\\"Rescue Medicine\\\", \\\"header\\\", \\\"6.5.3. Rescue Medicine\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7061b252-e419-40fa-ba9c-d7859e3b9dc7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Rescue Medicine\\\", \\\"6.5.3.\\\", \\\"3\\\", 778, \\\"\\\"], [\\\"3\\\", \\\"Rescue Medicine\\\", \\\"text\\\", \\\"Acetaminophen (paracetamol) is permitted as needed, both prior to and during the study as rescue medicine for pain management, up to 4g/day or to the maximum permitted under local label (if lower than 4g/day).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 12, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Acetaminophen\\\"}, {\\\"start_idx\\\": 15, \\\"end_idx\\\": 25, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"paracetamol\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"bf1615f6-a611-4227-b25c-c22c6171307d\\\", \\\"childbox\\\": \\\"2821081f-eb29-4e0a-b290-e0ab65351321\\\", \\\"subtext\\\": \\\"15785d6b-fe95-4d58-96a0-a1f9169ec9cf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Rescue Medicine\\\", \\\"6.5.3.\\\", \\\"3\\\", 779, \\\"\\\"], [\\\"3\\\", \\\"Rescue Medicine\\\", \\\"text\\\", \\\"However, acetaminophen (paracetamol) must\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 9, \\\"end_idx\\\": 21, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"acetaminophen\\\"}, {\\\"start_idx\\\": 24, \\\"end_idx\\\": 34, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"paracetamol\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"bf1615f6-a611-4227-b25c-c22c6171307d\\\", \\\"childbox\\\": \\\"f8eca40d-d89c-4b0a-8bde-f9adf080abf5\\\", \\\"subtext\\\": \\\"15785d6b-fe95-4d58-96a0-a1f9169ec9cf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Rescue Medicine\\\", \\\"6.5.3.\\\", \\\"3\\\", 780, \\\"\\\"], [\\\"3\\\", \\\"Rescue Medicine\\\", \\\"text\\\", \\\"not\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bf1615f6-a611-4227-b25c-c22c6171307d\\\", \\\"childbox\\\": \\\"f8eca40d-d89c-4b0a-8bde-f9adf080abf5\\\", \\\"subtext\\\": \\\"6eab1cdc-e008-403f-bd6f-6215a7d8df7b\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Rescue Medicine\\\", \\\"6.5.3.\\\", \\\"3\\\", 781, \\\"\\\"], [\\\"3\\\", \\\"Rescue Medicine\\\", \\\"text\\\", \\\"be taken within 24 hours prior to the baseline (Day 1) or any assessment visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bf1615f6-a611-4227-b25c-c22c6171307d\\\", \\\"childbox\\\": \\\"f8eca40d-d89c-4b0a-8bde-f9adf080abf5\\\", \\\"subtext\\\": \\\"4e68eb81-4088-4d70-b6d2-146b691362bc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Rescue Medicine\\\", \\\"6.5.3.\\\", \\\"3\\\", 782, \\\"\\\"], [\\\"2\\\", \\\"Dose Modification\\\", \\\"header\\\", \\\"6.6. Dose Modification\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45d2234c-6c3c-4abe-b106-e6530995756a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification\\\", \\\"6.6.\\\", \\\"2\\\", 783, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"header\\\", \\\"6.6.1. Dose Modification of Study Intervention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d94c68a-d3cf-49e1-96df-fe3878e93ed7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Study Intervention\\\", \\\"6.6.1.\\\", \\\"3\\\", 784, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"text\\\", \\\"Dose adjustment of the study SC injection is not permitted in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce5e4f82-4d99-40ee-93c4-449a3fe6bc1f\\\", \\\"childbox\\\": \\\"de20d7ab-cd4c-4455-b15c-cde8e85597c1\\\", \\\"subtext\\\": \\\"b2b05f9d-ada9-4442-bd9e-10dabdcd872e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Study Intervention\\\", \\\"6.6.1.\\\", \\\"3\\\", 785, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"text\\\", \\\"The dose adjustment criteria described in the Sarilumab prescribing information has been incorporated in the study stopping criteria (refer to the temporary discontinuation and stopping criteria guidance in Section 7).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 46, \\\"end_idx\\\": 54, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"Sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"87144786-c4e1-44ba-ac98-99047175da33\\\", \\\"childbox\\\": \\\"a06d64aa-6eef-4120-a65b-4e3195f6ad35\\\", \\\"subtext\\\": \\\"5ffc220b-89a4-4c06-97fb-47d7bc8808de\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Study Intervention\\\", \\\"6.6.1.\\\", \\\"3\\\", 786, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.6.2. Dose Modification of Background Therapy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87b89dbc-eeeb-45c1-923a-599cfd29e2a4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Background Therapy\\\", \\\"6.6.2.\\\", \\\"3\\\", 787, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose reduction or temporary interruption of the background csDMARD medication(s) may be performed at any time for safety reasons (e.g.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"589c03f6-1380-483d-b079-ae61d99d9d9c\\\", \\\"childbox\\\": \\\"19b13863-680d-43b5-a9a0-0f457b78152f\\\", \\\"subtext\\\": \\\"212fc0b4-261b-4ed7-bdd7-47b0c5182b9e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Background Therapy\\\", \\\"6.6.2.\\\", \\\"3\\\", 788, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"intolerance or toxicity) but must be clearly documented.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"589c03f6-1380-483d-b079-ae61d99d9d9c\\\", \\\"childbox\\\": \\\"bfd681bd-bd6f-4d32-9222-411ffbf2fc6a\\\", \\\"subtext\\\": \\\"7f76cac8-4283-49e8-9253-da2983963462\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Background Therapy\\\", \\\"6.6.2.\\\", \\\"3\\\", 789, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If clinically indicated, csDMARD may be re-started following an interruption and increased back to the dose taken prior to the change.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"589c03f6-1380-483d-b079-ae61d99d9d9c\\\", \\\"childbox\\\": \\\"37a472f6-71e5-4d40-809e-636e4184e63c\\\", \\\"subtext\\\": \\\"7f76cac8-4283-49e8-9253-da2983963462\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Background Therapy\\\", \\\"6.6.2.\\\", \\\"3\\\", 790, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose modifications for reasons other than safety are not permitted during the study treatment period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce35aa25-3f0d-4c2d-a882-bb360377d6e7\\\", \\\"childbox\\\": \\\"c5ddef94-04ff-4839-bc66-bbedf9475591\\\", \\\"subtext\\\": \\\"3946b252-3ea2-44fc-80ca-0726e66ce937\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Dose Modification of Background Therapy\\\", \\\"6.6.2.\\\", \\\"3\\\", 791, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.7. Intervention after the End of the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"233a70ba-8f40-4763-a3da-c218fa6a9ab7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Intervention after the End of the Study\\\", \\\"6.7.\\\", \\\"2\\\", 792, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants who complete the 24-week treatment period may have the option to transition into long term extension study 209564.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"33cdaab7-da44-4859-a58e-dbfaccd4f200\\\", \\\"childbox\\\": \\\"f5c71907-f0f7-409a-9392-7face9778d50\\\", \\\"subtext\\\": \\\"39521d77-992a-44ea-b8b3-9f80ecde2dd5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Intervention after the End of the Study\\\", \\\"6.7.\\\", \\\"2\\\", 793, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exceptionally, participants who missed their final dose at Week 23 in this study may still be eligible, after consultation with the medical monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"33cdaab7-da44-4859-a58e-dbfaccd4f200\\\", \\\"childbox\\\": \\\"875a3e9c-3d71-4f6f-bd34-8389bf2cc5b6\\\", \\\"subtext\\\": \\\"5e990941-167a-4277-8ee3-08fbc11ca85b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Intervention after the End of the Study\\\", \\\"6.7.\\\", \\\"2\\\", 794, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants receiving GSK3196165 in this study will continue to receive the same dose in the extension study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 23, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"33cdaab7-da44-4859-a58e-dbfaccd4f200\\\", \\\"childbox\\\": \\\"72dc6592-c6b7-4a54-9a3f-93f3cf862135\\\", \\\"subtext\\\": \\\"5e990941-167a-4277-8ee3-08fbc11ca85b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Intervention after the End of the Study\\\", \\\"6.7.\\\", \\\"2\\\", 795, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants receiving sarilumab in this study will be re-randomised in a 1:1 ratio to either GSK3196165 90 mg or GSK3196165 150 mg once-weekly in the extension study, following a blinded washout period (three weeks of placebo SC injection).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 23, \\\"end_idx\\\": 31, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"sarilumab\\\"}, {\\\"start_idx\\\": 94, \\\"end_idx\\\": 103, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 114, \\\"end_idx\\\": 123, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"33cdaab7-da44-4859-a58e-dbfaccd4f200\\\", \\\"childbox\\\": \\\"8d1dbfba-5b3f-41ad-b4dc-d421440c1ca2\\\", \\\"subtext\\\": \\\"43289693-5b9a-4ff9-9095-e629aa1054ae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Intervention after the End of the Study\\\", \\\"6.7.\\\", \\\"2\\\", 796, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants who do not transition into long term extension study 209564, will not receive any further treatment with GSK3196165 but will be treated according to local standard of care for RA disease.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 118, \\\"end_idx\\\": 127, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"82d61245-6588-4dfd-918e-b2ac59e7f999\\\", \\\"childbox\\\": \\\"7de5fff9-e857-419c-9fc5-b35f03689a9f\\\", \\\"subtext\\\": \\\"2bfd096e-1268-49a3-80a5-e96e4ab868d9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Population\\\", \\\"Intervention after the End of the Study\\\", \\\"6.7.\\\", \\\"2\\\", 797, \\\"\\\"], [\\\"1\\\", \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"header\\\", \\\"7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"031bc68e-f24e-44ec-bf0b-2ed3d13d66bf\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL\\\", \\\"7.\\\", \\\"1\\\", 798, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"header\\\", \\\"7.1. Discontinuation of Study Intervention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c7883c67-18a0-4725-b8f9-692e972f95c0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Discontinuation of Study Intervention\\\", \\\"7.1.\\\", \\\"2\\\", 799, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"text\\\", \\\"In rare instances, it may be necessary for a participant to permanently discontinue study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4d2975a-43d6-4e35-a6e5-e2c3419326f1\\\", \\\"childbox\\\": \\\"c64687dd-b923-43ef-be4a-6b1d04ba078d\\\", \\\"subtext\\\": \\\"2b29de01-ca31-44ed-88ef-fe92daf4c87d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Discontinuation of Study Intervention\\\", \\\"7.1.\\\", \\\"2\\\", 800, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"text\\\", \\\"A participant will permanently discontinue study intervention if there is no longer a positive risk:benefit ratio at any time point in the study as determined by the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4d2975a-43d6-4e35-a6e5-e2c3419326f1\\\", \\\"childbox\\\": \\\"dc34ad07-af58-4157-b773-264cf19914e7\\\", \\\"subtext\\\": \\\"2b29de01-ca31-44ed-88ef-fe92daf4c87d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Discontinuation of Study Intervention\\\", \\\"7.1.\\\", \\\"2\\\", 801, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"text\\\", \\\"If study intervention is permanently discontinued, the participant will, where possible, remain in the study and continue with study visits in order to be evaluated for efficacy and safety.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4d2975a-43d6-4e35-a6e5-e2c3419326f1\\\", \\\"childbox\\\": \\\"363b33c8-3b59-43cc-8d03-1a9c872ea948\\\", \\\"subtext\\\": \\\"13aba81d-013f-41db-8f67-5da3dd59fbac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Discontinuation of Study Intervention\\\", \\\"7.1.\\\", \\\"2\\\", 802, \\\"\\\"], [\\\"2\\\", \\\"Discontinuation of Study Intervention\\\", \\\"text\\\", \\\"These participants will not be eligible for the long term extension study 209564.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4d2975a-43d6-4e35-a6e5-e2c3419326f1\\\", \\\"childbox\\\": \\\"5e7f1c5f-3d0e-4848-9770-fb2b89918abc\\\", \\\"subtext\\\": \\\"13aba81d-013f-41db-8f67-5da3dd59fbac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Discontinuation of Study Intervention\\\", \\\"7.1.\\\", \\\"2\\\", 803, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"header\\\", \\\"7.1.1. Liver Chemistry Stopping Criteria\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a90ec2a2-a31f-48ca-ae6f-e5c5b961f719\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 804, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Liver chemistry stopping and increased monitoring criteria\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"daffa062-7af8-40dc-a6f2-8bc910b8caa2\\\", \\\"childbox\\\": \\\"7f894d9f-b65d-4b87-88a5-ecb4fe860a1d\\\", \\\"subtext\\\": \\\"48e2b014-2c0a-42f1-9f13-5fb520c20025\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 805, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"have been designed to assure participant safety and evaluate liver event etiology.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"daffa062-7af8-40dc-a6f2-8bc910b8caa2\\\", \\\"childbox\\\": \\\"7f894d9f-b65d-4b87-88a5-ecb4fe860a1d\\\", \\\"subtext\\\": \\\"c84d89cc-9305-4663-8a8d-210916679817\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 806, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Discontinuation of study intervention for abnormal liver tests is required when a participant meets one of the conditions outlined in the algorithm below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"90d48d4c-ac89-4487-97ca-3449a3f1f5c3\\\", \\\"childbox\\\": \\\"c6854b7d-0b53-4479-a11b-4cc091e84c46\\\", \\\"subtext\\\": \\\"bdc57e78-fa9d-4571-b174-9274b4aa2b3d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 807, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Additionally, study intervention must be discontinued if there are any clinical signs/symptoms suggestive of hepatic decompensation such as ascites and hepatic encephalopathy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"90d48d4c-ac89-4487-97ca-3449a3f1f5c3\\\", \\\"childbox\\\": \\\"106f200f-9c8a-4530-af6e-44d2b74dda40\\\", \\\"subtext\\\": \\\"07f735d0-e8b4-4a5b-acda-20b0bd37fa30\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 808, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Liver Chemistry Stopping and Increased Monitoring Algorithm for Study 202018\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"501b0262-cb8f-4de8-8352-98dd45470974\\\", \\\"childbox\\\": \\\"3d5ed006-59c0-4322-a1ff-967e38b8394e\\\", \\\"subtext\\\": \\\"42ab3bf6-394f-4aa5-a77d-c7681b866524\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 809, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf0d8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c18bf29c-897d-4c63-884f-0c445e572914\\\", \\\"childbox\\\": \\\"6f125202-d078-4214-b113-0ca84fb0721b\\\", \\\"subtext\\\": \\\"ae3a712c-204f-4e57-b153-9ab417dd529e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 810, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf020\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c18bf29c-897d-4c63-884f-0c445e572914\\\", \\\"childbox\\\": \\\"26ff5a41-b9fd-48be-9ae3-90f4efcc9c78\\\", \\\"subtext\\\": \\\"f534374e-b2fd-4d86-bf43-80fd1f559177\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 811, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"If participant to be monitored weekly, must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c18bf29c-897d-4c63-884f-0c445e572914\\\", \\\"childbox\\\": \\\"17ed3162-44ab-4b05-9027-006d629db693\\\", \\\"subtext\\\": \\\"6646e8ed-252d-4b3a-a8aa-408eae366f79\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 812, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Temporarily Discontinue Intervention and Monitor Weekly\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"bc032f2f-1635-4e16-8c27-cfecb056aed8\\\", \\\"subtext\\\": \\\"17d9afb1-85a6-4dc1-9796-dc214b3bd66b\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 813, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Study intervention may be restarted if ALT < 1.5 x ULN.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"bc032f2f-1635-4e16-8c27-cfecb056aed8\\\", \\\"subtext\\\": \\\"60074f89-6d31-4e66-9869-edfe6ff8a7eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 814, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Monitor ALT as directed in the Appendix.ORIf ALT does not resolve to \\\\u2264 1.5 x ULN within 4 weeks or other stopping criteria met, permanently discontinue study intervention*INR value not applicable to participants on anticoagulants\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 215, \\\"end_idx\\\": 228, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"anticoagulants\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"136979eb-5114-4f89-82eb-a9c545fcfbbc\\\", \\\"subtext\\\": \\\"60074f89-6d31-4e66-9869-edfe6ff8a7eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 815, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf0d8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"720b98c3-1e7b-4617-b0fd-a52186abba8c\\\", \\\"subtext\\\": \\\"48907578-cdd3-4b5d-af90-080b817b9624\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 816, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"fdd7ab34-52de-41c6-ab10-494dca1c816e\\\", \\\"subtext\\\": \\\"e29a6ceb-8553-4a45-8e5a-59bf6e4f0511\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 817, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf0d8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"96dab65f-bfd1-44fc-9dad-12bb29c0785d\\\", \\\"subtext\\\": \\\"d5429a7e-75fe-462f-82fc-aa6b1fa6c106\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 818, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Report as an SAE if possible Hy\\\\u2019s Law case:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"85a8ce69-1fb9-4ba2-a609-b09de63a23e7\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 819, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"eee56c65-810f-48b0-b687-88e6b4b3c89f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 820, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"and\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"608647d0-aeec-46e1-b73b-5755346f57c5\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 821, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Bilirubin \\\\u2265 2 x ULN (>35% direct)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"e49d280a-b7f8-4c35-b657-377538fc2d03\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 822, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"0c24fd29-a428-4c12-8e6c-88b2b5e809dd\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 823, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"INR > 1.5*\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"044345ec-35a1-4926-8247-fce2075754b8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 824, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Permanently Discontinue Study Intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"8b02d0f4-bdbb-4fe9-b0da-83c98d963008\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 825, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"YesYesYesNoPlus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"2095ec76-7499-4cb1-a4e2-a2f282d7f588\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 826, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Bilirubin \\\\u2265 2 x ULN (>35% direct)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"208a5976-bfd8-4b6b-a7c3-00fef4c85bf5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 827, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"or plus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"39321b85-7681-42a3-b8ae-5ced6211403c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 828, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"INR > 1.5*\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"4fe5668e-943f-4b35-937d-9fa468c5453f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 829, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"PossibleHy\\\\u2019s Law\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"7f196c8a-ac32-488e-8e46-fecb8b4f3473\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 830, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 5 x ULNALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"52716608-f3e9-43ca-80c4-01b54f97f5a8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 831, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Plus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"6df0f3b1-4e1a-4160-898b-70a6dcb801bd\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 832, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Symptoms of liver injuryor hypersensitivityALT \\\\u2265 3 x ULNbut able to monitor weekly for  weeks4ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"44d11928-66c8-4dff-81fe-ba9d17690920\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 833, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"YesNoNoNoYesNoContinue Study Intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"8df49449-2b43-43c4-a4f6-77c68e05319e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 834, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Temporarily Discontinue Intervention and Monitor Weekly\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"2b840ea3-f06d-4829-9b7f-ea728325c05d\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 835, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Study intervention may be restarted if ALT < 1.5 x ULN.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3a6c9d44-fe00-46e4-8d53-8ab3c614e225\\\", \\\"subtext\\\": \\\"c6df27b8-38bb-4d6c-9121-48e01abaae7e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 836, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Monitor ALT as directed in the Appendix.ORIf ALT does not resolve to \\\\u2264 1.5 x ULN within 4 weeks or other stopping criteria met, permanently discontinue study intervention*INR value not applicable to participants on anticoagulants\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 215, \\\"end_idx\\\": 228, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"anticoagulants\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"3dc71ac3-932c-48ad-9441-b5f4845913f5\\\", \\\"subtext\\\": \\\"c6df27b8-38bb-4d6c-9121-48e01abaae7e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 837, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf0d8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"5d9152bc-6543-40c8-8f2b-7d4f3a9fad87\\\", \\\"subtext\\\": \\\"8b7e6e4b-3302-40df-9f40-e367a0e1aa10\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 838, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"2624d12b-86ea-4918-8e39-9196113351f5\\\", \\\"subtext\\\": \\\"8891df51-c173-4889-84c6-d5c3b9779396\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 839, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf0d8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"e10f8177-afc0-4fc4-9b4d-3a35517a86de\\\", \\\"subtext\\\": \\\"28975eaf-5075-4746-bc6c-53f7c1d4a4b6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 840, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Report as an SAE if possible Hy\\\\u2019s Law case:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"c32cdf1b-101c-460a-b0ee-bc1d26a613b6\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 841, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"5e150e43-1443-4fbe-929f-0424577a4fd6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 842, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"and\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"0cc0541b-101b-4945-a879-b24f1dd10da6\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 843, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Bilirubin \\\\u2265 2 x ULN (>35% direct)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"82ff75fc-b3eb-4fe3-80f4-ee38ae808d7e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 844, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"77d5f41e-b5f3-4a2b-a676-57ef8440580d\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 845, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"INR > 1.5*\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"61921423-498a-4d39-8e94-988c5a3fc801\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 846, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Permanently Discontinue Study Intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"f67aa97f-9a3d-4aa1-b205-39db764b9409\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 847, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"YesYesYesNoPlus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"f91425ab-b61e-4c89-87e2-30f378d0278d\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 848, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Bilirubin \\\\u2265 2 x ULN (>35% direct)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"3b62d563-2b3d-4d4a-b98e-17c38855f989\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 849, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"or plus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"e3957572-7c05-4ba2-a623-57de2d17b32f\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 850, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"INR > 1.5*\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"83af7a2a-1872-47fc-a554-be5c46280ef6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 851, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"PossibleHy\\\\u2019s Law\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"13282cfe-4a81-4fcf-b0dd-52d05b0867d2\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 852, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 5 x ULNALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"6fd870cd-8974-40f0-a0b0-695479641391\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 853, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Plus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"7b946dea-dc35-4d1e-9865-6d4fb56b5eb1\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 854, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Symptoms of liver injuryor hypersensitivityALT \\\\u2265 3 x ULNbut able to monitor weekly for  weeks4ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"57f06c07-f13d-4af2-be82-79ebd6e3f59f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 855, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"YesNoNoNoYesNoContinue Study Intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fdc9b8f-e1af-4eec-bab3-4c8d5e62b445\\\", \\\"childbox\\\": \\\"f95bcdfb-f3d8-422c-b013-478824e27c56\\\", \\\"subtext\\\": \\\"4373c497-86da-4065-8400-bd30d4e74b52\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 856, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Temporarily Discontinue Intervention and Monitor Weekly\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8654ed0d-a668-4789-ab55-f129af0346b8\\\", \\\"childbox\\\": \\\"d90ead9a-d487-444b-ad80-f4b9c10e719a\\\", \\\"subtext\\\": \\\"17d9afb1-85a6-4dc1-9796-dc214b3bd66b\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 857, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Study intervention may be restarted if ALT < 1.5 x ULN.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c68f3c8d-cb66-4ceb-a2b5-6380048f5c9f\\\", \\\"childbox\\\": \\\"4beacb9e-143e-4bfc-beb8-766908f48779\\\", \\\"subtext\\\": \\\"60074f89-6d31-4e66-9869-edfe6ff8a7eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 858, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Monitor ALT as directed in the Appendix.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c68f3c8d-cb66-4ceb-a2b5-6380048f5c9f\\\", \\\"childbox\\\": \\\"de5ce0d6-ea5d-4d01-8836-898d3e0431cb\\\", \\\"subtext\\\": \\\"60074f89-6d31-4e66-9869-edfe6ff8a7eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 859, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"OR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9e610aff-3aa1-4f24-956c-3b307ea2c0e6\\\", \\\"childbox\\\": \\\"8f58bfae-7eb7-467d-b281-e6c7f7b3401f\\\", \\\"subtext\\\": \\\"8c4f5499-3ead-4a3f-a666-0d7e4b83e35a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 860, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"If ALT does not resolve to \\\\u2264 1.5 x ULN within 4 weeks or other stopping criteria met,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"36b8b576-e573-4bdd-b213-57266e1d0af5\\\", \\\"childbox\\\": \\\"7d17dbf0-72cb-4b2c-a093-f53424064bb6\\\", \\\"subtext\\\": \\\"5019f429-a2e8-4b7b-925f-6a447106710b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 861, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"permanently discontinue study intervention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fda1fa33-60b7-4bef-a669-247466cb4a14\\\", \\\"childbox\\\": \\\"58827a1b-c189-4640-b26f-5af8148542c0\\\", \\\"subtext\\\": \\\"97392920-63a6-431e-b144-b49d3cc1a194\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 862, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"*INR value not applicable to participants on anticoagulants\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 45, \\\"end_idx\\\": 58, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"anticoagulants\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"12a8922d-61a7-4a69-96ae-402895459279\\\", \\\"childbox\\\": \\\"81ba65d2-2b2d-4587-8c77-dd139f9509ab\\\", \\\"subtext\\\": \\\"e139dcc7-4048-4765-9282-b5197794a618\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 863, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf0d8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d3cba829-925d-4580-9fab-444f32505481\\\", \\\"childbox\\\": \\\"7fb9ade7-bbcc-4048-8f7c-93e09eeb6bb2\\\", \\\"subtext\\\": \\\"48907578-cdd3-4b5d-af90-080b817b9624\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 864, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fd297656-bbb3-4c8d-af84-b19eb399cc9f\\\", \\\"childbox\\\": \\\"86b70fcc-3ae8-4fda-8226-85cc89208eef\\\", \\\"subtext\\\": \\\"e29a6ceb-8553-4a45-8e5a-59bf6e4f0511\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 865, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\\uf0d8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2e86d5fe-c8bf-4ffa-bdff-66a791c0ec65\\\", \\\"childbox\\\": \\\"645d11e5-46ac-4f1b-8466-d73e43b4dc69\\\", \\\"subtext\\\": \\\"d5429a7e-75fe-462f-82fc-aa6b1fa6c106\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Wingdings\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 866, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Report as an SAE if possible Hy\\\\u2019s Law case:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cda5736c-c3f3-4881-a730-296d8a07d8b5\\\", \\\"childbox\\\": \\\"2e5cd16f-2533-417e-b21a-8d6800621ae0\\\", \\\"subtext\\\": \\\"85a8ce69-1fb9-4ba2-a609-b09de63a23e7\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 867, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9a96b166-c445-4512-a4cf-c5fbd7e62ce8\\\", \\\"childbox\\\": \\\"7cff78c8-93c3-4201-a8df-54b37635a258\\\", \\\"subtext\\\": \\\"eee56c65-810f-48b0-b687-88e6b4b3c89f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 868, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"and\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"77482098-7719-46cd-a010-88063e1841fd\\\", \\\"childbox\\\": \\\"892ad2ba-6ad4-44c3-bf60-98842d96b016\\\", \\\"subtext\\\": \\\"608647d0-aeec-46e1-b73b-5755346f57c5\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 869, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Bilirubin \\\\u2265 2 x ULN (>35% direct)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8223b1e0-1301-4af5-bb20-76a4817fd43f\\\", \\\"childbox\\\": \\\"9c9fa5d5-ade1-46c4-a74e-a3e48d7f3214\\\", \\\"subtext\\\": \\\"e49d280a-b7f8-4c35-b657-377538fc2d03\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 870, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"efa75f8d-674d-4c95-bcb3-a5c1e9a1eb29\\\", \\\"childbox\\\": \\\"295013d0-1844-47f6-adfa-66302e745240\\\", \\\"subtext\\\": \\\"0c24fd29-a428-4c12-8e6c-88b2b5e809dd\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 871, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"INR > 1.5*\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"81bab700-c5a6-414d-a10a-0118f819a37b\\\", \\\"childbox\\\": \\\"600e6996-04b5-44e8-94de-b4d6703e3920\\\", \\\"subtext\\\": \\\"044345ec-35a1-4926-8247-fce2075754b8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 872, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Permanently Discontinue Study Intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6f0a15e7-da0d-4b1b-ac41-3890a9e6bf46\\\", \\\"childbox\\\": \\\"ab60e01a-9bd8-4ff2-a1b4-4bace890982f\\\", \\\"subtext\\\": \\\"8b02d0f4-bdbb-4fe9-b0da-83c98d963008\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 873, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Yes\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b5f97a46-6472-4765-9b56-db1537e1a9ca\\\", \\\"childbox\\\": \\\"e6d663ee-65f8-4c7c-b451-1ba1b435b55e\\\", \\\"subtext\\\": \\\"2095ec76-7499-4cb1-a4e2-a2f282d7f588\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 874, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Yes\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a843a4f8-47e4-4594-bd85-4bfa5b4ecd58\\\", \\\"childbox\\\": \\\"9ae56e3e-2dad-41dc-ad21-7343fede45ac\\\", \\\"subtext\\\": \\\"fa63c50f-fcef-46d1-a575-125a6e124f0c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 875, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Yes\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cc9fcfa9-a0b6-4b11-9631-507fdd77c9fd\\\", \\\"childbox\\\": \\\"195236b2-d0c2-44a9-be0c-8662b57b5635\\\", \\\"subtext\\\": \\\"7fb7e331-4507-4395-95b8-43ad52b46efa\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 876, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"No\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"775674e9-27a4-47a2-99e8-c78b19d1e778\\\", \\\"childbox\\\": \\\"da9907f9-8405-4a98-bfce-6db6b985fd9d\\\", \\\"subtext\\\": \\\"8954f0a0-7486-4bce-b6c8-26c77abd39e4\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 877, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Plus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a156a46c-8c49-474e-998a-931f16586b06\\\", \\\"childbox\\\": \\\"a9984452-abd2-43ed-b688-f9a7f6e1cedb\\\", \\\"subtext\\\": \\\"448f0a3d-afcc-42b3-973a-12fd6129903a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 878, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Bilirubin \\\\u2265 2 x\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f7953e9c-9850-43ca-a4cd-0e9896813b34\\\", \\\"childbox\\\": \\\"eb215811-cb43-461a-8dc0-73299a0918b6\\\", \\\"subtext\\\": \\\"208a5976-bfd8-4b6b-a7c3-00fef4c85bf5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 879, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ULN (>35%\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6471fbbd-c889-4240-b6b9-c83b65967358\\\", \\\"childbox\\\": \\\"5fea1cf1-3e28-460c-92b2-b022236a51b9\\\", \\\"subtext\\\": \\\"e24def43-f4e4-4d67-a306-6e65e36eb84a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 880, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"direct)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"021e9d2c-a048-4061-8290-85f590674a6e\\\", \\\"childbox\\\": \\\"dd857720-4432-413c-ad02-90c66a18566d\\\", \\\"subtext\\\": \\\"6f33b5b8-6639-4bbf-a5ac-0762d17dec85\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 881, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"or plus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ee2db833-e7f2-4791-a3ac-21f8b342ac79\\\", \\\"childbox\\\": \\\"f9289ba5-1864-46ac-9848-ba356b61d376\\\", \\\"subtext\\\": \\\"39321b85-7681-42a3-b8ae-5ced6211403c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 882, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"INR > 1.5*\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"01dc56fb-d622-4647-b377-d085b36302dd\\\", \\\"childbox\\\": \\\"ed2352ba-cb2a-416f-846e-cfc9a13d9117\\\", \\\"subtext\\\": \\\"4fe5668e-943f-4b35-937d-9fa468c5453f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 883, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Possible\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d9c42e06-d108-4dc7-8d2c-b893a82d734a\\\", \\\"childbox\\\": \\\"ee1e8134-1ea6-4b24-aa86-41e3d2c0deaa\\\", \\\"subtext\\\": \\\"7f196c8a-ac32-488e-8e46-fecb8b4f3473\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 884, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Hy\\\\u2019s Law\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"173cca0b-d92f-4fd2-94e2-433d99552669\\\", \\\"childbox\\\": \\\"fa50be3a-1fbf-4b2c-8614-9d3b433c42d8\\\", \\\"subtext\\\": \\\"90acc9c8-37c5-419e-af7c-63602d7d1d1c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 885, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 5 x\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8be4f5fb-1892-4475-bec8-93ee5139cf95\\\", \\\"childbox\\\": \\\"916d3344-235a-40ce-bf34-8cb3669b8719\\\", \\\"subtext\\\": \\\"52716608-f3e9-43ca-80c4-01b54f97f5a8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 886, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bb6f4709-c012-42a3-bb80-52800915bcda\\\", \\\"childbox\\\": \\\"857aedb5-653d-4139-bdba-08dbf02c581e\\\", \\\"subtext\\\": \\\"0bce62f8-642f-4474-be16-9b7c0991d6f2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 887, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c25b749c-a614-4253-b894-2998d15ef7d9\\\", \\\"childbox\\\": \\\"a4db686a-2bf1-4809-8d46-758fe5d4af7f\\\", \\\"subtext\\\": \\\"b692a620-5535-4cef-8f1c-fb432d44f265\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 888, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Plus\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1bf66d0b-ad0e-4c59-a2a5-139a4a27d97d\\\", \\\"childbox\\\": \\\"1565bed9-57b8-4997-9836-f2a657f572b2\\\", \\\"subtext\\\": \\\"6df0f3b1-4e1a-4160-898b-70a6dcb801bd\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 889, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Symptoms of liver\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"092aef88-4b70-44ef-af5f-ba969a91d78d\\\", \\\"childbox\\\": \\\"345cff33-9be8-4a59-8460-73a819965d78\\\", \\\"subtext\\\": \\\"44d11928-66c8-4dff-81fe-ba9d17690920\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 890, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"injury\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dcf74863-563d-44ad-8138-dfb81618cd04\\\", \\\"childbox\\\": \\\"aafd3036-7759-4968-acb3-f371ad845454\\\", \\\"subtext\\\": \\\"1cd4e249-d9f1-4bfc-8e96-b5a02494cb58\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 891, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"or hypersensitivity\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"be818a4c-9265-461a-be05-eaa7c40a59e9\\\", \\\"childbox\\\": \\\"6b10d78a-82e9-42d0-b598-3463023b2fe8\\\", \\\"subtext\\\": \\\"aad8d07f-50ad-4ef9-8a93-8b0987a1ef5f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 892, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8bae3c05-c10b-4883-bd66-fb079461916d\\\", \\\"childbox\\\": \\\"9f3267c8-6047-434c-8f86-8e5cb4e47788\\\", \\\"subtext\\\": \\\"06dc866b-c20a-480b-98db-1a7a8a7c8c14\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 893, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"but able to\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17eb7a0a-9523-4ef8-aab9-0f8da2d91999\\\", \\\"childbox\\\": \\\"e1deef3e-4f4a-47ca-b267-c6d11a154cb6\\\", \\\"subtext\\\": \\\"797ed1bd-a843-4320-9d61-1dc3d1d39eea\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 894, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"monitor weekly\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"48030678-b88e-4b30-807e-7dcb84e8031a\\\", \\\"childbox\\\": \\\"640a5eb0-0a49-4ca5-9b77-77adb15875dd\\\", \\\"subtext\\\": \\\"b564cd2a-7dd5-4810-8ead-3bf4936df6bb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 895, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"for\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6b0db532-5d1b-4f1c-87f9-a0f81a9b9b5d\\\", \\\"childbox\\\": \\\"496e3a61-360c-4771-80e5-988071fd88a0\\\", \\\"subtext\\\": \\\"0bb432f6-707b-46f5-9a1d-efd43ef8c68e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 896, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"weeks\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6bb03f7d-bacb-434f-a040-2e41f8c63af4\\\", \\\"childbox\\\": \\\"ebce2835-bdde-4028-a369-6edb0b5c3d6e\\\", \\\"subtext\\\": \\\"97b8dc52-eb02-4971-aa0e-d7d448084562\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 897, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c54f929d-183f-4481-80ce-960a6b74588e\\\", \\\"childbox\\\": \\\"f77f47b7-b54d-4d00-9437-bf14f0a6e505\\\", \\\"subtext\\\": \\\"a6af8ef0-a97e-4909-961d-65eea104e854\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 898, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"ALT \\\\u2265 3 x ULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9a93c112-1161-4672-8a7a-a1b06ba2a14f\\\", \\\"childbox\\\": \\\"657e47e3-c06e-4262-96fc-91255fd4493f\\\", \\\"subtext\\\": \\\"be441cbb-6de5-41ae-bcf1-134b43c729ca\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 899, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Yes\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"658af147-57ed-4281-ba90-41ffc9231acc\\\", \\\"childbox\\\": \\\"eed5b6a7-5b33-4147-94c0-d885819cd8f8\\\", \\\"subtext\\\": \\\"8df49449-2b43-43c4-a4f6-77c68e05319e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 900, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"No\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3b553dbd-7f9f-4220-b5a3-682db9d600eb\\\", \\\"childbox\\\": \\\"75ba40f4-09b5-44e0-b32e-ab470236a0f3\\\", \\\"subtext\\\": \\\"9f6623c0-0274-4bc8-af01-da70c39fc89a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 901, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"No\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3ce0b156-b28d-4b98-9d09-bc4943d7ad68\\\", \\\"childbox\\\": \\\"c389cb81-506d-4f18-807a-5f4c7c8a7483\\\", \\\"subtext\\\": \\\"7ce4a952-3372-4f76-8248-0a9a9ab52085\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 902, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"No\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a91ebb65-3441-490b-b121-b43fe0beec3f\\\", \\\"childbox\\\": \\\"08f16190-c2a2-45c1-a786-0956cc266140\\\", \\\"subtext\\\": \\\"ead8bb55-7a3d-41db-9f46-ce6897513f0a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 903, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Yes\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0018037b-5093-4fd6-8fad-7d003de92521\\\", \\\"childbox\\\": \\\"0af91485-5c6b-4a8f-842c-7389a4037190\\\", \\\"subtext\\\": \\\"8adabc09-3637-4fb6-9d65-7bc36e561bc3\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 904, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"No\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d2a64c2d-b6ea-4997-b382-cd8060c180dc\\\", \\\"childbox\\\": \\\"e11a2437-fc50-4d31-95b9-921ab0e6e4a3\\\", \\\"subtext\\\": \\\"76dfd311-78bf-46b1-9c2a-b817d8729a0c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 905, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Continue\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0d345e02-3cc1-4444-b5e8-d2a46e536fd3\\\", \\\"childbox\\\": \\\"ba3f1179-c33b-4aa4-afab-d4a9d0c8dee4\\\", \\\"subtext\\\": \\\"0872271d-31eb-46a5-994c-82b221218492\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 906, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Study\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"380e56f3-3aa1-469d-b2ee-c66797ec900b\\\", \\\"childbox\\\": \\\"7df36283-22f1-4979-a032-3f48f4e73d6c\\\", \\\"subtext\\\": \\\"a1cf6c68-9d14-4a96-8897-1ba77425e809\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 907, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 14, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4d1854c6-a25e-4cde-9f86-2314746c0d18\\\", \\\"childbox\\\": \\\"ad416027-a7eb-4172-a3c3-507faff8680c\\\", \\\"subtext\\\": \\\"0fb4eef3-6a14-4521-8779-819055ad571e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 14, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 908, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0b142660-c9d6-4ff0-9998-eb0dc678afee\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 909, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"49a8348c-59f5-4655-b06c-e0c46efb4be0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 910, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9f8a5b0-6cc5-4e1a-a8f8-93b14b1c23b0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 911, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d99eba7c-3722-49ec-85ed-6bd362a9a898\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 912, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"db17ffa6-ca3a-4346-b590-9272b782297a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 913, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fea2402-7e64-4b6b-9ea0-3a0d201c958a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 914, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b78e0be0-8c65-47e6-9b6e-e57b81927f42\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 915, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c48bcb33-421a-4b77-adbf-7ce4a66c9cfc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 916, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87a7a919-b538-46ad-8f1e-7c798c3ff13d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 917, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0c112fc8-a4f1-4703-a7bc-e173bc54109e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 918, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7f30e3b7-f0cf-48a2-9754-a54a77a70d89\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 919, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a3e59860-14c9-4bab-8e67-2d9d2d4a12f7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 920, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"191ccc3d-b06f-4f6f-a82c-9e1e49268c11\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 921, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"824ecf57-5fa7-4b73-9c0b-3cba2b8bb650\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 922, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"49dd5061-6b4f-440c-bfec-e315434740e4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 923, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"233e70e0-25d6-4d26-ac95-fafd158c3c9a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 924, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d9033628-5c6a-48e9-96e6-fd836844b27f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 925, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1a9c1491-e987-4b2d-975f-c2cf0980c951\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 926, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f8268d02-6988-48ed-b3b6-56d1dc36c04f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 927, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ba8b8022-5a64-4834-adde-905f492d7bd4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 928, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2bbc27c2-464c-4dd9-9f6e-9a5c7745b5b7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 929, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dc80f62b-9584-42a7-a91b-ab49fe5c9f8b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 930, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0a1e8db5-c939-4d6d-8f52-3879d557058e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 931, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0f5fd523-494b-44ac-8cf1-ed2faf51971e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 932, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cab71d3f-2c43-4818-a76c-4d0939b3aa37\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 933, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a2f9ad49-abe6-4f06-86fd-6086495ebf12\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 934, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"785fa2cc-2790-4238-8f97-f6e23cc2f1d6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 935, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b00e5bce-06c0-4ef1-90be-453d24a3e4de\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 936, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"03ffea20-3900-4492-be09-da056373af0b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 937, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ffc35f74-eb5c-44e9-8342-110895a11896\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 938, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"021a84e8-90f0-4510-8990-27c4b47aa23a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 939, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0ff747e2-5dce-4995-ac9f-bd45341d662f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 940, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ea6867ce-aff7-4559-9edc-449bf28be035\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 941, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9aed68e7-85ec-4ae3-bcd7-93cba00ed266\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 942, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9523403e-196d-42e2-985d-840049e48e78\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 943, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f98bacce-5b96-479e-8e3a-89ed076db627\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 944, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0fba0f09-435d-4fff-b138-7bc8419cca46\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 945, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"756ea3ca-d78f-4ac1-8d0c-24f94c6b096e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 946, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6eaba90a-529c-496d-97df-eba81cc4585b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 947, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ec7a8000-823d-44f0-83f7-5832a33947d6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 948, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb8b64f0-64e0-44a9-85ff-ef701403ebd7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 949, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b67d4e26-1f4f-4d14-8abc-767304b5cd8b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 950, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"70de3559-732c-4c36-9600-63f2383ca005\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 951, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"18c250c6-1fca-4db4-b919-9ed2247ca621\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 952, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ac93c50e-5b9e-4cfb-976c-4cf5428477a5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 953, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7d12cc6d-c5b1-49fb-8328-ed0208b9c1b2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 954, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9b8951ca-347b-4e4e-a841-f7b2f940984d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 955, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"18129638-88b0-4bac-87bd-ad9a9d2965f6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 956, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e068b723-dfc5-4993-84e4-d905fa3da872\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 957, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"823c63dc-009f-467a-b314-a2b9dd230a48\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 958, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c9c481b-5690-41b7-ae5b-cb86c2eb613a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 959, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Abbreviations: ALT = alanine transaminase; bili = bilirubin; INR = international normalised ratio; SAE = serious adverse event; ULN = upper limit of normal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e3044f73-a67f-4359-b6c7-fdf959319e2f\\\", \\\"childbox\\\": \\\"0b5d2c34-c397-46ef-9398-3e8b02eb4c8f\\\", \\\"subtext\\\": \\\"3e666748-04e6-4903-a82b-69de5625838d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 960, \\\"\\\"], [\\\"3\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"text\\\", \\\"Liver Safety Required Actions and Follow up Assessments Section can be found in Appendix 6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c8832b98-00d8-41f4-a9fd-26ce68dd0f79\\\", \\\"childbox\\\": \\\"be51d2d4-bb7e-442b-a10c-812aab33976d\\\", \\\"subtext\\\": \\\"31c5d8f1-37ea-4369-ae68-5b6359cbdd94\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Liver Chemistry Stopping Criteria\\\", \\\"7.1.1.\\\", \\\"3\\\", 961, \\\"\\\"], [\\\"4\\\", \\\"Study Intervention Restart or Rechallenge After Liver Stopping Criteria Met\\\", \\\"header\\\", \\\"7.1.1.1. Study Intervention Restart or Rechallenge after liver stopping criteria met\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"57adae84-7abf-4d2d-b636-05fe2ca10724\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Study Intervention Restart or Rechallenge after liver stopping criteria met\\\", \\\"7.1.1.1.\\\", \\\"4\\\", 962, \\\"\\\"], [\\\"4\\\", \\\"Study Intervention Restart or Rechallenge After Liver Stopping Criteria Met\\\", \\\"text\\\", \\\"Study intervention restart or rechallenge after liver chemistry stopping criteria are met by any participant in this study is not allowed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e1702189-64e6-45e5-b9b1-95ccb76df39a\\\", \\\"childbox\\\": \\\"6bece253-d059-43f1-9052-d90f2f1cad8e\\\", \\\"subtext\\\": \\\"450a4bb6-1e23-4cca-91cb-fcad4830f248\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Study Intervention Restart or Rechallenge after liver stopping criteria met\\\", \\\"7.1.1.1.\\\", \\\"4\\\", 963, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"header\\\", \\\"7.1.2. Other Stopping Criteria\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a57e4a1b-8f2e-4c84-80de-127e89c5c7ff\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 964, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"A participant will be permanently discontinued from study intervention (but may continue to be followed in the study) if any of the following criteria are met:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0e4eb315-4186-422e-beb1-f8b4a78e4789\\\", \\\"childbox\\\": \\\"68cd55dc-a9d9-43e5-92ce-869588689392\\\", \\\"subtext\\\": \\\"b284a997-5a79-4134-ae26-c361725796c6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 965, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Pregnancy (see Section 8.3.5 and Appendix 4).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dd1af1b3-3d78-463c-ac0a-b20b61309868\\\", \\\"childbox\\\": \\\"7fb87cfe-fce3-4b02-b7bd-e310a3a99d5e\\\", \\\"subtext\\\": \\\"845c95e4-9993-4e66-890a-4de78cb20742\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 966, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Confirmed pulmonary alveolar proteinosis (see Section 8.2.6).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fbfedc0a-ed06-45e8-a05b-95750c194928\\\", \\\"childbox\\\": \\\"5ed5416f-7cfb-40c6-9bc2-31b282433c7f\\\", \\\"subtext\\\": \\\"485723bb-59ea-4f3e-8d6b-1776a5558d08\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 967, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Serious hypersensitivity reactions (see Section 8.3.7).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4f011bb0-620a-4f62-bf50-8fb9dc4be560\\\", \\\"childbox\\\": \\\"f56fd2e7-a50a-40ec-a3dc-a60db3c9e877\\\", \\\"subtext\\\": \\\"f26dae8b-fed9-48ef-aca2-11d6ac4911e7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 968, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Other serious or severe adverse events, at the discretion of the investigator, after consultation with the Medical Monitor (see Section 8.2.7).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"84fa43f3-9f08-4456-9f1c-b776dbebfce4\\\", \\\"childbox\\\": \\\"cf9215aa-798c-4d37-956d-47d9e010a2f1\\\", \\\"subtext\\\": \\\"2c3c7f8a-a648-4d9d-a3b8-42f3ba2f90ad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 969, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 HBV DNA level \\\\u2265200 IU/mL or HBV DNA detected at any level with recent increase in hepatic transaminases (see Figure 2 in Section 8.2.8).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"afc8a409-6c4b-4dfe-9dde-8e29d172a617\\\", \\\"childbox\\\": \\\"86359699-2701-43e7-9cd0-fa3f561c843f\\\", \\\"subtext\\\": \\\"e148456e-4991-40d2-b681-8af3e9c0bac2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 970, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"645b3f2c-2a64-4d68-9de4-3258cdf6677b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 971, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"HBV DNA positive (any level \\\\u2264200 IU/mL) and on repeat testing within 1 week (see Figure 2 in Section 8.2.8) either:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d7baa7c5-0d31-4617-a01e-39a8392cd346\\\", \\\"childbox\\\": \\\"8fad6604-955c-496d-8329-41f19464b831\\\", \\\"subtext\\\": \\\"f0211fc1-9868-49ff-b95a-948688c414b4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 972, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45b82e00-5fcf-4fd5-b3fc-8e44f3e7b18c\\\", \\\"childbox\\\": \\\"73c1eb68-9fa2-4d22-ba8a-755c4db48ce8\\\", \\\"subtext\\\": \\\"2b53746d-8adb-4785-83b1-fe6d5898af58\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 973, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"HBV DNA positive (any level) OR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45b82e00-5fcf-4fd5-b3fc-8e44f3e7b18c\\\", \\\"childbox\\\": \\\"73c1eb68-9fa2-4d22-ba8a-755c4db48ce8\\\", \\\"subtext\\\": \\\"511cd88c-60da-407e-a7e2-27e957fe0f46\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 974, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45b82e00-5fcf-4fd5-b3fc-8e44f3e7b18c\\\", \\\"childbox\\\": \\\"73c1eb68-9fa2-4d22-ba8a-755c4db48ce8\\\", \\\"subtext\\\": \\\"a7f5a1dc-323e-4417-930e-ab6cc904a5a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 975, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"HBV surface antigen positive OR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45b82e00-5fcf-4fd5-b3fc-8e44f3e7b18c\\\", \\\"childbox\\\": \\\"73c1eb68-9fa2-4d22-ba8a-755c4db48ce8\\\", \\\"subtext\\\": \\\"4f81c6f6-df85-4b17-94a2-0ff82f377d12\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 976, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45b82e00-5fcf-4fd5-b3fc-8e44f3e7b18c\\\", \\\"childbox\\\": \\\"73c1eb68-9fa2-4d22-ba8a-755c4db48ce8\\\", \\\"subtext\\\": \\\"b297a895-f617-48b1-8262-83e588b95f3d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 977, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"increase in hepatic transaminases.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45b82e00-5fcf-4fd5-b3fc-8e44f3e7b18c\\\", \\\"childbox\\\": \\\"73c1eb68-9fa2-4d22-ba8a-755c4db48ce8\\\", \\\"subtext\\\": \\\"e5f6424b-b2cb-4980-98f3-15945a310c8d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 978, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 New latent or active TB infection (see Section 8.2.7.4).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"925e86ef-7fc5-472e-b9bc-7cfa558665fe\\\", \\\"childbox\\\": \\\"d2722b30-a2ce-465b-a353-6a0592ca9e37\\\", \\\"subtext\\\": \\\"dffa4999-672b-4066-b0c8-e9d618087830\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 979, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Gastrointestinal perforation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"060028fa-7d43-4533-8884-d24796fbedda\\\", \\\"childbox\\\": \\\"35a20012-a32a-41dd-a00f-d2461f8596b9\\\", \\\"subtext\\\": \\\"ae265857-9384-4baa-b206-1f9740252e17\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 980, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Platelet count <50 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d4170b1f-a83d-417d-b995-c35325826c8d\\\", \\\"childbox\\\": \\\"aa6aafc1-299d-4642-bdf4-2d777e5d3796\\\", \\\"subtext\\\": \\\"77c21ed2-7896-465f-bd79-3a7b1e041b42\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 981, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d4170b1f-a83d-417d-b995-c35325826c8d\\\", \\\"childbox\\\": \\\"aa6aafc1-299d-4642-bdf4-2d777e5d3796\\\", \\\"subtext\\\": \\\"91550ce2-29ce-480d-86be-e45614069941\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 982, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"/L.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d4170b1f-a83d-417d-b995-c35325826c8d\\\", \\\"childbox\\\": \\\"aa6aafc1-299d-4642-bdf4-2d777e5d3796\\\", \\\"subtext\\\": \\\"b5deb065-d2f2-43e9-9810-3579705c55e7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 983, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Absolute neutrophil count (ANC) <0.5 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d8301dc1-5008-4eba-be19-ff54a3802b5f\\\", \\\"childbox\\\": \\\"6b2a1f5d-2205-4016-bd24-c98306ff246a\\\", \\\"subtext\\\": \\\"f85bf166-b82c-43e0-a3cb-1b0214340e3b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 984, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d8301dc1-5008-4eba-be19-ff54a3802b5f\\\", \\\"childbox\\\": \\\"6b2a1f5d-2205-4016-bd24-c98306ff246a\\\", \\\"subtext\\\": \\\"8feb701c-3632-432f-9a9f-298e3e6324ee\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 985, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"/L.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d8301dc1-5008-4eba-be19-ff54a3802b5f\\\", \\\"childbox\\\": \\\"6b2a1f5d-2205-4016-bd24-c98306ff246a\\\", \\\"subtext\\\": \\\"987d4901-0b5e-408b-938f-99c848024c6c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 986, \\\"\\\"], [\\\"3\\\", \\\"QTc Stopping Criteria\\\", \\\"text\\\", \\\"\\\\u2022 Introduction of prohibited therapies or dosages where continuation of the study intervention would place the participant at risk in the opinion of the investigator and medical monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1e752d70-5ac1-4db0-8c8e-b8aef972b1a1\\\", \\\"childbox\\\": \\\"1e86a70f-7790-4a9b-84c3-5bc1f5e162fd\\\", \\\"subtext\\\": \\\"8db98119-4da9-400b-b2f1-9d303576f4e4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Other Stopping Criteria\\\", \\\"7.1.2.\\\", \\\"3\\\", 987, \\\"\\\"], [\\\"3\\\", \\\"Temporary Discontinuation\\\", \\\"header\\\", \\\"7.1.3. Temporary Discontinuation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f76ea642-dd6b-4140-85ab-58925b273ef2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Temporary Discontinuation\\\", \\\"7.1.3.\\\", \\\"3\\\", 988, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.1.3.1. Respiratory Symptoms\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e1502302-d9ac-4d96-a169-61a94a332021\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 989, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study intervention will be temporarily discontinued if a participant develops a persistent cough (CTCAE Grade \\\\u22652) [NCI, 2017] or persistent dyspnoea (dyspnoea scale Grade\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 115, \\\"end_idx\\\": 117, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"NCI\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"6e3780a9-54e6-49f1-924c-a33aec6573cd\\\", \\\"childbox\\\": \\\"8c5be7ee-cabe-47e7-9742-fc629af07906\\\", \\\"subtext\\\": \\\"965472e8-ee97-41b5-9cc6-737bf330df62\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 990, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e63018b3-eb9e-4d4d-8ad9-7dfd3146a7b2\\\", \\\"childbox\\\": \\\"c03cffb3-b659-4d3f-b35d-4895f49b7d2e\\\", \\\"subtext\\\": \\\"e3e3af4f-c430-4b0b-80a0-caf454846dd1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 991, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2) for 3 consecutive weeks (21 days)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e63018b3-eb9e-4d4d-8ad9-7dfd3146a7b2\\\", \\\"childbox\\\": \\\"c03cffb3-b659-4d3f-b35d-4895f49b7d2e\\\", \\\"subtext\\\": \\\"d2e4a000-0f8a-4815-96d2-cf0238a2cee5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 992, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\". The participant should be referred to a pulmonologist for further assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e63018b3-eb9e-4d4d-8ad9-7dfd3146a7b2\\\", \\\"childbox\\\": \\\"ee9541a5-7fa5-4d83-b0cc-1d8b9d808437\\\", \\\"subtext\\\": \\\"d2e4a000-0f8a-4815-96d2-cf0238a2cee5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 993, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".  Study intervention should remain suspended until the symptoms or signs that caused referral have resolved and/or the diagnosis has been determined and clinically significant events have been excluded by the pulmonologist\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e63018b3-eb9e-4d4d-8ad9-7dfd3146a7b2\\\", \\\"childbox\\\": \\\"f1cf2a17-0db5-405c-a592-269ef1a64151\\\", \\\"subtext\\\": \\\"9f0c8fed-c575-4146-b056-e9fe2bbb8170\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 994, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\". Participants with a confirmed diagnosis of pulmonary alveolar proteinosis must permanently discontinue study intervention (Section 7.1)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e63018b3-eb9e-4d4d-8ad9-7dfd3146a7b2\\\", \\\"childbox\\\": \\\"488827c9-09bf-40fa-89a5-91a3c639dfda\\\", \\\"subtext\\\": \\\"9f0c8fed-c575-4146-b056-e9fe2bbb8170\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 995, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\". Suggested pulmonary assessment and management algorithms are provided in a separate Pulmonary Safety Guidance Document in the SRM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e63018b3-eb9e-4d4d-8ad9-7dfd3146a7b2\\\", \\\"childbox\\\": \\\"13942c63-431a-4197-8fd7-c95fd6f8f3dd\\\", \\\"subtext\\\": \\\"2c6f0a12-eff3-42d9-b9b8-10d7215ec531\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Respiratory Symptoms\\\", \\\"7.1.3.1.\\\", \\\"4\\\", 996, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.1.3.2. Serious and Opportunistic Infections\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c1cf8c66-a384-4a64-ab35-43539b64757d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Serious and Opportunistic Infections\\\", \\\"7.1.3.2.\\\", \\\"4\\\", 997, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a serious or opportunistic infection or sepsis develops, temporarily discontinue study intervention until the infection is controlled and discuss further management with the medical monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"33fa2281-c1df-4bb0-b7c8-2ba6696724cf\\\", \\\"childbox\\\": \\\"e706979e-afe3-4395-9d81-e9c78780b8ec\\\", \\\"subtext\\\": \\\"d7aee6e2-b282-4588-81d7-79e0c357a985\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Serious and Opportunistic Infections\\\", \\\"7.1.3.2.\\\", \\\"4\\\", 998, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.1.3.3. Hematologic Abnormalities\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"355f0c12-b211-4426-8561-9d5ee5193e61\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 999, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study intervention will be temporarily discontinued for the following haematological abnormalities that must be reported as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b7994a5d-a82b-4596-9859-061208456582\\\", \\\"childbox\\\": \\\"71710dd5-9823-4ba3-a395-a046455d3dad\\\", \\\"subtext\\\": \\\"e25b13c8-7730-43ed-acaa-b6677b202a78\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1000, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These should be promptly re-tested, ideally within 3-5 days:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b7994a5d-a82b-4596-9859-061208456582\\\", \\\"childbox\\\": \\\"f4f54360-630a-4925-97c2-84dc6c110034\\\", \\\"subtext\\\": \\\"a2b8c22e-4d3b-4c01-976f-8f99bfaa2887\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1001, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Platelet count \\\\u2264100 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64521b7c-98e4-469b-a861-8160f2cd3156\\\", \\\"childbox\\\": \\\"7671cf7e-1272-47a5-960a-a9cbcd5886f9\\\", \\\"subtext\\\": \\\"cd04d6e7-49a9-48a3-9cf3-97f5c21c6a53\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1002, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64521b7c-98e4-469b-a861-8160f2cd3156\\\", \\\"childbox\\\": \\\"7671cf7e-1272-47a5-960a-a9cbcd5886f9\\\", \\\"subtext\\\": \\\"621a3436-b31a-47d5-aae9-aa8207980daf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1003, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/L.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64521b7c-98e4-469b-a861-8160f2cd3156\\\", \\\"childbox\\\": \\\"7671cf7e-1272-47a5-960a-a9cbcd5886f9\\\", \\\"subtext\\\": \\\"ea4f052d-e35e-4fff-ac31-544a95cea544\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1004, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(Dosing should be interrupted until Platelets \\\\u2265150 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64521b7c-98e4-469b-a861-8160f2cd3156\\\", \\\"childbox\\\": \\\"95be6046-c66b-4f0d-bf19-9d15c665796b\\\", \\\"subtext\\\": \\\"ea4f052d-e35e-4fff-ac31-544a95cea544\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1005, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64521b7c-98e4-469b-a861-8160f2cd3156\\\", \\\"childbox\\\": \\\"95be6046-c66b-4f0d-bf19-9d15c665796b\\\", \\\"subtext\\\": \\\"3d472e5c-4c05-4fb7-a63d-520744d26e0e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1006, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/L.)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64521b7c-98e4-469b-a861-8160f2cd3156\\\", \\\"childbox\\\": \\\"95be6046-c66b-4f0d-bf19-9d15c665796b\\\", \\\"subtext\\\": \\\"6645e052-18dc-4776-992f-b164e584f5d4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1007, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Absolute neutrophil count (ANC) \\\\u22641 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae06bb1a-5e38-49f9-bc0d-12195c597365\\\", \\\"childbox\\\": \\\"6b49b652-38e7-4374-b004-7fe0b38d4d48\\\", \\\"subtext\\\": \\\"0d4bb606-f570-47e2-be30-c2ffa81a4e82\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1008, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae06bb1a-5e38-49f9-bc0d-12195c597365\\\", \\\"childbox\\\": \\\"6b49b652-38e7-4374-b004-7fe0b38d4d48\\\", \\\"subtext\\\": \\\"95badcb9-da7c-444f-a483-aadb1af2c0d2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1009, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/L.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae06bb1a-5e38-49f9-bc0d-12195c597365\\\", \\\"childbox\\\": \\\"6b49b652-38e7-4374-b004-7fe0b38d4d48\\\", \\\"subtext\\\": \\\"b7bcd956-e61e-4b56-975a-a17b06e35b2a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1010, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(Dosing should be interrupted until ANC >2 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae06bb1a-5e38-49f9-bc0d-12195c597365\\\", \\\"childbox\\\": \\\"d9369e06-347f-4d5f-a5da-fbc782a0afb0\\\", \\\"subtext\\\": \\\"b7bcd956-e61e-4b56-975a-a17b06e35b2a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1011, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae06bb1a-5e38-49f9-bc0d-12195c597365\\\", \\\"childbox\\\": \\\"d9369e06-347f-4d5f-a5da-fbc782a0afb0\\\", \\\"subtext\\\": \\\"c0a56625-863f-4431-9a8a-2fcd433783b4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1012, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/L.)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae06bb1a-5e38-49f9-bc0d-12195c597365\\\", \\\"childbox\\\": \\\"d9369e06-347f-4d5f-a5da-fbc782a0afb0\\\", \\\"subtext\\\": \\\"b91df560-4ec0-4dce-adf3-8febb3bfb4ee\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1013, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 White blood cell (WBC) count <2.0 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7584474c-8133-433e-b3b8-8594a041386d\\\", \\\"childbox\\\": \\\"14f86a12-ac39-4f37-9ecc-fbdd5ecb53eb\\\", \\\"subtext\\\": \\\"d0d7f39f-4198-43e9-adf9-6fcb4ada6947\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1014, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7584474c-8133-433e-b3b8-8594a041386d\\\", \\\"childbox\\\": \\\"14f86a12-ac39-4f37-9ecc-fbdd5ecb53eb\\\", \\\"subtext\\\": \\\"4509f896-17e7-4ff7-8aa8-0e99ba31e5f7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1015, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/L\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7584474c-8133-433e-b3b8-8594a041386d\\\", \\\"childbox\\\": \\\"14f86a12-ac39-4f37-9ecc-fbdd5ecb53eb\\\", \\\"subtext\\\": \\\"beece105-77d1-400f-b692-7fd9b3e65fb9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1016, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Lymphocyte count <0.5 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce003951-809c-4525-96d1-e433ad839cea\\\", \\\"childbox\\\": \\\"961cd993-a3ab-4343-9fe0-d7c09da15cc0\\\", \\\"subtext\\\": \\\"f6dfcfc1-a574-4dad-9590-36e1f675c4b1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1017, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce003951-809c-4525-96d1-e433ad839cea\\\", \\\"childbox\\\": \\\"961cd993-a3ab-4343-9fe0-d7c09da15cc0\\\", \\\"subtext\\\": \\\"5186db82-9640-448c-9f75-34b4c1edc9d8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1018, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/L\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce003951-809c-4525-96d1-e433ad839cea\\\", \\\"childbox\\\": \\\"961cd993-a3ab-4343-9fe0-d7c09da15cc0\\\", \\\"subtext\\\": \\\"c3c7b9b2-3a3f-497a-bb5a-c9e75c1e2e54\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1019, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Do not restart study intervention until the hematological parameters rise above these values and monitor the participant until the event has resolved.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f3aa5813-0717-4de1-bf72-29909a027cd4\\\", \\\"childbox\\\": \\\"9a87f468-503c-4251-b950-9e4d3d62af01\\\", \\\"subtext\\\": \\\"f29c962a-488f-423d-8d9b-c4ffda1a6a59\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1020, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Note that for the above haematological abnormalities, a repeat test must be performed locally and assessed within 7 days with additional samples sent for central testing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f3aa5813-0717-4de1-bf72-29909a027cd4\\\", \\\"childbox\\\": \\\"ae61deba-a5dd-40fd-8333-a6de89fcc165\\\", \\\"subtext\\\": \\\"3f6dcf80-f3af-4373-8eef-8dd1b44b7b87\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1021, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The medical monitor should be consulted if the repeat test is still abnormal and a further repeat test performed again within 7 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f3aa5813-0717-4de1-bf72-29909a027cd4\\\", \\\"childbox\\\": \\\"16430259-525d-487f-bf48-4577bda0add5\\\", \\\"subtext\\\": \\\"3f6dcf80-f3af-4373-8eef-8dd1b44b7b87\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Hematologic Abnormalities\\\", \\\"7.1.3.3.\\\", \\\"4\\\", 1022, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.1.3.4. TB Reactivation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f50c6239-3300-481d-ac11-cefe85aede08\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"TB Reactivation\\\", \\\"7.1.3.4.\\\", \\\"4\\\", 1023, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study intervention may be temporarily discontinued for the following after consultation with the medical monitor:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"81d5c5f0-64f1-4010-8814-4e83dfb2ce02\\\", \\\"childbox\\\": \\\"65bc206c-fc8f-4a1f-a6c4-4a8f9547f61b\\\", \\\"subtext\\\": \\\"fd5f96bc-f7bf-4cc5-b727-cb77c23021d6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"TB Reactivation\\\", \\\"7.1.3.4.\\\", \\\"4\\\", 1024, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"74098f00-e40f-47bf-b1c9-5ee88b0d5fdb\\\", \\\"childbox\\\": \\\"4ccf1984-fbfb-4fe8-9fdc-ed52e2c96065\\\", \\\"subtext\\\": \\\"39dbf7d4-07ce-485c-9f1c-4de2c1e14b9d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"TB Reactivation\\\", \\\"7.1.3.4.\\\", \\\"4\\\", 1025, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Suspected TB reactivation (see Section 8.2.7.4).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 11, \\\"standard_entity_name\\\": \\\"SPONSOR MONITOR: Person Name\\\", \\\"subcategory\\\": \\\"SPONSOR MONITOR: Person Name\\\", \\\"confidence\\\": 100.0, \\\"text\\\": \\\"Suspected TB\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"74098f00-e40f-47bf-b1c9-5ee88b0d5fdb\\\", \\\"childbox\\\": \\\"4ccf1984-fbfb-4fe8-9fdc-ed52e2c96065\\\", \\\"subtext\\\": \\\"32df8b5d-3456-46e5-8f72-c9e9096cf1e0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"TB Reactivation\\\", \\\"7.1.3.4.\\\", \\\"4\\\", 1026, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"header\\\", \\\"7.2. Participant Discontinuation/Withdrawal from the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22a6fcb2-4dd0-4766-a853-86631a0a0369\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1027, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"text\\\", \\\"\\\\u2022 A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance or administrative reasons.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f5192919-962f-4852-9122-c5ec296f48d5\\\", \\\"childbox\\\": \\\"2477e116-d06f-4814-9ee0-a101ab0e2919\\\", \\\"subtext\\\": \\\"b1b88d2e-ffc6-4636-8817-899db30add30\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1028, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"text\\\", \\\"This is expected to be uncommon.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f5192919-962f-4852-9122-c5ec296f48d5\\\", \\\"childbox\\\": \\\"7bfa1d76-2559-4e92-8293-15213b82f1c8\\\", \\\"subtext\\\": \\\"87dafca2-805e-4909-9961-bc03c1ecae2f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1029, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"text\\\", \\\"\\\\u2022 At the time of discontinuing from the study, if possible, an early withdrawal visit should be conducted following the procedures at the Week 24 visit, as shown in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f67d4094-5e4f-41e9-a476-8075836e1e2a\\\", \\\"childbox\\\": \\\"e261cc11-08f5-466a-9971-8a5f1dab44ed\\\", \\\"subtext\\\": \\\"5ff39659-d1b4-465a-ac6a-aea4403cc873\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1030, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"text\\\", \\\"A safety follow-up visit should also be scheduled, per the SoA, to take place 12 weeks post last dose of study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f67d4094-5e4f-41e9-a476-8075836e1e2a\\\", \\\"childbox\\\": \\\"7fb59f88-fc26-4427-b49b-dc1b236d62be\\\", \\\"subtext\\\": \\\"5595daff-5c50-4930-a2a5-a6ddc334e487\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1031, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"text\\\", \\\"\\\\u2022 The participant will be permanently discontinued both from the study intervention and from the study at that time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4f92ad65-20c6-4fd1-9c37-06b566bdfddc\\\", \\\"childbox\\\": \\\"34e127c7-3f94-4b3e-a210-8df3039906e6\\\", \\\"subtext\\\": \\\"134f9004-30ed-4327-85b6-856f242e6446\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1032, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"text\\\", \\\"\\\\u2022 If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9739990a-a871-40b1-b2cc-f4fae96e843a\\\", \\\"childbox\\\": \\\"9eb0ac94-e60a-4196-a1f8-76b2889cf1ad\\\", \\\"subtext\\\": \\\"22b5550c-d96f-4e3c-8674-f41d6dc32131\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1033, \\\"\\\"], [\\\"2\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"text\\\", \\\"\\\\u2022 If a participant withdraws from the study, he/she may request destruction of any samples taken and not tested, and the investigator must document this in the site study records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3fb62e92-5f5a-480a-8df5-cc94ae81fb4b\\\", \\\"childbox\\\": \\\"dcfa7e04-336d-47a9-bf66-29ef212df851\\\", \\\"subtext\\\": \\\"0db556b4-4186-4d02-9025-e8f8a3510e4b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Participant Discontinuation/Withdrawal from the Study\\\", \\\"7.2.\\\", \\\"2\\\", 1034, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"header\\\", \\\"7.3. Lost to Follow Up\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5079a326-625a-45cb-ba4b-fbc0050c4bb7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1035, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"77a27630-7967-44d3-bceb-a6691639e01e\\\", \\\"childbox\\\": \\\"38268bf8-0c95-414c-8d48-5b2dbc3ef701\\\", \\\"subtext\\\": \\\"cd56044e-5d6c-40c5-9661-ad1b47158519\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1036, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"The following actions must be taken if a participant fails to return to the clinic for a required study visit:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"720ca9d1-2ea4-4e20-8988-404f8673d1ae\\\", \\\"childbox\\\": \\\"b3952e99-f8ba-47b5-a09e-54b6505b632e\\\", \\\"subtext\\\": \\\"ca30ec8f-aeb9-4c85-8876-187fd79bb762\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1037, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"\\\\u2022 The site must attempt to contact the participant and reschedule the missed visit as soon as possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether or not the participant wishes to and/or should continue in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eabe282c-500f-4ade-a347-72208624e842\\\", \\\"childbox\\\": \\\"1b7dcf73-145d-4d54-842a-34a79c757cd6\\\", \\\"subtext\\\": \\\"7f6811d4-f0bc-4a2d-8d7f-402bd4076433\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1038, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"Before a participant is deemed lost to follow up, the investigator or designee must make every effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, a certified letter to the participant\\\\u2019s last known mailing address or local equivalent methods).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"30958dea-2abe-4889-a4ad-1cd86e5774c9\\\", \\\"childbox\\\": \\\"a20355a6-d84a-4abe-9b49-f780dfca0833\\\", \\\"subtext\\\": \\\"c2c9ba63-dcf5-4e13-98be-6b9f21331105\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1039, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"These contact attempts should be documented in the participant\\\\u2019s medical record.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"30958dea-2abe-4889-a4ad-1cd86e5774c9\\\", \\\"childbox\\\": \\\"83bdff7a-e05f-475a-a1be-01e0bb386dbf\\\", \\\"subtext\\\": \\\"3337b9ef-dbeb-4fe8-aa23-6daa16bda0e2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1040, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"\\\\u2022 Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f30fc401-740d-41a0-ba1a-d5e5d20a49c6\\\", \\\"childbox\\\": \\\"da7d9cb1-51e2-4621-919e-c5183182e5aa\\\", \\\"subtext\\\": \\\"af47fd7c-b774-4bcf-a304-5892905c8a21\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1041, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c02deabc-4e3e-4a28-93a6-645324924220\\\", \\\"childbox\\\": \\\"ad9f3a26-bac8-4c36-b626-a8e3664a7e36\\\", \\\"subtext\\\": \\\"ca2c6796-620b-421e-ad49-1323c4f7bfba\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1042, \\\"\\\"], [\\\"2\\\", \\\"Lost to Follow up\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af6c7867-27a4-4d58-b92e-ea55e8d9af4d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\\\", \\\"Lost to Follow Up\\\", \\\"7.3.\\\", \\\"2\\\", 1043, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"header\\\", \\\"8. STUDY ASSESSMENTS AND PROCEDURES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"16f3ad4e-7a8a-4362-b5c9-92b7c8af767d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1044, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 Study procedures and their timing are summarised in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"443d86ca-82f2-4461-abff-d5d8e814e8fc\\\", \\\"childbox\\\": \\\"c9877176-8269-44d2-a627-2fea18057bbf\\\", \\\"subtext\\\": \\\"68f52d82-1be1-49a8-9b19-d159d4944e37\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1045, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 Protocol waivers or exemptions are not allowed\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"73dd18d6-b472-4554-b316-3ab362a54de8\\\", \\\"childbox\\\": \\\"068a40ac-b19e-4a15-89b1-e7d793ed2465\\\", \\\"subtext\\\": \\\"53721c98-d443-4d51-a39d-d1aaef658f06\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1046, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 Immediate safety concerns should be discussed with the medical monitor immediately upon occurrence or awareness to determine if the participant should continue or discontinue study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e6f86f25-1c42-4806-8d99-a76c2f9b74c1\\\", \\\"childbox\\\": \\\"d85c0a65-dedd-4450-a76c-d53a533ad9a7\\\", \\\"subtext\\\": \\\"9bfbd7ac-4dac-46b0-b41b-a8b4d13b9cab\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1047, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 Adherence to the study design requirements, including those specified in the SoA (Section 1.3), is essential and required for study conduct.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dcf6d24c-1167-4789-a9c8-54f3f56177fd\\\", \\\"childbox\\\": \\\"6238dcb1-4dab-4ee8-99c7-82d8cf00cf4b\\\", \\\"subtext\\\": \\\"1bfd442f-9490-4665-9e1e-5a5a6d451800\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1048, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"491fcf31-3c87-4bb6-9f81-2b1cbd539936\\\", \\\"childbox\\\": \\\"e88f7165-57a1-44a8-8c83-e97c93564fbb\\\", \\\"subtext\\\": \\\"1151ef6e-3208-4426-bff3-2171baa437c2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1049, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"491fcf31-3c87-4bb6-9f81-2b1cbd539936\\\", \\\"childbox\\\": \\\"04212d03-ddea-4c19-a468-1986146b5789\\\", \\\"subtext\\\": \\\"1151ef6e-3208-4426-bff3-2171baa437c2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1050, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 Procedures conducted as part of the participant\\\\u2019s routine clinical management (e.g., blood count) and obtained before signing of ICF may be utilised for screening or baseline purposes provided the procedure met the protocol-specified criteria and was performed within the time frame defined in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b5ad90b3-af07-4c3c-90d9-24b21830c0f4\\\", \\\"childbox\\\": \\\"4a4368b1-5a3c-41a5-b433-c44614d99ac0\\\", \\\"subtext\\\": \\\"8863d9f0-f22a-4a47-a0a4-aa12873242b4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1051, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 The maximum amount of blood collected from each participant over the duration of the study, including any extra assessments that may be required, will not exceed 400 mL.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8b56650f-a302-4a37-96a4-90c99364fe1b\\\", \\\"childbox\\\": \\\"80f529af-9c6d-40b0-8857-22fb96f27bbb\\\", \\\"subtext\\\": \\\"c67ee507-4764-4b9c-b90c-a23682f8684e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1052, \\\"\\\"], [\\\"1\\\", \\\"Study Assessments and Procedures\\\", \\\"text\\\", \\\"\\\\u2022 Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c9f25b76-c781-4ed1-8001-781d01c8049c\\\", \\\"childbox\\\": \\\"8a8ab194-fefa-496b-8f47-0a2a2ace2b8e\\\", \\\"subtext\\\": \\\"3752b6dd-ffd5-4773-a9d5-68833eb01344\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"STUDY ASSESSMENTS AND PROCEDURES\\\", \\\"8.\\\", \\\"1\\\", 1053, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1. Efficacy Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"da162aed-de37-48b3-bfdb-7063148336f0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Efficacy Assessments\\\", \\\"8.1.\\\", \\\"2\\\", 1054, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"header\\\", \\\"8.1.1. Joint Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"58d53dfb-99a2-4d8b-abf9-ba1342c4c95b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1055, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"An evaluation of all 68 joints for tenderness and 66 joints for swelling will be performed by an independent joint evaluator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b40fbba0-9808-478a-a26c-83a8c5a26862\\\", \\\"childbox\\\": \\\"ab4b5706-ca62-4400-801d-5a143cdb0234\\\", \\\"subtext\\\": \\\"05b22c85-5c1f-47e2-b4d1-2b8111522011\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1056, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"Replaced or fused joints are considered non-evaluable and will not be included in joint evaluations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b40fbba0-9808-478a-a26c-83a8c5a26862\\\", \\\"childbox\\\": \\\"c8eedb90-23b4-464a-bc5a-a20f1da23aa0\\\", \\\"subtext\\\": \\\"05b22c85-5c1f-47e2-b4d1-2b8111522011\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1057, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"The reason for absence of the evaluations of those joints must be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b40fbba0-9808-478a-a26c-83a8c5a26862\\\", \\\"childbox\\\": \\\"d4bbd5cf-c770-43f5-a565-0a017b120e18\\\", \\\"subtext\\\": \\\"eb0553f8-ae98-4182-92ae-bd7d95ddca29\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1058, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"If a joint has undergone intra-articular injection of corticosteroid during the course of the study, the injected joint must be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 54, \\\"end_idx\\\": 67, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"corticosteroid\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b40fbba0-9808-478a-a26c-83a8c5a26862\\\", \\\"childbox\\\": \\\"e1ed5a80-bec3-4532-878d-c9bf17bb5ddc\\\", \\\"subtext\\\": \\\"eb0553f8-ae98-4182-92ae-bd7d95ddca29\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1059, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"One or more independent assessors, who have documented experience in performing joint assessments, will be designated at each trial site to perform joint assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f47d7124-590a-4f74-bef8-569518c65f58\\\", \\\"childbox\\\": \\\"ddb6b3eb-916e-4db6-b518-2c05b70248bd\\\", \\\"subtext\\\": \\\"ab1f8dc4-b7f3-42bc-abd3-3c45739df6c4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1060, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"Preferably the same independent assessor will perform all joint assessment for the same participant throughout the trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f47d7124-590a-4f74-bef8-569518c65f58\\\", \\\"childbox\\\": \\\"0813c041-5cc7-4d49-9462-38ece57db1a9\\\", \\\"subtext\\\": \\\"f5528c00-834e-4112-8187-945f74a0bead\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1061, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"The principal investigator must ensure that the independent joint assessor has documented experience and he/she is adhering to locally accepted and implemented standards.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f47d7124-590a-4f74-bef8-569518c65f58\\\", \\\"childbox\\\": \\\"521798b0-c32b-41a8-91ac-17a45a2b9f67\\\", \\\"subtext\\\": \\\"4a22eba2-3c37-46a6-8510-cd94002199cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1062, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"This also applies if the independent joint assessor is replaced during the trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f47d7124-590a-4f74-bef8-569518c65f58\\\", \\\"childbox\\\": \\\"3b167943-7c84-4cc6-99e2-aaf570c0ffb1\\\", \\\"subtext\\\": \\\"4a22eba2-3c37-46a6-8510-cd94002199cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1063, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"The independent joint assessor should have no other contact with the participant during the trial, must not be the treating physician (investigator), should not discuss the clinical status of the participant with them during the joint assessment nor with other site personnel, and will not be permitted to review the participant\\\\u2019s medical records, the eCRF, nor any of the previous joint assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"23b413f5-01c8-4268-afe6-054c982c537e\\\", \\\"childbox\\\": \\\"d09c5c99-2fde-4499-a8f9-f15ce6fb4fcb\\\", \\\"subtext\\\": \\\"6e14c10b-3692-4aee-afc7-17fe831c3aca\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1064, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"The procedure for joint assessments is provided in the SRM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fdc7bf7b-1237-470e-b5fb-988ef8cdae26\\\", \\\"childbox\\\": \\\"617d2611-aa98-4be8-a3f0-d7df59efe499\\\", \\\"subtext\\\": \\\"60f3071e-ffcd-4503-a9e6-2dc239751935\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Joint Assessments\\\", \\\"8.1.1.\\\", \\\"3\\\", 1065, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.2. Physician\\\\u2019s Global Assessment of Arthritis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5c2e4618-8eab-46f9-9773-ff542d9180ef\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physician\\\\u2019s Global Assessment of Arthritis\\\", \\\"8.1.2.\\\", \\\"3\\\", 1066, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigators will complete a global assessment of RA disease activity using the physician global assessment item (PhGA), a visual analogue scale (VAS) with anchors \\\\u201c0\\\\u201d (none) to \\\\u201c100\\\\u201d (extremely active), respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"79c46d7e-aa9d-4add-a030-e5b4744d0843\\\", \\\"childbox\\\": \\\"0dee1c35-308c-48d8-9d6f-0983de57af80\\\", \\\"subtext\\\": \\\"f2b40553-a2e5-432d-b1d9-9a89334aff3a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physician\\\\u2019s Global Assessment of Arthritis\\\", \\\"8.1.2.\\\", \\\"3\\\", 1067, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3. Patient Reported Outcomes\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8b34639c-46b4-41a8-88c5-0d64946d6301\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient Reported Outcomes\\\", \\\"8.1.3.\\\", \\\"3\\\", 1068, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All patient reported outcomes (PROs) should be administered before any laboratory assessments and other procedures or consultations to avoid influencing the participants\\\\u2019 perception of their RA disease.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f130004b-8943-4b92-bc6d-fd17830f6016\\\", \\\"childbox\\\": \\\"6fba35aa-da58-45fa-9298-2d9fe064d6ac\\\", \\\"subtext\\\": \\\"e52e84d5-58dc-4634-a5aa-a435b0194bda\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient Reported Outcomes\\\", \\\"8.1.3.\\\", \\\"3\\\", 1069, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.1. Patient\\\\u2019s Assessment of Arthritis Pain\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fdeed439-55e0-4a2e-b170-3e7ebc162de7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient\\\\u2019s Assessment of Arthritis Pain\\\", \\\"8.1.3.1.\\\", \\\"4\\\", 1070, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants will assess the severity of their arthritis pain over the past week, using a 100 unit VAS, with anchors \\\\u201c0\\\\u201d (no pain) and \\\\u201c100\\\\u201d (most severe pain).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8bf63612-e95f-4cf3-8dfe-340f0e70510d\\\", \\\"childbox\\\": \\\"6238fa9c-c59b-4a81-9067-e462eba2e27f\\\", \\\"subtext\\\": \\\"7397a18d-d06f-4550-8a07-5cf2f9f0a3a6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient\\\\u2019s Assessment of Arthritis Pain\\\", \\\"8.1.3.1.\\\", \\\"4\\\", 1071, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The results of this question will be used for the HAQ-DI, where the local version of HAQ-DI asks the same question.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0e675d39-ff5a-4365-8187-1963bf33fd7c\\\", \\\"childbox\\\": \\\"716a0ad3-17af-4d14-b0a2-02f403835989\\\", \\\"subtext\\\": \\\"4cd58831-f25b-4a61-a0ea-714d6d195083\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient\\\\u2019s Assessment of Arthritis Pain\\\", \\\"8.1.3.1.\\\", \\\"4\\\", 1072, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.2. Patient\\\\u2019s Global Assessment of Arthritis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"68c29f57-7364-4a55-a028-160559fb1ca5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient\\\\u2019s Global Assessment of Arthritis\\\", \\\"8.1.3.2.\\\", \\\"4\\\", 1073, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants will complete a global assessment of disease activity using the patient global assessment (PtGA) item, a VAS with anchors \\\\u201c0\\\\u201d (very well) to \\\\u201c100\\\\u201d (very poor).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2910232d-f882-4a0a-8de2-5aa4369c910d\\\", \\\"childbox\\\": \\\"7c6c5e10-9f48-4c36-9cab-98f1d9b907d2\\\", \\\"subtext\\\": \\\"cd3569b1-e9a6-48e7-b7ed-05cbb5374e9c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient\\\\u2019s Global Assessment of Arthritis\\\", \\\"8.1.3.2.\\\", \\\"4\\\", 1074, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.3. Health Assessment Questionnaire \\\\u2013 Disability Index (HAQ-DI)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7d59acc1-9d5e-470e-8eed-fd8a01cc3412\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Health Assessment Questionnaire \\\\u2013 Disability Index (HAQ-DI)\\\", \\\"8.1.3.3.\\\", \\\"4\\\", 1075, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The functional status of the participant will be assessed by means of the Disability Index of the Stanford Health Assessment Questionnaire (HAQ-DI).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"da19737a-9ca1-40e2-b979-8e536c4e7fb4\\\", \\\"childbox\\\": \\\"4a83e47d-1217-4397-9173-97383a2ca247\\\", \\\"subtext\\\": \\\"4afb4b50-da55-4c96-8828-5db7b75d6f2d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Health Assessment Questionnaire \\\\u2013 Disability Index (HAQ-DI)\\\", \\\"8.1.3.3.\\\", \\\"4\\\", 1076, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in eight functional areas [Fries, 1980]: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"da19737a-9ca1-40e2-b979-8e536c4e7fb4\\\", \\\"childbox\\\": \\\"a668e95e-95fc-48fd-9b36-cbcb6e5af1ca\\\", \\\"subtext\\\": \\\"4afb4b50-da55-4c96-8828-5db7b75d6f2d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Health Assessment Questionnaire \\\\u2013 Disability Index (HAQ-DI)\\\", \\\"8.1.3.3.\\\", \\\"4\\\", 1077, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.4. Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"54a43b3f-4074-4c2c-a3c1-c41dd9235b21\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference\\\", \\\"8.1.3.4.\\\", \\\"4\\\", 1078, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8ea800d0-cdb9-4fd8-8001-3d0cfab697fc\\\", \\\"childbox\\\": \\\"b6720ad1-80dd-4610-b81a-1996bab20c41\\\", \\\"subtext\\\": \\\"dc7fb5a2-5caf-4c6b-9d51-7c187ce57d8b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference\\\", \\\"8.1.3.4.\\\", \\\"4\\\", 1079, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It can be used with the general population and with individuals living with chronic conditions such as RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8ea800d0-cdb9-4fd8-8001-3d0cfab697fc\\\", \\\"childbox\\\": \\\"9198262e-8abd-4313-b595-a71da73b3ebd\\\", \\\"subtext\\\": \\\"dc7fb5a2-5caf-4c6b-9d51-7c187ce57d8b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference\\\", \\\"8.1.3.4.\\\", \\\"4\\\", 1080, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PROMIS instruments are scored using an item response theory based scoring algorithm [Bjorner, 2014; Cella, 2010].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8ea800d0-cdb9-4fd8-8001-3d0cfab697fc\\\", \\\"childbox\\\": \\\"f64d7a3f-9116-42bf-9fec-5a0c7ad60f96\\\", \\\"subtext\\\": \\\"5b6b56d3-4c2c-4e5d-b992-3a71ba633aae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference\\\", \\\"8.1.3.4.\\\", \\\"4\\\", 1081, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study, a subset of items from the PROMIS Pain Interference item bank will be administered to assess the extent to which pain hindered engagement with social, cognitive, emotional, physical, and recreational activities over the past 7 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8ea800d0-cdb9-4fd8-8001-3d0cfab697fc\\\", \\\"childbox\\\": \\\"75455cd0-1848-4ac5-91ab-ecbab001c98a\\\", \\\"subtext\\\": \\\"0c084a78-c0f5-424c-ab31-2067d68513b2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference\\\", \\\"8.1.3.4.\\\", \\\"4\\\", 1082, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.5. PROMIS Sleep Disturbance\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"be390eb6-1484-46ab-bf24-53d1cc2899e0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"PROMIS Sleep Disturbance\\\", \\\"8.1.3.5.\\\", \\\"4\\\", 1083, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PROMIS Sleep Disturbance instrument is designed to assess perceptions of sleep over the past 7 days, specifically assessing sleep quality, sleep depth, and restoration associated with sleep.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aba10a1d-059d-46f7-a207-c50b1b4348f6\\\", \\\"childbox\\\": \\\"2282edd1-1f5d-4730-b977-be39897c8e12\\\", \\\"subtext\\\": \\\"49b6fcd8-e615-412e-a0aa-eac35dd8737b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"PROMIS Sleep Disturbance\\\", \\\"8.1.3.5.\\\", \\\"4\\\", 1084, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.6. Rheumatoid Arthritis Symptom and Impact Questionnaire\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6f545228-5e20-4cc9-9e49-973e6e5e0b0b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Rheumatoid Arthritis Symptom and Impact Questionnaire\\\", \\\"8.1.3.6.\\\", \\\"4\\\", 1085, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Symptoms associated with RA will be assessed using a RA Symptom and Impact Questionnaire.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"73b0a3e6-30e5-4d4e-bece-36642f70709d\\\", \\\"childbox\\\": \\\"e672e0f3-a6d7-47b2-8e56-940122970b81\\\", \\\"subtext\\\": \\\"025d97fd-7937-482f-bb3f-2a114b791c47\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Rheumatoid Arthritis Symptom and Impact Questionnaire\\\", \\\"8.1.3.6.\\\", \\\"4\\\", 1086, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The RA Symptom and Impact Questionnaire is designed to assess the incidence and severity of RA symptoms and their impact on patients with moderate to severe disease.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"73b0a3e6-30e5-4d4e-bece-36642f70709d\\\", \\\"childbox\\\": \\\"81e18da5-8374-4b26-86fa-021452e6a6d9\\\", \\\"subtext\\\": \\\"025d97fd-7937-482f-bb3f-2a114b791c47\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Rheumatoid Arthritis Symptom and Impact Questionnaire\\\", \\\"8.1.3.6.\\\", \\\"4\\\", 1087, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The instrument was developed with patient input and is easily understood and relevant to RA patients.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"73b0a3e6-30e5-4d4e-bece-36642f70709d\\\", \\\"childbox\\\": \\\"eaf5c3e2-ed23-4e43-a0d7-8addb49fd1bd\\\", \\\"subtext\\\": \\\"dcafa0c2-08f9-46c6-88c5-46713f171004\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Rheumatoid Arthritis Symptom and Impact Questionnaire\\\", \\\"8.1.3.6.\\\", \\\"4\\\", 1088, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The 16-item instrument includes 13 items measuring symptom intensity (joint pain, energy/tiredness, joint stiffness) and three items measuring direct impacts of symptoms on rest and sleep\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"73b0a3e6-30e5-4d4e-bece-36642f70709d\\\", \\\"childbox\\\": \\\"0d1b8f9b-a854-4b7b-838f-8ad29490fc9f\\\", \\\"subtext\\\": \\\"dcafa0c2-08f9-46c6-88c5-46713f171004\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Rheumatoid Arthritis Symptom and Impact Questionnaire\\\", \\\"8.1.3.6.\\\", \\\"4\\\", 1089, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.7. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"11a72772-dfbf-488d-a1c7-76d3df985743\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue\\\", \\\"8.1.3.7.\\\", \\\"4\\\", 1090, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue questionnaire is a validated patient-reported measure developed originally to assess fatigue in individuals with cancer.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4c08bef5-a05a-499d-9b97-6adabd691fb4\\\", \\\"childbox\\\": \\\"58629799-2335-4509-aa5c-4bf2bc7abb67\\\", \\\"subtext\\\": \\\"0eded72c-faa1-465e-84fa-abc089a0cfff\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue\\\", \\\"8.1.3.7.\\\", \\\"4\\\", 1091, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The FACIT-fatigue has subsequently been used and validated in numerous chronic conditions, including RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4c08bef5-a05a-499d-9b97-6adabd691fb4\\\", \\\"childbox\\\": \\\"51098a4e-edb4-41ea-9eac-75680b298e9f\\\", \\\"subtext\\\": \\\"94012458-fb53-4ad5-b632-ec3c99aae45c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue\\\", \\\"8.1.3.7.\\\", \\\"4\\\", 1092, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.8. SF-36 Short Form Health Survey\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"98b12661-284e-49f0-b00f-59a7fa9d09c3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"SF-36 Short Form Health Survey\\\", \\\"8.1.3.8.\\\", \\\"4\\\", 1093, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Health-related quality of life (HRQL) will be assessed using the participant-completed Medical Outcomes Study (MOS) Short-Form 36 (SF-36) which is a generic health survey that contains 36 questions covering eight domains of health.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e31ec085-9788-46df-849a-840bfb9afd8e\\\", \\\"childbox\\\": \\\"acd22dae-e4d7-4990-a08e-c4b1cfbe9dd8\\\", \\\"subtext\\\": \\\"940d55c7-b422-493a-927c-77d51299c9bf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"SF-36 Short Form Health Survey\\\", \\\"8.1.3.8.\\\", \\\"4\\\", 1094, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The SF-36 yields an eightscale profile of functional health and well-being scores as well as physical and mental component health summary scores.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e31ec085-9788-46df-849a-840bfb9afd8e\\\", \\\"childbox\\\": \\\"f2e4b06b-cc81-4884-a5be-b42752fc8b3d\\\", \\\"subtext\\\": \\\"a478b71b-d918-402e-926c-751e094e428b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"SF-36 Short Form Health Survey\\\", \\\"8.1.3.8.\\\", \\\"4\\\", 1095, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The version 2, 1-week recall questionnaire will be used.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e31ec085-9788-46df-849a-840bfb9afd8e\\\", \\\"childbox\\\": \\\"9fa1b6a3-1ba2-461e-bae1-1ee922325eb9\\\", \\\"subtext\\\": \\\"0a8f3aa6-0f20-4a81-87a1-2f463f229311\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"SF-36 Short Form Health Survey\\\", \\\"8.1.3.8.\\\", \\\"4\\\", 1096, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.9. PainDETECT Questionnaire\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a2095a7c-8ea2-43ba-985a-bc44bfb5c151\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"PainDETECT Questionnaire\\\", \\\"8.1.3.9.\\\", \\\"4\\\", 1097, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All participants will complete the PainDETECT questionnaire at baseline only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8282bd5d-ce6e-476a-8f58-f10e08cd0588\\\", \\\"childbox\\\": \\\"eff79540-a136-42d1-9f9d-c434e4b8bf79\\\", \\\"subtext\\\": \\\"a5cd91d7-eeb0-4547-bfe6-2fd01b871215\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"PainDETECT Questionnaire\\\", \\\"8.1.3.9.\\\", \\\"4\\\", 1098, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This questionnaire contains 13 questions and is used to predict the likelihood of a neuropathic pain component in chronic pain disorders.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8282bd5d-ce6e-476a-8f58-f10e08cd0588\\\", \\\"childbox\\\": \\\"6c6f81f0-d5be-4150-bc65-8386bb43fab9\\\", \\\"subtext\\\": \\\"a5cd91d7-eeb0-4547-bfe6-2fd01b871215\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"PainDETECT Questionnaire\\\", \\\"8.1.3.9.\\\", \\\"4\\\", 1099, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.10. Participant Feedback Questionnaire\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b8e5f55c-2278-4ab4-a640-e4e0305bac22\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Participant Feedback Questionnaire\\\", \\\"8.1.3.10.\\\", \\\"4\\\", 1100, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This is an optional multiple-choice questionnaire administered by ePRO at the visits specified in the SoA (Section 1.3), for participants to provide feedback on aspects of their clinical trial experience including satisfaction with study intervention, intervention administration and pre-filled syringes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"953164be-316f-48d4-b211-439d96120f88\\\", \\\"childbox\\\": \\\"7be06bb8-25f3-4d53-bd29-46d76ff60e92\\\", \\\"subtext\\\": \\\"293704ed-96bd-432b-b2f3-19d0112e53bf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Participant Feedback Questionnaire\\\", \\\"8.1.3.10.\\\", \\\"4\\\", 1101, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Responses will be used by the sponsor to understand where improvements can be made in the clinical trial process and study intervention delivery.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"953164be-316f-48d4-b211-439d96120f88\\\", \\\"childbox\\\": \\\"8001df85-75b5-4e49-abe3-c4f64c87ee96\\\", \\\"subtext\\\": \\\"f014085d-ca19-4d93-a990-111b89c9cf52\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Participant Feedback Questionnaire\\\", \\\"8.1.3.10.\\\", \\\"4\\\", 1102, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This questionnaire does not collect specific data about the participant\\\\u2019s disease, symptoms, treatment effect or AEs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"953164be-316f-48d4-b211-439d96120f88\\\", \\\"childbox\\\": \\\"21f4160e-f331-42e3-af44-bde73cd191a3\\\", \\\"subtext\\\": \\\"f917e5ae-098a-430b-ac4f-9732bf4f80f9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Participant Feedback Questionnaire\\\", \\\"8.1.3.10.\\\", \\\"4\\\", 1103, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"header\\\", \\\"8.2. Safety Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a97094f9-744f-4a35-988c-61a8499eb19b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Safety Assessments\\\", \\\"8.2.\\\", \\\"2\\\", 1104, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"Planned time points for all safety assessments are provided in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1212ec35-c2b5-4609-8691-97b564096dc7\\\", \\\"childbox\\\": \\\"59117ea4-81f6-4df9-bc5d-c189af365648\\\", \\\"subtext\\\": \\\"bc1bede4-ee7f-4c14-afd5-0691c93482ba\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Safety Assessments\\\", \\\"8.2.\\\", \\\"2\\\", 1105, \\\"\\\"], [\\\"2\\\", \\\"Safety Assessments\\\", \\\"text\\\", \\\"In the event that pulmonary follow-up criteria are triggered, all sites must have access to a pulmonologist (see Section 7.1.3.1 and Section 8.2.6).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e36be296-744b-4505-9761-738bf2db8346\\\", \\\"childbox\\\": \\\"b4fdbfbe-532c-4b18-8031-04385580c21a\\\", \\\"subtext\\\": \\\"1b6b61b7-947b-499b-b115-ae566951076f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Safety Assessments\\\", \\\"8.2.\\\", \\\"2\\\", 1106, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.1. Dyspnoea Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e733521f-d6eb-4d28-8104-07342207df4e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Dyspnoea Assessments\\\", \\\"8.2.1.\\\", \\\"3\\\", 1107, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The dyspnoea scale grades the effect of breathlessness on daily activities and measures perceived respiratory disability.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce5e51ca-affc-48f5-9dac-d01b9388107e\\\", \\\"childbox\\\": \\\"931de58c-22f4-4353-80cd-9f7e0df3b882\\\", \\\"subtext\\\": \\\"af3d756f-221d-4fd3-980b-62ac060ac516\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Dyspnoea Assessments\\\", \\\"8.2.1.\\\", \\\"3\\\", 1108, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The scale will be completed by the investigator in consultation with the participant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce5e51ca-affc-48f5-9dac-d01b9388107e\\\", \\\"childbox\\\": \\\"ddcb79b3-5bc8-4766-b496-59b06f693696\\\", \\\"subtext\\\": \\\"af3d756f-221d-4fd3-980b-62ac060ac516\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Dyspnoea Assessments\\\", \\\"8.2.1.\\\", \\\"3\\\", 1109, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dyspnoea will be reported on a rating scale from 0 (not breathless at rest or on exertion) through 4 (breathless at rest).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ce5e51ca-affc-48f5-9dac-d01b9388107e\\\", \\\"childbox\\\": \\\"9abeeee6-6062-4f4e-b81c-350a21beb2f7\\\", \\\"subtext\\\": \\\"af3d756f-221d-4fd3-980b-62ac060ac516\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Dyspnoea Assessments\\\", \\\"8.2.1.\\\", \\\"3\\\", 1110, \\\"\\\"], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"header\\\", \\\"8.2.2. Physical Examinations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6db91b29-33f5-4354-9b3f-6f01b9a1d81f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physical Examinations\\\", \\\"8.2.2.\\\", \\\"3\\\", 1111, \\\"\\\"], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"\\\\u2022 A complete physical examination (e.g.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0cdb05f7-349f-4f9b-9e62-10b12b86bfe7\\\", \\\"childbox\\\": \\\"5f4df584-8e9c-4b6b-9486-c7822e036076\\\", \\\"subtext\\\": \\\"644ed58b-685d-49c8-bd89-10b0db9b1e3d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physical Examinations\\\", \\\"8.2.2.\\\", \\\"3\\\", 1112, \\\"\\\"], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"at the Screening visit) will include, at a minimum, assessments of the Skin, Cardiovascular, Respiratory, Gastrointestinal and Neurological systems.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0cdb05f7-349f-4f9b-9e62-10b12b86bfe7\\\", \\\"childbox\\\": \\\"3d6f666e-75c4-40cd-98e7-9c4754947ede\\\", \\\"subtext\\\": \\\"644ed58b-685d-49c8-bd89-10b0db9b1e3d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physical Examinations\\\", \\\"8.2.2.\\\", \\\"3\\\", 1113, \\\"\\\"], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"Height and weight will also be measured and recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0cdb05f7-349f-4f9b-9e62-10b12b86bfe7\\\", \\\"childbox\\\": \\\"d8243c40-4571-4b2d-ab0c-d6aab615c2ef\\\", \\\"subtext\\\": \\\"01aaa266-9a32-427b-a16b-f601ec8e7a80\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physical Examinations\\\", \\\"8.2.2.\\\", \\\"3\\\", 1114, \\\"\\\"], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"\\\\u2022 A brief physical examination will include, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"82a4228d-cede-47c4-b8de-cbd5d291a73f\\\", \\\"childbox\\\": \\\"0fc38217-164d-4d2d-ad46-593262b082bb\\\", \\\"subtext\\\": \\\"89801aa4-377a-44ff-a35e-21b7a244ae15\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physical Examinations\\\", \\\"8.2.2.\\\", \\\"3\\\", 1115, \\\"\\\"], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"\\\\u2022 Investigators should pay special attention to clinical signs related to previous serious illnesses.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dd5507fb-d7ed-46cd-8c0a-9cae85b62f13\\\", \\\"childbox\\\": \\\"fb87eb70-ada2-4bad-8e59-041a2b102a1b\\\", \\\"subtext\\\": \\\"954581f9-08d0-4759-ab91-f8fb182e98d2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physical Examinations\\\", \\\"8.2.2.\\\", \\\"3\\\", 1116, \\\"\\\"], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"\\\\u2022 All physical examinations will include monitoring for signs and symptoms of TB (see Section 8.2.1).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b167cb4e-d87d-4c96-a6ab-6cb27516f585\\\", \\\"childbox\\\": \\\"08b8bbe1-6345-46f5-ac0e-7bf5e35b7ae6\\\", \\\"subtext\\\": \\\"3eab699a-7b80-4294-a296-1b2ebecd82eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Physical Examinations\\\", \\\"8.2.2.\\\", \\\"3\\\", 1117, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"header\\\", \\\"8.2.3. Electrocardiograms\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8de5476e-c496-4bfd-95b5-7fb6bca32b3c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1118, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"text\\\", \\\"\\\\u2022 12-lead ECG measurements should be recorded pre-dose and where possible before vital sign measurements and blood draws.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d6edfa4-9cea-4d72-be46-6dd9862a6c85\\\", \\\"childbox\\\": \\\"ce129895-9e7b-4c79-be24-12db312fd9d8\\\", \\\"subtext\\\": \\\"6186e2d1-b450-4d11-9e29-9ee7dace0b1e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1119, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"text\\\", \\\"\\\\u2022 Participants should be in a quiet setting without distractions and rest in a supine position for at least 5 or 10 minutes before ECG collection.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c2f4de5f-ab5a-4c33-8b89-2d365aea8752\\\", \\\"childbox\\\": \\\"843de072-5c94-456c-a852-8263c7a9fef4\\\", \\\"subtext\\\": \\\"c3b0e0dd-3684-46e7-a185-5f6eb4b8c1ff\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1120, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"text\\\", \\\"\\\\u2022 Triplicate 12-lead ECG measurements will be obtained at screening with single\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9cd865b5-40bc-4382-a354-7724a9528cf1\\\", \\\"childbox\\\": \\\"e56227ab-a002-4ad4-8178-999c83f0fd44\\\", \\\"subtext\\\": \\\"b6092882-3383-4ccf-a04e-cab887721a6b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1121, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"text\\\", \\\"ECG measurements obtained post-baseline as outlined in the SoA (see Section 1.3) using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2bc7c8f4-661a-483b-90d7-a3d1d714aeec\\\", \\\"childbox\\\": \\\"1beb8968-c06e-4282-a9a3-7511a6ce8b28\\\", \\\"subtext\\\": \\\"35eb8ce2-73b3-4dd0-a164-b09146b14f2b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1122, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"text\\\", \\\"\\\\u2022 At the screening visit where triplicate ECG are required, three individual ECG tracings should be obtained as closely as possible in succession, but no more than 2 minutes apart.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"acf7c15d-5893-4ca3-afb7-cf3a92f24a7e\\\", \\\"childbox\\\": \\\"14fb8411-5694-44ee-9fc9-1932deddeff2\\\", \\\"subtext\\\": \\\"1d955704-d260-4bfe-a55e-491c63e95106\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1123, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"text\\\", \\\"The full set of triplicates should be completed in less than 4 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"acf7c15d-5893-4ca3-afb7-cf3a92f24a7e\\\", \\\"childbox\\\": \\\"aa30090d-506f-4729-847f-c7fdd7aa6576\\\", \\\"subtext\\\": \\\"c86fa32c-4bac-483c-8d6d-1f691ead5522\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1124, \\\"\\\"], [\\\"3\\\", \\\"Electrocardiograms\\\", \\\"text\\\", \\\"\\\\u2022 ECG traces will be read locally.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"614dbf5b-f808-4651-9a15-a79e3650c810\\\", \\\"childbox\\\": \\\"717651da-fbad-44e2-a509-8d8c3a3237d0\\\", \\\"subtext\\\": \\\"a202da43-0a88-453b-9fbe-eb943934bf0b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Electrocardiograms\\\", \\\"8.2.3.\\\", \\\"3\\\", 1125, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"header\\\", \\\"8.2.4. Vital Signs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8989985d-00fb-486b-8d50-a8e4b29f65d6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1126, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"\\\\u2022 Vital signs should be measured pre-dose, and where possible before blood draws.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d78e92b3-3596-47a0-ae3d-2985aa21b61c\\\", \\\"childbox\\\": \\\"9133a207-e1c5-4826-a12a-1b86567d7574\\\", \\\"subtext\\\": \\\"6c8eb704-6ca3-426c-af84-8ec82019ceae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1127, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"\\\\u2022 Temperature, pulse rate, respiratory rate and blood pressure will be assessed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"544af09c-81f3-47d9-b3dd-207b1dc2e504\\\", \\\"childbox\\\": \\\"3960bce7-4ace-4ea4-9f00-477910443d3a\\\", \\\"subtext\\\": \\\"66c9dd8f-073f-4c21-801f-23b2153c5011\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1128, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"\\\\u2022 Blood pressure and pulse measurements will be assessed with a completely automated device.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22df7fc9-1288-48fc-a145-8959418ff6cf\\\", \\\"childbox\\\": \\\"fab6bc58-f98f-443e-9115-2b5fd8896e07\\\", \\\"subtext\\\": \\\"48a9e81d-e53b-4bfc-be45-c6e5bf567d85\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1129, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"Manual techniques will be used only if an automated device is not available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22df7fc9-1288-48fc-a145-8959418ff6cf\\\", \\\"childbox\\\": \\\"d93abde7-3325-4e58-b465-247c8b360ebf\\\", \\\"subtext\\\": \\\"48a9e81d-e53b-4bfc-be45-c6e5bf567d85\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1130, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"The participant should use the same position throughout all visits.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22df7fc9-1288-48fc-a145-8959418ff6cf\\\", \\\"childbox\\\": \\\"5d0b9ba5-0293-4c31-ae10-b9678653e9b8\\\", \\\"subtext\\\": \\\"48a9e81d-e53b-4bfc-be45-c6e5bf567d85\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1131, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"\\\\u2022 All blood pressure readings will be recorded using an appropriate cuff size with the same arm being used throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0118cff9-4a70-4b4c-bde8-0013505292f8\\\", \\\"childbox\\\": \\\"f373606e-d00c-45a2-84c5-66b72529e5f3\\\", \\\"subtext\\\": \\\"9e3a9b49-cca0-4619-a73b-ef123f5f22ca\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1132, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"\\\\u2022 Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d4d9e77f-24d4-4cfc-b983-5ff37531efa9\\\", \\\"childbox\\\": \\\"2b7465a2-47a1-4f80-95c6-568f73edd80d\\\", \\\"subtext\\\": \\\"6635c9ca-bbc2-4d8d-8a3b-bda9587acb6d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1133, \\\"\\\"], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"\\\\u2022 When the timing of these measurements coincides with blood collection, the blood pressure and heart rate should be obtained first.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"97067f2a-eb2d-4ea3-ac7c-0ec450b53033\\\", \\\"childbox\\\": \\\"2a70c6f9-e90b-4f19-9ce0-fa4bff6e851c\\\", \\\"subtext\\\": \\\"7916c029-a330-4804-91d3-5c7a34e265e8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Vital Signs\\\", \\\"8.2.4.\\\", \\\"3\\\", 1134, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"header\\\", \\\"8.2.5. Clinical Safety Laboratory Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [{\\\"start_idx\\\": 7, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Clinical Safety Laboratory\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"6de29da4-de19-49a5-8409-22333067c118\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1135, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA in Section 1.3 for the timing and frequency.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6e0e64ae-163d-401b-912f-91762ce174b7\\\", \\\"childbox\\\": \\\"c16e1ad9-ddc1-46d2-a8ce-ade43eaa6e7a\\\", \\\"subtext\\\": \\\"e0217d6d-da0b-4e0c-88b2-b73ff7fbaa58\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1136, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 All study-required laboratory assessments will be performed by a central laboratory except erythrocyte sedimentation rate (ESR), dipstick urinalysis, and urine pregnancy tests which will be analysed locally.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e08e099-c733-4497-81b9-3b6b68962b3c\\\", \\\"childbox\\\": \\\"b27f72ba-e6a3-4fd4-a4da-c56ed09e7c18\\\", \\\"subtext\\\": \\\"3e327982-313e-4561-a48d-de5e93995227\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1137, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 The investigator must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb9a36ee-a232-489c-9914-ecb32fa62c1b\\\", \\\"childbox\\\": \\\"aabad3b4-f4ed-4f23-82e2-6f8629237284\\\", \\\"subtext\\\": \\\"95176b33-57a6-4ead-8d14-df127d32a92e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1138, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"The laboratory reports must be filed with the source documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb9a36ee-a232-489c-9914-ecb32fa62c1b\\\", \\\"childbox\\\": \\\"937d5085-3a2c-4e1f-a6b5-f9210acde333\\\", \\\"subtext\\\": \\\"95176b33-57a6-4ead-8d14-df127d32a92e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1139, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant\\\\u2019s condition.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb9a36ee-a232-489c-9914-ecb32fa62c1b\\\", \\\"childbox\\\": \\\"b6493ce8-0635-49e0-9963-2784e15101a9\\\", \\\"subtext\\\": \\\"af452fab-261b-4613-bbc1-70d96f77c2d9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1140, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 All laboratory tests with values considered clinically significantly abnormal during participation in the study or within 15 weeks after the last dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered significantly abnormal by the investigator or medical monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8dc7cb27-accf-426e-b769-1a5fb483527a\\\", \\\"childbox\\\": \\\"577abdd8-d91f-443b-9ac6-551c508af10a\\\", \\\"subtext\\\": \\\"c506a068-4200-41a1-aa18-899205011730\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1141, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 If such values do not return to normal/baseline within a period of time judged reasonable by the investigator, the etiology should be identified and the sponsor notified.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a2b0e3df-aa00-496b-99a8-d10a083a7d75\\\", \\\"childbox\\\": \\\"15fc7977-4644-4f12-8049-0d2fdf88b9c1\\\", \\\"subtext\\\": \\\"37d7b3d6-c362-4df4-aa76-d4c62374d7ca\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1142, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 In this study, the\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8338accd-b1a9-4977-8e2a-3719c1bcf4eb\\\", \\\"childbox\\\": \\\"3fd12d3e-c429-48cf-ad84-e200dde948d5\\\", \\\"subtext\\\": \\\"2b3434c9-a9ac-4899-b881-0591c0f4c0da\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1143, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"key\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8338accd-b1a9-4977-8e2a-3719c1bcf4eb\\\", \\\"childbox\\\": \\\"3fd12d3e-c429-48cf-ad84-e200dde948d5\\\", \\\"subtext\\\": \\\"a45ae7c7-8915-4fa8-a1f2-01532af9c725\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1144, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"laboratory parameters are WBCs, lipids, haemoglobin, platelets, lymphocytes, neutrophils and liver function tests.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8338accd-b1a9-4977-8e2a-3719c1bcf4eb\\\", \\\"childbox\\\": \\\"3fd12d3e-c429-48cf-ad84-e200dde948d5\\\", \\\"subtext\\\": \\\"fcb94f71-ef33-4726-8922-30a43324b252\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1145, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 Participants who develop hyperlipidemia should be managed according to clinical guidelines [e.g., National Cholesterol Educational Program (NCEP)].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"50d9ef49-4a5e-4291-aa9a-b1db96dda94d\\\", \\\"childbox\\\": \\\"c7b63d7f-b949-4638-bd57-8db4a47edf6f\\\", \\\"subtext\\\": \\\"b3a19561-c702-40e9-8cfe-9599f377014d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1146, \\\"\\\"], [\\\"3\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"text\\\", \\\"\\\\u2022 All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in accordance with the laboratory manual and the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"527792d2-86a7-44ca-ad9b-67e3637cfba3\\\", \\\"childbox\\\": \\\"79f7ea8f-b52c-43e0-9a7b-69dcbeca2eed\\\", \\\"subtext\\\": \\\"0c3f9dbb-b39e-486a-ad2f-8a8a6cddeff2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Clinical Safety Laboratory Assessments\\\", \\\"8.2.5.\\\", \\\"3\\\", 1147, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.6. Pulmonary Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1ec29aa-5faa-43a3-9c2f-0146c3c6ac72\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1148, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pulmonary assessments are a key aspect of the safety monitoring in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"002706f1-a462-4234-b9a2-0e88361078f9\\\", \\\"childbox\\\": \\\"c59563d8-96d3-4506-ba5a-fefa123b1363\\\", \\\"subtext\\\": \\\"fc2afdc4-598f-4a4b-bb6b-3273d69a72b3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1149, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following pulmonary assessments will be performed as specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"002706f1-a462-4234-b9a2-0e88361078f9\\\", \\\"childbox\\\": \\\"c2d1e5aa-92dd-41ab-a704-96b041a8fe58\\\", \\\"subtext\\\": \\\"d60db066-30fd-431c-8a99-3b371c403caf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1150, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Chest X-ray (posteroanterior).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bbd1e32f-5780-49bd-b880-b7c32bc2afce\\\", \\\"childbox\\\": \\\"59c30335-a434-4a64-9dda-4f9f498f00fa\\\", \\\"subtext\\\": \\\"c10d0336-f81e-4a4d-b77b-e6d0e7177ac9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1151, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Cough assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b44232ea-6074-4d07-b7fa-1a48e7a023bf\\\", \\\"childbox\\\": \\\"9ba7b0ba-c6c4-4575-ba92-6058ee5b16d0\\\", \\\"subtext\\\": \\\"71b3640b-4418-4623-81a9-738aa3b6002c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1152, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Dyspnoea assessment (see Section 8.2.1).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2365baea-f1f8-4a8a-ae43-b4b364ddcf3e\\\", \\\"childbox\\\": \\\"8e3fa94d-6cc8-4b8f-ab79-18cf0dc6bea1\\\", \\\"subtext\\\": \\\"436b9520-36ce-4088-aefc-109137e2bfd8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1153, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Lung auscultation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a6e37bb1-26f0-4b14-aae4-ec14eb397d1d\\\", \\\"childbox\\\": \\\"4f97c94e-5e3e-414b-b6f4-13d38557b638\\\", \\\"subtext\\\": \\\"f5f623c6-92b7-4e1b-91ab-c67ca9a2d8d9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1154, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Pulse oximetry.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6f19d504-a86f-44c4-87fc-4262061bd262\\\", \\\"childbox\\\": \\\"00543a8a-4d5d-46e4-aaac-8dabf8921d14\\\", \\\"subtext\\\": \\\"c6dffecb-2465-427e-aa07-15040e18c72b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1155, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Pulmonary function tests (PFTs) \\\\u2013 spirometry (FEV1 and FVC) at baseline only (or prior to Day 1) or as required by the pulmonologist in the event of participant referrals for further assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"86fecec1-7805-453a-b7fd-153e60fb1b30\\\", \\\"childbox\\\": \\\"66b405d3-44f3-41ad-b264-e37021e0be69\\\", \\\"subtext\\\": \\\"d555dba6-83fc-427e-812f-cf8a7057e28c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1156, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the event of any new or clinically significant pulmonary abnormalities that may develop during the study (e.g., increased shortness of breath/dyspnoea, or unexplained and persistent coughing), it is recommended that the participant be referred to a pulmonologist for further assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4128427d-dfd4-4457-831b-bcad5c7de3ee\\\", \\\"childbox\\\": \\\"3baf687c-9351-4fb3-a03a-b81801d0c63b\\\", \\\"subtext\\\": \\\"faec1182-dcd9-4159-bba7-e64c31e070fb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1157, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If, at any time during the study, a participant reports new onset or increase (if present at baseline) in cough (CTC Grade \\\\u22652) or dyspnoea (Grade \\\\u22652), they must be asked again (either by phone or during the site visit) on a weekly basis for 3 further consecutive weeks or until symptoms resolve, if earlier.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c1df3a34-3d6c-4629-b21d-162dfc8ccb33\\\", \\\"childbox\\\": \\\"eefdce9f-aa9f-4667-bafc-5fd4c793dd27\\\", \\\"subtext\\\": \\\"596a287c-ee9e-44e6-b983-e1d07c463236\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1158, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any new onset or worsening cough and/or dyspnoea must be reported as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c1df3a34-3d6c-4629-b21d-162dfc8ccb33\\\", \\\"childbox\\\": \\\"4d48222c-7c53-4531-8296-d3c24631a56e\\\", \\\"subtext\\\": \\\"6ecbd4c8-c4ba-47c1-b1d2-d5cb93fb70f4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1159, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a participant experiences persistent cough Grade \\\\u22652 for three consecutive weeks (\\\\u226521 days) or persistent dyspnoea Grade \\\\u22652 for three consecutive weeks (\\\\u226521 days), study intervention must be temporarily discontinued immediately, and the participant undergo a local pulmonologist review within 1-2 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6505ac84-b5ba-46cb-b585-e5b29af87495\\\", \\\"childbox\\\": \\\"66a41c8d-e435-460e-b706-47d3032f551f\\\", \\\"subtext\\\": \\\"0313e21c-2927-4a6d-8dff-567b98d65247\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1160, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Chest X-ray and repeat spirometry must be performed within 1 week in addition to any other assessments deemed appropriate by the consulting pulmonologist.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6505ac84-b5ba-46cb-b585-e5b29af87495\\\", \\\"childbox\\\": \\\"9e509940-6176-4f3f-9ddf-20821dbec84a\\\", \\\"subtext\\\": \\\"213d1ddb-f587-4994-9662-0c87747e081b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1161, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The study intervention must be temporarily discontinued as per the pulmonary guidance document until the symptoms or signs that caused referral have resolved and/or the underlying diagnosis has been determined and clinically significant events have been excluded by the pulmonologist.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6505ac84-b5ba-46cb-b585-e5b29af87495\\\", \\\"childbox\\\": \\\"f141a940-a60b-4859-8c0f-e6d0bf60c6d9\\\", \\\"subtext\\\": \\\"bba9a19a-3084-4527-8e3f-7134f4fc3728\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1162, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pulmonary assessment/management algorithms are provided in a separate Pulmonary Safety Guidance Document in the SRM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6505ac84-b5ba-46cb-b585-e5b29af87495\\\", \\\"childbox\\\": \\\"424ce13b-17a3-4447-8346-05a62647dbac\\\", \\\"subtext\\\": \\\"1399853e-992b-4cc4-8037-b0ee754b120b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1163, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The participant may undergo additional pulmonary imaging (high-resolution computed tomography [HRCT]) or other tests during the study to investigate pulmonary abnormalities; the Pulmonary Adjudication Committee (PAC), IDMC or SRT may request copies of any reports or images for central review.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"10ae450e-9152-4111-950d-7c605abb71b3\\\", \\\"childbox\\\": \\\"9be87c7a-466b-45d6-ad21-59d07cec428b\\\", \\\"subtext\\\": \\\"75860b25-75ae-4817-a9f7-d5aa89ca0f8e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1164, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any participant with a diagnosis of pulmonary alveolar proteinosis must permanently discontinue study intervention (Section 7.1.2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"29fc7dce-cd04-4ea1-8cdc-b38fe7f52709\\\", \\\"childbox\\\": \\\"09d03729-09ee-4870-a991-0be0e7da94b7\\\", \\\"subtext\\\": \\\"ecd83b4c-b6f4-4b4b-b246-cd3164a80372\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pulmonary Assessments\\\", \\\"8.2.6.\\\", \\\"3\\\", 1165, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.7. Tuberculosis Monitoring\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"533e2b6f-8fd4-499b-a387-3c0cda755780\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Monitoring\\\", \\\"8.2.7.\\\", \\\"3\\\", 1166, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.7.1. Tuberculosis Status Definitions\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"39260c42-f384-4dc7-b62e-7ef650acb284\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1167, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study the following definitions for active TB, latent TB and adequate treatment of latent TB will be utilised.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"13eae9f0-ff72-4ac9-81f3-1394d804f405\\\", \\\"childbox\\\": \\\"4a40e340-f3cf-48ed-8324-3991d293cb60\\\", \\\"subtext\\\": \\\"33630aae-6236-4bbf-8ec2-6e2e56e3272f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1168, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Active\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"819d2f98-26b5-4115-8d04-cf112d995c3e\\\", \\\"childbox\\\": \\\"9fb09ea4-4fe9-4302-a065-739ac47fda31\\\", \\\"subtext\\\": \\\"d98518c1-35e7-4c90-9676-33cb311cdb4f\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1169, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TB is defined as:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"819d2f98-26b5-4115-8d04-cf112d995c3e\\\", \\\"childbox\\\": \\\"9fb09ea4-4fe9-4302-a065-739ac47fda31\\\", \\\"subtext\\\": \\\"4d9c4b4c-bf1c-47bb-b92e-9cfd8afc7d88\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1170, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Microbiological evidence of TB (including, but not limited to, microscopy for acid-fast bacilli, mycobacterial culture, GeneXpert, or other validated PCR) in any clinical sample (including, but not limited to, sputum, pus, or biopsied tissue),\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f688e335-8023-4adf-8ba8-a96772d38ae7\\\", \\\"childbox\\\": \\\"29385b1a-14f7-4f81-8289-11ffe96d958e\\\", \\\"subtext\\\": \\\"9ae4351f-9f23-46df-bb5d-33c8631ce46b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1171, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"OR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"528e06c8-7712-4013-a495-453ec59e44fa\\\", \\\"childbox\\\": \\\"ebc500b2-ac67-443c-afb5-560dd982c987\\\", \\\"subtext\\\": \\\"23663781-34ab-4e0b-abfd-2792f0d995ed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1172, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Findings on medical history or clinical examination and/or chest radiograph consistent with active TB as assessed by a physician specialising in TB, sufficient to warrant empirical treatment for active TB even in the absence of microbiological evidence of TB.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7efaef9b-b708-421e-aeb3-f5265eae81e7\\\", \\\"childbox\\\": \\\"147451a5-f262-41f1-944f-a993b0a1f07e\\\", \\\"subtext\\\": \\\"edc2959b-49ee-4bc0-ad1e-21f594360bba\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1173, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Latent\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6fe35211-136e-4a80-ab9e-ace5a6addf2e\\\", \\\"childbox\\\": \\\"03bf5fea-3788-4f36-8235-5e12da6fa7d3\\\", \\\"subtext\\\": \\\"06329aba-4baf-4f18-ad3e-067f3070b20c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1174, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TB is defined as:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6fe35211-136e-4a80-ab9e-ace5a6addf2e\\\", \\\"childbox\\\": \\\"03bf5fea-3788-4f36-8235-5e12da6fa7d3\\\", \\\"subtext\\\": \\\"65de7ae6-2c56-4ecd-bc37-86726a280681\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1175, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A positive QuantiFERON-TB Gold plus test or T-SPOT.TB test, no findings on medical history or clinical examination consistent with active TB and a normal chest radiograph.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0f48c9c3-9288-45d0-875e-05a2309a0957\\\", \\\"childbox\\\": \\\"fe182bf4-89b5-4ae4-85c8-7c41a8cf0300\\\", \\\"subtext\\\": \\\"d332342f-9ef3-4e82-ae98-dae9a3ab1f11\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1176, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Adequate latent TB treatment status\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c321b80a-4330-4151-9d9f-3f1f2685b03e\\\", \\\"childbox\\\": \\\"5ba30243-e230-4d81-a7c4-f8e2e7f50474\\\", \\\"subtext\\\": \\\"f8d1de60-6291-4daf-b776-4c219173ee5b\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1177, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For participants that have received treatment for latent TB within the previous 5 years, a participant is considered to have received adequate treatment if a physician specialising in TB agrees that:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1e8df28e-43ea-4c15-ac41-7abfd71fcc05\\\", \\\"childbox\\\": \\\"3ff8f085-fd52-4946-bf19-603e14cc52a2\\\", \\\"subtext\\\": \\\"8682bf15-0ae1-49be-9285-15e6cbd38ecb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1178, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 sufficient evidence exists demonstrating that completion of treatment has occurred AND\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"29bc3133-c0dc-460a-86e3-fcf4c50c1c80\\\", \\\"childbox\\\": \\\"404854a6-3047-4f38-aa2e-1a451381f9b0\\\", \\\"subtext\\\": \\\"6b3f2ee5-4dd7-4f50-9f86-b44a292ff2f8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1179, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 the participant has no findings on medical history or clinical examination consistent with active TB, and a normal chest radiograph.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8541533c-25ac-40bb-8667-8279bfd1ce16\\\", \\\"childbox\\\": \\\"607bb560-d72d-4cf4-b017-313e2c82a163\\\", \\\"subtext\\\": \\\"5639a598-7e30-477f-8e40-65cf9c22d97b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1180, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Appropriate treatment for latent TB is considered to be:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d0f3652b-16f6-4e24-ba68-80369f97a801\\\", \\\"childbox\\\": \\\"40a772f4-37be-4082-9ebd-e0c7d771aa69\\\", \\\"subtext\\\": \\\"fe4686d9-6d6f-4e10-8e4b-d64754cc9d66\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1181, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Completion of at least 6 months of INH or an alternative regimen consistent with WHO or national guidelines.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 37, \\\"end_idx\\\": 39, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"INH\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"bd52798a-2c9a-4d09-98cc-df460c9f99b4\\\", \\\"childbox\\\": \\\"36231686-286d-4b6a-93a7-3cbbf90a075f\\\", \\\"subtext\\\": \\\"28499d26-b807-4349-acc9-9485c3a75487\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1182, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Participants who received treatment more than 5 years ago for latent TB infection and who remain QuantiFERON-TB Gold plus or T-SPOT.TB test positive will need to complete treatment for latent TB prior to study entry as per Section 8.2.7.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"25d99736-4f67-4353-b1d7-86897b953bfc\\\", \\\"childbox\\\": \\\"9dccdca6-921d-4e43-aa2a-084203f0e212\\\", \\\"subtext\\\": \\\"19a7a217-76bc-489f-bb61-15c29c9ff24c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Status Definitions\\\", \\\"8.2.7.1.\\\", \\\"4\\\", 1183, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.7.2. Tuberculosis Testing\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"51adde89-472e-49d1-8695-5eaf55e60e71\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Testing\\\", \\\"8.2.7.2.\\\", \\\"4\\\", 1184, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study the following testing for TB must be followed:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af421c31-f8b7-4b82-865e-073cc0263d80\\\", \\\"childbox\\\": \\\"a882b143-0adf-4dc8-be70-5af11d5b4db3\\\", \\\"subtext\\\": \\\"3e294d8b-919e-4961-916f-bca68e33615a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Testing\\\", \\\"8.2.7.2.\\\", \\\"4\\\", 1185, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The QuantiFERON-TB Gold plus test will be used in countries where it is licensed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b2f73343-001a-45ed-9570-063ee419184a\\\", \\\"childbox\\\": \\\"5c2740d1-3ff6-432a-8422-37bc743206cf\\\", \\\"subtext\\\": \\\"b04b021f-7b19-41e7-b164-9f87ec3de1df\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Testing\\\", \\\"8.2.7.2.\\\", \\\"4\\\", 1186, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Where QuantiFERON-TB Gold plus test is not available T-SPOT.TB will be used.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b2f73343-001a-45ed-9570-063ee419184a\\\", \\\"childbox\\\": \\\"57a0f02e-b466-47fa-ba58-1d9187d51618\\\", \\\"subtext\\\": \\\"3a3c1317-d745-4d9e-a90d-7a312122d5d3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Testing\\\", \\\"8.2.7.2.\\\", \\\"4\\\", 1187, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A QuantiFERON-TB Gold plus test may be repeated once during screening if the initial result is indeterminate, alternatively a T-SPOT.TB test may be used following an indeterminate result.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"546cdba3-131d-4d2a-bf7e-f574b7abf99f\\\", \\\"childbox\\\": \\\"24754f62-d763-4ed6-a31f-2f4d8762dedf\\\", \\\"subtext\\\": \\\"f853bfd7-a54a-430f-89a0-dd1957299540\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Testing\\\", \\\"8.2.7.2.\\\", \\\"4\\\", 1188, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This is not considered a rescreening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"546cdba3-131d-4d2a-bf7e-f574b7abf99f\\\", \\\"childbox\\\": \\\"afdc67db-ed44-4c38-b515-cabdc9f3113d\\\", \\\"subtext\\\": \\\"fda68457-2c5d-4db8-8c38-d1fc367b7feb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Testing\\\", \\\"8.2.7.2.\\\", \\\"4\\\", 1189, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Note that where a participant has been successfully treated for prior latent TB (as documented in medical notes), a QuantiFERON-TB Gold plus test or a TSPOT.TB need not be obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"35513797-92c8-4576-9e33-3d0372465e21\\\", \\\"childbox\\\": \\\"96ed0034-e66f-4bca-8356-606210397e55\\\", \\\"subtext\\\": \\\"d4940268-e01a-4d99-8ac0-3d5ffb69dc60\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Tuberculosis Testing\\\", \\\"8.2.7.2.\\\", \\\"4\\\", 1190, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.7.3. Treatment of Latent TB During the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d49f6f03-0cec-4097-b5a6-3b8b9bd8bc0c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Latent TB During the Study\\\", \\\"8.2.7.3.\\\", \\\"4\\\", 1191, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants diagnosed with latent TB during screening will need to complete a course of at least 6 months of INH therapy during the study including at least 4 weeks of therapy prior to randomisation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 110, \\\"end_idx\\\": 112, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"INH\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f61bfddc-3784-4151-a907-2679400317b8\\\", \\\"childbox\\\": \\\"8531918b-4785-4eeb-9e88-3f678e30619c\\\", \\\"subtext\\\": \\\"3b462feb-f1b0-40e0-9791-3e445905ebd2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Latent TB During the Study\\\", \\\"8.2.7.3.\\\", \\\"4\\\", 1192, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Following 3 weeks of INH treatment in screening, LFTs must be assessed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 21, \\\"end_idx\\\": 23, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"INH\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ade13de6-d735-453c-9847-821e3d8ec110\\\", \\\"childbox\\\": \\\"5927c5e8-7fc6-4649-a9d1-9cc0c04eab29\\\", \\\"subtext\\\": \\\"0d1ec50f-a9fe-450d-abd7-eb3655525be5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Latent TB During the Study\\\", \\\"8.2.7.3.\\\", \\\"4\\\", 1193, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants will fail screening if ALT >1.5 x ULN is identified, these participants may be re-screened if ALT elevation resolves to ALT <x 1.5 ULN during ongoing INH therapy following discussion with the medical monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 163, \\\"end_idx\\\": 165, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"INH\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ade13de6-d735-453c-9847-821e3d8ec110\\\", \\\"childbox\\\": \\\"ae522fda-9f48-469f-b173-cd93480d87b4\\\", \\\"subtext\\\": \\\"326a988a-84ad-4b54-8b49-ca7a6b26e981\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Latent TB During the Study\\\", \\\"8.2.7.3.\\\", \\\"4\\\", 1194, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants who are randomised will require LFT assessment every 4 weeks during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ade13de6-d735-453c-9847-821e3d8ec110\\\", \\\"childbox\\\": \\\"2c618235-5b06-4ddc-8b82-e3cb1a4fc8e1\\\", \\\"subtext\\\": \\\"f97b3cbe-1e31-4cf2-a37f-7194b0a158a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Latent TB During the Study\\\", \\\"8.2.7.3.\\\", \\\"4\\\", 1195, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.7.4. Monitoring for TB Infection and Re-activation During the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fecf0d7d-8a16-4068-b077-2ff0689f3a62\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Monitoring for TB Infection and Re-activation During the Study\\\", \\\"8.2.7.4.\\\", \\\"4\\\", 1196, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Routine monitoring for the signs and symptoms of TB will be performed during this study as part of every full or brief physical exam (see SoA in Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c9b27252-6924-4e71-9bc9-d383a4f93caf\\\", \\\"childbox\\\": \\\"c41af897-de25-472b-94d7-6746f54970d0\\\", \\\"subtext\\\": \\\"2b8737a1-4aa6-4623-bdf9-94ea279737ac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Monitoring for TB Infection and Re-activation During the Study\\\", \\\"8.2.7.4.\\\", \\\"4\\\", 1197, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If at any point during the study, the investigator suspects that a participant may have TB reactivation or new TB infection, an immediate and thorough investigation should be undertaken including consultation with a physician specialising in TB.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"19301b11-927a-47f7-a38d-dd7f120cabb9\\\", \\\"childbox\\\": \\\"e25fc61b-4022-4228-8eaf-a52d664505f3\\\", \\\"subtext\\\": \\\"260bc2a8-6cd1-43c8-888a-06ec5064035c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Monitoring for TB Infection and Re-activation During the Study\\\", \\\"8.2.7.4.\\\", \\\"4\\\", 1198, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator should discuss with the medical monitor and interruption of study intervention should be considered.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"19301b11-927a-47f7-a38d-dd7f120cabb9\\\", \\\"childbox\\\": \\\"953ad550-9ae0-411c-874c-f4e32256441f\\\", \\\"subtext\\\": \\\"5d19fafb-44c5-4638-81fd-af7c11071062\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Monitoring for TB Infection and Re-activation During the Study\\\", \\\"8.2.7.4.\\\", \\\"4\\\", 1199, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A QuantiFERON-TB Gold Plus test or a T.SPOT.TB test must be performed as part of the Week 22 assessment (see SoA in Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e6a1f2dd-9685-4cc8-b536-7db120cb8f05\\\", \\\"childbox\\\": \\\"4bc2ff51-e99c-4200-8a70-007e043d9910\\\", \\\"subtext\\\": \\\"82d080b1-86f7-416b-a6d6-19fd526f6adb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Monitoring for TB Infection and Re-activation During the Study\\\", \\\"8.2.7.4.\\\", \\\"4\\\", 1200, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a participant has a positive result at Week 22 who previously had a negative result at study start, then the participant must be referred to a physician specialising in TB to determine if the participant has active or latent TB.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e6a1f2dd-9685-4cc8-b536-7db120cb8f05\\\", \\\"childbox\\\": \\\"fe645237-a59b-4681-923a-3b84da5f4544\\\", \\\"subtext\\\": \\\"15c5ea80-ae79-47d9-9768-487fecf1f109\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Monitoring for TB Infection and Re-activation During the Study\\\", \\\"8.2.7.4.\\\", \\\"4\\\", 1201, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If TB infection is diagnosed, study intervention must be discontinued.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"51195ee5-7a50-4cd2-af6c-ed9c585efdf6\\\", \\\"childbox\\\": \\\"ecb17143-4807-4cee-b522-139c8797f666\\\", \\\"subtext\\\": \\\"f92a91a5-efef-4e9e-adc5-f679b0e88250\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Monitoring for TB Infection and Re-activation During the Study\\\", \\\"8.2.7.4.\\\", \\\"4\\\", 1202, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.8. Hepatitis B Monitoring\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4bd6d64e-9b59-4b01-a1e9-33839f595213\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Hepatitis B Monitoring\\\", \\\"8.2.8.\\\", \\\"3\\\", 1203, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All participants with positive HBcAb results will have HBV DNA levels monitored throughout the study as summarised in Figure 2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a19ac4db-a056-413b-8830-600e153631ad\\\", \\\"childbox\\\": \\\"e64bc1ab-9931-4aa3-a4d8-c41c29f492d2\\\", \\\"subtext\\\": \\\"070990c0-8f28-400a-adf7-fdf66350de69\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Hepatitis B Monitoring\\\", \\\"8.2.8.\\\", \\\"3\\\", 1204, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Figure 2 Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e6c087ab-a2db-4c3f-9e8f-daa0233dd8b1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1205, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV DNA level \\\\u2265 200 IU/mL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"4d8f6b1e-4230-4fc9-b410-e79a3ae3fe99\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1206, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"7e3f701e-7469-4a74-aa2a-95970bbb47ae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1207, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV DNA detected at any level with recent increase in hepatic transaminasesHBV DNA level <200 IU/mL (with no increase in hepatic transaminases)Discontinue study interventionand refer to expert for initiation of appropriate antiviral therapyRepeat HBV DNA with HBV surface antigen and hepatic transaminases within 1 weekResult:  HBV DNA positive (any level)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 223, \\\"end_idx\\\": 231, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"antiviral\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"3485a14f-aa2b-4bcf-87ef-ec88e88558c8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1208, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"4b5e666d-67fd-451d-bbc8-709e4296c7a2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1209, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV surface\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"6c457875-986e-4772-a1b6-458406f29c84\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1210, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"8696d4f5-04f3-4e41-9abe-50882dfaeebb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1211, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"antigen positive increase in hepatic transaminasesDiscontinue study intervention and refer to expert for initiation ofappropriate antiviral therapyResult: HBV DNA negative, HBV surface antigen negative and no increase in hepatic transaminasesRepeat HBV DNA at  weeks then return 4to routine monitoringHBV DNA detectedHBV DNA level \\\\u2265 200 IU/mL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 130, \\\"end_idx\\\": 138, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"antiviral\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"1dd5a02a-3924-46e2-8229-54f905f7e20d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1212, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"8d294514-390e-4b9a-8135-a0a5b357d702\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1213, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV DNA detected at any level with recent increase in hepatic transaminasesHBV DNA level <200 IU/mL (with no increase in hepatic transaminases)Discontinue study interventionand refer to expert for initiation of appropriate antiviral therapyRepeat HBV DNA with HBV surface antigen and hepatic transaminases within 1 weekResult:  HBV DNA positive (any level)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 223, \\\"end_idx\\\": 231, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"antiviral\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"4aac151b-66ee-411f-a510-e9520454ee7a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1214, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"8a8204ab-127c-43c9-8974-91888b3fd8b8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1215, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV surface\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"c033e6e7-7154-46f0-9a4c-7f0be06630e9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1216, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"598accdb-56e8-4c6e-9c17-70e3ed937e29\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1217, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"antigen positive increase in hepatic transaminasesDiscontinue study intervention and refer to expert for initiation ofappropriate antiviral therapyResult: HBV DNA negative, HBV surface antigen negative and no increase in hepatic transaminasesRepeat HBV DNA at  weeks then return 4to routine monitoringHBV DNA detected\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 130, \\\"end_idx\\\": 138, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"antiviral\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"17410184-1754-4c77-90c7-ebd2f0de84b4\\\", \\\"childbox\\\": \\\"023296a8-9c63-43c8-8ff6-5785e77737a5\\\", \\\"subtext\\\": \\\"b2917e25-e9c0-4b6b-a8aa-0211c21de237\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1218, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV DNA level \\\\u2265 2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c409583b-2124-42fa-8565-b6e7b7647226\\\", \\\"childbox\\\": \\\"0057e96a-eb57-4b7d-857e-032b227d427d\\\", \\\"subtext\\\": \\\"4d8f6b1e-4230-4fc9-b410-e79a3ae3fe99\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1219, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"00\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ca8da563-4190-410e-9d6f-fdd08f3a05cf\\\", \\\"childbox\\\": \\\"1d69dc09-7405-43b4-bb78-869145b0f48e\\\", \\\"subtext\\\": \\\"71d45e5e-44aa-42b1-beef-5854a02a1795\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1220, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"IU/mL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b4fa3a00-2927-4304-a636-5315c214bb08\\\", \\\"childbox\\\": \\\"2910463f-d0b4-469a-9d6a-21d0f451d436\\\", \\\"subtext\\\": \\\"f6e2be92-2efc-4b30-8c30-07537f71495a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1221, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eae17d1f-1b8b-4ac3-b35c-2f11ca0caf7b\\\", \\\"childbox\\\": \\\"939c65ba-e45e-4a98-9d49-dfd570e3f49e\\\", \\\"subtext\\\": \\\"7e3f701e-7469-4a74-aa2a-95970bbb47ae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1222, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV DNA detected at any level wit\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"29ece1a0-cbb3-4ddb-8ca4-6dcf53cc5a84\\\", \\\"childbox\\\": \\\"9f96aaff-7052-4cbb-9e5e-0f0355b74680\\\", \\\"subtext\\\": \\\"3485a14f-aa2b-4bcf-87ef-ec88e88558c8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1223, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"h\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"585c1604-5a7e-45f9-81c0-557d94f68629\\\", \\\"childbox\\\": \\\"e0956862-4e32-4f2c-a799-aaa84f74320a\\\", \\\"subtext\\\": \\\"620c6854-df0c-447f-8041-eee24bee246e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1224, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"recent increase in hepatic\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dde9d1af-ac60-48b9-9f2e-b1f9766c70e6\\\", \\\"childbox\\\": \\\"67b6c79b-6bc1-4d5c-a7e7-eeb6db865e22\\\", \\\"subtext\\\": \\\"d0b14b5e-eb51-4b54-9876-13913c5a393f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1225, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"transaminases\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aa6a4a1a-f0d0-4bc1-b706-68cd030888f4\\\", \\\"childbox\\\": \\\"9a055a15-5e68-4f69-8f05-3b6c593a7f0e\\\", \\\"subtext\\\": \\\"37bfab69-ee1f-4c4e-b2a0-8b2df2d2a886\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1226, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV DNA level <\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1b1dc54a-3c17-4591-8935-244b78fe4a9a\\\", \\\"childbox\\\": \\\"5cc8cc2f-dd6c-4a6f-b709-d9afd4dd581e\\\", \\\"subtext\\\": \\\"b751da59-fc0a-43b0-9eab-9b990ff5a709\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1227, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"00df460a-0698-41ae-8abe-1cf8083b7204\\\", \\\"childbox\\\": \\\"255972b8-e058-4f47-bbc0-61c7fbe69bbc\\\", \\\"subtext\\\": \\\"73128e17-df2c-4a2f-a19f-cebf84aa29cc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1228, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"00\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"790e1b4c-eb45-4054-938f-d4f5b98a92a8\\\", \\\"childbox\\\": \\\"09362015-b489-4948-a178-ff8afb9b8272\\\", \\\"subtext\\\": \\\"7b4de962-1a16-48a2-83f6-5ea625761ccd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1229, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"IU/mL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52382b3a-a08f-43d0-bc24-d4395ce25d89\\\", \\\"childbox\\\": \\\"7dd809e9-17b4-4ac4-aacf-341a15153ef4\\\", \\\"subtext\\\": \\\"fe27efd6-5a5b-4bfa-bfdb-6d59a1e2c5b5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1230, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0dc70299-536c-49f2-8779-c069a82219a1\\\", \\\"childbox\\\": \\\"b7301220-71a0-42b1-b424-dba1a159171d\\\", \\\"subtext\\\": \\\"1fa53708-53d6-4186-a6b3-bf0f52a74ce5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1231, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"with no increase in hepatic\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2ba99638-dd38-45fd-817e-032c5a5b7120\\\", \\\"childbox\\\": \\\"546ee6b8-d6a5-49fd-aa23-82d63f484de9\\\", \\\"subtext\\\": \\\"c6817065-7a5d-4ccd-85e8-9fc03915afc8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1232, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"transaminases)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"21aba5db-3d50-47aa-947a-629f97ac1fd1\\\", \\\"childbox\\\": \\\"3935eecb-85a9-499d-8956-f148644d4714\\\", \\\"subtext\\\": \\\"563f48e8-88c3-4bff-8c47-9c52038f8caa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1233, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Discontinue study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"36db9607-8041-4837-a699-d1c28cd002e1\\\", \\\"childbox\\\": \\\"a9ed87fa-acf2-486e-ac58-68bc01dac28f\\\", \\\"subtext\\\": \\\"f93df6da-b7d0-40a0-aca9-083958406542\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1234, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"intervention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b1056bab-969b-4acc-9e8f-90c617b10565\\\", \\\"childbox\\\": \\\"aefb41e3-6ac9-407c-91c3-3c55c2be14f3\\\", \\\"subtext\\\": \\\"e19c62d9-0632-4585-b5ad-f6648524bf10\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1235, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d9c12dc1-2b37-4beb-aed6-7eed500d4c06\\\", \\\"childbox\\\": \\\"a79f1bbf-ad80-440b-a499-70592b6e5382\\\", \\\"subtext\\\": \\\"06a85c42-4420-47a2-b873-a132347e21bf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1236, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"refer to expert for initiation of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bdc00498-c1d6-4254-ad97-09928dfa0998\\\", \\\"childbox\\\": \\\"fe4e99d3-a75a-4b29-bcaf-ac98121f8092\\\", \\\"subtext\\\": \\\"b2cb9fe6-8c65-41e4-ac24-5c09e218ef18\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1237, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"appropriate antiviral therapy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"beb7d710-0da6-4727-b54d-b211f8d7ed99\\\", \\\"childbox\\\": \\\"2e0cc8b4-48d5-40f2-ba21-97133fea2046\\\", \\\"subtext\\\": \\\"117c4dfc-7684-45e7-883c-dc3d8f811187\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1238, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Repeat HBV DNA with HBV surface\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"761b4873-1e8e-4ae7-b2a5-d545fd22856b\\\", \\\"childbox\\\": \\\"c35d35ae-2c97-4364-bd23-cb9aba0b6e0d\\\", \\\"subtext\\\": \\\"adb9c67f-acc4-4ec8-a113-649921be8206\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1239, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"antigen and hepatic transaminases\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0788c0b1-e191-4470-a270-f48fb0579c48\\\", \\\"childbox\\\": \\\"700d1ca7-2beb-4ea3-977b-7e6b2c7f180c\\\", \\\"subtext\\\": \\\"b6ee587c-256c-4e04-8b36-af3f65e2f7f3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1240, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"within 1 week\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"32101655-9577-441b-878e-f483a8651d94\\\", \\\"childbox\\\": \\\"3c6cd906-a280-4c7e-92fc-f70101539497\\\", \\\"subtext\\\": \\\"53d73f42-2283-46ef-a085-c66a84c84b6a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1241, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Result:  HBV DNA\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"127e8d19-8c74-4b2e-a809-c0a4a34b3ab0\\\", \\\"childbox\\\": \\\"e1bcdd28-d3d1-4a9f-a64d-7648b850d084\\\", \\\"subtext\\\": \\\"b4efe45f-7fdd-4ebe-b5b2-394615783f5c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1242, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"positive (any level)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a9173843-68e3-4f9e-bf97-8d8bad962909\\\", \\\"childbox\\\": \\\"3fd3c217-00f9-4839-bce0-e7a42bf6c444\\\", \\\"subtext\\\": \\\"3fadb415-007a-4a7d-9b80-3a10749269af\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1243, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7aff6447-f8f0-482a-a112-7071a278f489\\\", \\\"childbox\\\": \\\"587321dd-42fc-4d87-9ffd-397fa6b55188\\\", \\\"subtext\\\": \\\"4b5e666d-67fd-451d-bbc8-709e4296c7a2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1244, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV surface\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"96cff4af-9a4f-4441-bffb-6a8aec2ea71a\\\", \\\"childbox\\\": \\\"d523c7cd-0350-49bb-a9e6-abae3e04d42c\\\", \\\"subtext\\\": \\\"6c457875-986e-4772-a1b6-458406f29c84\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1245, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6e89b617-20bd-41a6-8490-1ba34d35d228\\\", \\\"childbox\\\": \\\"f0074f57-eb4f-4455-8c18-51e3447054f7\\\", \\\"subtext\\\": \\\"8696d4f5-04f3-4e41-9abe-50882dfaeebb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1246, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d1a1e038-b9d8-432e-a660-9cde03cb3226\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1247, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"antigen positive\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c477ad89-af61-4794-b773-e364b87008cf\\\", \\\"childbox\\\": \\\"6dd94fa6-f506-45d2-a65e-112f6bf548be\\\", \\\"subtext\\\": \\\"29d72ce6-0378-4c48-8ca7-8e6a2f0b0f59\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1248, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"increase in hepatic\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"273e6606-e15b-40c1-b060-4bc7b6c939ce\\\", \\\"childbox\\\": \\\"350dba48-3364-46dc-b752-d058a5dd1c78\\\", \\\"subtext\\\": \\\"d6155390-32af-4156-b1f0-132c3ee38dbc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1249, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"transaminases\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4e16e452-c9b7-46da-91ac-4f4dbdd7d125\\\", \\\"childbox\\\": \\\"8c4301ee-ea1d-4c9a-967c-6770ec77f017\\\", \\\"subtext\\\": \\\"fc2b4666-4dc1-44de-886f-54f6b045d364\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1250, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Discontinue study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5bc0bc3e-bbe1-4ec9-939b-51cc04d2884f\\\", \\\"childbox\\\": \\\"f3638edc-88ac-4585-9507-59bbffa88a80\\\", \\\"subtext\\\": \\\"62b1c849-34bf-4f7b-b30b-83259595c319\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1251, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"intervention and refer\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7a4b2da0-64f1-4049-a4f3-20c0404bbc3a\\\", \\\"childbox\\\": \\\"58bed6ee-df98-46a3-baa8-e5645afdd72d\\\", \\\"subtext\\\": \\\"e0b11ea0-5cec-44f0-ba4e-bf1041044c69\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1252, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"to expert for initiation of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1ddb742d-2ae5-45b0-8ae8-1d9a74dcdecf\\\", \\\"childbox\\\": \\\"eea8a477-d17c-4f5a-adfd-7ab80a161bc8\\\", \\\"subtext\\\": \\\"07a5b51b-53ae-42a5-8a9e-b771ae40bca6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1253, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"appropriate antiviral\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"93f2582d-c6fc-46e5-ae59-0a5507c47cd4\\\", \\\"childbox\\\": \\\"ce268f57-25c0-4a08-b4ec-b672e07e196a\\\", \\\"subtext\\\": \\\"1e5f4dc2-894c-4bd6-958b-1c423c7dd3d0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1254, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"therapy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"46b1e0ff-0e71-4753-ab9e-b7cc2b87a251\\\", \\\"childbox\\\": \\\"29e7aabf-d6df-4b4a-8629-b7a101e25c22\\\", \\\"subtext\\\": \\\"2e1974df-12c9-4ab1-8bf2-9d5901c74735\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1255, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Result: HBV DNA\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fae8f6d9-2797-4169-8094-40d60c93c74b\\\", \\\"childbox\\\": \\\"9f48e7b4-2460-4b3f-80fe-673804786787\\\", \\\"subtext\\\": \\\"a2b7c27b-54fa-4830-bdca-ad453cbd61f8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1256, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"negative, HBV surface\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3cba9cc8-f6ac-48c3-97a6-0b2ef490162d\\\", \\\"childbox\\\": \\\"df045e93-f246-4ac0-971f-beb7019be31f\\\", \\\"subtext\\\": \\\"b7af71a7-05ea-40ec-8a37-df56bc0dde1b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1257, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"antigen negative and no\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f45e3fd5-1c9f-4eb4-bbbf-43244d2ef0f7\\\", \\\"childbox\\\": \\\"429ddb48-ec6f-43ae-9077-60d896c1f248\\\", \\\"subtext\\\": \\\"de056af9-79dc-4f64-bc00-34c7892f6264\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1258, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"increase in hepatic\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bb36e729-4d67-49d1-80f7-eb74d20de564\\\", \\\"childbox\\\": \\\"3b781307-7648-4ec9-a387-1f681d82b1bb\\\", \\\"subtext\\\": \\\"bb613fd4-b994-4bb7-9e13-75be5d8fd438\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1259, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"transaminases\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8d45ae00-c778-435f-a743-aeb56dd5efe6\\\", \\\"childbox\\\": \\\"c5e2e531-7e9d-44c1-a853-05460d373b9a\\\", \\\"subtext\\\": \\\"7a295992-acfe-4fe9-9770-fb7f3f780388\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1260, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Repeat HBV DNA at\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"82806e86-8535-4a98-b66b-d0d6e74b1ec6\\\", \\\"childbox\\\": \\\"4c2ec90d-bcf7-4758-ba91-d00e6e6c5fa0\\\", \\\"subtext\\\": \\\"233c7cfe-6322-46bd-b58e-3cbba270560d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1261, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"weeks then return\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"74dbe16f-7bd6-4413-999f-1d742dc9093c\\\", \\\"childbox\\\": \\\"79664a2d-4862-4a37-8d85-eb7360967775\\\", \\\"subtext\\\": \\\"adb255d9-bb94-4a5d-8893-f4368097c156\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1262, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"78987a77-fe8e-4d0e-8218-1b7554f2de09\\\", \\\"childbox\\\": \\\"d69f8600-2a54-4b1a-8535-f69d5fc73ae0\\\", \\\"subtext\\\": \\\"7dc08d28-8b01-44cb-b346-d2272354a6ae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1263, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"to routine\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e9352fc9-b710-4019-b9ef-15e72c307e0a\\\", \\\"childbox\\\": \\\"cfaec42d-2641-47ac-a0a4-4ca8e5c1ba64\\\", \\\"subtext\\\": \\\"2fe81f38-d7c3-4a08-a744-b13b55dccade\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1264, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"monitoring\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f24f37b9-3bc0-4652-ae96-1d0b48aeadda\\\", \\\"childbox\\\": \\\"26247911-9706-4c92-9b3d-4c16eceeea12\\\", \\\"subtext\\\": \\\"fb179a2e-4cf3-4ab3-b9f6-7bf6315f8031\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1265, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBV DNA detected\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 21, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"94f1130f-d2c9-4ee8-b0af-c9662413565a\\\", \\\"childbox\\\": \\\"1dd524e3-fadf-4aca-9130-7143d721c29b\\\", \\\"subtext\\\": \\\"5abe9e84-6def-4aa3-8d37-946b507bea9b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 21, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1266, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"97bcfb1d-b3d4-495c-972d-bb0843003f06\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1267, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45fe94a0-bd45-40e9-a7bd-653e89355bde\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1268, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"274ff4dc-25db-4989-aa11-0e46da90b5d0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1269, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2c10076f-99ba-4b55-b884-8358a58e4d50\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1270, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1174cf78-4839-4e4f-9c89-8cc605fff092\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1271, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64e5c450-f538-4986-b2d0-1d14f207c571\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1272, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fd2dc7db-1831-4913-952b-c2bf64b8d100\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1273, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0b23a284-b428-4caf-88e5-617dadcb414a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1274, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7a814911-187c-4078-b7d8-1b1f1dc92ad4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1275, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"99344b01-0bf6-41b7-b81a-3c7e6cf2476d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1276, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8bb474c8-673d-4917-b3ef-e7fa702a20d2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1277, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a76c8b73-247f-4648-b642-306803b01a65\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1278, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f87e9a5a-3397-4809-8052-ea4b02058b06\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1279, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3562d66b-e9c6-4752-9e71-42720157ee82\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1280, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9384bd1b-57fa-4060-8c87-463e8febbc3a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1281, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b71f61af-4378-4921-9de4-a6280e1187ef\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1282, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b70e5813-134b-4a76-a089-19c2a232578b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1283, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4eabcfa2-c283-461d-931a-bca41e916bb2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1284, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"36cd6502-4e30-455b-a2fd-04ffbf4c6781\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1285, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"44642310-bb32-45bd-8683-e6c6c50dec18\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1286, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6a6d05f8-df73-4bde-9e6d-3b5a0bbe4ed7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1287, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5f7245ee-570b-4ad9-a4e4-f14885bb2ebf\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1288, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"76d24a8f-98ad-4889-bc83-9a08660e7e3d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1289, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"97babb34-fa86-45b0-9d00-02a096110ec1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1290, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"86cb41d1-7060-4ca7-807c-4e32b94788f2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1291, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"435ab725-e8ef-460e-906a-1bad5682f9a6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1292, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4ba293eb-1525-42e5-8e6b-a2b8fb192dba\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1293, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ea236f9e-7d4f-436a-96ee-699f1cc1e473\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1294, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f726339a-75a7-49b5-8692-a1cc70e1fb66\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1295, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e8a7a367-22ce-4ada-a434-5629e429ecb2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1296, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"08c4f0f1-3538-4841-ae02-08db9da600fb\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1297, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ec295e4c-b9b7-40a2-9e39-ebb20431dded\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1298, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"34a8f58b-5a87-4a29-b96c-de425b744346\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1299, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22c3444e-e3c1-4adb-8c27-af66dac16675\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1300, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a5c7bd8d-9f9d-49fc-8d68-35aed706d5df\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1301, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"711377be-0bc2-4ada-9875-699145295091\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1302, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cc2f3f93-ca08-419c-ba5d-2cca2a6e3ffc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1303, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e44d9b8b-e136-4ed3-837e-294ef9f04f1b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1304, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9e40cb11-faca-46cc-aa1d-fa4927803f0b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1305, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6ebc3807-df72-4a4f-aa37-eca2b899e26f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1306, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9cba960f-8036-44ed-bda4-bd23803f7d36\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1307, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f1ce857d-8368-453e-8ed0-469496d693e2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1308, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d6d35c3d-c213-4f19-9780-e422d0d560af\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1309, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3003394e-4611-4b30-b228-fd9324015623\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1310, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"db6d691a-c943-47a0-bc46-633f5025da34\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1311, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bb4cba3f-c3c0-4b7d-a059-15036c954e78\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1312, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a987f774-b5d4-49cf-9c6a-23bf7354e20a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1313, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aa99ef61-e4f3-4e2a-b422-d524838063af\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1314, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"From the start of study intervention, HBV DNA levels will be assessed every 4 weeks to Week 24.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"880f1710-ddbc-4642-8bb1-fbec95194ac4\\\", \\\"childbox\\\": \\\"19f4abbe-a7e1-4983-a5aa-3ee54bf34478\\\", \\\"subtext\\\": \\\"23b40a20-1260-4111-bf8f-a342c2f2aaa8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Figure 2  Monitoring of HBV DNA Levels in HBcAb Positive Participants\\\", \\\"\\\", \\\"4\\\", 1315, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.8.1. Risk of Reactivation in Participants Positive for Hepatitis B Core Antibody (HBcAb)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"154b9fce-741a-4c80-a633-7e0a21a73673\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Risk of Reactivation in Participants Positive for Hepatitis B Core Antibody (HBcAb)\\\", \\\"8.2.8.1.\\\", \\\"4\\\", 1316, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants who are HBcAb positive, will be informed of the risk of reactivation and that if this occurs treatment with antiviral therapy, such as with nucleo(s)tide analogues like entecavir or tenofovir, will be needed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 182, \\\"end_idx\\\": 190, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"entecavir\\\"}, {\\\"start_idx\\\": 195, \\\"end_idx\\\": 203, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"tenofovir\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b6fc2672-300b-44c6-8258-627b6c63e097\\\", \\\"childbox\\\": \\\"4b8d04e0-a66b-4c88-ac40-e4fcad5b25ca\\\", \\\"subtext\\\": \\\"72a7c287-0908-45f9-a6df-db698155d31a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Risk of Reactivation in Participants Positive for Hepatitis B Core Antibody (HBcAb)\\\", \\\"8.2.8.1.\\\", \\\"4\\\", 1317, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.8.2. Treatment of Participants Who Are HBcAb Positive and Who Develop Detectable HBV DNA Requiring Initiation of Antiviral Therapy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ba9a099c-12e0-4773-925c-6960b99bc231\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Participants Who Are HBcAb Positive and Who Develop Detectable HBV DNA Requiring Initiation of Antiviral Therapy\\\", \\\"8.2.8.2.\\\", \\\"4\\\", 1318, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HBcAb positive participants who become positive for HBV DNA and require antiviral therapy must have study intervention discontinued.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52903a6d-dc3c-4411-bf48-a239b0ec9b27\\\", \\\"childbox\\\": \\\"b9040e42-9834-49e6-b2c4-4d14c675202d\\\", \\\"subtext\\\": \\\"1171f71f-d085-4e73-8440-910eddd493cb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Participants Who Are HBcAb Positive and Who Develop Detectable HBV DNA Requiring Initiation of Antiviral Therapy\\\", \\\"8.2.8.2.\\\", \\\"4\\\", 1319, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The participant must also be referred to a hepatologist or infectious diseases expert so that treatment advice regarding whether to commence anti-viral therapy is received within 7 days of HBV DNA elevation being identified.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52903a6d-dc3c-4411-bf48-a239b0ec9b27\\\", \\\"childbox\\\": \\\"c81e948f-4c57-47c7-bd8e-ba508b1f566f\\\", \\\"subtext\\\": \\\"1171f71f-d085-4e73-8440-910eddd493cb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Participants Who Are HBcAb Positive and Who Develop Detectable HBV DNA Requiring Initiation of Antiviral Therapy\\\", \\\"8.2.8.2.\\\", \\\"4\\\", 1320, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The participant should then be reviewed by the expert within 14 days of HBV DNA elevation being identified and managed as per local guidelines or under EASL or AASLD guidelines if none are available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52903a6d-dc3c-4411-bf48-a239b0ec9b27\\\", \\\"childbox\\\": \\\"05160abd-7af4-4fe4-9289-370f15600da5\\\", \\\"subtext\\\": \\\"8f6eda88-5ddf-4023-9521-cdd48d2417fd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Participants Who Are HBcAb Positive and Who Develop Detectable HBV DNA Requiring Initiation of Antiviral Therapy\\\", \\\"8.2.8.2.\\\", \\\"4\\\", 1321, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.8.3. Follow Up of Participants Treated With Anti-viral Therapy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"247a6b7a-67f2-413c-a87a-504dfe62d725\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Follow Up of Participants Treated With Anti-viral Therapy\\\", \\\"8.2.8.3.\\\", \\\"4\\\", 1322, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All participants will be followed up within the study by the investigator in addition to local expert follow up.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bb8aab09-80c6-4f99-a990-20d8bc132fec\\\", \\\"childbox\\\": \\\"ebcd9639-16f4-4870-97b6-f47f23d5b330\\\", \\\"subtext\\\": \\\"6039d48d-f033-456a-8514-63f3d88db02f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Follow Up of Participants Treated With Anti-viral Therapy\\\", \\\"8.2.8.3.\\\", \\\"4\\\", 1323, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After completion of the study, participants should be followed up as per local expert opinion based on guideline recommendations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bb8aab09-80c6-4f99-a990-20d8bc132fec\\\", \\\"childbox\\\": \\\"8016fcf9-c371-4abe-a99e-4ffb7ba6eea8\\\", \\\"subtext\\\": \\\"e1a88f1e-d2ba-45d6-bd20-bde8ce00a1a0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Follow Up of Participants Treated With Anti-viral Therapy\\\", \\\"8.2.8.3.\\\", \\\"4\\\", 1324, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.2.9. Markers of drug-drug interactions\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a262b6b6-969d-4623-9798-5be0ccb7c417\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Markers of drug-drug interactions\\\", \\\"8.2.9.\\\", \\\"3\\\", 1325, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Plasma derived from whole blood of approximately 2 mL will be collected for 4\\\\u03b2hydroxycholesterol and cholesterol concentration analysis, at the visits specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"756de613-4038-45d6-873b-2427818bf47c\\\", \\\"childbox\\\": \\\"a6680661-f2a4-4afd-aa3d-486150ca7655\\\", \\\"subtext\\\": \\\"c84b9575-5218-488d-b699-bd3d2a38d03b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Markers of drug-drug interactions\\\", \\\"8.2.9.\\\", \\\"3\\\", 1326, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The actual date and time (24-hour clock time) of each sample will be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"756de613-4038-45d6-873b-2427818bf47c\\\", \\\"childbox\\\": \\\"73dde4d1-89a4-4e39-9faa-274647e09616\\\", \\\"subtext\\\": \\\"1109fcf6-8f93-479c-ae50-bd21371fca6f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Markers of drug-drug interactions\\\", \\\"8.2.9.\\\", \\\"3\\\", 1327, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Plasma samples will be analysed for 4\\\\u03b2-hydroxycholesterol and cholesterol as a potential marker of CYP3A4 enzyme activity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"756de613-4038-45d6-873b-2427818bf47c\\\", \\\"childbox\\\": \\\"aa7c5993-cf19-4d3e-a882-0021d7fd79cb\\\", \\\"subtext\\\": \\\"1109fcf6-8f93-479c-ae50-bd21371fca6f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Markers of drug-drug interactions\\\", \\\"8.2.9.\\\", \\\"3\\\", 1328, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ratios of 4\\\\u03b2-hydroxycholesterol:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"756de613-4038-45d6-873b-2427818bf47c\\\", \\\"childbox\\\": \\\"0df927f1-39d4-43a0-928b-62ec425616b9\\\", \\\"subtext\\\": \\\"4f2be135-20bb-4555-bb32-7833c8ddb980\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Markers of drug-drug interactions\\\", \\\"8.2.9.\\\", \\\"3\\\", 1329, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"cholesterol at baseline and at steady-state (week 12 & 24) will be compared to evaluate potential changes in CYP3A4 enzyme activity following GSK3196165 intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 142, \\\"end_idx\\\": 151, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"7ca61d65-8015-4101-a938-37376853a42f\\\", \\\"childbox\\\": \\\"16eb6045-09ee-4eac-9817-3e94a5e33407\\\", \\\"subtext\\\": \\\"9a70d12b-f5a6-4332-961c-a37eb1d2ab37\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Markers of drug-drug interactions\\\", \\\"8.2.9.\\\", \\\"3\\\", 1330, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.3. Adverse Events and Serious Adverse Events\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"747a7cbd-2244-41af-b75b-db1bbf94f1a4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1331, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The definitions of an AE or SAE can be found in Appendix 3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a63731be-16ae-400e-a9b0-b671b069c358\\\", \\\"childbox\\\": \\\"6f026244-1a49-4a67-8792-379da8576605\\\", \\\"subtext\\\": \\\"36df8129-baf9-4c8e-861b-6ce3c29b8b3a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1332, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The investigator and any qualified designees are responsible for detecting, documenting, and reporting events that meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, considered related to the study intervention or the study, or that caused the participant to discontinue the study intervention (see Section 7).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9792545d-b896-48f9-a695-808b6a741f3a\\\", \\\"childbox\\\": \\\"1db57bbb-6679-4a18-945e-052d6a28ba13\\\", \\\"subtext\\\": \\\"dc4a955f-8ccd-4fed-b2fa-a42cf5e913bc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1333, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Participants will be assessed for cough or dyspnoea at selected visits as specified in the SoA (Section 1.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c3197fd-fe5d-4eed-9835-00d51962168e\\\", \\\"childbox\\\": \\\"8239a866-b2f8-491b-9d52-dfac976affed\\\", \\\"subtext\\\": \\\"6f985eab-2491-4e0c-a92c-8509cf62c978\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1334, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator will complete the CTC cough scale if a cough is present and will record dyspnoea as per the dyspnoea scale.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c3197fd-fe5d-4eed-9835-00d51962168e\\\", \\\"childbox\\\": \\\"dced9266-9b22-48e0-9bec-3b0338c2360f\\\", \\\"subtext\\\": \\\"96d12c7c-d847-4f6f-a313-f09793c0ba0d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1335, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Lung auscultation and pulse oximetry will also be performed at the visits specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c3197fd-fe5d-4eed-9835-00d51962168e\\\", \\\"childbox\\\": \\\"5809fd5a-1343-439d-b22a-d3ef5e5824c1\\\", \\\"subtext\\\": \\\"96d12c7c-d847-4f6f-a313-f09793c0ba0d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1336, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 If a participant, at times other than scheduled visits, reports new onset or an increase (if present at baseline) in cough (CTCAE Grade \\\\u22652) or dyspnoea (dyspnoea scale Grade \\\\u22652), the participant will be questioned (in clinic or by phone) on a weekly basis for 3 further consecutive weeks or until symptoms resolve, if earlier.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9322f665-fb0b-449f-b19d-0f76d7672d36\\\", \\\"childbox\\\": \\\"2fb3c108-9775-4ed3-94c8-228d17aaee97\\\", \\\"subtext\\\": \\\"6c16e4a8-881b-4183-900f-f049dae85382\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1337, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any new onset or worsening cough and/or dyspnoea must be reported as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9322f665-fb0b-449f-b19d-0f76d7672d36\\\", \\\"childbox\\\": \\\"60ac33b1-3d40-4e7b-9811-2e40cf0748d7\\\", \\\"subtext\\\": \\\"10a8af86-4806-4c46-9820-5b97406c463a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Adverse Events and Serious Adverse Events\\\", \\\"8.3.\\\", \\\"2\\\", 1338, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"header\\\", \\\"8.3.1. Time Period and Frequency for Collecting AE and SAE\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9e2bbb2d-e7d6-48a6-8dbf-bb9c6d952e3e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1339, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"header\\\", \\\"Information\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"07a7efe2-3370-49c9-8bf6-63b754b59b53\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1340, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"text\\\", \\\"\\\\u2022 All SAEs will be collected from the signing of the informed consent form until the follow-up visit (for participants who do not enter the long-term safety study) or the Week 24 visit (for participants who enter the long-term safety study) at the time points specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1a080b32-c739-41b7-b2d6-ae0ac12aafd1\\\", \\\"childbox\\\": \\\"65ad5c99-4993-4b7f-9486-f9cc16e9f7a6\\\", \\\"subtext\\\": \\\"3e125469-2d94-4f5f-a762-dc49e0d04b38\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1341, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"text\\\", \\\"\\\\u2022 All AEs will be collected from the start of study intervention until the follow-up visit (for participants who do not enter the long-term safety study) or the Week 24 visit (for participants who enter the long-term safety study) at the time points specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5952e8b6-b6eb-455a-81d8-cb2d44c34b14\\\", \\\"childbox\\\": \\\"01286e98-f9b7-42e5-b97f-ddc7d89c4217\\\", \\\"subtext\\\": \\\"bc508a26-dbc2-4f04-9d37-6ebde867c8b1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1342, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"text\\\", \\\"\\\\u2022 Medical occurrences that begin before the start of study intervention but after obtaining informed consent will be recorded on the Medical History/Current Medical Conditions section of the case report form (CRF) not the AE section.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d0169774-ae5f-4e85-aa81-977b892cc243\\\", \\\"childbox\\\": \\\"fb137796-153d-4a8d-98dd-31db5085ca72\\\", \\\"subtext\\\": \\\"50b929de-22f2-41d5-97e9-7ed716c10980\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1343, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"text\\\", \\\"\\\\u2022 All SAEs will be recorded and reported to the sponsor or designee immediately and under no circumstance should this exceed 24 hours, as indicated in Appendix 3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"df87167a-da77-40b4-9a8b-87f366008369\\\", \\\"childbox\\\": \\\"5f3b3995-af2f-4b0d-ac3b-6a75f1b61fbc\\\", \\\"subtext\\\": \\\"6bdcc798-e1b8-414c-9e65-9d8fc33adac0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1344, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"text\\\", \\\"The investigator will submit any updated SAE data to the sponsor within 24 hours of it being available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"df87167a-da77-40b4-9a8b-87f366008369\\\", \\\"childbox\\\": \\\"22e577c0-3a63-46d8-b7f5-e1fb20245929\\\", \\\"subtext\\\": \\\"01429ec5-7a18-4dfb-bfac-e5eba81b243a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1345, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"text\\\", \\\"\\\\u2022 Investigators are not obligated to actively seek AEs or SAEs after the conclusion of the study participation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"002d0a64-9686-4106-b697-2855d3c45f65\\\", \\\"childbox\\\": \\\"9ac195ff-cde7-40f6-b93f-8ad3fd448e0d\\\", \\\"subtext\\\": \\\"520a20b4-93a5-4c28-9237-9ed4f228f395\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1346, \\\"\\\"], [\\\"3\\\", \\\"Time Period and Frequency for Collecting AE and SAE Information\\\", \\\"text\\\", \\\"However, if the investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and he/she considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"002d0a64-9686-4106-b697-2855d3c45f65\\\", \\\"childbox\\\": \\\"e4b7360c-94dd-43fd-9d26-b9fad4bf188e\\\", \\\"subtext\\\": \\\"520a20b4-93a5-4c28-9237-9ed4f228f395\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Time Period and Frequency for Collecting AE and SAE\\\", \\\"8.3.1.\\\", \\\"3\\\", 1347, \\\"\\\"], [\\\"3\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"header\\\", \\\"8.3.2. Method of Detecting AEs and SAEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9f06bc85-4ae7-477c-8fa1-71ec3b32c725\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"8.3.2.\\\", \\\"3\\\", 1348, \\\"\\\"], [\\\"3\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"text\\\", \\\"\\\\u2022 The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Appendix 3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ef92bfc2-2371-4213-907d-0c078ebcd62b\\\", \\\"childbox\\\": \\\"cf2a6c6e-712c-47cc-9b0c-a0e26ccd884d\\\", \\\"subtext\\\": \\\"cf051ac3-04f2-44fd-9019-084b4656dd1d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"8.3.2.\\\", \\\"3\\\", 1349, \\\"\\\"], [\\\"3\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"text\\\", \\\"The intensity of AEs will be graded using the NCI-CTCAE v5.0 [NCI, 2017].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 46, \\\"end_idx\\\": 54, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"NCI-CTCAE\\\"}, {\\\"start_idx\\\": 46, \\\"end_idx\\\": 48, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"NCI\\\"}, {\\\"start_idx\\\": 62, \\\"end_idx\\\": 64, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"NCI\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ef92bfc2-2371-4213-907d-0c078ebcd62b\\\", \\\"childbox\\\": \\\"bd29fab2-b343-4913-a0af-45ffe3aa9737\\\", \\\"subtext\\\": \\\"00c14b8c-01be-4089-9f60-c98052f44baa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"8.3.2.\\\", \\\"3\\\", 1350, \\\"\\\"], [\\\"3\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Care will be taken not to introduce bias when detecting AE and/or SAE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e4f9d83-dd0d-4ce4-9e92-3d2186782590\\\", \\\"childbox\\\": \\\"7dcf2985-9619-4cb1-88a3-95eee2d2eb9c\\\", \\\"subtext\\\": \\\"91fdcd25-9c7f-4799-916e-2075d5bbfbad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"8.3.2.\\\", \\\"3\\\", 1351, \\\"\\\"], [\\\"3\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"text\\\", \\\"Openended and non-leading verbal questioning of the participant is the preferred method to inquire about AE occurrence.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e4f9d83-dd0d-4ce4-9e92-3d2186782590\\\", \\\"childbox\\\": \\\"db0db5b5-a08c-4edf-8f84-c37115f5e921\\\", \\\"subtext\\\": \\\"91fdcd25-9c7f-4799-916e-2075d5bbfbad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Method of Detecting AEs and SAEs\\\", \\\"8.3.2.\\\", \\\"3\\\", 1352, \\\"\\\"], [\\\"3\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"header\\\", \\\"8.3.3. Follow-up of AEs and SAEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"56adebb3-f748-467f-bcb1-ffbf9e0d61cc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"8.3.3.\\\", \\\"3\\\", 1353, \\\"\\\"], [\\\"3\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"text\\\", \\\"After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87663d51-2a26-4a51-824c-e9c2589fae4a\\\", \\\"childbox\\\": \\\"fcc2168e-c17c-43ca-a464-47701d6d4cba\\\", \\\"subtext\\\": \\\"3b738992-1a66-4d4d-a7ab-65ea0ea94290\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"8.3.3.\\\", \\\"3\\\", 1354, \\\"\\\"], [\\\"3\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"text\\\", \\\"All SAEs, and non-serious AEs of special interest (as defined in Section 8.3.7), will be followed until the event is resolved, stabilised, otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87663d51-2a26-4a51-824c-e9c2589fae4a\\\", \\\"childbox\\\": \\\"0c9a64d7-517f-496a-9b25-6c2caf8797eb\\\", \\\"subtext\\\": \\\"3b738992-1a66-4d4d-a7ab-65ea0ea94290\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"8.3.3.\\\", \\\"3\\\", 1355, \\\"\\\"], [\\\"3\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"text\\\", \\\"Further information on follow-up procedures is given in Appendix 3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87663d51-2a26-4a51-824c-e9c2589fae4a\\\", \\\"childbox\\\": \\\"bbac2563-1e71-423e-bd67-e791e063655f\\\", \\\"subtext\\\": \\\"702ad150-6345-4598-9ba9-9665d847671d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Follow-up of AEs and SAEs\\\", \\\"8.3.3.\\\", \\\"3\\\", 1356, \\\"\\\"], [\\\"3\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"header\\\", \\\"8.3.4. Regulatory Reporting Requirements for SAEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e024a2ab-b59a-41bc-85bf-a5798093694a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"8.3.4.\\\", \\\"3\\\", 1357, \\\"\\\"], [\\\"3\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Prompt notification by the investigator to the sponsor of a SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e6849ff1-5cc6-4571-893f-7431e81ad84a\\\", \\\"childbox\\\": \\\"3a590b8e-6a6e-45fc-81a9-e589c9a1d6dc\\\", \\\"subtext\\\": \\\"2992e7c7-5999-4ff5-8318-316dfb566d92\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"8.3.4.\\\", \\\"3\\\", 1358, \\\"\\\"], [\\\"3\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"text\\\", \\\"\\\\u2022 The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2e7c8d46-e650-493f-8b24-33faea1397e6\\\", \\\"childbox\\\": \\\"5eba61f7-3ddb-4ebd-98ac-12aa6a565f2b\\\", \\\"subtext\\\": \\\"43fa84a0-9bc1-44d3-93f8-d4de97f6dd7c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"8.3.4.\\\", \\\"3\\\", 1359, \\\"\\\"], [\\\"3\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"text\\\", \\\"The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2e7c8d46-e650-493f-8b24-33faea1397e6\\\", \\\"childbox\\\": \\\"d55ff127-f2fd-41f9-a216-3a28c19387c6\\\", \\\"subtext\\\": \\\"43fa84a0-9bc1-44d3-93f8-d4de97f6dd7c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"8.3.4.\\\", \\\"3\\\", 1360, \\\"\\\"], [\\\"3\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR) according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f0d98a00-67f4-4f1d-a258-0290562b82e8\\\", \\\"childbox\\\": \\\"1ae2bb1c-9072-41b9-aeb6-1a0fb89a50e4\\\", \\\"subtext\\\": \\\"a3657949-8fe0-4294-a202-ccfe35e4977b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"8.3.4.\\\", \\\"3\\\", 1361, \\\"\\\"], [\\\"3\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"text\\\", \\\"\\\\u2022 An investigator who receives an investigator safety report describing a SAE or other specific safety information e.g., summary or listing of SAE) from the sponsor will review and then file it along with the Investigator\\\\u2019s Brochure and will notify the IRB/IEC, if appropriate according to local requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bd2ac774-acf2-45c5-928f-cacc22281ae2\\\", \\\"childbox\\\": \\\"475874df-8987-4eaa-b19a-6f2189d78f8b\\\", \\\"subtext\\\": \\\"18ca0d7e-78d4-44eb-a369-8d0b743fabee\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Regulatory Reporting Requirements for SAEs\\\", \\\"8.3.4.\\\", \\\"3\\\", 1362, \\\"\\\"], [\\\"3\\\", \\\"Pregnancy\\\", \\\"header\\\", \\\"8.3.5. Pregnancy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"14e607ad-1008-45c1-b3d8-d6e29cf68398\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pregnancy\\\", \\\"8.3.5.\\\", \\\"3\\\", 1363, \\\"\\\"], [\\\"3\\\", \\\"Pregnancy\\\", \\\"text\\\", \\\"\\\\u2022 Details of all pregnancies in female participants and, if indicated, female partners of male participants will be collected after the start of study intervention and until the safety follow-up visit at Week 34 (or until 12 weeks after the last dose, for participants who withdraw from the study early).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5f35cd7a-1650-4920-ac38-38a51eaf5122\\\", \\\"childbox\\\": \\\"1f7f2087-bd4c-4f7c-ab2f-82616019b917\\\", \\\"subtext\\\": \\\"d94a3f3e-cf75-4cae-ab6f-92394b3571c4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pregnancy\\\", \\\"8.3.5.\\\", \\\"3\\\", 1364, \\\"\\\"], [\\\"3\\\", \\\"Pregnancy\\\", \\\"text\\\", \\\"\\\\u2022 If a pregnancy is reported, the investigator should inform GSK within 24 hours of learning of the pregnancy and should follow the procedures outlined in Appendix 4.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 61, \\\"end_idx\\\": 63, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 61, \\\"end_idx\\\": 63, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"38cc4085-9de5-49c3-9f02-f9557799fea7\\\", \\\"childbox\\\": \\\"869a5a22-0e84-43f0-a119-e95961c3e6c3\\\", \\\"subtext\\\": \\\"09bb7e65-6925-459c-aa38-04b28ffe73b9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pregnancy\\\", \\\"8.3.5.\\\", \\\"3\\\", 1365, \\\"\\\"], [\\\"3\\\", \\\"Pregnancy\\\", \\\"text\\\", \\\"\\\\u2022 Female participants who become pregnant after the start of study intervention must be permanently discontinue study intervention but can continue to be followed in the study if they wish (Section 7.1.2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"72055a16-aca9-4c1d-9cd9-efe9971b6182\\\", \\\"childbox\\\": \\\"d10d4d36-dce0-432b-9200-2b85d0752bd9\\\", \\\"subtext\\\": \\\"f86f75ec-4997-48b8-94fe-b1347acc4535\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pregnancy\\\", \\\"8.3.5.\\\", \\\"3\\\", 1366, \\\"\\\"], [\\\"3\\\", \\\"Pregnancy\\\", \\\"text\\\", \\\"If the participant does not wish to continue in the study, follow guidance in Section 7.2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"72055a16-aca9-4c1d-9cd9-efe9971b6182\\\", \\\"childbox\\\": \\\"a84549fd-75f4-453a-8909-e1c3ce6cc326\\\", \\\"subtext\\\": \\\"ac6a45ee-16c0-41be-b193-7ba8145da069\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pregnancy\\\", \\\"8.3.5.\\\", \\\"3\\\", 1367, \\\"\\\"], [\\\"3\\\", \\\"Pregnancy\\\", \\\"text\\\", \\\"\\\\u2022 Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f929a146-ce0b-4c4d-ba99-685c3bacb314\\\", \\\"childbox\\\": \\\"b65d0c07-f0a3-431a-bd88-d377cf9cb436\\\", \\\"subtext\\\": \\\"9c9e07a9-6a7f-4d70-af4d-32b07da8ef6b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pregnancy\\\", \\\"8.3.5.\\\", \\\"3\\\", 1368, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"header\\\", \\\"8.3.6. Cardiovascular and Death Events\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0b193f0d-1d5e-4ea5-8a32-0d4df86fd573\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1369, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"For any cardiovascular (CV) events detailed in Appendix 3 and all deaths, whether or not they are considered SAEs, specific CV and Death sections of the CRF will be required to be completed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a370836e-b695-4bbc-acd1-e9a1192b35b1\\\", \\\"childbox\\\": \\\"f6c13677-4f39-48a4-9cd3-9a529ec81c1e\\\", \\\"subtext\\\": \\\"8380163e-6ef5-40ad-9933-ff3757c42773\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1370, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"These sections include questions regarding CV (including sudden cardiac death) and non-CV death.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a370836e-b695-4bbc-acd1-e9a1192b35b1\\\", \\\"childbox\\\": \\\"ff665b0b-5fb4-4454-ab56-144b9c99aa8d\\\", \\\"subtext\\\": \\\"40543886-040b-4d93-a899-3e368a01a353\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1371, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"The CV CRFs are presented as queries in response to reporting of certain CV MedDRA (Medical dictionary for regulatory activities) terms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8ba4af80-4758-41ab-a8a8-14d624369277\\\", \\\"childbox\\\": \\\"64ac5117-9d46-495d-8cdf-672754df10d3\\\", \\\"subtext\\\": \\\"2e46cec0-c72f-4a9d-9440-8e3b4cb9a434\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1372, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"The CV information should be recorded in the specific CV section of the CRF within one week of receipt of a CV Event data query prompting its completion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8ba4af80-4758-41ab-a8a8-14d624369277\\\", \\\"childbox\\\": \\\"fd5059be-40fd-4fbf-9f61-2f0f200790ac\\\", \\\"subtext\\\": \\\"4f802295-fa97-47ef-be02-843995f37a80\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1373, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"The Death CRF is provided immediately after the occurrence or outcome of death is reported.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"09c34f54-20f5-45d6-96c4-eb184f57b663\\\", \\\"childbox\\\": \\\"d7b52d11-5a5c-47ae-8da2-c9b528b13c22\\\", \\\"subtext\\\": \\\"9f5ffc58-424e-4826-aa64-002899fb7912\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1374, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"Initial and follow-up reports regarding death must be completed within one week of when the death is reported.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"09c34f54-20f5-45d6-96c4-eb184f57b663\\\", \\\"childbox\\\": \\\"ef368c07-6a63-4d28-bf8b-fd9cf85e1465\\\", \\\"subtext\\\": \\\"9f5ffc58-424e-4826-aa64-002899fb7912\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1375, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"Investigators will be required to fill out event specific data collection tools for the following AEs and SAEs:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d7ec7c4a-b8c8-489a-9cc9-2c43510ae728\\\", \\\"childbox\\\": \\\"aeb48ba5-b4ac-4c29-8036-36c6fdbea43c\\\", \\\"subtext\\\": \\\"d604bb32-0770-4d6a-b63d-3724781cde3c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1376, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Myocardial infarction/unstable angina.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"feb8e4b0-e764-433f-b157-62b2f041fdf3\\\", \\\"childbox\\\": \\\"f6114b71-4126-4756-9156-94e189225a10\\\", \\\"subtext\\\": \\\"b3f51e32-9773-4594-a2ba-95437e66a621\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1377, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Congestive heart failure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7df7d4e2-3704-432c-8ed1-f7d03cfd5448\\\", \\\"childbox\\\": \\\"08951d1c-40ea-487d-9b6c-84ad6673441f\\\", \\\"subtext\\\": \\\"4791cb69-9aba-4e2d-97a8-0ffbd3b2a2d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1378, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Arrhythmias.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dded73db-0ec6-4b69-8a1a-10faf955bf6e\\\", \\\"childbox\\\": \\\"2b671b84-6f8f-4e74-a7a0-f109c2fbcfb7\\\", \\\"subtext\\\": \\\"c6b456cb-754e-43c8-a562-d9d1c9e7c96b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1379, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Valvulopathy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"daf5120c-ff1f-416f-bfcc-eb8e9c327c7f\\\", \\\"childbox\\\": \\\"0f9f18a4-ab08-413c-a265-52370444f7ac\\\", \\\"subtext\\\": \\\"240b3085-b62a-4e65-8362-a4dd7ceba4ed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1380, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Pulmonary hypertension.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5ac10ecd-d898-4406-b024-9454468dbcc2\\\", \\\"childbox\\\": \\\"12d750a9-9ca3-4af3-a92a-bf352d47a0ec\\\", \\\"subtext\\\": \\\"3b95c3d3-a0e2-4222-a6db-232743707e85\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1381, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Cerebrovascular events/stroke and transient ischemic attack.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f1e07787-adfa-438c-b3a6-982ecb03002e\\\", \\\"childbox\\\": \\\"c437a59c-0109-46ba-b957-5050baef3384\\\", \\\"subtext\\\": \\\"3ab3320f-3625-48c7-9f07-0b97e09a082e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1382, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Peripheral arterial thromboembolism.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"96a366b2-18ea-44eb-b25a-7cbcd5556df4\\\", \\\"childbox\\\": \\\"2ea17bb4-678d-4a2a-abd6-0a046f20493e\\\", \\\"subtext\\\": \\\"93226d78-ace7-430d-a6fc-a0cccecf40f2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1383, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Deep venous thrombosis/pulmonary embolism.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1bf3f26e-2e80-47f9-be1c-82f62d46ba68\\\", \\\"childbox\\\": \\\"63080b3d-1ae1-4cd1-9090-dc81eb082c9b\\\", \\\"subtext\\\": \\\"66836cd5-3123-44a5-8df7-ccd7ebb427df\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1384, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"\\\\u2022 Revascularisation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2a10b6d2-42c4-4932-a95a-5ef9b6a55dff\\\", \\\"childbox\\\": \\\"ba9ec89b-bc8c-4041-8de9-99540026960b\\\", \\\"subtext\\\": \\\"aa27c88c-2151-4821-8438-4568acb2faaf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1385, \\\"\\\"], [\\\"3\\\", \\\"Cardiovascular and Death Events\\\", \\\"text\\\", \\\"This information should be recorded in the specific CV eCRF within one week of when the AE/SAE(s) are first reported.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8631d49e-595c-450d-ac93-d4a97932b5f2\\\", \\\"childbox\\\": \\\"45c64c84-401e-425b-b991-332065396e31\\\", \\\"subtext\\\": \\\"0238bcee-8bba-4aa8-b811-51e81355f9aa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Cardiovascular and Death Events\\\", \\\"8.3.6.\\\", \\\"3\\\", 1386, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.3.7. AEs of Special Interest\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"90190949-d827-41e0-b9bf-a86a4b99ae0a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1387, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The potential risks with GSK3196165 are discussed in Section 2.3.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 25, \\\"end_idx\\\": 34, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"d6abe4de-67ca-4cde-8166-b0175b1d1258\\\", \\\"childbox\\\": \\\"fc975a05-25fc-4e1b-9054-e1ee3b81d472\\\", \\\"subtext\\\": \\\"61b7e915-7aab-48b1-bc31-562f88953a72\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1388, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Adverse events of special interest (AESIs) for GSK3196165 include:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 47, \\\"end_idx\\\": 56, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"441b9f3d-6691-4d59-b735-2303ea386758\\\", \\\"childbox\\\": \\\"ded13e57-458b-4f46-ac90-bfba3bdafd49\\\", \\\"subtext\\\": \\\"32e21012-0db2-4e5b-88db-291ce4048c33\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1389, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Serious infections\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0d309e6a-3aef-44c5-9740-fce9e17c1802\\\", \\\"childbox\\\": \\\"09e0c067-ca0e-4042-9c9d-a00216ddd77e\\\", \\\"subtext\\\": \\\"95cfcb19-b174-43ef-83e1-ff87b7108a3d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1390, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0d309e6a-3aef-44c5-9740-fce9e17c1802\\\", \\\"childbox\\\": \\\"09e0c067-ca0e-4042-9c9d-a00216ddd77e\\\", \\\"subtext\\\": \\\"a8b3a631-9c89-4c04-a435-7d075befbfe9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1391, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Opportunistic infections.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0d309e6a-3aef-44c5-9740-fce9e17c1802\\\", \\\"childbox\\\": \\\"09e0c067-ca0e-4042-9c9d-a00216ddd77e\\\", \\\"subtext\\\": \\\"ef82a1ca-91ea-4d75-a7aa-443f87110791\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1392, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 TB and TB reactivation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"526afcd3-2b82-4996-aa67-49facfdc093a\\\", \\\"childbox\\\": \\\"a6e81d09-63d0-45d8-bf2b-ceafcde78d9f\\\", \\\"subtext\\\": \\\"8ba37f10-a64e-44ab-864d-28ed596b1ac0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1393, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Neutropenia\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"610246a7-6df9-4fa0-8195-8ce41761f38d\\\", \\\"subtext\\\": \\\"dfbaaeba-421d-4a43-84f1-87ecad60873a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1394, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"610246a7-6df9-4fa0-8195-8ce41761f38d\\\", \\\"subtext\\\": \\\"c45e23d6-1732-4f4c-b250-bba30b71745d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1395, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Grade 3 (<1.0 x 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"610246a7-6df9-4fa0-8195-8ce41761f38d\\\", \\\"subtext\\\": \\\"9e8d253d-c49b-4daf-9187-29994912197b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1396, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"610246a7-6df9-4fa0-8195-8ce41761f38d\\\", \\\"subtext\\\": \\\"c3f66e22-3c03-4c31-8696-da94a57d2d7f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1397, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/L).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"610246a7-6df9-4fa0-8195-8ce41761f38d\\\", \\\"subtext\\\": \\\"16cb06a4-b0fc-41eb-ae1f-7cf75541a140\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1398, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"b08c5359-f6ad-4866-98ca-9aa9ded1ca06\\\", \\\"subtext\\\": \\\"db1e2e6d-d844-4c75-a45f-152c9f017aaf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1399, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pulmonary alveolar proteinosis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"b08c5359-f6ad-4866-98ca-9aa9ded1ca06\\\", \\\"subtext\\\": \\\"b36a1927-2709-4fbd-8b7f-f2fefd19e147\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1400, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"b08c5359-f6ad-4866-98ca-9aa9ded1ca06\\\", \\\"subtext\\\": \\\"c45ded15-bf89-4787-9e9f-c72c3adf14a9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1401, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hypersensitivity reactions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a1ce654-fb1a-44db-9b68-1f201aefd8e4\\\", \\\"childbox\\\": \\\"b08c5359-f6ad-4866-98ca-9aa9ded1ca06\\\", \\\"subtext\\\": \\\"dceaca92-9dd6-473f-9b79-d47473ebfad5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1402, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Injection site reactions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9d8197ac-543c-4e8a-8bf1-db2acd86b27c\\\", \\\"childbox\\\": \\\"8f5ab12e-a432-4064-8a45-7ee487ec5936\\\", \\\"subtext\\\": \\\"b5927636-4b04-4eaf-8643-81e5b2a402fd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1403, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Persistent cough (CTCAE Grade\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"411e4706-9180-44ac-b775-7ca93e5ef6db\\\", \\\"childbox\\\": \\\"442648d4-2cf7-4536-815c-4dc62725898e\\\", \\\"subtext\\\": \\\"b924ab41-ac86-428c-bd87-681224362d49\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1404, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"411e4706-9180-44ac-b775-7ca93e5ef6db\\\", \\\"childbox\\\": \\\"442648d4-2cf7-4536-815c-4dc62725898e\\\", \\\"subtext\\\": \\\"3e887bac-068b-4378-9141-6f8d04e806a0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1405, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"411e4706-9180-44ac-b775-7ca93e5ef6db\\\", \\\"childbox\\\": \\\"442648d4-2cf7-4536-815c-4dc62725898e\\\", \\\"subtext\\\": \\\"e2ec27aa-c7e1-4ead-8cf0-df5b4a64dba2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1406, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Persistent dyspnoea (dyspnoea scale Grade\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4d4d3039-72e4-435a-b786-6ac50dcb16a0\\\", \\\"childbox\\\": \\\"c160cb39-7125-4f29-884e-2e6284a35c40\\\", \\\"subtext\\\": \\\"94afaaad-d453-4b10-a138-f091a3380111\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1407, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4d4d3039-72e4-435a-b786-6ac50dcb16a0\\\", \\\"childbox\\\": \\\"c160cb39-7125-4f29-884e-2e6284a35c40\\\", \\\"subtext\\\": \\\"eb9b6f9a-fbe2-40bd-b6cc-311d39de2046\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1408, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4d4d3039-72e4-435a-b786-6ac50dcb16a0\\\", \\\"childbox\\\": \\\"c160cb39-7125-4f29-884e-2e6284a35c40\\\", \\\"subtext\\\": \\\"64a0f537-5e38-4ff2-9e7b-f0056c5cdc35\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"AEs of Special Interest\\\", \\\"8.3.7.\\\", \\\"3\\\", 1409, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"header\\\", \\\"8.4. Treatment of Overdose\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"866c5613-fb85-470e-bda4-66ea4469d28d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1410, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"For this study, any dose of GSK3196165 greater than the highest dose used in this study (150 mg once-weekly) will be considered an overdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 28, \\\"end_idx\\\": 37, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ae754139-313a-42bc-a65b-3a6b591e4b6e\\\", \\\"childbox\\\": \\\"8e75921a-6e23-47ce-96af-3d01cb80b9dd\\\", \\\"subtext\\\": \\\"ac848545-98e0-4939-9ca1-66c8b5255c25\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1411, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"It should be noted that the minimum time between dosing with GSK3916165 is 5 days but it is strongly recommended that dosing should revert back to 7 days as soon as possible.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae754139-313a-42bc-a65b-3a6b591e4b6e\\\", \\\"childbox\\\": \\\"6541d504-f55f-4d06-9318-0aaebbf8b2e1\\\", \\\"subtext\\\": \\\"c609bda0-19f6-4fbc-899c-9dd00ca3d698\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1412, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"No specific treatment is recommended for an overdose of GSK3196165 or sarilumab, and the investigator should treat as clinically indicated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 56, \\\"end_idx\\\": 65, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 70, \\\"end_idx\\\": 78, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"a5e77463-cfb7-4946-b2f7-636dd78c05a7\\\", \\\"childbox\\\": \\\"20696559-57a6-46ab-830b-073af02d25d6\\\", \\\"subtext\\\": \\\"a72b1274-a920-4347-9194-31c84aac157d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1413, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"In the event of an overdose, the investigator should:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a3b8b013-0259-4728-9f8c-dafbd6c7e20d\\\", \\\"childbox\\\": \\\"fee0b17a-1e6d-4919-8a88-2ec3df1f689c\\\", \\\"subtext\\\": \\\"4a379f6b-6f41-4f4d-917e-ffb85726f409\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1414, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"\\\\u2022 Contact the Medical Monitor immediately.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbab2718-2afe-4667-8152-cb7d73f2d16b\\\", \\\"childbox\\\": \\\"49a4de9a-b58b-49dc-a2a1-c27933a658a3\\\", \\\"subtext\\\": \\\"86e6fbf3-59ee-4d9e-8336-1efdf7b508ff\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1415, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"\\\\u2022 Closely monitor the participant for AE/SAE and laboratory abnormalities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb80531e-5d9b-4fc5-afe4-bde1455a2bc2\\\", \\\"childbox\\\": \\\"7fafb1c3-340c-4990-9959-b5fae2e50153\\\", \\\"subtext\\\": \\\"f2e5996b-88d1-4d8b-a46f-80c94a7067c6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1416, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"\\\\u2022 Obtain a plasma sample for PK analysis within 3-5 days from the date of the last dose of study intervention if requested by the Medical Monitor (determined on a case-by-case basis).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3b191681-cddd-483d-8d97-72edb50db2ff\\\", \\\"childbox\\\": \\\"1a720ff5-4f2a-4d3c-a302-f0d81b8d7389\\\", \\\"subtext\\\": \\\"f857e3ec-6280-4c9d-993d-b234a2502d9a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1417, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"\\\\u2022 Document the quantity of the excess dose as well as the duration of the overdosing in the CRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a072573f-2c69-4ded-860d-7f350a788a54\\\", \\\"childbox\\\": \\\"35a45ee5-9b88-4fc5-b2b8-f4b3fd19aa52\\\", \\\"subtext\\\": \\\"4595549a-c5f1-453d-8d40-75a7de292061\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1418, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"Decisions regarding dose interruptions or modifications will be made by the investigator in consultation with the Medical Monitor based on the clinical evaluation of the participant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"13169397-ea40-4333-9a0f-6f725c66b54e\\\", \\\"childbox\\\": \\\"6362e2c1-533d-4397-9858-2e5f3b979ff8\\\", \\\"subtext\\\": \\\"e7aaba2b-1f6d-4d7b-bf84-f93c83403ae4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1419, \\\"\\\"], [\\\"2\\\", \\\"Treatment of Overdose\\\", \\\"text\\\", \\\"Investigators should refer to the approved product label or local prescribing information for treatment of an overdose of sarilumab.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 122, \\\"end_idx\\\": 130, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"74a162ef-587a-4e74-ae33-1612a9c00e99\\\", \\\"childbox\\\": \\\"79157dea-425c-4af9-af6c-82ea14d15107\\\", \\\"subtext\\\": \\\"13f633dc-c78d-43c1-92fc-3b546bad8d6d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Treatment of Overdose\\\", \\\"8.4.\\\", \\\"2\\\", 1420, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"header\\\", \\\"8.5. Pharmacokinetics\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cff83892-139f-4f84-a811-a56981a39fc4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1421, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"\\\\u2022 Whole blood samples of approximately 3.5 mL will be collected prior to dosing, for measurement of serum concentrations of GSK3196165 at the visits specified in the SoA (Section 1.3); SC study intervention must be withheld until after PK sampling has been performed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 124, \\\"end_idx\\\": 133, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"aadd2e40-eae2-466c-827f-5634c3fa6f40\\\", \\\"childbox\\\": \\\"fd6279b7-85d7-4f35-adc9-101563413f7d\\\", \\\"subtext\\\": \\\"4eeb9fdd-0705-4024-9689-4310a7f20582\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1422, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"The actual date and time (24-hour clock time) of each sample will be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aadd2e40-eae2-466c-827f-5634c3fa6f40\\\", \\\"childbox\\\": \\\"47b841a1-c728-4de8-abc8-76a09014b1a0\\\", \\\"subtext\\\": \\\"61502fce-dac6-4440-b869-636f724b9666\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1423, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"\\\\u2022 Samples will be used to evaluate the PK of GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 45, \\\"end_idx\\\": 54, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"c08a9b64-6c31-47f4-bcc8-efeb089e6fd0\\\", \\\"childbox\\\": \\\"d9848fc7-e480-4c07-a3ac-739c91c165cf\\\", \\\"subtext\\\": \\\"098a28ed-fab5-4a40-bd94-abd5ee7197f4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1424, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"Each serum sample will be divided into 2 aliquots (1 each for PK and target engagement (TE) [Section 8.8]).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c08a9b64-6c31-47f4-bcc8-efeb089e6fd0\\\", \\\"childbox\\\": \\\"5754bbfd-3321-4a2c-8b65-f3c5253c95a9\\\", \\\"subtext\\\": \\\"098a28ed-fab5-4a40-bd94-abd5ee7197f4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1425, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"Samples collected for analyses of GSK3196165 serum concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 34, \\\"end_idx\\\": 43, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"c08a9b64-6c31-47f4-bcc8-efeb089e6fd0\\\", \\\"childbox\\\": \\\"207b1eab-a462-401c-9a69-f7c700f13a3a\\\", \\\"subtext\\\": \\\"665b6d22-d33a-45d8-827a-e7f115d93471\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1426, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"\\\\u2022 Samples may be stored for a maximum of 15 years (or according to local regulations) following the last participant\\\\u2019s last visit for the study at a facility selected by the sponsor to enable further analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"38fc5450-1289-414d-9bd6-dee363b93672\\\", \\\"childbox\\\": \\\"12b1d306-20db-4932-8b13-a330f4164026\\\", \\\"subtext\\\": \\\"ca1a15fd-115d-414d-8594-a258819bed2f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1427, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"Further details on the blood sample collection, processing, storage and shipping procedures are provided in the Central Laboratory Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"38fc5450-1289-414d-9bd6-dee363b93672\\\", \\\"childbox\\\": \\\"cda6a5d5-1581-4e31-9961-3047d32a6877\\\", \\\"subtext\\\": \\\"7985eb2f-fb0e-47ab-a9cf-1e9cb0626346\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1428, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"\\\\u2022 Note: Drug concentration information that would unblind the study will not be reported to investigative sites or blinded personnel until the study has been unblinded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a5a861b2-f4e8-41d9-b2a1-d48f8383fe1c\\\", \\\"childbox\\\": \\\"03cb26f6-e53d-4fbb-93e4-93d7ede2166a\\\", \\\"subtext\\\": \\\"8af58b9b-37b0-4b72-87ed-b9e2013cae9e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacokinetics\\\", \\\"8.5.\\\", \\\"2\\\", 1429, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"header\\\", \\\"8.6. Pharmacodynamics\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"efe18e5a-9b53-4faa-abc0-8aae92d40495\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamics\\\", \\\"8.6.\\\", \\\"2\\\", 1430, \\\"\\\"], [\\\"2\\\", \\\"Pharmacokinetics\\\", \\\"text\\\", \\\"The pharmacodynamic (PD) biomarkers evaluated in this study are described in Section 8.8.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"28c4b2c1-69c1-49df-852b-2e212be16126\\\", \\\"childbox\\\": \\\"597daaff-1703-4a07-8a14-3695d5f3a770\\\", \\\"subtext\\\": \\\"f5651759-04b7-4d55-8d6d-b8d1b7428d04\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamics\\\", \\\"8.6.\\\", \\\"2\\\", 1431, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.6.1. Target engagement\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f7c9fc8d-365f-4bb8-bee7-9c6868759aa7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Target engagement\\\", \\\"8.6.1.\\\", \\\"3\\\", 1432, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The same blood samples obtained for PK analysis (see Section 8.5) will also be assessed for target engagement of GSK3196165, by measurement of serum concentrations of soluble GM-CSF-GSK3196165 complex, at the time points specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 113, \\\"end_idx\\\": 122, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 182, \\\"end_idx\\\": 191, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 175, \\\"end_idx\\\": 191, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GM-CSF-GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"63ea0da2-5a61-47ab-937d-b5a0c94715fc\\\", \\\"childbox\\\": \\\"2c42e449-3dab-4d32-88df-7a9107488c4f\\\", \\\"subtext\\\": \\\"18f53fc3-6540-4ba6-8fab-d40274ae035b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Target engagement\\\", \\\"8.6.1.\\\", \\\"3\\\", 1433, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.7. Genetics\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"be6d4f69-74be-4624-8764-0ea52be4fab5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1434, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A 6 mL blood sample for DNA isolation will be collected from participants who have consented to participate in the genetics analysis component of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aafa2581-ac1a-4ade-a026-b3dd3c8a25aa\\\", \\\"childbox\\\": \\\"d6d4c48a-ed2d-4a18-9fdb-64639963fbc1\\\", \\\"subtext\\\": \\\"4574931e-b302-4240-961b-612b4919fd55\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1435, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participation is optional.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aafa2581-ac1a-4ade-a026-b3dd3c8a25aa\\\", \\\"childbox\\\": \\\"891349a3-f934-4910-ab0a-c49da7ff9e7f\\\", \\\"subtext\\\": \\\"7259ad38-7316-43dd-a08b-4707740b21d6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1436, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Participants who do not wish to participate in the genetic research may still participate in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aafa2581-ac1a-4ade-a026-b3dd3c8a25aa\\\", \\\"childbox\\\": \\\"e43c8242-f87a-492e-9b0b-9f5533493e4c\\\", \\\"subtext\\\": \\\"7259ad38-7316-43dd-a08b-4707740b21d6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1437, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the event of DNA extraction failure, a replacement genetic blood sample may be requested from the participant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b6dec567-2d2f-460b-9811-da81021b1019\\\", \\\"childbox\\\": \\\"44789a66-24cd-4777-b700-7f7c09da8e15\\\", \\\"subtext\\\": \\\"5ff57c51-5572-419d-9f99-6fd8cf698507\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1438, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Signed informed consent will be required to obtain a replacement sample unless it was included in the original consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b6dec567-2d2f-460b-9811-da81021b1019\\\", \\\"childbox\\\": \\\"e6c7b41b-71b4-49ce-90c3-f85ec0ea3d25\\\", \\\"subtext\\\": \\\"87b606d7-624c-4fb1-9cb7-d12ef279667d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1439, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"See Appendix 5 for Information regarding genetic research.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"89e60212-9035-467e-8b18-61c71897ba47\\\", \\\"childbox\\\": \\\"9ce43662-6c92-4353-a9be-403da0d3731c\\\", \\\"subtext\\\": \\\"26bda35c-6d90-4b64-8940-55ac2c44c1b6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1440, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Further details on the blood sample collection, processing, storage and shipping procedures are provided in the Central Laboratory Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"89e60212-9035-467e-8b18-61c71897ba47\\\", \\\"childbox\\\": \\\"bfb492f4-c167-4f70-a625-b54d9e24c96c\\\", \\\"subtext\\\": \\\"3e976841-390e-42c0-bb2e-c710beba3615\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Genetics\\\", \\\"8.7.\\\", \\\"2\\\", 1441, \\\"\\\"], [\\\"2\\\", \\\"Biomarkers\\\", \\\"header\\\", \\\"8.8. Biomarkers\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a6919ab-292d-439f-8f73-c6526fe2dd73\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Biomarkers\\\", \\\"8.8.\\\", \\\"2\\\", 1442, \\\"\\\"], [\\\"2\\\", \\\"Biomarkers\\\", \\\"text\\\", \\\"Biomarker research carried out in this study is described in the sections below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aab87f1a-6948-4a90-a605-b34f17d27bb1\\\", \\\"childbox\\\": \\\"d2f204b0-3068-45cd-b8dd-0de8a32faf81\\\", \\\"subtext\\\": \\\"919aa54d-08a6-45e7-a7fa-1c8d2d656c38\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Biomarkers\\\", \\\"8.8.\\\", \\\"2\\\", 1443, \\\"\\\"], [\\\"2\\\", \\\"Biomarkers\\\", \\\"text\\\", \\\"Biomarker samples will be collected from participants enrolled at selected sites/countries (refer to site information/SRM), at the time points specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aab87f1a-6948-4a90-a605-b34f17d27bb1\\\", \\\"childbox\\\": \\\"b01895fc-f2fd-43dd-ad2a-3feb81992ca2\\\", \\\"subtext\\\": \\\"919aa54d-08a6-45e7-a7fa-1c8d2d656c38\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Biomarkers\\\", \\\"8.8.\\\", \\\"2\\\", 1444, \\\"\\\"], [\\\"2\\\", \\\"Biomarkers\\\", \\\"text\\\", \\\"Note: Further details on the blood sample collection, processing, storage and shipping procedures are provided in the Central Laboratory Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"38fa5f73-03b4-4546-8971-eaf92500d763\\\", \\\"childbox\\\": \\\"fe57bafd-fcbb-429b-b895-8293b8618db3\\\", \\\"subtext\\\": \\\"c93511a0-c436-4dc8-9084-8abb9209b3c2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Biomarkers\\\", \\\"8.8.\\\", \\\"2\\\", 1445, \\\"\\\"], [\\\"2\\\", \\\"Biomarkers\\\", \\\"text\\\", \\\"Collected samples may be stored for a maximum of 15 years (or according to local regulations) following the last participant\\\\u2019s last visit for the study at a facility selected by the sponsor to enable further analysis of biomarker and/or other responses to\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"80969d2d-7af3-4e2e-b513-f527043445ec\\\", \\\"childbox\\\": \\\"c4d677e7-88df-4491-bcca-30122d7c013b\\\", \\\"subtext\\\": \\\"926a8b68-e7f3-4142-b359-526d94b5ccd8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Biomarkers\\\", \\\"8.8.\\\", \\\"2\\\", 1446, \\\"\\\"], [\\\"2\\\", \\\"Biomarkers\\\", \\\"text\\\", \\\"GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"620237f8-685c-411b-b5e2-0f782ad300be\\\", \\\"childbox\\\": \\\"0e1ad1b5-f08e-4670-8f9a-aa39612ea123\\\", \\\"subtext\\\": \\\"d5e388f0-b3ad-4d09-85c2-da291453000b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Biomarkers\\\", \\\"8.8.\\\", \\\"2\\\", 1447, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.8.1. Pharmacodynamic (PD) Biomarkers\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a422c369-82fb-4a52-9966-58c3d1f1b6ca\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1448, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A blood sample of approximately 12 mL will be collected and divided into suitable portions for measurement of the following biomarkers associated with GM-CSF signalling and/or disease pathology:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 151, \\\"end_idx\\\": 156, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f6736793-f5df-4f08-b4b4-5791d6480af8\\\", \\\"childbox\\\": \\\"d0ca9519-072b-4f56-abc0-5a7e426a7e8d\\\", \\\"subtext\\\": \\\"0bab4441-34df-4ae2-8c21-a27815256d40\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1449, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Measurement of serum PD biomarkers of downstream signalling of GM-CSF to assess the response to GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 65, \\\"end_idx\\\": 70, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 62.0, \\\"text\\\": \\\"GM-CSF\\\"}, {\\\"start_idx\\\": 98, \\\"end_idx\\\": 107, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"3f29310a-646e-4619-b8ac-2e6b81e1e7d5\\\", \\\"childbox\\\": \\\"01748291-39e4-4d35-98f4-58a37a7e3989\\\", \\\"subtext\\\": \\\"944d0745-f804-41dd-af29-ba817cc5651b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1450, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The biomarkers may include but are not limited to CCL17.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3f29310a-646e-4619-b8ac-2e6b81e1e7d5\\\", \\\"childbox\\\": \\\"bb1ebec5-0203-44d6-90ae-d8dbdbffe8a9\\\", \\\"subtext\\\": \\\"dd721f05-2895-41e7-ae40-0638e6aa2792\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1451, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Measurement of serum PD biomarkers to assess or predict the response to GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 74, \\\"end_idx\\\": 83, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"945138d4-59df-4738-92be-bd5e1267babc\\\", \\\"childbox\\\": \\\"8c5bc5f2-fad3-4a7b-a51e-31818fcfadcb\\\", \\\"subtext\\\": \\\"f67faa1f-5e10-44be-a97c-8848d4588c15\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1452, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The biomarkers may include but are not limited to CCL22, soluble interleukin (IL)2R, and IL6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"945138d4-59df-4738-92be-bd5e1267babc\\\", \\\"childbox\\\": \\\"1c0647c3-27b8-481c-8506-383228638bec\\\", \\\"subtext\\\": \\\"f67faa1f-5e10-44be-a97c-8848d4588c15\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1453, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Assessment of serum biomarkers of ECM degradation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"577dd8d1-3abf-4bda-84e2-b898c578f417\\\", \\\"childbox\\\": \\\"137e7d55-626f-4b55-a1cf-f34214404843\\\", \\\"subtext\\\": \\\"8ae21972-cb54-477f-b13b-765e7a74b65b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1454, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The biomarkers may include but are not limited to C1M, C3M, and P4NP7S.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"577dd8d1-3abf-4bda-84e2-b898c578f417\\\", \\\"childbox\\\": \\\"129272cf-c2e5-4a7e-b5b0-f5ab6637560d\\\", \\\"subtext\\\": \\\"8ae21972-cb54-477f-b13b-765e7a74b65b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Pharmacodynamic (PD) Biomarkers\\\", \\\"8.8.1.\\\", \\\"3\\\", 1455, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.8.2. RNA Transcriptome Research\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a443f2b8-b0e5-4d8a-b507-03e0daf31e5c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Transcriptome Research\\\", \\\"8.8.2.\\\", \\\"3\\\", 1456, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A blood sample of approximately 2.5 mL will be collected to measure whole blood RNA markers of response to GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 107, \\\"end_idx\\\": 116, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"2b2b6746-c502-46f8-b67d-3bcbeb81b6d9\\\", \\\"childbox\\\": \\\"73e1fa7f-9820-4558-b8b6-a9a56e31f136\\\", \\\"subtext\\\": \\\"aff572df-4f63-4da8-9c14-484f9fe108aa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Transcriptome Research\\\", \\\"8.8.2.\\\", \\\"3\\\", 1457, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Transcriptome studies may be conducted using microarray, and/or alternative equivalent technologies, including RNA sequencing, which facilitates the simultaneous measurement of the relative abundances of thousands of ribonucleic acid (RNA) species resulting in a transcriptome profile for each blood sample.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"08c55847-ec8c-4c94-a71d-240125a42c5f\\\", \\\"childbox\\\": \\\"41126432-85ed-4af2-b7ae-ea0ab5e21d5b\\\", \\\"subtext\\\": \\\"0c399d79-8577-416c-89ee-c21ab6e7647a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Transcriptome Research\\\", \\\"8.8.2.\\\", \\\"3\\\", 1458, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This will enable the evaluation of changes in transcriptome profiles that may correlate with biological response relating to RA and medically related conditions or the action of GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 178, \\\"end_idx\\\": 187, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"08c55847-ec8c-4c94-a71d-240125a42c5f\\\", \\\"childbox\\\": \\\"eb8556e8-b3e0-4e5b-a7ad-13064bf05788\\\", \\\"subtext\\\": \\\"6b4efa14-eaac-4d90-8668-8c452bb72022\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Transcriptome Research\\\", \\\"8.8.2.\\\", \\\"3\\\", 1459, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The same samples may also be used to confirm findings by application of alternative technologies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"85cfba18-2be3-4588-98ed-c9ffeb9d84bc\\\", \\\"childbox\\\": \\\"78dfa62a-19a6-415a-9967-51c803bf0a26\\\", \\\"subtext\\\": \\\"68e95eea-2c17-4c96-9fc5-1ca5eae4885f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Transcriptome Research\\\", \\\"8.8.2.\\\", \\\"3\\\", 1460, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.8.3. RNA Expression Research of a Subset of RNA Species\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"edd23750-f155-4162-9b0f-c7162c8dbdbd\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Expression Research of a Subset of RNA Species\\\", \\\"8.8.3.\\\", \\\"3\\\", 1461, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"RNA expression studies may be conducted using quantitative or semi-quantitative real time polymerase chain reaction (qPCR), and/or alternative equivalent technologies, which can facilitate the measurement of the relative abundances of RNA species resulting in a RNA expression profile for each blood sample (as collected in Section 8.8.2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d26e011d-e68e-4a7e-abae-397933b7cb86\\\", \\\"childbox\\\": \\\"6ab07041-f504-45dc-8d1f-22de96c8f7a4\\\", \\\"subtext\\\": \\\"3645b694-f827-4bbb-bd0e-6401f3493f40\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Expression Research of a Subset of RNA Species\\\", \\\"8.8.3.\\\", \\\"3\\\", 1462, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The RNAs assayed may be those involved with the pathogenesis of RA; the absorption, distribution, metabolism, or excretion of GSK3196165; or in the participant\\\\u2019s response to GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 126, \\\"end_idx\\\": 135, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 174, \\\"end_idx\\\": 183, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"d26e011d-e68e-4a7e-abae-397933b7cb86\\\", \\\"childbox\\\": \\\"f02c6b77-f151-4230-977c-f6378fa14a2d\\\", \\\"subtext\\\": \\\"3f51817e-9df0-4257-aa90-d96975f3d88f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Expression Research of a Subset of RNA Species\\\", \\\"8.8.3.\\\", \\\"3\\\", 1463, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, continuing research may identify other proteins or regulatory RNAs that may be involved in the response to GSK3196165 or the pathogenesis of RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 120, \\\"end_idx\\\": 129, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"d26e011d-e68e-4a7e-abae-397933b7cb86\\\", \\\"childbox\\\": \\\"50acdcdb-a66f-4e45-b9ce-51fb3d0ee1d6\\\", \\\"subtext\\\": \\\"e8f91bc4-6d8e-49a3-b199-2c7733d7d146\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Expression Research of a Subset of RNA Species\\\", \\\"8.8.3.\\\", \\\"3\\\", 1464, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The RNAs that code for these proteins and/or regulatory RNAs may also be studied.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d26e011d-e68e-4a7e-abae-397933b7cb86\\\", \\\"childbox\\\": \\\"2247c1c5-1a5c-42dd-b056-b4c2ca285147\\\", \\\"subtext\\\": \\\"14868bf4-96d3-48f5-8c77-5a0315d85524\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Expression Research of a Subset of RNA Species\\\", \\\"8.8.3.\\\", \\\"3\\\", 1465, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This will enable the evaluation of changes in RNA expression profiles that may correlate with biological response relating to RA and medically related conditions or the action of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d26e011d-e68e-4a7e-abae-397933b7cb86\\\", \\\"childbox\\\": \\\"aa22ede0-fb4e-45f5-895e-c44816680e37\\\", \\\"subtext\\\": \\\"14868bf4-96d3-48f5-8c77-5a0315d85524\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Expression Research of a Subset of RNA Species\\\", \\\"8.8.3.\\\", \\\"3\\\", 1466, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"0faa71dd-8a37-40ec-8b6d-5922b45fa761\\\", \\\"childbox\\\": \\\"83fbd91b-be87-4d8a-8162-7bb67520d1ae\\\", \\\"subtext\\\": \\\"dc3ccaaf-d83a-44b8-abac-63f88d1ec49b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"RNA Expression Research of a Subset of RNA Species\\\", \\\"8.8.3.\\\", \\\"3\\\", 1467, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"header\\\", \\\"8.9. Immunogenicity Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a3ff962-710d-4fc1-9662-609310713919\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1468, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"Whole blood samples of approximately 6 mL will be collected from all participants and divided into suitable portions for immunogenicity assessments of anti-drug antibody (ADA) development.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b22fd9ba-b7bb-4502-9d52-c440250fa34a\\\", \\\"childbox\\\": \\\"c80e88ca-a9e3-46bf-992b-384cc2e3274b\\\", \\\"subtext\\\": \\\"a4359d09-e91a-47c5-9210-647852686238\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1469, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"Antibodies to GSK3196165 will be evaluated in serum samples collected from all participants according to the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 14, \\\"end_idx\\\": 23, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b22fd9ba-b7bb-4502-9d52-c440250fa34a\\\", \\\"childbox\\\": \\\"63c85af0-2341-43e8-9124-c9603ce7361c\\\", \\\"subtext\\\": \\\"9226a24a-d4cc-4bb7-8dd8-382a85c8bf08\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1470, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"Serum samples should also be collected at the final visit from participants who discontinued study intervention or are withdrawn from the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b22fd9ba-b7bb-4502-9d52-c440250fa34a\\\", \\\"childbox\\\": \\\"902f72ab-ee57-4cf6-a11f-c4edbe7dc4f3\\\", \\\"subtext\\\": \\\"a2e3ac19-952c-4fa0-aebc-ad12f8dacd8b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1471, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"In addition to scheduled immunogenicity assessments, \\\\u201cevent-driven\\\\u201d testing will be performed in the context of serious hypersensitivity reactions or AEs deemed to be clinically significant in the opinion of the investigator resulting in withdrawal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b22fd9ba-b7bb-4502-9d52-c440250fa34a\\\", \\\"childbox\\\": \\\"dc0d8337-5a6d-4e92-a84f-44a44a07137d\\\", \\\"subtext\\\": \\\"044edbf3-830f-43a5-a6fc-6af7d3696a8b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1472, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"Serum samples will be screened for antibodies binding to GSK3196165 and the titer of confirmed positive samples will be reported.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 57, \\\"end_idx\\\": 66, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ad10cace-b7a3-4965-a55e-6bc943210876\\\", \\\"childbox\\\": \\\"97b06821-0b45-4644-9383-d239a264aec7\\\", \\\"subtext\\\": \\\"a8ba2a55-eb04-410b-a144-57e8dda7f155\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1473, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"Other analyses may be performed to verify the stability of antibodies to GSK3196165 and/or further characterise the immunogenicity of GSK3196165.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 73, \\\"end_idx\\\": 82, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 134, \\\"end_idx\\\": 143, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ad10cace-b7a3-4965-a55e-6bc943210876\\\", \\\"childbox\\\": \\\"f289ac4b-b9b6-437c-8cf1-e1e256620bcc\\\", \\\"subtext\\\": \\\"a8ba2a55-eb04-410b-a144-57e8dda7f155\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1474, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"The serum sample collected at Day 1 will also be analysed for anti-GMCSF auto-antibodies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ad10cace-b7a3-4965-a55e-6bc943210876\\\", \\\"childbox\\\": \\\"c6e0dc78-f4ac-48b2-85d9-e052badcb3b4\\\", \\\"subtext\\\": \\\"82ac9776-0590-48c9-9b9c-8c857751562d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1475, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"The detection and characterisation of antibodies to GSK3196165 will be performed using validated assay methods by or under the supervision of the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 52, \\\"end_idx\\\": 61, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"7ff5ca90-33a1-4d4c-b01e-44c41191e516\\\", \\\"childbox\\\": \\\"0bc19b51-7c37-4a95-9670-8044c6b19fb2\\\", \\\"subtext\\\": \\\"0c2271b8-386a-4d59-96e4-68f09d8c6d94\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1476, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"Antibodies may be further characterised and/or evaluated for their ability to neutralise the activity of the study intervention(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7ff5ca90-33a1-4d4c-b01e-44c41191e516\\\", \\\"childbox\\\": \\\"36fd4101-5ec1-4ee4-a5f8-2c1ba963a1f9\\\", \\\"subtext\\\": \\\"8ffab90e-62ab-4f31-b2f5-96d1bd3349e7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1477, \\\"\\\"], [\\\"2\\\", \\\"Immunogenicity Assessments\\\", \\\"text\\\", \\\"Samples may be stored for a maximum of 15 years (or according to local regulations) following the last participant\\\\u2019s last visit for the study at a facility selected by the sponsor to enable further analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7ff5ca90-33a1-4d4c-b01e-44c41191e516\\\", \\\"childbox\\\": \\\"40dfdaa0-efcd-421b-a569-5cd9cc2adc58\\\", \\\"subtext\\\": \\\"8ffab90e-62ab-4f31-b2f5-96d1bd3349e7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Immunogenicity Assessments\\\", \\\"8.9.\\\", \\\"2\\\", 1478, \\\"\\\"], [\\\"2\\\", \\\"[Health Economics OR Medical Resource Utilization and Health Economics]\\\", \\\"header\\\", \\\"8.10. Medical Resource Utilisation and Health Economics\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7299ad14-14ee-474b-a4d0-86e72d7c6148\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Medical Resource Utilisation and Health Economics\\\", \\\"8.10.\\\", \\\"2\\\", 1479, \\\"\\\"], [\\\"2\\\", \\\"[Health Economics OR Medical Resource Utilization and Health Economics]\\\", \\\"text\\\", \\\"Medical Resource Utilisation and Health Economics parameters are not evaluated in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"09eff58f-b4e3-41aa-8abf-3dec6e792991\\\", \\\"childbox\\\": \\\"a08560b2-2795-4879-a535-f43b4e6673da\\\", \\\"subtext\\\": \\\"bae07e60-9cc2-4aad-8fda-9c861ff36557\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Assessments and Procedures\\\", \\\"Medical Resource Utilisation and Health Economics\\\", \\\"8.10.\\\", \\\"2\\\", 1480, \\\"\\\"], [\\\"1\\\", \\\"Statistical Considerations\\\", \\\"header\\\", \\\"9. STATISTICAL CONSIDERATIONS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d6ff7641-0775-4c05-941c-605ff7cbc5dc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"STATISTICAL CONSIDERATIONS\\\", \\\"9.\\\", \\\"1\\\", 1481, \\\"\\\"], [\\\"2\\\", \\\"Statistical Hypotheses\\\", \\\"header\\\", \\\"9.1. Statistical Hypotheses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"320c3006-286f-4be4-9a06-510ec2a68a19\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Hypotheses\\\", \\\"9.1.\\\", \\\"2\\\", 1482, \\\"\\\"], [\\\"2\\\", \\\"Statistical Hypotheses\\\", \\\"text\\\", \\\"The primary objective of the study is to determine whether GSK3196165 is superior to placebo in the treatment of participants with moderately to severely active RA despite treatment with biological DMARDs and/or Janus Kinase inhibitors (i.e.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 59, \\\"end_idx\\\": 68, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"45c01000-6824-46ed-b8b8-f72cdb6fd2ab\\\", \\\"childbox\\\": \\\"0c779d43-8f0a-4a03-9ad5-3c39b62e946e\\\", \\\"subtext\\\": \\\"a075e8e4-0bb2-4aac-974a-6de7e9159552\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Hypotheses\\\", \\\"9.1.\\\", \\\"2\\\", 1483, \\\"\\\"], [\\\"2\\\", \\\"Statistical Hypotheses\\\", \\\"text\\\", \\\"bDMARD-IR and/or JAK-IR), as assessed by the proportion of participants achieving ACR20 at Week 12.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"45c01000-6824-46ed-b8b8-f72cdb6fd2ab\\\", \\\"childbox\\\": \\\"76d409b0-fe04-44af-bb85-9cd51556e7f0\\\", \\\"subtext\\\": \\\"a075e8e4-0bb2-4aac-974a-6de7e9159552\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Hypotheses\\\", \\\"9.1.\\\", \\\"2\\\", 1484, \\\"\\\"], [\\\"2\\\", \\\"Statistical Hypotheses\\\", \\\"text\\\", \\\"The study will test the null hypothesis that there is no difference between either dose of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3893d95c-25ce-41b1-b7e1-0c52ad0190fd\\\", \\\"childbox\\\": \\\"313f0e2e-8d32-464d-9ce3-175a74fe603e\\\", \\\"subtext\\\": \\\"d57fc709-263e-4f6b-af1a-4f445b79d140\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Hypotheses\\\", \\\"9.1.\\\", \\\"2\\\", 1485, \\\"\\\"], [\\\"2\\\", \\\"Statistical Hypotheses\\\", \\\"text\\\", \\\"GSK3196165 and placebo in the proportion of participants achieving ACR20 response at Week 12 versus the alternative hypothesis that at least one of the GSK3196165 dose groups differs from placebo in the proportion of participants with ACR20 response at Week 12.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 9, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 152, \\\"end_idx\\\": 161, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"eeff8228-1a91-4473-9677-2fb2a807c104\\\", \\\"childbox\\\": \\\"a234a75e-8eb5-4cfd-8ca4-4d4a6b6b7a9b\\\", \\\"subtext\\\": \\\"9f1c726c-7130-4f39-93a7-65acf52d81d5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Hypotheses\\\", \\\"9.1.\\\", \\\"2\\\", 1486, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"header\\\", \\\"9.2. Sample Size Determination\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dc08d28f-50df-4abd-aa72-459a8bdc1d60\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1487, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"Approximately 1050-1200 participants will be screened to achieve between 525 and 600 randomly assigned to study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"32c78f84-a408-4b39-b590-b1063159d2e5\\\", \\\"childbox\\\": \\\"63c39acc-5072-428e-b433-a1caf6549ee9\\\", \\\"subtext\\\": \\\"e79eaf56-ad46-48da-9744-eddba0c1ea4f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1488, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"Approximately 525 evaluable participants are expected to be included in the primary analysis, of whom approximately 473 are expected to complete the week 12 visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"32c78f84-a408-4b39-b590-b1063159d2e5\\\", \\\"childbox\\\": \\\"72c98d7e-9278-4f3a-abf1-6df6ea1f2448\\\", \\\"subtext\\\": \\\"cddc5848-7610-46bf-bd3f-9887c1141101\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1489, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"The maximum of 600 participants may be recruited if necessary to ensure sufficient numbers in key Asian country subgroups.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"32c78f84-a408-4b39-b590-b1063159d2e5\\\", \\\"childbox\\\": \\\"914d2895-42b9-4647-a588-c4d8bbe6ce74\\\", \\\"subtext\\\": \\\"cddc5848-7610-46bf-bd3f-9887c1141101\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1490, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"For the purpose of analyses up to week 12, the placebo-sequence groups will be pooled into a single pooled placebo arm.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1a0db9b-343a-4283-93d9-163f9875a524\\\", \\\"childbox\\\": \\\"e9f4b2a0-5f0a-4623-bd46-5bae01ef34e4\\\", \\\"subtext\\\": \\\"de36ab2a-7c2e-4e0a-8b80-df6d2fd7a120\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1491, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"The minimum sample size of 525 will provide:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f91cb0fd-ebda-4f07-a448-85033e2c18e5\\\", \\\"childbox\\\": \\\"4d0f52f7-874a-4d82-bfb3-15fb37e4367f\\\", \\\"subtext\\\": \\\"e4eba1b2-1f86-4ba0-970b-0f2317295e23\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1492, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"\\\\u2022 96% power to detect a 25% difference between GSK3196165 and the pooled placebo group in ACR20 response rate (52% vs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 47, \\\"end_idx\\\": 56, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ed84277e-5af3-49bc-8343-4f5847a3806e\\\", \\\"childbox\\\": \\\"032473c0-d565-4187-b79f-60d179134a19\\\", \\\"subtext\\\": \\\"8351ecb6-6cd1-4836-83c0-5e935e097afc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1493, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"27%) at Week 12 based on a 2sided significance level of 0.05, using a pooled Z-test.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ed84277e-5af3-49bc-8343-4f5847a3806e\\\", \\\"childbox\\\": \\\"4f90da45-02da-455e-bac8-f775fb0884b7\\\", \\\"subtext\\\": \\\"8351ecb6-6cd1-4836-83c0-5e935e097afc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1494, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"The Least Significant Difference this sample size will detect is 13.3%.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ed84277e-5af3-49bc-8343-4f5847a3806e\\\", \\\"childbox\\\": \\\"ec446c38-5ba9-48a6-89f9-6489904ae2eb\\\", \\\"subtext\\\": \\\"8351ecb6-6cd1-4836-83c0-5e935e097afc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1495, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"\\\\u2022 In addition, the above sample size will detect a Least Significant Difference of 3.5 against sarilumab in the CDAI score change from baseline at Week 12, based on a 2-sided significance level of 0.05, using a Z-test assuming equal variance of 15.6 in each group.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 95, \\\"end_idx\\\": 103, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"cf932c47-cde3-45aa-86e7-b9a67bc55295\\\", \\\"childbox\\\": \\\"bbd6673a-39de-42ba-bde6-bf89bffcf24a\\\", \\\"subtext\\\": \\\"e44f5ea4-1e3d-415e-8c80-da0584ffba82\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1496, \\\"\\\"], [\\\"2\\\", \\\"Sample Size Determination\\\", \\\"text\\\", \\\"The above sample size and power estimates were obtained from PASS version 12.0.2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b3f38145-ea7e-428e-9a9f-0c9f77600bd2\\\", \\\"childbox\\\": \\\"742e1b3c-1d46-4787-9615-cdd41cdef806\\\", \\\"subtext\\\": \\\"940ed078-7ccf-4799-a327-cd41015463f9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Determination\\\", \\\"9.2.\\\", \\\"2\\\", 1497, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.1. Sample Size Sensitivity\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"509a5e48-85b9-4c7d-b7dd-7933365b8314\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Sensitivity\\\", \\\"9.2.1.\\\", \\\"3\\\", 1498, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The power of the primary analysis of the study will be affected by changes in the assumed response rate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d1978bef-f52d-4fe8-8d33-5638063a633f\\\", \\\"childbox\\\": \\\"7a143286-0f18-403e-b754-c1f549d3731c\\\", \\\"subtext\\\": \\\"44e33a85-5467-4d16-a4b3-88f6fa80928d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Sensitivity\\\", \\\"9.2.1.\\\", \\\"3\\\", 1499, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The effect on power under varying response rates on both placebo and GSK3196165 assuming a fixed sample size of 150 in the GSK3196165 arm and 75 in the placebo arm, based on a 2-sided significance level of 0.05, using a pooled Z-test are shown in Table 4:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 69, \\\"end_idx\\\": 78, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 123, \\\"end_idx\\\": 132, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"d1978bef-f52d-4fe8-8d33-5638063a633f\\\", \\\"childbox\\\": \\\"ec8b1744-8780-4787-a929-c679e32c93e1\\\", \\\"subtext\\\": \\\"890558f9-c276-4f6d-9854-a8dc33211c1d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Sample Size Sensitivity\\\", \\\"9.2.1.\\\", \\\"3\\\", 1500, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 4 Power for ACR20 Response at Week 12 under varying response rates on GSK3196165 and Placebo\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"entity\\\": [{\\\"start_idx\\\": 76, \\\"end_idx\\\": 85, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"224a2036-2630-40c8-847f-1e38fa4be135\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Power for ACR20 Response at Week 12 under varying response rates on GSK3196165 and Placebo\\\", \\\"Table 4\\\", \\\"4\\\", 1501, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6bf1b2ce-f839-4382-a90f-178e5ba5a6ee\\\", \\\"childbox\\\": \\\"da773158-15a2-4c7f-bd87-03b18b181ec2\\\", \\\"subtext\\\": \\\"ec129604-8d2e-4eb6-82a6-c029745c4f08\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Power for ACR20 Response at Week 12 under varying response rates on GSK3196165 and Placebo\\\", \\\"Table 4\\\", \\\"4\\\", 1502, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"25b889b5-638e-4321-888c-cd00a68d5e36\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Statistical Considerations\\\", \\\"Power for ACR20 Response at Week 12 under varying response rates on GSK3196165 and Placebo\\\", \\\"Table 4\\\", \\\"4\\\", 1503, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3. Populations for Analyses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52046daa-cb61-4291-ab55-96ed92cb8a20\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Populations for Analyses\\\", \\\"9.3.\\\", \\\"2\\\", 1504, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For purposes of analysis, the following populations are defined:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"29647417-d353-4b9e-bab4-3a669db537cf\\\", \\\"childbox\\\": \\\"36377fe6-8770-4678-ac84-50e65d48103d\\\", \\\"subtext\\\": \\\"62ab8eae-f933-44cd-b4e3-74d4287d760d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Populations for Analyses\\\", \\\"9.3.\\\", \\\"2\\\", 1505, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1624de31-05bb-4760-a9c2-8c40acaa99e8\\\", \\\"childbox\\\": \\\"e38d591f-bb23-45e6-87d1-804636571a1b\\\", \\\"subtext\\\": \\\"6f8911ef-96ce-45a0-a0f7-d3dd4fa64d03\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Populations for Analyses\\\", \\\"9.3.\\\", \\\"2\\\", 1506, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary analysis population will be the ITT population.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c15d9e6a-31bf-458a-ab02-b976f5702bb9\\\", \\\"childbox\\\": \\\"c11ed01b-cb68-48aa-8a45-4b1c41579a8b\\\", \\\"subtext\\\": \\\"9f13185e-4161-4f22-8503-275da7369537\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Populations for Analyses\\\", \\\"9.3.\\\", \\\"2\\\", 1507, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, the primary and major secondary analyses will be repeated using the PP population.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c15d9e6a-31bf-458a-ab02-b976f5702bb9\\\", \\\"childbox\\\": \\\"89a8a14f-596a-45f5-89a3-cd7fc91c000c\\\", \\\"subtext\\\": \\\"9f13185e-4161-4f22-8503-275da7369537\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Populations for Analyses\\\", \\\"9.3.\\\", \\\"2\\\", 1508, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Full details of all protocol violations that lead to exclusion from the PP population will be listed in the Reporting and Analysis plan (RAP).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c15d9e6a-31bf-458a-ab02-b976f5702bb9\\\", \\\"childbox\\\": \\\"d998c3d4-1588-42e5-b483-4a492aa8ffe5\\\", \\\"subtext\\\": \\\"9f13185e-4161-4f22-8503-275da7369537\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Populations for Analyses\\\", \\\"9.3.\\\", \\\"2\\\", 1509, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"header\\\", \\\"9.4. Statistical Analyses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22b6e7c9-cdc0-4cb0-8ff1-40b114f4dab4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1510, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"Full details of all analyses will be described in the RAP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b53f459d-d2be-4a32-a2ef-e5c65d64aaf9\\\", \\\"childbox\\\": \\\"dc0982ac-ab0e-42e9-923e-9308fbfd876c\\\", \\\"subtext\\\": \\\"4f172250-341e-4ca2-8ce9-af1e72221ab4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1511, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"The primary analysis will be performed when the minimum target sample size of 525 has been achieved.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"35b3d62a-f915-4afa-85e1-e47e8814bcd5\\\", \\\"childbox\\\": \\\"36772afd-3aa6-42c9-83a7-2e7dc79f8623\\\", \\\"subtext\\\": \\\"5289307f-0606-4166-9bfd-656c37bec000\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1512, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"All inferences will be drawn from the primary analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"35b3d62a-f915-4afa-85e1-e47e8814bcd5\\\", \\\"childbox\\\": \\\"0cf10ad8-91ae-475f-9c8a-caf73fd3938b\\\", \\\"subtext\\\": \\\"5289307f-0606-4166-9bfd-656c37bec000\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1513, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"The proposed sequence of primary and key secondary endpoints is:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3d0db753-9b70-47d9-ae2c-f349c7d2f78d\\\", \\\"childbox\\\": \\\"611867fa-6e7e-4c6c-b333-938f7c69af08\\\", \\\"subtext\\\": \\\"3f5cf792-4b75-43d0-8084-cc4483853991\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1514, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"1. ACR20 at week 12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"761211b8-4237-4914-b2ad-dbac74da8e8d\\\", \\\"childbox\\\": \\\"ccd1879d-c614-4ec3-9fe5-1d7b4878aa1d\\\", \\\"subtext\\\": \\\"96710a2a-215e-429f-ad78-5744b66cce79\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1515, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"2. HAQ-DI at week 12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c5ca2f93-b838-4c3a-ae52-24b7fa91a535\\\", \\\"childbox\\\": \\\"0095b2f9-31ea-4ecf-8e64-01f01fb6a7e1\\\", \\\"subtext\\\": \\\"821c5ddb-ef12-4fc7-9123-c644867d6ae6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1516, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"3. CDAI total score at week 12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"33467136-c2d6-4c2e-93f9-2e983c272480\\\", \\\"childbox\\\": \\\"6722e1ce-f8e2-4e00-ba68-9364d962e989\\\", \\\"subtext\\\": \\\"81faf225-277d-4fcc-821d-a03e99957afa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1517, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"4. Pain VAS at week 12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"067dbc74-4f04-4c3b-8f85-b2264e8ddc58\\\", \\\"childbox\\\": \\\"cfcd04d5-ac5f-45c1-a656-1cf38fe3d8d8\\\", \\\"subtext\\\": \\\"c37c884b-a285-43e7-a63e-874ac1c16bcb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1518, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"In order to preserve the type I error, each endpoint will be assessed sequentially using a step-down approach where statistical significance can be claimed for the second endpoint only if the first endpoint in the sequence meets the requirements for significance.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c35e1474-942d-4ab1-aef4-3322c1ac41a0\\\", \\\"childbox\\\": \\\"0d37a074-9cc9-40d8-ba92-6daac766d3e9\\\", \\\"subtext\\\": \\\"4268084b-d485-4842-9642-550539acad78\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1519, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"Additionally, as there are two doses of GSK3196165 within each endpoint, each to be compared with placebo, a step-down procedure, where the high dose will be tested first, will be used within each endpoint, i.e.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 40, \\\"end_idx\\\": 49, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"043f6aee-f9fb-4a09-848e-eab52086544e\\\", \\\"childbox\\\": \\\"23c2fd4a-03c6-4b05-a6ca-c730b27588ea\\\", \\\"subtext\\\": \\\"edd170ee-3065-480e-a7e5-2118ce2bb9e9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1520, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"the high dose (150mg) at a given endpoint can achieve significance only if the high dose at the prior endpoint is significant; the low dose (90mg) at a given endpoint can achieve significance only if both the high dose at the same endpoint and the low dose at the prior endpoint are significant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"043f6aee-f9fb-4a09-848e-eab52086544e\\\", \\\"childbox\\\": \\\"814eb934-394c-4342-b4e6-983a72a77b58\\\", \\\"subtext\\\": \\\"2d03b641-1ad3-425f-af0d-b715d8653393\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1521, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"For each endpoint, and for each GSK3196165 dose group, the comparison will be conducted using a 2-sided significance level of 0.05.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 32, \\\"end_idx\\\": 41, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"043f6aee-f9fb-4a09-848e-eab52086544e\\\", \\\"childbox\\\": \\\"c0f40a76-b32c-4dc8-a09b-3925ab2eb297\\\", \\\"subtext\\\": \\\"fc10f827-804f-4412-ba0c-de248059915c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1522, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"The comparisons for ACR20 and HAQ-DI will be against placebo, after which the comparisons for CDAI and Pain VAS will be against sarilumab.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 128, \\\"end_idx\\\": 136, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f9a23e1f-f398-46ee-b6be-ba7119fd28dd\\\", \\\"childbox\\\": \\\"fe813065-0764-4916-a3a5-c01c5106085c\\\", \\\"subtext\\\": \\\"72268980-a8d8-4013-94c3-2d09804b5f72\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1523, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"The schematic is shown in Appendix 8.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9a23e1f-f398-46ee-b6be-ba7119fd28dd\\\", \\\"childbox\\\": \\\"28602d4e-c538-4f3f-891f-44baa9100e47\\\", \\\"subtext\\\": \\\"72268980-a8d8-4013-94c3-2d09804b5f72\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1524, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"This step-down approach strongly protects the Type I error rate at the 0.05 (2-sided) level across endpoints within each dose and across doses within each endpoint.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fd3e387a-3d9a-4dfc-a956-86f646c2156d\\\", \\\"childbox\\\": \\\"26894b6e-1ff5-404f-b4f0-3611715b445e\\\", \\\"subtext\\\": \\\"4d9e78c6-614f-43ef-9eb0-9c59eb74bed2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1525, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"However, there is weak control of the Type I error rate when the low dose at the first endpoint and the high dose at the second endpoint are tested simultaneously.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fd3e387a-3d9a-4dfc-a956-86f646c2156d\\\", \\\"childbox\\\": \\\"7653417b-fffb-4eec-a872-362fb00a4d7a\\\", \\\"subtext\\\": \\\"552c4341-0d3a-43fd-970d-532173ce7b57\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1526, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"Note this is only a risk in situations where the high dose has some effect at the first endpoint but not the second, and the low dose is not effective at the first endpoint.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fd3e387a-3d9a-4dfc-a956-86f646c2156d\\\", \\\"childbox\\\": \\\"bcc940bb-c706-4d5c-902d-858bcc27f76b\\\", \\\"subtext\\\": \\\"8c4c80e8-557a-4771-b625-73533a07eaaa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1527, \\\"\\\"], [\\\"2\\\", \\\"Statistical Analyses\\\", \\\"text\\\", \\\"This is a situation that is not expected since if the high dose is effective for a given endpoint, there is likely to be some effect (non-zero) at the low dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fd3e387a-3d9a-4dfc-a956-86f646c2156d\\\", \\\"childbox\\\": \\\"a435c9a4-05c2-49a0-b439-18c499c797bb\\\", \\\"subtext\\\": \\\"8c4c80e8-557a-4771-b625-73533a07eaaa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Statistical Analyses\\\", \\\"9.4.\\\", \\\"2\\\", 1528, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.4.1. Efficacy Analyses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7e969e30-1d45-46b4-a125-45b9af816ef2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Efficacy Analyses\\\", \\\"9.4.1.\\\", \\\"3\\\", 1529, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2128a547-5011-4ddf-934b-382bca102501\\\", \\\"childbox\\\": \\\"d433144b-210d-4d05-9c43-6f53c0f382a9\\\", \\\"subtext\\\": \\\"55ca2254-5a07-4510-8a8d-bb648c386594\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Efficacy Analyses\\\", \\\"9.4.1.\\\", \\\"3\\\", 1530, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e8488052-61b0-494e-9b45-31757a3c9882\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Statistical Considerations\\\", \\\"Efficacy Analyses\\\", \\\"9.4.1.\\\", \\\"3\\\", 1531, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.4.1.1. Estimand strategy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0c281e8c-6a90-4f52-b1dc-ca9a7214dc28\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1532, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The main intercurrent (post-randomisation) event anticipated to impact on the interpretation of the treatment effect for the primary objective is withdrawal from study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9fc8f78e-9cb1-4268-87b0-6e2aa2404fe4\\\", \\\"childbox\\\": \\\"9e060707-db92-485a-965d-7faa77f5ccf4\\\", \\\"subtext\\\": \\\"4892444f-3a60-463b-9b2f-565c68774865\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1533, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The estimand for the primary comparison will be defined using:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"feb3932d-b082-48a5-a910-40e4ff7e2e22\\\", \\\"childbox\\\": \\\"2373ecb3-3c40-403a-b340-b7fd71bcb4ca\\\", \\\"subtext\\\": \\\"42839b62-eb10-487a-8aa0-b3fe90cbc695\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1534, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Population: defined through the inclusion/exclusion criteria\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"733a71c7-bcd7-497b-ba75-790994e1ae75\\\", \\\"childbox\\\": \\\"d326ee78-8c24-445b-b991-494bd9d2bf90\\\", \\\"subtext\\\": \\\"b4bc8fd3-01e0-4eff-b029-131a524d5ee8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1535, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. Variable: Proportion of participants at week 12 with ACR20 response\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b83cd0b4-3eba-4010-9f32-d365a3adef73\\\", \\\"childbox\\\": \\\"b7ed3317-dbf1-4fb1-bb42-0c79e8f75251\\\", \\\"subtext\\\": \\\"de27ca18-b145-4b24-84f1-b45ea3f16ee4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1536, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. Intercurrent Event: the participant withdrew from intervention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22689555-1e27-4910-8d7b-4f8eee8f0bab\\\", \\\"childbox\\\": \\\"044ea80c-6da7-4548-81ff-3053255475a5\\\", \\\"subtext\\\": \\\"bf7c2cad-dd9f-4b5b-8033-c0d4aa526e6a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1537, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. Population Level Summary: Comparisons of proportions between the active groups and placebo\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1bbfd989-12e5-4dc4-960e-d7c8d89f03cb\\\", \\\"childbox\\\": \\\"6f7e78f0-a46d-497b-a8d3-02f8883ae6f1\\\", \\\"subtext\\\": \\\"c77b4279-ff6a-4bc2-ab12-02de38bf4971\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1538, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary estimand used will be the treatment policy estimand.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af45c75b-f39c-4faa-a266-b50ae8d3894d\\\", \\\"childbox\\\": \\\"452f9769-1ea6-4ff2-af73-0696a4634b6e\\\", \\\"subtext\\\": \\\"e8cc51a0-4d4c-4301-b8ff-851353fd75e6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1539, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This follows the principle that participants should be followed up, assessed and analysed irrespective of compliance to planned intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af45c75b-f39c-4faa-a266-b50ae8d3894d\\\", \\\"childbox\\\": \\\"d59d2d1b-640d-4634-ba97-1c31b5b742b1\\\", \\\"subtext\\\": \\\"e8cc51a0-4d4c-4301-b8ff-851353fd75e6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1540, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This strategy answers the question of what the effect is of assigning participants to an intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af45c75b-f39c-4faa-a266-b50ae8d3894d\\\", \\\"childbox\\\": \\\"1538686c-6509-4ca4-b380-f106d01cb505\\\", \\\"subtext\\\": \\\"e8cc51a0-4d4c-4301-b8ff-851353fd75e6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1541, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, if a participant withdraws from study intervention but efficacy data continues to be collected, their data will be analysed as if they were still on the original randomised intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af45c75b-f39c-4faa-a266-b50ae8d3894d\\\", \\\"childbox\\\": \\\"f2ec7109-548a-4144-81ba-3b9f0383bb6f\\\", \\\"subtext\\\": \\\"0d297dc4-b4c4-4cec-a700-1ed1ea8472e5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1542, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Further details will be provided in the RAP on any sensitivity estimators and supplementary estimands used to assess the primary objective and any estimands used to assess the secondary objectives.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f3f98a21-2232-4677-b59d-515bcb9920a0\\\", \\\"childbox\\\": \\\"41b5dd3b-951f-4f84-9ce1-1104189e38f7\\\", \\\"subtext\\\": \\\"9ce12d8c-94b1-48d8-bfb8-5c0b1590c75e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Estimand strategy\\\", \\\"9.4.1.1.\\\", \\\"4\\\", 1543, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.4.2. Safety Analyses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b8d2ca13-716f-4ffa-b84d-bac26de3ff99\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Safety Analyses\\\", \\\"9.4.2.\\\", \\\"3\\\", 1544, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All safety analyses will be performed on the Safety Population.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a012d83c-4551-46ae-b9c8-2fde0dfc5a7b\\\", \\\"childbox\\\": \\\"d8eaacb1-e76c-4572-8110-45ed132773a5\\\", \\\"subtext\\\": \\\"4382a36d-1c46-4c38-b7d8-99cfdaf647e3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Safety Analyses\\\", \\\"9.4.2.\\\", \\\"3\\\", 1545, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0827672f-03ff-4df4-9d5b-96e0e631422e\\\", \\\"childbox\\\": \\\"a6dc855c-e871-4fe5-a8e7-0ef55b9f56e7\\\", \\\"subtext\\\": \\\"ea7bab30-8aeb-4030-9d26-29a766d78803\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Safety Analyses\\\", \\\"9.4.2.\\\", \\\"3\\\", 1546, \\\"\\\"], [\\\"3\\\", \\\"Other Analysis\\\", \\\"header\\\", \\\"9.4.3. Other Analyses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"32155c09-d67e-4d7e-8cdb-9e7a4b936371\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Other Analyses\\\", \\\"9.4.3.\\\", \\\"3\\\", 1547, \\\"\\\"], [\\\"3\\\", \\\"Other Analysis\\\", \\\"text\\\", \\\"PK, pharmacodynamic, and biomarker exploratory analyses will be described in the reporting and analysis plan, as well as PROs (Patient Reported Outcomes).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d0b70ee3-84c8-4eb2-9b39-80b17b3a43ae\\\", \\\"childbox\\\": \\\"8b198a5b-4b40-43e0-9fd6-35f08fd5b4f2\\\", \\\"subtext\\\": \\\"026cbace-f2a8-453c-8473-1980668d303b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Other Analyses\\\", \\\"9.4.3.\\\", \\\"3\\\", 1548, \\\"\\\"], [\\\"3\\\", \\\"Other Analysis\\\", \\\"text\\\", \\\"The population PK analysis and pharmacodynamic analyses will be presented separately from the main clinical study report (CSR).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d0b70ee3-84c8-4eb2-9b39-80b17b3a43ae\\\", \\\"childbox\\\": \\\"07a94621-9eae-41be-adff-c6e8dbbec470\\\", \\\"subtext\\\": \\\"026cbace-f2a8-453c-8473-1980668d303b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Other Analyses\\\", \\\"9.4.3.\\\", \\\"3\\\", 1549, \\\"\\\"], [\\\"2\\\", \\\"Interim Analysis\\\", \\\"header\\\", \\\"9.5. Interim Analyses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ac0ed65b-a2fa-4aef-8348-48fb429a6f52\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Interim Analyses\\\", \\\"9.5.\\\", \\\"2\\\", 1550, \\\"\\\"], [\\\"2\\\", \\\"Interim Analysis\\\", \\\"text\\\", \\\"If at the time of the primary analysis a sufficient number of participants that are required for the key Asian country subgroups is not reached, then recruitment in these countries may continue.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2eb2a358-d125-4384-9e08-a67ec640c5ad\\\", \\\"childbox\\\": \\\"f01c1b23-6f29-4e0a-aefb-c603795b0052\\\", \\\"subtext\\\": \\\"710cb947-edb5-4387-a2ba-431813ce09d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Interim Analyses\\\", \\\"9.5.\\\", \\\"2\\\", 1551, \\\"\\\"], [\\\"2\\\", \\\"Interim Analysis\\\", \\\"text\\\", \\\"If this is a requirement, then at the time of the primary analysis the separate randomisation cohort for the key Asian country subgroups will be handled as an interim analysis which will allow for participants from this cohort to be included in the primary analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2eb2a358-d125-4384-9e08-a67ec640c5ad\\\", \\\"childbox\\\": \\\"297b717e-9170-4355-9db8-5bd50e1dad0d\\\", \\\"subtext\\\": \\\"710cb947-edb5-4387-a2ba-431813ce09d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Interim Analyses\\\", \\\"9.5.\\\", \\\"2\\\", 1552, \\\"\\\"], [\\\"2\\\", \\\"Interim Analysis\\\", \\\"text\\\", \\\"Any data collected post primary analysis will be pooled with all other data from the key country subgroups and will be analysed separately.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2eb2a358-d125-4384-9e08-a67ec640c5ad\\\", \\\"childbox\\\": \\\"7607deff-4562-49e0-bcc2-d95415ebc52c\\\", \\\"subtext\\\": \\\"b4aca1a8-7474-4890-b35d-9ea66bdf48cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Interim Analyses\\\", \\\"9.5.\\\", \\\"2\\\", 1553, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.5.1. Data Monitoring Committee (DMC)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"885d0841-404c-4667-ad18-15e041aeb6f4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Data Monitoring Committee (DMC)\\\", \\\"9.5.1.\\\", \\\"3\\\", 1554, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An IDMC will be utilised in this study to ensure ongoing objective medical and/or statistical review of safety data in order to protect the ethical and safety interests of participants and to protect the scientific validity of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"287b7226-c609-4590-b990-01b7a5f2f3cf\\\", \\\"childbox\\\": \\\"dc6e159c-1e83-45ea-ae5b-ce8e2cf888fd\\\", \\\"subtext\\\": \\\"83a84457-f446-47aa-a9c0-75c376b8703c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Data Monitoring Committee (DMC)\\\", \\\"9.5.1.\\\", \\\"3\\\", 1555, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"See Section 10.1.5 for further details.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"287b7226-c609-4590-b990-01b7a5f2f3cf\\\", \\\"childbox\\\": \\\"ef93b92a-f935-4e29-a240-a66a57066aa9\\\", \\\"subtext\\\": \\\"4ca5c284-5df0-44c5-926d-ef62ad8b6265\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Data Monitoring Committee (DMC)\\\", \\\"9.5.1.\\\", \\\"3\\\", 1556, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Full details of the data to be reviewed and membership of the committee will be available in the charter which will be available prior to the first participant\\\\u2019s visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9fe883ac-78aa-4e32-90eb-dd8ce8b99161\\\", \\\"childbox\\\": \\\"335db75d-ba13-4d7e-aa9f-da6daa639cbb\\\", \\\"subtext\\\": \\\"5fdea03e-9be4-4148-9d1b-18856f5374cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Statistical Considerations\\\", \\\"Data Monitoring Committee (DMC)\\\", \\\"9.5.1.\\\", \\\"3\\\", 1557, \\\"\\\"], [\\\"1\\\", \\\"Supporting Documentation and Operational Considerations\\\", \\\"header\\\", \\\"10. SUPPORTING DOCUMENTATION AND OPERATIONAL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"661c77be-7cc8-4162-98e3-ba5c280099b4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"SUPPORTING DOCUMENTATION AND OPERATIONAL\\\", \\\"10.\\\", \\\"1\\\", 1558, \\\"\\\"], [\\\"1\\\", \\\"Supporting Documentation and Operational Considerations\\\", \\\"header\\\", \\\"CONSIDERATIONS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 28, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0fa737aa-8d3a-43af-bed0-c01b85c0ea11\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 28, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"SUPPORTING DOCUMENTATION AND OPERATIONAL\\\", \\\"10.\\\", \\\"1\\\", 1559, \\\"\\\"], [\\\"2\\\", \\\"Appendix 1: Regulatory, Ethical, and Study Oversight Considerations\\\", \\\"header\\\", \\\"10.1. Appendix 1: Regulatory, Ethical, and Study Oversight\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2ca9d30a-cecf-4dda-ab73-0a79d3d109a8\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 1: Regulatory, Ethical, and Study Oversight\\\", \\\"10.1.\\\", \\\"2\\\", 1560, \\\"\\\"], [\\\"2\\\", \\\"Appendix 1: Regulatory, Ethical, and Study Oversight Considerations\\\", \\\"header\\\", \\\"Considerations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 26, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c647f7d3-8d4c-41b8-bf6c-b1259371d6b1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 26, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 1: Regulatory, Ethical, and Study Oversight\\\", \\\"10.1.\\\", \\\"2\\\", 1561, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"header\\\", \\\"10.1.1. Regulatory and Ethical Considerations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a380f095-4e40-41e9-9d49-f7fbc04984e7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1562, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 This study will be conducted in accordance with the protocol and with:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1e39b064-40ca-4721-a9f1-ecfb9f73ceac\\\", \\\"childbox\\\": \\\"eca5b14a-f543-49f2-98c0-6f6ddac52c8e\\\", \\\"subtext\\\": \\\"b94401ef-229a-4bf0-92ab-69081f64a46f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1563, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a2e70043-766f-4cef-8312-79919ab9b11b\\\", \\\"childbox\\\": \\\"9cabf5f8-eaef-4c90-94c2-995e3c940ca4\\\", \\\"subtext\\\": \\\"c7d6b96e-aa66-453f-9764-894c857b4c75\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1564, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"Organisations of Medical Sciences (CIOMS) International Ethical Guidelines\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"97b2eed8-a937-4805-8026-c490c26a8e63\\\", \\\"childbox\\\": \\\"65c36626-750c-4e42-953f-1e94b011fbfd\\\", \\\"subtext\\\": \\\"c9ff6d3a-06fe-42f1-982d-0a9894c23a99\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1565, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 Applicable ICH Good Clinical Practice (GCP) Guidelines\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"879ad0b9-d0ed-42dd-86d7-a354c91b0f91\\\", \\\"childbox\\\": \\\"ee35dc13-a399-4926-9ebd-3d562879d870\\\", \\\"subtext\\\": \\\"572d632d-bbdd-4540-94aa-e667c37e6ba0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1566, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 Applicable laws and regulations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a8de2956-4e32-40b5-b12a-66c5f4a3d80c\\\", \\\"childbox\\\": \\\"41ee6ee4-2598-4549-a29a-d4be7964b3a9\\\", \\\"subtext\\\": \\\"69e48300-732c-4af1-b506-f8e2fb2f85d3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1567, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and approved by the IRB/IEC before the study is initiated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"474815bb-2c0b-4728-8e38-ad64b82d3f11\\\", \\\"childbox\\\": \\\"bf6681f7-3de2-4992-872c-b561572420c1\\\", \\\"subtext\\\": \\\"961349f3-00ee-4a99-adbf-892ada7b4452\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1568, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 Any amendments to the protocol will require IEC/IRB approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"416f2598-c0b2-458b-bd55-ce2f98685679\\\", \\\"childbox\\\": \\\"43f13e26-d92e-4d92-ace2-bc07614fc43a\\\", \\\"subtext\\\": \\\"d8b2a96e-8501-4b7b-b67d-dd027b49b377\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1569, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 The investigator will be responsible for the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2ea97f9d-e095-4123-b131-90547fd66c0e\\\", \\\"childbox\\\": \\\"1b03d4fd-e899-436f-a888-5f1ddf3c93a6\\\", \\\"subtext\\\": \\\"e48e2e2f-7539-4045-9e43-e225839663d4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1570, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eda3e2a6-2bc6-47cf-8d1f-8b6d40c89496\\\", \\\"childbox\\\": \\\"3550a780-acd5-421b-a216-1ebac006d245\\\", \\\"subtext\\\": \\\"0dfd7e5b-b1b8-4bc4-a941-8d5c9381552a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1571, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 Notifying the IRB/IEC of SAE or other significant safety findings as required by IRB/IEC procedures\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fbea4abb-d7b1-46e1-b52b-855519853a4d\\\", \\\"childbox\\\": \\\"0a07833f-4ff8-4d06-ac61-ed1032671acf\\\", \\\"subtext\\\": \\\"15a4eff7-794c-4790-bc00-a75075fd4315\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1572, \\\"\\\"], [\\\"3\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"text\\\", \\\"\\\\u2022 Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 98, \\\"end_idx\\\": 100, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 12.0, \\\"text\\\": \\\"CFR\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"0dd3e329-4ead-4258-a14e-41d772db4ea5\\\", \\\"childbox\\\": \\\"a587d18c-734f-4497-bc80-a491e953cec2\\\", \\\"subtext\\\": \\\"1bd0d28c-52e5-40d7-8566-9205297f9b3b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Regulatory and Ethical Considerations\\\", \\\"10.1.1.\\\", \\\"3\\\", 1573, \\\"\\\"], [\\\"3\\\", \\\"Financial Disclosure\\\", \\\"header\\\", \\\"10.1.2. Financial Disclosure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"410eb431-e5c8-4d44-95a0-005561143099\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Financial Disclosure\\\", \\\"10.1.2.\\\", \\\"3\\\", 1574, \\\"\\\"], [\\\"3\\\", \\\"Financial Disclosure\\\", \\\"text\\\", \\\"Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fe468441-2ba2-43fb-b768-53c82f77e1f2\\\", \\\"childbox\\\": \\\"2621faa7-565c-42b2-9fdd-384c80af746a\\\", \\\"subtext\\\": \\\"6c645eba-0a04-4376-8ced-fe97604ca59b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Financial Disclosure\\\", \\\"10.1.2.\\\", \\\"3\\\", 1575, \\\"\\\"], [\\\"3\\\", \\\"Financial Disclosure\\\", \\\"text\\\", \\\"Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fe468441-2ba2-43fb-b768-53c82f77e1f2\\\", \\\"childbox\\\": \\\"88f62aba-5d01-4181-ad7d-6d8674270546\\\", \\\"subtext\\\": \\\"365bea27-44e1-4434-96a8-5895adff2517\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Financial Disclosure\\\", \\\"10.1.2.\\\", \\\"3\\\", 1576, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"header\\\", \\\"10.1.3. Informed Consent Process\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"439dc92f-5272-4437-b072-dc8ba50da194\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1577, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"\\\\u2022 The investigator or his/her representative will explain the nature of the study to the participant or his/her legally authorised representative and answer all questions regarding the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e5f92a39-e4f3-461c-b98e-2a968fe8588a\\\", \\\"childbox\\\": \\\"d72be411-b844-4abf-8701-671163b18268\\\", \\\"subtext\\\": \\\"6a30777c-0f01-48f3-bbb0-fa869fe8e7ef\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1578, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"\\\\u2022 Participants must be informed that their participation is voluntary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eaea5a0e-9371-40fe-b955-28c30fdb6bc2\\\", \\\"childbox\\\": \\\"e7095e16-8620-4745-a774-c1190db0a41c\\\", \\\"subtext\\\": \\\"76d8a7e3-9b26-4bd1-baf3-b0611cdf4abd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1579, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"Participants or their legally authorised representative will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 147, \\\"end_idx\\\": 149, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 12.0, \\\"text\\\": \\\"CFR\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"eaea5a0e-9371-40fe-b955-28c30fdb6bc2\\\", \\\"childbox\\\": \\\"456be8e0-5ee7-4829-b642-aed1961bd763\\\", \\\"subtext\\\": \\\"76d8a7e3-9b26-4bd1-baf3-b0611cdf4abd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1580, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"\\\\u2022 The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"391546d5-35a9-442c-b356-82c211d41a06\\\", \\\"childbox\\\": \\\"6a26da31-dca8-4631-bfb0-da37f6d07424\\\", \\\"subtext\\\": \\\"3aa89644-5174-4757-9eca-1d884cc7bf44\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1581, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"The authorised person obtaining the informed consent must also sign the ICF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"391546d5-35a9-442c-b356-82c211d41a06\\\", \\\"childbox\\\": \\\"6ae67777-ad5b-40a7-b331-2e0f929260f0\\\", \\\"subtext\\\": \\\"2a8f599c-98ac-4dc1-895b-f0ef0a05e791\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1582, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"\\\\u2022 Participants must be re-consented to the most current version of the ICF(s) during their participation in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0bbc09bd-b3c8-47d5-a912-0375b68e8fa7\\\", \\\"childbox\\\": \\\"a1624c45-3e3b-42d8-83c9-e8431b6d8f28\\\", \\\"subtext\\\": \\\"629e35b4-7b37-4f43-a3fd-b36f8fa959a9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1583, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"\\\\u2022 A copy of the ICF(s) must be provided to the participant or the participant\\\\u2019s legally authorised representative.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"88898882-80c0-4bd6-bb99-547845388d3c\\\", \\\"childbox\\\": \\\"462bee6f-93b2-4b9d-8bfb-8a2f55161c46\\\", \\\"subtext\\\": \\\"bcda7ba0-6c17-48e6-9df6-619d5a3de1f9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1584, \\\"\\\"], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"\\\\u2022 Participants who are rescreened are required to sign a new ICF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4a0d7508-5a45-40f3-af7f-d2a6e377506c\\\", \\\"childbox\\\": \\\"bcf8fc3f-f5c8-4f8a-bf85-b1af58fce2ee\\\", \\\"subtext\\\": \\\"c379d1e3-7033-414c-8ec7-f0590a938b47\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Informed Consent Process\\\", \\\"10.1.3.\\\", \\\"3\\\", 1585, \\\"\\\"], [\\\"3\\\", \\\"Data Protection\\\", \\\"header\\\", \\\"10.1.4. Data Protection\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d983c2f-5447-4ad7-8f5c-76c55a0ff7e4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Protection\\\", \\\"10.1.4.\\\", \\\"3\\\", 1586, \\\"\\\"], [\\\"3\\\", \\\"Data Protection\\\", \\\"text\\\", \\\"\\\\u2022 Participants will be assigned a unique identifier by the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7fdee590-ccaa-478f-9c10-d976af0638f3\\\", \\\"childbox\\\": \\\"8c7a7bc9-22c8-4a4f-8a5d-c8b9516262a5\\\", \\\"subtext\\\": \\\"49f89f1d-5cb5-4f60-93f9-c7a321bf5a1d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Protection\\\", \\\"10.1.4.\\\", \\\"3\\\", 1587, \\\"\\\"], [\\\"3\\\", \\\"Data Protection\\\", \\\"text\\\", \\\"Any participant records or datasets that are transferred to the sponsor will contain the identifier only; participant names or any information which would make the participant identifiable will not be transferred.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7fdee590-ccaa-478f-9c10-d976af0638f3\\\", \\\"childbox\\\": \\\"f7d4d536-398d-4264-80c3-2db0fe593a57\\\", \\\"subtext\\\": \\\"49f89f1d-5cb5-4f60-93f9-c7a321bf5a1d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Protection\\\", \\\"10.1.4.\\\", \\\"3\\\", 1588, \\\"\\\"], [\\\"3\\\", \\\"Data Protection\\\", \\\"text\\\", \\\"\\\\u2022 The participant must be informed that his/her personal study-related data will be used by the sponsor in accordance with local data protection law.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6a0f96d7-603b-4235-b6b4-66a190e278b4\\\", \\\"childbox\\\": \\\"1df19658-8c66-4e5f-91eb-21410d265e9e\\\", \\\"subtext\\\": \\\"1f748778-3cbf-4424-bcd2-06ed93e97687\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Protection\\\", \\\"10.1.4.\\\", \\\"3\\\", 1589, \\\"\\\"], [\\\"3\\\", \\\"Data Protection\\\", \\\"text\\\", \\\"The level of disclosure must also be explained to the participant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6a0f96d7-603b-4235-b6b4-66a190e278b4\\\", \\\"childbox\\\": \\\"3bb512f8-dd7b-44ca-a59a-d4fa8c3bd7c8\\\", \\\"subtext\\\": \\\"1f748778-3cbf-4424-bcd2-06ed93e97687\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Protection\\\", \\\"10.1.4.\\\", \\\"3\\\", 1590, \\\"\\\"], [\\\"3\\\", \\\"Data Protection\\\", \\\"text\\\", \\\"\\\\u2022 The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorised personnel appointed by the sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"18a5f9db-3987-4972-81a3-f4872f237e92\\\", \\\"childbox\\\": \\\"820fde08-091f-41ef-b857-804c06cb3ce5\\\", \\\"subtext\\\": \\\"984607aa-2bda-4679-a83b-db2c098f68a2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Protection\\\", \\\"10.1.4.\\\", \\\"3\\\", 1591, \\\"\\\"], [\\\"3\\\", \\\"Committees Structure\\\", \\\"header\\\", \\\"10.1.5. Committees Structure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d92d5330-3510-488b-8693-a0545f379925\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Committees Structure\\\", \\\"10.1.5.\\\", \\\"3\\\", 1592, \\\"\\\"], [\\\"3\\\", \\\"Committees Structure\\\", \\\"text\\\", \\\"An Independent Data Monitoring Committee (IDMC), a Major Adverse Cardiac Event (MACE) Adjudication Committee and a Pulmonary Adjudication Committee (PAC) will be utilised in this study, in addition to the routine sponsor review of blinded safety data that will occur approximately every 4 weeks during the period of study conduct.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"51194770-6c99-4a85-bd3f-c247ff3748dc\\\", \\\"childbox\\\": \\\"250cae20-b0ba-4fcc-adc1-1ac942f2f9b2\\\", \\\"subtext\\\": \\\"8dbc11a2-7dd6-47e4-bfa2-a79faa1fb4c6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Committees Structure\\\", \\\"10.1.5.\\\", \\\"3\\\", 1593, \\\"\\\"], [\\\"3\\\", \\\"Committees Structure\\\", \\\"text\\\", \\\"The overall responsibility of the IDMC is to protect the ethical and safety interests of participants recruited into this study while protecting as far as possible the scientific validity of the data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3cbdb074-279e-42c9-ad79-f267f1d0ba52\\\", \\\"childbox\\\": \\\"ef32dcdb-f109-4aa2-83c8-3a3e6aaff575\\\", \\\"subtext\\\": \\\"94ae490b-c5e1-4fdb-8482-37e4a0e5426b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Committees Structure\\\", \\\"10.1.5.\\\", \\\"3\\\", 1594, \\\"\\\"], [\\\"3\\\", \\\"Committees Structure\\\", \\\"text\\\", \\\"The IDMC and Adjudication Committees will include physicians with relevant clinical expertise and a statistician, none of whom is affiliated with the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3cbdb074-279e-42c9-ad79-f267f1d0ba52\\\", \\\"childbox\\\": \\\"23fc720a-7401-42b6-ac24-390e22ad3cc0\\\", \\\"subtext\\\": \\\"776356c6-65a0-4d90-8edb-0b2611ea012f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Committees Structure\\\", \\\"10.1.5.\\\", \\\"3\\\", 1595, \\\"\\\"], [\\\"3\\\", \\\"Committees Structure\\\", \\\"text\\\", \\\"The IDMC will adopt a staggered approach to reviewing unblinded data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3cbdb074-279e-42c9-ad79-f267f1d0ba52\\\", \\\"childbox\\\": \\\"0dcacb64-67df-4144-a271-43a42983d531\\\", \\\"subtext\\\": \\\"776356c6-65a0-4d90-8edb-0b2611ea012f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Committees Structure\\\", \\\"10.1.5.\\\", \\\"3\\\", 1596, \\\"\\\"], [\\\"3\\\", \\\"Committees Structure\\\", \\\"text\\\", \\\"The initial early review, frequency of further reviews and the safety data included, will be detailed in the IDMC charter.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3cbdb074-279e-42c9-ad79-f267f1d0ba52\\\", \\\"childbox\\\": \\\"a2d64f08-0935-43f7-b66f-18133a3820ce\\\", \\\"subtext\\\": \\\"f258bb37-d6af-4dc0-ad15-699376d5ce1c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Committees Structure\\\", \\\"10.1.5.\\\", \\\"3\\\", 1597, \\\"\\\"], [\\\"3\\\", \\\"Committees Structure\\\", \\\"text\\\", \\\"The MACE Adjudication Committee and PAC will function as detailed in the IDMC charter.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"03868308-0b03-4ca7-b914-ea2a8c0a2bf9\\\", \\\"childbox\\\": \\\"c9f7a0de-936e-4f8a-9621-3bd7f59b3331\\\", \\\"subtext\\\": \\\"66c6e657-fe7d-4d38-b3d1-bd1dcc4b4e05\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Committees Structure\\\", \\\"10.1.5.\\\", \\\"3\\\", 1598, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"header\\\", \\\"10.1.6. Publication Policy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c0ec00eb-3f7a-4757-b5da-52a466fd663c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1599, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"text\\\", \\\"\\\\u2022 The results of this study may be published or presented at scientific meetings.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"292d9696-6567-47c1-86d8-71999f00b7c4\\\", \\\"childbox\\\": \\\"11ffa576-8879-4393-87f7-cd115fa9d067\\\", \\\"subtext\\\": \\\"6b6d1dcc-2abb-4a29-b938-b6014ad2f1d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1600, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"text\\\", \\\"If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"292d9696-6567-47c1-86d8-71999f00b7c4\\\", \\\"childbox\\\": \\\"2e36c2d9-9ebd-4ac8-a8f2-13c26197ec6e\\\", \\\"subtext\\\": \\\"6b6d1dcc-2abb-4a29-b938-b6014ad2f1d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1601, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"text\\\", \\\"This allows the sponsor to protect proprietary information and to provide comments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"292d9696-6567-47c1-86d8-71999f00b7c4\\\", \\\"childbox\\\": \\\"339b5876-2e66-4e8f-8878-f11879b9b97b\\\", \\\"subtext\\\": \\\"3986e223-d060-4c1c-bb03-4a3a28055867\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1602, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"text\\\", \\\"\\\\u2022 The sponsor will comply with the requirements for publication of study results.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"080e086a-b41d-45f6-b55f-6587e4a80092\\\", \\\"childbox\\\": \\\"d86ba8c9-48b0-4425-b5d6-4dc949122ddf\\\", \\\"subtext\\\": \\\"41814ed6-7df6-43eb-b0cf-7866ec83ad20\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1603, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"text\\\", \\\"In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"080e086a-b41d-45f6-b55f-6587e4a80092\\\", \\\"childbox\\\": \\\"acd8d5fd-ac62-4ee7-b694-978045243f3d\\\", \\\"subtext\\\": \\\"41814ed6-7df6-43eb-b0cf-7866ec83ad20\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1604, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"text\\\", \\\"In this case, a coordinating investigator will be designated by mutual agreement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"080e086a-b41d-45f6-b55f-6587e4a80092\\\", \\\"childbox\\\": \\\"6918fac5-eaac-4bcb-9083-27e0320095b4\\\", \\\"subtext\\\": \\\"e0472431-a8d8-4f2f-99e2-55ec89ebc8d6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1605, \\\"\\\"], [\\\"3\\\", \\\"Publication Policy\\\", \\\"text\\\", \\\"\\\\u2022 Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9f55fc77-49dd-445f-bc90-196ae437201c\\\", \\\"childbox\\\": \\\"5154b1fd-60c9-40d1-a535-6fbeb3d8e675\\\", \\\"subtext\\\": \\\"37d95e14-2932-42d5-984b-a0422091288c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Publication Policy\\\", \\\"10.1.6.\\\", \\\"3\\\", 1606, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"header\\\", \\\"10.1.7. Dissemination of Clinical Study Data\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2142bad9-7d39-4c80-a2a4-eff0407601c2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1607, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"\\\\u2022 Where required by applicable regulatory requirements, an investigator signatory will be identified for the approval of the clinical study report.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"de418f69-0580-4573-8abc-cb3afbba2f09\\\", \\\"childbox\\\": \\\"19c7fcfd-d0ce-4065-8b32-2a938a365181\\\", \\\"subtext\\\": \\\"c6ff22c4-8498-4916-9c95-9cee71ddbbe7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1608, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the opportunity to review the complete study results at a GSK site or other mutually-agreeable location.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 177, \\\"end_idx\\\": 179, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 177, \\\"end_idx\\\": 179, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"de418f69-0580-4573-8abc-cb3afbba2f09\\\", \\\"childbox\\\": \\\"946a2004-511f-4c9a-ad18-99e9a47bafb3\\\", \\\"subtext\\\": \\\"882863d7-31ee-41ba-afce-cdd45ae6fe98\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1609, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"\\\\u2022 GSK will also provide the investigator with the full summary of the study results.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 2, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 2, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ec463941-4317-47c7-98f2-6a7ef06545df\\\", \\\"childbox\\\": \\\"aea9edaa-e624-4329-99cc-ab1a20900fca\\\", \\\"subtext\\\": \\\"9665f3f1-cf28-4f82-8079-805541ad8ec5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1610, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"The investigator is encouraged to share the summary results with the study participants, as appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ec463941-4317-47c7-98f2-6a7ef06545df\\\", \\\"childbox\\\": \\\"0b6dc9c6-89c1-4e31-a8fe-9ef47812237a\\\", \\\"subtext\\\": \\\"9665f3f1-cf28-4f82-8079-805541ad8ec5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1611, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"\\\\u2022 GSK will provide the investigator with the randomisation codes for their site only after completion of the full statistical analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 2, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 2, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"48b0f6bc-a066-4417-9ac9-8dd8f5b8b2a4\\\", \\\"childbox\\\": \\\"ea94201c-0bcd-4e37-b64c-ff53a3b81faf\\\", \\\"subtext\\\": \\\"eff00fc5-bb0c-42bf-8695-714cdce95ff6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1612, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"\\\\u2022 The procedures and timing for public disclosure of the protocol and results summary and for development of a manuscript for publication for this study will be in accordance with GSK Policy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 180, \\\"end_idx\\\": 182, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 180, \\\"end_idx\\\": 182, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"c5e0b451-5bcc-4481-85ea-84ea3697aca8\\\", \\\"childbox\\\": \\\"0a229ed8-2af7-4956-ad46-2a74f0bfc664\\\", \\\"subtext\\\": \\\"da87eab6-b788-4c09-a7c3-b694ad90387d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1613, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"\\\\u2022 GSK intends to make anonymised participant-level data from this trial available to external researchers for scientific analyses or to conduct further research that can help advance medical science or improve patient care.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 2, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 2, \\\"end_idx\\\": 4, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"63917cff-003e-436f-b03d-8336bc3582fa\\\", \\\"childbox\\\": \\\"58230f70-b1b0-4aa2-a128-5acb6cb414fb\\\", \\\"subtext\\\": \\\"6dfbd79c-c86b-44d6-9a1e-b536acfddbe4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1614, \\\"\\\"], [\\\"3\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"text\\\", \\\"This helps ensure the data provided by trial participants are used to maximum effect in the creation of knowledge and understanding\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"63917cff-003e-436f-b03d-8336bc3582fa\\\", \\\"childbox\\\": \\\"5bbd3a0e-85e9-4a1d-9b9b-d4a6008faaa3\\\", \\\"subtext\\\": \\\"6dfbd79c-c86b-44d6-9a1e-b536acfddbe4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Dissemination of Clinical Study Data\\\", \\\"10.1.7.\\\", \\\"3\\\", 1615, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"header\\\", \\\"10.1.8. Data Quality Assurance\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"925a61ae-fd15-41ea-8ca1-aaa0a05923fe\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1616, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the sponsor or designee electronically (e.g., laboratory data).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3adfcbe1-09f9-4142-91a9-6f7836e8ac12\\\", \\\"childbox\\\": \\\"2fd9da81-3d8d-4f5a-b117-45c2ccc90dca\\\", \\\"subtext\\\": \\\"beef4267-4143-4b4b-8035-28332a298530\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1617, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"The investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3adfcbe1-09f9-4142-91a9-6f7836e8ac12\\\", \\\"childbox\\\": \\\"41c7e209-da7b-4fd5-bed5-773808f871d2\\\", \\\"subtext\\\": \\\"beef4267-4143-4b4b-8035-28332a298530\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1618, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"63211246-cd11-4fce-9a76-11fc9391d92e\\\", \\\"childbox\\\": \\\"cc12e19c-3f13-406f-a10f-288f2862c3eb\\\", \\\"subtext\\\": \\\"22032e31-4bbe-455f-a1ed-35fc0cb720fa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1619, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"766500ab-e322-47d7-9d7e-ac61a63e28a6\\\", \\\"childbox\\\": \\\"acbe5cbf-dedc-4109-b12a-9a3ccd9b66ac\\\", \\\"subtext\\\": \\\"e647b0f4-ca6c-4678-aed3-24ecd6c9891b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1620, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality such as Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), methods, responsibilities and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) are provided in the Monitoring Plan.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"770ac652-229f-4862-b47d-c510b6517cfe\\\", \\\"childbox\\\": \\\"5439ee53-600a-49c6-a335-570514c7b124\\\", \\\"subtext\\\": \\\"c1dee2e6-6b42-4086-a95d-9ca1d670b725\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1621, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 The sponsor or designee is responsible for the data management of this study including quality checking of the data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2a4bf25c-3741-49cc-8b21-71b53555875b\\\", \\\"childbox\\\": \\\"172c08aa-fcc5-4aca-a36b-6940b7462b6b\\\", \\\"subtext\\\": \\\"4d506404-0b00-45cc-93df-f0f32281c54b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1622, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 The sponsor assumes accountability for actions delegated to other individuals (e.g., Contract Research Organisations).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"98028d6e-1a64-403f-b4e2-bf30894bb520\\\", \\\"childbox\\\": \\\"65afc947-972d-4d47-9e36-6142d63e5a65\\\", \\\"subtext\\\": \\\"2ea7a2ef-73eb-4e25-8fb7-0aa818d986a7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1623, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorised site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ab804e5c-b8d4-4dea-97f6-4f247c3a7cd4\\\", \\\"childbox\\\": \\\"3bdbc286-da53-4988-afeb-461d54438314\\\", \\\"subtext\\\": \\\"a64ef7f5-5236-4c82-8b62-68f11c461a8c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1624, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"\\\\u2022 Records and documents, including signed ICF, pertaining to the conduct of this study must be retained by the investigator for 25 years from the issue of the final Clinical Study Report (CSR)/ equivalent summary unless local regulations or institutional policies require a longer retention period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87f4c76e-5c08-40a2-acca-fb5208605960\\\", \\\"childbox\\\": \\\"815e16a0-2ee7-4561-b92d-c5b6620f9a43\\\", \\\"subtext\\\": \\\"06e19823-0aef-4fa3-8354-c528fe8e5ab0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1625, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"No records may be destroyed during the retention period without the written approval of the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87f4c76e-5c08-40a2-acca-fb5208605960\\\", \\\"childbox\\\": \\\"992efac1-d980-4a01-bf91-d5c761722d61\\\", \\\"subtext\\\": \\\"96260bfd-53ea-4661-995f-face9792f193\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1626, \\\"\\\"], [\\\"3\\\", \\\"Data Quality Assurance\\\", \\\"text\\\", \\\"No records may be transferred to another location or party without written notification to the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"87f4c76e-5c08-40a2-acca-fb5208605960\\\", \\\"childbox\\\": \\\"1d8f20ec-678a-400d-b28b-3a636a478143\\\", \\\"subtext\\\": \\\"96260bfd-53ea-4661-995f-face9792f193\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Data Quality Assurance\\\", \\\"10.1.8.\\\", \\\"3\\\", 1627, \\\"\\\"], [\\\"3\\\", \\\"Source Documents\\\", \\\"header\\\", \\\"10.1.9. Source Documents\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"812ee2cc-289f-45f4-b712-ccf69d8f4a36\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Source Documents\\\", \\\"10.1.9.\\\", \\\"3\\\", 1628, \\\"\\\"], [\\\"3\\\", \\\"Source Documents\\\", \\\"text\\\", \\\"\\\\u2022 Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65fadb14-2b67-4acc-bb28-2ab40d36717b\\\", \\\"childbox\\\": \\\"aecfcc71-b387-41d8-9ea7-3df53fb98aa9\\\", \\\"subtext\\\": \\\"3b19abd3-2719-4663-892e-2b03a6906d12\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Source Documents\\\", \\\"10.1.9.\\\", \\\"3\\\", 1629, \\\"\\\"], [\\\"3\\\", \\\"Source Documents\\\", \\\"text\\\", \\\"Source documents are filed at the investigator\\\\u2019s site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65fadb14-2b67-4acc-bb28-2ab40d36717b\\\", \\\"childbox\\\": \\\"715793a2-470d-4f7d-8244-35ba07ff9753\\\", \\\"subtext\\\": \\\"3b19abd3-2719-4663-892e-2b03a6906d12\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Source Documents\\\", \\\"10.1.9.\\\", \\\"3\\\", 1630, \\\"\\\"], [\\\"3\\\", \\\"Source Documents\\\", \\\"text\\\", \\\"\\\\u2022 Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d89c3a47-e9f2-4b97-a09e-6e312fb399a6\\\", \\\"childbox\\\": \\\"cd398e14-4a46-4e5f-bca7-857f93f86253\\\", \\\"subtext\\\": \\\"5aa866a5-f7d6-47b6-ad6f-a21ee78c9c1a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Source Documents\\\", \\\"10.1.9.\\\", \\\"3\\\", 1631, \\\"\\\"], [\\\"3\\\", \\\"Source Documents\\\", \\\"text\\\", \\\"The investigator may need to request previous medical records or transfer records, depending on the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d89c3a47-e9f2-4b97-a09e-6e312fb399a6\\\", \\\"childbox\\\": \\\"0f283e39-0298-4679-8dca-eab259269943\\\", \\\"subtext\\\": \\\"5aa866a5-f7d6-47b6-ad6f-a21ee78c9c1a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Source Documents\\\", \\\"10.1.9.\\\", \\\"3\\\", 1632, \\\"\\\"], [\\\"3\\\", \\\"Source Documents\\\", \\\"text\\\", \\\"Also, current medical records must be available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d89c3a47-e9f2-4b97-a09e-6e312fb399a6\\\", \\\"childbox\\\": \\\"206f67d6-8395-433e-a9cc-d8b02f7d040a\\\", \\\"subtext\\\": \\\"d7e46829-acb7-4fc0-9586-392df737fb67\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Source Documents\\\", \\\"10.1.9.\\\", \\\"3\\\", 1633, \\\"\\\"], [\\\"3\\\", \\\"Source Documents\\\", \\\"text\\\", \\\"10.3.1 \\\\u2022 Definition of what constitutes source data can be found in the Source Data Agreement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1390edc2-ac20-4b2d-a6f4-ac021abe0b35\\\", \\\"childbox\\\": \\\"a16a4452-8c8b-4029-8368-e578a8fbec92\\\", \\\"subtext\\\": \\\"0e3bd7d6-c658-4930-9274-75f657498b42\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Source Documents\\\", \\\"10.1.9.\\\", \\\"3\\\", 1634, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.1.10. Study and Site Closure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"13bfc57c-78ae-4a10-9019-13de78073fda\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1635, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GSK or its designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of GSK.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 2, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 139, \\\"end_idx\\\": 141, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 0, \\\"end_idx\\\": 2, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 139, \\\"end_idx\\\": 141, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"3dbb45e5-8bba-4902-90b0-1d31d38b1654\\\", \\\"childbox\\\": \\\"d7a8d518-8336-4acd-ab8d-32da40698f14\\\", \\\"subtext\\\": \\\"8552d4ff-b3f5-4b90-b26f-b9f84011e5bf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1636, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study sites will be closed upon study completion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3dbb45e5-8bba-4902-90b0-1d31d38b1654\\\", \\\"childbox\\\": \\\"b1071591-a49a-4032-8455-3a64a8b52714\\\", \\\"subtext\\\": \\\"71348fd6-d6c0-4484-a379-b0c2a728ecb2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1637, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3dbb45e5-8bba-4902-90b0-1d31d38b1654\\\", \\\"childbox\\\": \\\"5ebbcf93-94f7-46ba-b74d-b78e3b758b76\\\", \\\"subtext\\\": \\\"71348fd6-d6c0-4484-a379-b0c2a728ecb2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1638, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1b633a72-dca9-4983-9dc0-5f53261e3ece\\\", \\\"childbox\\\": \\\"95d0cc3c-b2ed-4295-8e49-5bf0cad52eda\\\", \\\"subtext\\\": \\\"6592e5a6-5740-4d7c-964b-31a8e035403f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1639, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Reasons for the early closure of a study site by the sponsor or investigator may include but are not limited to:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9c7dfd3d-c1c1-44c2-93c1-8c40fdbede9f\\\", \\\"childbox\\\": \\\"6331a849-42fd-47bd-9143-11a833d3a805\\\", \\\"subtext\\\": \\\"1ed5ba5a-dc8d-4bdb-828a-4305f8cc0f76\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1640, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor\\\\u2019s procedures, or GCP guidelines\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9a664930-314c-47de-87fe-2b5b2e9d925a\\\", \\\"childbox\\\": \\\"c76ddb69-39d6-475d-96ec-faf121f1f640\\\", \\\"subtext\\\": \\\"0437c0b7-5846-4429-a7e8-caf1247440b0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1641, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Inadequate recruitment of participants by the investigator\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"be49b438-8962-497d-998f-dfa80a81f03a\\\", \\\"childbox\\\": \\\"28d89930-d81f-4704-8fa2-28a43a0b61f9\\\", \\\"subtext\\\": \\\"56dcddc3-b4b8-4cce-ad52-e24c70bdf39f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1642, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Discontinuation of further study intervention development\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e564a81-5064-4408-b107-11faac94e44e\\\", \\\"childbox\\\": \\\"abe33b2a-9e00-4dc3-a246-ff5e187f1824\\\", \\\"subtext\\\": \\\"c6b7e6a8-3007-4af8-85b4-29ab443d2137\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1643, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e564a81-5064-4408-b107-11faac94e44e\\\", \\\"childbox\\\": \\\"18e4922a-8db6-4001-b35a-116e335ca074\\\", \\\"subtext\\\": \\\"c18d9bdd-3081-4d79-9e69-a1b0f6c86fec\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Study and Site Closure\\\", \\\"10.1.10.\\\", \\\"3\\\", 1644, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"header\\\", \\\"10.2. Appendix 2: Clinical Laboratory Tests\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b55ecd83-b1c2-4586-8de8-59a67319e6dc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1645, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"\\\\u2022 The tests detailed in Table 5 will be performed by the central laboratory except for ESR, dipstick urinalysis and urine pregnancy tests, which will be analysed by the local laboratory.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbae2230-815a-41a6-a9da-1d83dbf3e15a\\\", \\\"childbox\\\": \\\"f82fd396-f55a-4329-9608-01e4e54a33f1\\\", \\\"subtext\\\": \\\"8094e7cf-5fbe-49b3-9b81-3eab1b1d4b84\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1646, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"\\\\u2022 Except for ESR, dipstick urinalysis, and urine pregnancy tests, local laboratory results are only required in the event that the central laboratory results are not available in time for either study intervention administration and/or safety evaluation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e1240204-2ffd-40cc-9c0d-fed13afcae7f\\\", \\\"childbox\\\": \\\"c4e082e4-dff1-45dc-bca5-3b8585583070\\\", \\\"subtext\\\": \\\"9ddf2344-487a-482d-bcb7-0db5ebcbf197\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1647, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"If a local sample is required, it is important that the sample for central analysis is obtained at the same time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e1240204-2ffd-40cc-9c0d-fed13afcae7f\\\", \\\"childbox\\\": \\\"78a249de-4bb0-422f-a9f1-8391c6416742\\\", \\\"subtext\\\": \\\"51d819d5-165b-4600-a9fa-7ab8026f8f68\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1648, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"\\\\u2022 Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dece7bfb-8824-4501-9fd5-ded1a81119fb\\\", \\\"childbox\\\": \\\"5107a6c0-b1c7-44f3-929c-38e2a3437d69\\\", \\\"subtext\\\": \\\"ecb9cebf-f132-49e7-be2a-e3853341c298\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1649, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"\\\\u2022 Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"428eef63-c50d-4267-86ef-613d9b58ca93\\\", \\\"childbox\\\": \\\"b45a0851-186b-46fe-b7ef-02fb6f167665\\\", \\\"subtext\\\": \\\"0172e3f0-d7fe-42c8-87d3-135200da5fa8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1650, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"\\\\u2022 Pregnancy Testing\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7b6bd32b-e383-42f2-b380-52cba3e47eeb\\\", \\\"childbox\\\": \\\"ff0efcf0-9139-4631-b1a8-42013471dcc3\\\", \\\"subtext\\\": \\\"0e678f97-242d-47b4-8681-059c25c54097\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1651, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7b6bd32b-e383-42f2-b380-52cba3e47eeb\\\", \\\"childbox\\\": \\\"ff0efcf0-9139-4631-b1a8-42013471dcc3\\\", \\\"subtext\\\": \\\"05eda191-338d-45bc-9639-980bf1f3ed8c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1652, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"Refer to Section 5.1 Inclusion Criteria for screening pregnancy criteria.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7b6bd32b-e383-42f2-b380-52cba3e47eeb\\\", \\\"childbox\\\": \\\"ff0efcf0-9139-4631-b1a8-42013471dcc3\\\", \\\"subtext\\\": \\\"c1589764-31e7-4f22-b8c7-37e8492f7258\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1653, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"o Pregnancy testing (urine or serum as required by local regulations) for WOCBP should be conducted once every 4 weeks to Week 16 and then again at Week 24.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"52bd607a-5285-44bc-a172-d7e6d64d955c\\\", \\\"childbox\\\": \\\"719255e8-a351-49b2-ab82-15378455011f\\\", \\\"subtext\\\": \\\"ef818881-ebec-4cfc-9c09-ae873b3a9059\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1654, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"o Pregnancy testing (urine or serum as required by local regulations) will also be conducted at the safety follow up visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"41304e46-be97-47ce-b069-da342ab2b04c\\\", \\\"childbox\\\": \\\"957fabe9-c3c7-4305-a573-5e082c7e7b29\\\", \\\"subtext\\\": \\\"2174d01a-d13f-4676-8a98-a3ceb866b2e4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1655, \\\"\\\"], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"o Additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local regulation, to establish the absence of pregnancy at any time during the participation of a WOCBP in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"218b2464-adb1-40ec-a6ff-39b0ee6433f5\\\", \\\"childbox\\\": \\\"02a500a1-92d5-4b76-8743-301ab6a3486b\\\", \\\"subtext\\\": \\\"da755f8f-50c1-4fbe-b61e-0e905aa2403c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"10.2.\\\", \\\"2\\\", 1656, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Table 5\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f87668e6-4820-44b7-87b6-356d0c459f45\\\", \\\"childbox\\\": \\\"fda2e6e2-6dc5-4a0f-bd1b-81a7a8c7ef7a\\\", \\\"subtext\\\": \\\"66b02a04-4c8c-424d-a99c-215db4fe1e5c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1657, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f87668e6-4820-44b7-87b6-356d0c459f45\\\", \\\"childbox\\\": \\\"84710ba8-7e93-4faa-b8d7-ca7ca8a4c07a\\\", \\\"subtext\\\": \\\"0e1f2208-ae30-4c54-9cce-87ec922b909f\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1658, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 34, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Protocol-Required Safety Laboratory\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"f87668e6-4820-44b7-87b6-356d0c459f45\\\", \\\"childbox\\\": \\\"4eb3d4b0-a6e0-424c-aae5-9064aa7202da\\\", \\\"subtext\\\": \\\"0e1f2208-ae30-4c54-9cce-87ec922b909f\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1659, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"31c73fb6-8ac4-4db5-b5b9-849077ec2d3d\\\", \\\"childbox\\\": \\\"9b56718f-4ed2-4d25-8dd5-40aaa1e5ff69\\\", \\\"subtext\\\": \\\"fdb150d8-918b-4090-833f-49a38abd2f8c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1660, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d7ac049f-c974-481a-ad20-8f9f0f2c8895\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1661, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4b1b2f0b-a106-4341-bbd0-5c4d89d57792\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1662, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4db46fd3-c8b0-41c0-97de-c96ec80f7d2a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1663, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b7b8b9be-8995-4a5a-8338-bb7e53877d46\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1664, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e6d497aa-9d9b-4088-a742-f3b9c3a5c54a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1665, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7c603adf-8809-44cc-a994-60a359e32355\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1666, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b42a621f-e365-4c45-8639-84e15afa1cd0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1667, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4873a5ac-5711-49da-8521-ef78067337eb\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1668, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c669ee18-af9c-4d89-82a4-44113e6663f6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1669, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"47e1857f-9923-4696-849d-70608ba19e00\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1670, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4eabd1ae-7907-488f-b022-25d4e34fcbb9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1671, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"14bf3912-77e2-4a9d-a54a-5934807fb48b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1672, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"64a3bb2e-54a0-45d0-9932-3723d15579db\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1673, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"492f9b02-b822-47dc-8db2-f5280adc8de7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1674, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e637a38b-4422-490c-8c51-d991d058ef4d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1675, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e9d2825e-1487-40c9-bf8e-7f8d50541c4f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1676, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c8092deb-05c0-4985-ba63-ea31701aa12d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1677, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb6bf4d3-8695-4317-9331-337169427b28\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1678, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1b3ca2b6-da6c-4f13-9acd-97ce620a0cd2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1679, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a1c17ed8-2ff3-4497-b36c-b8ec44908d87\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1680, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NOTES :\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d458d880-ebc6-460d-a00b-6ea7b427db40\\\", \\\"childbox\\\": \\\"66e7d24a-b48a-48cc-a63b-5adc8d0f3932\\\", \\\"subtext\\\": \\\"f3138b1a-a6a2-4f57-93b4-74da2d5beb56\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1681, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver stopping or monitoring event are given in Section 7.1 and Appendix 6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"6eeadd35-785e-4eba-a785-b1618f0f9c8f\\\", \\\"subtext\\\": \\\"d7751911-f651-4c95-8271-d4af68ded05b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1682, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All events of ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"10746bc0-4dc4-46ee-844b-c2b1d32fe835\\\", \\\"subtext\\\": \\\"061d429d-c8fb-4417-a1f3-224d19e1c18f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1683, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"10746bc0-4dc4-46ee-844b-c2b1d32fe835\\\", \\\"subtext\\\": \\\"6b60cc4c-bda4-421e-97b5-059ca6499189\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1684, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3 \\\\u00d7 upper limit of normal (ULN) and bilirubin\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"10746bc0-4dc4-46ee-844b-c2b1d32fe835\\\", \\\"subtext\\\": \\\"c75b1ed0-0d1c-49f0-9c9f-6cc5d988ab1e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1685, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"10746bc0-4dc4-46ee-844b-c2b1d32fe835\\\", \\\"subtext\\\": \\\"547ff218-7c3c-4075-9aef-1f6eab180ca7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1686, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2 \\\\u00d7 ULN (>35% direct bilirubin) or ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"10746bc0-4dc4-46ee-844b-c2b1d32fe835\\\", \\\"subtext\\\": \\\"f8ea0493-482e-416b-803a-8bf1a297bceb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1687, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"10746bc0-4dc4-46ee-844b-c2b1d32fe835\\\", \\\"subtext\\\": \\\"d846cbf2-6b28-40a3-ae26-c9b1b738bda7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1688, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3 \\\\u00d7 ULN and international normalised ratio (INR) >1.5, if INR measured, which may indicate severe liver injury (possible Hy\\\\u2019s Law), must be reported as an SAE (excluding studies of hepatic impairment or cirrhosis).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f49e2b27-aeaa-4ef6-9160-8c84b2ec5412\\\", \\\"childbox\\\": \\\"10746bc0-4dc4-46ee-844b-c2b1d32fe835\\\", \\\"subtext\\\": \\\"12053a37-3724-48dc-a6ee-3fc31267f2e3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1689, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0ec0313d-db5f-44f6-8ea3-3f7213fe3f12\\\", \\\"childbox\\\": \\\"94dc98b0-34f5-43e6-8a46-21eb9a472329\\\", \\\"subtext\\\": \\\"cc3f9264-b33c-4857-8188-6527076378e9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1690, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Laboratory/analyte results that could unblind the study will not be reported to investigative sites or other blinded personnel until the study has been unblinded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"99aa37a4-44c4-4596-9fba-3062946ddee5\\\", \\\"childbox\\\": \\\"d3fc7d6d-76bc-4e90-9fe3-0151108fd86d\\\", \\\"subtext\\\": \\\"0405f3c5-1b52-445b-8f2b-4b8a406b7625\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1691, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following results will not be reported to investigative sites or the study team involved in the conduct of the study:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"99aa37a4-44c4-4596-9fba-3062946ddee5\\\", \\\"childbox\\\": \\\"aab89431-8825-4d66-a34f-64e421546fbd\\\", \\\"subtext\\\": \\\"f3417741-4dc6-4caa-aa88-ee21a288774f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1692, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 hsCRP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0eedf7f7-1b99-4c21-a587-b5361a8ed770\\\", \\\"childbox\\\": \\\"544ffb28-2ed0-4dff-b68c-c036524d0496\\\", \\\"subtext\\\": \\\"9e08ec73-f9da-4628-8fc5-58a7ac00164d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1693, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 ESR (performed locally by an unblinded independent study team member).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5efc821b-8169-4c66-903d-35c1cb7be62d\\\", \\\"childbox\\\": \\\"bdc83a94-c070-4cfb-a6c3-aab2a8df9d10\\\", \\\"subtext\\\": \\\"dcefd950-9ef5-4a6e-aaa7-f6ef5b9e70fe\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1694, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 PK analyses.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"84aacc83-b523-40b2-9009-b8e3968b017c\\\", \\\"childbox\\\": \\\"4124382f-75ba-45fb-9eb9-c88525a9d8c4\\\", \\\"subtext\\\": \\\"53162e69-738c-402f-8bf5-810a17754549\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1695, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Note: Monitoring of CRP/hsCRP during the course of this study by local measurements, is not permitted, in order to protect the blind.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"41c00d11-109a-4e4e-a893-87bb55fb0a2e\\\", \\\"childbox\\\": \\\"33cf65b4-8a6c-4f3b-80d4-0c2cdfad4be4\\\", \\\"subtext\\\": \\\"00d659a5-31bd-4a89-a8a5-ea5f3331e5bb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1696, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However individual local measured CRP/hsCRP may be performed if required for safety reasons.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"41c00d11-109a-4e4e-a893-87bb55fb0a2e\\\", \\\"childbox\\\": \\\"eedbbf3d-b5d9-4618-9c58-5e10b97c0433\\\", \\\"subtext\\\": \\\"135cb868-ea34-4bb3-bd27-19192e618a62\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Protocol-Required Safety Laboratory Assessments\\\", \\\"Table 5\\\", \\\"3\\\", 1697, \\\"\\\"], [\\\"2\\\", \\\"Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting\\\", \\\"header\\\", \\\"10.3. Appendix 3: Adverse Events: Definitions and Procedures for\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3eef2347-d76c-4301-9887-bd6a57a9242d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 3: Adverse Events: Definitions and Procedures for\\\", \\\"10.3.\\\", \\\"2\\\", 1698, \\\"\\\"], [\\\"2\\\", \\\"Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting\\\", \\\"header\\\", \\\"Recording, Evaluating, Follow-up, and Reporting\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 26, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"89c61d5c-c505-4e2d-8af8-968d37f6c6e2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 26, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 3: Adverse Events: Definitions and Procedures for\\\", \\\"10.3.\\\", \\\"2\\\", 1699, \\\"\\\"], [\\\"3\\\", \\\"Definition of AE\\\", \\\"header\\\", \\\"10.3.1. Definition of AE\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"48336d21-44d0-42d3-87c4-806dc28fca8b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of AE\\\", \\\"10.3.1.\\\", \\\"3\\\", 1700, \\\"\\\"], [\\\"3\\\", \\\"Definition of AE\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"66851f1b-4f4b-4d1d-907c-e39e8638b2fb\\\", \\\"childbox\\\": \\\"854c4a51-444e-4870-89f1-5b34a7f5dc04\\\", \\\"subtext\\\": \\\"ad991743-2d51-430d-ba4a-dd0dd9015ef9\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of AE\\\", \\\"10.3.1.\\\", \\\"3\\\", 1701, \\\"\\\"], [\\\"3\\\", \\\"Definition of AE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"029f3eb6-5ad4-4282-8ea9-38004466fd3a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of AE\\\", \\\"10.3.1.\\\", \\\"3\\\", 1702, \\\"\\\"], [\\\"3\\\", \\\"Definition of AE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4c72fd97-7152-4feb-ad61-dfdc7f0be59e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of AE\\\", \\\"10.3.1.\\\", \\\"3\\\", 1703, \\\"\\\"], [\\\"3\\\", \\\"Definition of AE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"564f4ce9-cd77-45dd-a941-e547a1a908e5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of AE\\\", \\\"10.3.1.\\\", \\\"3\\\", 1704, \\\"\\\"], [\\\"3\\\", \\\"Definition of AE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"10523a2e-aed1-4297-991c-360898b8cbc3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of AE\\\", \\\"10.3.1.\\\", \\\"3\\\", 1705, \\\"\\\"], [\\\"3\\\", \\\"Definition of SAE\\\", \\\"header\\\", \\\"10.3.2. Definition of SAE\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eb3610a6-b03b-491b-a1a7-c60aa0723a2f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of SAE\\\", \\\"10.3.2.\\\", \\\"3\\\", 1706, \\\"\\\"], [\\\"3\\\", \\\"Definition of SAE\\\", \\\"text\\\", \\\"If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospitalisation for signs/symptoms of the disease under study, death due to progression of disease).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"58e0c110-3e94-4cc6-9c56-d0a47d9046e5\\\", \\\"childbox\\\": \\\"38727e42-b598-452b-aa91-0ac147a34e59\\\", \\\"subtext\\\": \\\"bb727bbd-115f-4eb2-9074-06986b317c7f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of SAE\\\", \\\"10.3.2.\\\", \\\"3\\\", 1707, \\\"\\\"], [\\\"3\\\", \\\"Definition of SAE\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae48e7d0-fb2a-4ae7-89a3-5d61a0a9a8d6\\\", \\\"childbox\\\": \\\"f4b76f75-20d9-4a46-b0dd-6ff5e16b8ceb\\\", \\\"subtext\\\": \\\"b20973e8-7ec1-4d78-aa09-398f37b477bb\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of SAE\\\", \\\"10.3.2.\\\", \\\"3\\\", 1708, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.3.3. Definition of Cardiovascular Events\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f2634505-8f15-47e6-bda1-e0d832c38c6b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of Cardiovascular Events\\\", \\\"10.3.3.\\\", \\\"3\\\", 1709, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"345ccfc7-f415-44a9-9721-93f1c4a808bc\\\", \\\"childbox\\\": \\\"6283f268-36ec-47a1-83d1-adb645b636e7\\\", \\\"subtext\\\": \\\"339b5368-8dbc-48b6-999e-f580522f47a8\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definition of Cardiovascular Events\\\", \\\"10.3.3.\\\", \\\"3\\\", 1710, \\\"\\\"], [\\\"3\\\", \\\"Recording and Follow-Up of AE and/or SAE\\\", \\\"header\\\", \\\"10.3.4. Recording and Follow-Up of AE and SAE\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0b59afc4-b3fc-4911-a003-e4029e5b26a2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Recording and Follow-Up of AE and SAE\\\", \\\"10.3.4.\\\", \\\"3\\\", 1711, \\\"\\\"], [\\\"3\\\", \\\"Recording and Follow-Up of AE and/or SAE\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"abd1b35a-b336-4694-abd7-84616a34c283\\\", \\\"childbox\\\": \\\"7a8de14a-f83c-41da-ba10-041b8c240ad9\\\", \\\"subtext\\\": \\\"8a6ecdcd-d1f1-41c5-8b4e-dca227bd83af\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Recording and Follow-Up of AE and SAE\\\", \\\"10.3.4.\\\", \\\"3\\\", 1712, \\\"\\\"], [\\\"3\\\", \\\"Recording and Follow-Up of AE and/or SAE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1d47aa74-baf6-42fd-ae18-180131885920\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Recording and Follow-Up of AE and SAE\\\", \\\"10.3.4.\\\", \\\"3\\\", 1713, \\\"\\\"], [\\\"3\\\", \\\"Recording and Follow-Up of AE and/or SAE\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 19, \\\"end_idx\\\": 21, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 52, \\\"end_idx\\\": 54, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 19, \\\"end_idx\\\": 21, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 52, \\\"end_idx\\\": 54, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"bc566cf3-948f-4c2a-b3af-9516319a247c\\\", \\\"childbox\\\": \\\"498ea548-6c4e-4abe-8477-6fd94c52738d\\\", \\\"subtext\\\": \\\"613e9ccb-1c6f-46f5-9e17-afc54655d9b8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Recording and Follow-Up of AE and SAE\\\", \\\"10.3.4.\\\", \\\"3\\\", 1714, \\\"\\\"], [\\\"3\\\", \\\"Recording and Follow-Up of AE and/or SAE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e038cdd5-03a5-4c42-8ce0-88eefb7c9e90\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Recording and Follow-Up of AE and SAE\\\", \\\"10.3.4.\\\", \\\"3\\\", 1715, \\\"\\\"], [\\\"3\\\", \\\"Recording and Follow-Up of AE and/or SAE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d34d8a6b-90a1-4892-9d2c-c64f15267bc4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Recording and Follow-Up of AE and SAE\\\", \\\"10.3.4.\\\", \\\"3\\\", 1716, \\\"\\\"], [\\\"3\\\", \\\"Recording and Follow-Up of AE and/or SAE\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1bd7e59f-04ec-4720-9d26-b75bd2382c0b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Recording and Follow-Up of AE and SAE\\\", \\\"10.3.4.\\\", \\\"3\\\", 1717, \\\"\\\"], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"header\\\", \\\"10.3.5. Reporting of SAE to GSK\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [{\\\"start_idx\\\": 28, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 28, \\\"end_idx\\\": 30, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4a51c063-e55c-4ebe-a7fa-7b2e2545ba1b\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Reporting of SAE to GSK\\\", \\\"10.3.5.\\\", \\\"3\\\", 1718, \\\"\\\"], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a58f473c-4c9e-43b1-8b7d-6389ced3d6d4\\\", \\\"childbox\\\": \\\"1c111864-9844-4432-ac7c-893a7205b47a\\\", \\\"subtext\\\": \\\"e3df38a9-6e0c-4937-949f-d5b0e0ad7ffc\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Reporting of SAE to GSK\\\", \\\"10.3.5.\\\", \\\"3\\\", 1719, \\\"\\\"], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"873c714b-c606-4e16-b960-59014d4e4854\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Reporting of SAE to GSK\\\", \\\"10.3.5.\\\", \\\"3\\\", 1720, \\\"\\\"], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d403230c-9578-4648-b03c-a2ed87edc8d4\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Reporting of SAE to GSK\\\", \\\"10.3.5.\\\", \\\"3\\\", 1721, \\\"\\\"], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a92910b8-cdae-41ce-9b81-73fe6415eec5\\\", \\\"childbox\\\": \\\"89f1fa3c-b481-46c9-9d41-c837ecd1fce7\\\", \\\"subtext\\\": \\\"2090dd9a-7557-4d65-af64-cd56218f3235\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Reporting of SAE to GSK\\\", \\\"10.3.5.\\\", \\\"3\\\", 1722, \\\"\\\"], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a7f9af54-e702-457b-b5fa-0ee5fd604e22\\\", \\\"childbox\\\": \\\"f78f0201-afe3-4f75-89cc-9bd632a9b847\\\", \\\"subtext\\\": \\\"9e8b106f-abcb-4601-a815-e0063da3f702\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Reporting of SAE to GSK\\\", \\\"10.3.5.\\\", \\\"3\\\", 1723, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.4. Appendix 4: Contraceptive Guidance and Collection of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d6a37d80-f1ba-4321-b641-6efc561e9f2f\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 4: Contraceptive Guidance and Collection of\\\", \\\"10.4.\\\", \\\"2\\\", 1724, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Pregnancy Information\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 26, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cf0e8e4a-793a-479d-a956-fb32d074181c\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 26, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 4: Contraceptive Guidance and Collection of\\\", \\\"10.4.\\\", \\\"2\\\", 1725, \\\"\\\"], [\\\"3\\\", \\\"Definitions\\\", \\\"header\\\", \\\"10.4.1. Definitions:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9728e8a2-0ec0-419b-9010-862d373d038d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Definitions:\\\", \\\"10.4.1.\\\", \\\"3\\\", 1726, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.4.1.1. Woman of Childbearing Potential (WOCBP)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ae3697aa-e4b1-4933-b730-5d4c74407813\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Woman of Childbearing Potential (WOCBP)\\\", \\\"10.4.1.1.\\\", \\\"4\\\", 1727, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1e323f1b-1579-4ae2-887d-4b0e44114f59\\\", \\\"childbox\\\": \\\"5f1fb67e-59b1-44d2-b48a-826c393e06d4\\\", \\\"subtext\\\": \\\"f478c6a4-2ba4-431b-a275-facaff131da5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Woman of Childbearing Potential (WOCBP)\\\", \\\"10.4.1.1.\\\", \\\"4\\\", 1728, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0e270481-dfc4-43c5-9e42-df5996f362df\\\", \\\"childbox\\\": \\\"e28e53d2-4bd4-4d42-85ce-044e264d2fc7\\\", \\\"subtext\\\": \\\"b4a966cf-eca3-497b-bce1-f1d0e559bda7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Woman of Childbearing Potential (WOCBP)\\\", \\\"10.4.1.1.\\\", \\\"4\\\", 1729, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.4.1.2. Women in the following categories are not considered WOCBP\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"feebc58c-deab-4e04-9e6c-fe998cb8959e\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1730, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Premenarchal\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e7d0b400-7c03-4ff1-a773-bb79b671ac6a\\\", \\\"childbox\\\": \\\"57a9d4af-f305-45cf-9c74-4c447151d219\\\", \\\"subtext\\\": \\\"9be880af-7877-4320-ad06-d692acf8a8f8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1731, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. Premenopausal female with 1 of the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e60cd7c8-219e-4ef1-b043-12b5a630c423\\\", \\\"childbox\\\": \\\"132db40c-2d5a-4aac-834d-30f7c65653f5\\\", \\\"subtext\\\": \\\"f0dc197f-c3c9-4409-92f3-f9f7a89e4fd3\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1732, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Documented hysterectomy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"35d1a41b-67ab-430c-a201-15b1b882ce06\\\", \\\"childbox\\\": \\\"436de539-3fb8-4db8-a29a-f142685db711\\\", \\\"subtext\\\": \\\"f7c4d5f3-d2fa-4e92-9fc9-4819b461a6dd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1733, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Documented bilateral salpingectomy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6cb2143f-6f20-4433-aad6-006ea37b7e1f\\\", \\\"childbox\\\": \\\"e0d39179-6211-4fe4-9688-aa2fc2bbbcad\\\", \\\"subtext\\\": \\\"39389c8c-19c5-463d-9ec8-b7707bd71d5b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1734, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Documented bilateral oophorectomy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4f5452cf-c45d-452b-b03b-e9f585b88759\\\", \\\"childbox\\\": \\\"7f227c98-7dd5-45a8-af62-275e715ef341\\\", \\\"subtext\\\": \\\"b209450b-5e03-4718-82fc-05bf7d1ca608\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1735, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 126, \\\"end_idx\\\": 133, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"androgen\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"8d635123-deb9-4f8f-a6d0-a2df09c6727c\\\", \\\"childbox\\\": \\\"f970c85a-c241-420f-954b-e1180742330e\\\", \\\"subtext\\\": \\\"b0071a2a-9fde-40d1-9cc4-33cd62973343\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1736, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Note: Documentation can come from the site personnel\\\\u2019s: review of the participant\\\\u2019s medical records, medical examination, or medical history interview.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ad7830fc-15e6-429c-89d2-6a84f03d9809\\\", \\\"childbox\\\": \\\"86acf591-0871-41a5-8ff2-b76b5ef31bbc\\\", \\\"subtext\\\": \\\"efe8a79b-b7c8-4d8a-b7ba-032cdeaeffaa\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1737, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. Postmenopausal female\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1fba173a-c1c9-426d-895e-1fae234f46a8\\\", \\\"childbox\\\": \\\"9a8392f2-cd56-4249-a46b-f259e7ecea1a\\\", \\\"subtext\\\": \\\"6e1b6de1-c16b-47fe-bb5c-39b402a68101\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1738, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8cac58bc-7e7a-49cb-a472-a265ccc1b35e\\\", \\\"childbox\\\": \\\"b816a0f6-1a14-4601-9f22-f90324887a33\\\", \\\"subtext\\\": \\\"a26e5f0c-680c-42f1-9321-eeaca6b27b1d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1739, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 9, \\\"end_idx\\\": 36, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle stimulating hormone\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"e3d3e3cd-32c2-44ee-a5f3-14adc70048fd\\\", \\\"childbox\\\": \\\"56a75f7b-a0f6-414b-9e56-d8fc5258ef6c\\\", \\\"subtext\\\": \\\"78995ea2-3729-4d66-965c-95790101be61\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1740, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e3d3e3cd-32c2-44ee-a5f3-14adc70048fd\\\", \\\"childbox\\\": \\\"bfc5af29-1756-42ea-aa08-dc1586e9f76c\\\", \\\"subtext\\\": \\\"78995ea2-3729-4d66-965c-95790101be61\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1741, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"72b9829a-2c0c-4c45-99af-f8c2cff35932\\\", \\\"childbox\\\": \\\"eaf58ba9-b276-4de8-ae7d-c112118fc820\\\", \\\"subtext\\\": \\\"b23c6ae4-fb78-46b5-a023-e73a5ce95b2b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1742, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"72b9829a-2c0c-4c45-99af-f8c2cff35932\\\", \\\"childbox\\\": \\\"3a66382e-9f88-41cd-b0b1-955e6373cbce\\\", \\\"subtext\\\": \\\"9e58387d-9eda-4b37-999c-973fc8aa15b2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Women in the following categories are not considered WOCBP\\\", \\\"10.4.1.2.\\\", \\\"4\\\", 1743, \\\"\\\"], [\\\"3\\\", \\\"Contraception Guidance\\\", \\\"header\\\", \\\"10.4.2. Contraception Guidance:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c9d99358-1692-4162-89f6-7a9b448355ac\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Guidance:\\\", \\\"10.4.2.\\\", \\\"3\\\", 1744, \\\"\\\"], [\\\"3\\\", \\\"Contraception Guidance\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2f7caed4-250b-442f-a1fe-172ffc0d4638\\\", \\\"childbox\\\": \\\"bc119bcb-7848-4922-a803-0e4c1b164a93\\\", \\\"subtext\\\": \\\"20dacc46-9247-4e38-afd0-430c65526290\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Guidance:\\\", \\\"10.4.2.\\\", \\\"3\\\", 1745, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.4.3. Collection of Pregnancy Information:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aa7a12ed-43a8-4182-9fc8-f13e31580333\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1746, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Male participants with partners who become pregnant\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f5b0b8d4-6475-4b63-8970-622bbf4c7870\\\", \\\"childbox\\\": \\\"5ad28d3e-5f4c-4a8c-91d2-7600982666dc\\\", \\\"subtext\\\": \\\"150aabf0-4a03-468c-8fa7-301d9552f49b\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1747, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Investigator will attempt to collect pregnancy information on any male participant\\\\u2019s female partner of a male study participant who becomes pregnant while participating in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3c4f718d-4fef-4df0-aad7-1ae59b56ed71\\\", \\\"childbox\\\": \\\"5d3f14f8-d30c-43e6-9e8a-2ab1b1a08821\\\", \\\"subtext\\\": \\\"e262c0d0-5dee-4d62-9c84-35261ca4ba5f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1748, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This applies only to male participants who receive study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3c4f718d-4fef-4df0-aad7-1ae59b56ed71\\\", \\\"childbox\\\": \\\"0fa1d3fb-ab70-4093-9a10-9beb685e262d\\\", \\\"subtext\\\": \\\"00fdb0ed-a0ab-404e-a503-302a62ae88ec\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1749, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 After obtaining the necessary signed informed consent from the pregnant female partner directly, the investigator will record pregnancy information on the appropriate form and submit it to GSK within 24 hours of learning of the partner\\\\u2019s pregnancy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 191, \\\"end_idx\\\": 193, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 191, \\\"end_idx\\\": 193, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"2eb0fc29-aee4-49ed-a001-2b32c1bc4507\\\", \\\"childbox\\\": \\\"5c5de504-8a03-4d50-b637-adeb79730a30\\\", \\\"subtext\\\": \\\"96913214-7571-4082-a11e-fdfff8410693\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1750, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The female partner will also be followed to determine the outcome of the pregnancy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8e2f2ff6-4f8a-4a39-bea8-5f680e42615a\\\", \\\"childbox\\\": \\\"0f105d1c-0114-409c-8429-5a5ffd2a83fd\\\", \\\"subtext\\\": \\\"066130de-dc9f-4e5e-813e-5a129120dfc7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1751, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Information on the status of the mother and child will be forwarded to GSK.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 71, \\\"end_idx\\\": 73, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 71, \\\"end_idx\\\": 73, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"8e2f2ff6-4f8a-4a39-bea8-5f680e42615a\\\", \\\"childbox\\\": \\\"18452c3b-0c3d-4599-9ff3-78aeeaa30780\\\", \\\"subtext\\\": \\\"066130de-dc9f-4e5e-813e-5a129120dfc7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1752, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery date.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5ec6c665-b210-4552-8bbd-d76aa2abb15c\\\", \\\"childbox\\\": \\\"9d76f30b-9c57-4dad-b72a-54c231244f3b\\\", \\\"subtext\\\": \\\"81b1a3f6-f3e5-4b97-a8e7-34d9a6a50959\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1753, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5ec6c665-b210-4552-8bbd-d76aa2abb15c\\\", \\\"childbox\\\": \\\"be131529-19fa-470e-be3c-3ddcaf4b7084\\\", \\\"subtext\\\": \\\"81b1a3f6-f3e5-4b97-a8e7-34d9a6a50959\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1754, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Female Participants who become pregnant\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"af508ddc-2903-4641-a545-2a717b19ea49\\\", \\\"childbox\\\": \\\"2a7c7096-8387-4a4d-a50b-70424dea5fa5\\\", \\\"subtext\\\": \\\"3c83f57f-c703-4f05-bcc7-4a48a63e6c75\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1755, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Investigator will collect pregnancy information on any female participant, who becomes pregnant while participating in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"0c319737-ae77-4c9c-a782-64437c42cedd\\\", \\\"childbox\\\": \\\"3985e8dd-5237-4895-a271-ab84f9f5538e\\\", \\\"subtext\\\": \\\"83f959fe-93b0-442a-8d5d-442fb1440bc7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1756, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Information will be recorded on the appropriate form and submitted to GSK within 24 hours of learning of a participant\\\\u2019s pregnancy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 72, \\\"end_idx\\\": 74, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 72, \\\"end_idx\\\": 74, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"743b908f-da3e-4862-94a1-735de63390c5\\\", \\\"childbox\\\": \\\"6a62066f-a32d-4c73-8aa8-1b0b3f604317\\\", \\\"subtext\\\": \\\"92969ce1-256b-4bb5-97d4-129e11587e12\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1757, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Participant will be followed to determine the outcome of the pregnancy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5f34621e-5ed1-4e3f-b3bf-297ea7960b6e\\\", \\\"childbox\\\": \\\"6474be7d-4df5-46fc-9c88-e81a905e83fe\\\", \\\"subtext\\\": \\\"af3ac5dc-b683-44d8-bd37-12e8c763f4f6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1758, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator will collect follow up information on participant and neonate, which will be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 107, \\\"end_idx\\\": 109, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 107, \\\"end_idx\\\": 109, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5f34621e-5ed1-4e3f-b3bf-297ea7960b6e\\\", \\\"childbox\\\": \\\"a29ead69-a1f1-4fe9-ac44-51ba0e6091b8\\\", \\\"subtext\\\": \\\"af3ac5dc-b683-44d8-bd37-12e8c763f4f6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1759, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"00246cc3-bfe2-4aff-8f82-91e9c291d358\\\", \\\"childbox\\\": \\\"9648b5a1-3ee1-4604-b087-b6e42b698884\\\", \\\"subtext\\\": \\\"99630739-24ef-4ee3-bc92-7331abffff2b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1760, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6266c0f8-ab43-41d6-b32e-88fd3d507f6d\\\", \\\"childbox\\\": \\\"4db58adb-e877-4791-9a56-b7e6d29fd358\\\", \\\"subtext\\\": \\\"8c3d9467-6675-46cd-867d-59145bf1c94b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1761, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A spontaneous abortion is always considered to be an SAE and will be reported as such.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"abba5a62-8458-4c19-8b33-8fb9c8297862\\\", \\\"childbox\\\": \\\"3e98821f-def3-494d-855e-c013fe89b059\\\", \\\"subtext\\\": \\\"1abd1748-7ebb-4ec8-823d-b1a98e0bdf73\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1762, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Any SAE occurring as a result of a post-study pregnancy which is considered reasonably related to the study intervention by the investigator, will be reported to GSK as described in Appendix 3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 164, \\\"end_idx\\\": 166, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}, {\\\"start_idx\\\": 164, \\\"end_idx\\\": 166, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"GSK\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"24669cdb-716a-4194-913a-9b6979b2262b\\\", \\\"childbox\\\": \\\"ea786e6d-b02c-41b4-83b9-30a1782ed3e9\\\", \\\"subtext\\\": \\\"5f3a43e6-2f43-4cdd-8b2c-6998890f51b7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1763, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"24669cdb-716a-4194-913a-9b6979b2262b\\\", \\\"childbox\\\": \\\"587980f1-8c10-4c9c-a654-4dac1a9b3776\\\", \\\"subtext\\\": \\\"c2e022d5-6948-47ad-91e2-2a466bfc16fe\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1764, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any female participant who becomes pregnant while participating will discontinue study intervention but may continue in the study and attend all clinic visits if she wishes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2acf2602-9ee2-4922-bf7b-d6b26b9f05a1\\\", \\\"childbox\\\": \\\"37a283e1-b177-4ee4-aae0-de6d9587b4e8\\\", \\\"subtext\\\": \\\"5cf23ff5-983a-4182-9b16-aff86cc60295\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Collection of Pregnancy Information:\\\", \\\"10.4.3.\\\", \\\"3\\\", 1765, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.4.4. Contraception Eligibility Criteria for Female and Male Participants\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d6e4e0fe-5eae-4307-97d5-92c3fab68e5d\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1766, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"57aa1c0a-e913-46be-a7a5-ec0436c98e3f\\\", \\\"childbox\\\": \\\"c98e1fce-7075-4ee0-b8ac-85a7c4f81acd\\\", \\\"subtext\\\": \\\"d2a667ff-0e35-4a03-b09e-8edf5368f7c6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1767, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a. Male Participants:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"eaad444e-3d3a-4464-ab5b-3b48798e44ca\\\", \\\"childbox\\\": \\\"d9596141-71c9-46ae-bba1-ce1d9551929a\\\", \\\"subtext\\\": \\\"fd41a9e4-82e0-4616-acc4-23a1221671ad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1768, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Male participants are eligible to participate if they agree to the following during the intervention period and for at least 12 weeks post last dose of study intervention:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4c0c5e36-c773-444c-8985-4806fa307717\\\", \\\"childbox\\\": \\\"878698bf-4467-4b8b-8253-922824eab999\\\", \\\"subtext\\\": \\\"a49aa934-e6d7-4002-a749-3cf2bc90b16a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1769, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Refrain from donating sperm PLUS, either:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8fd4ff23-0a15-43de-8137-43593d039388\\\", \\\"childbox\\\": \\\"f65f2a05-3d9f-46df-b399-b0274db1cfed\\\", \\\"subtext\\\": \\\"3c65be17-367c-469e-82af-b256256b1c2e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1770, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Be abstinent from heterosexual or homosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"31874757-22ac-4f4b-9733-3d0cf20417a1\\\", \\\"childbox\\\": \\\"ddf5571f-f74f-4825-be67-44b0843fc0bf\\\", \\\"subtext\\\": \\\"1b25dffe-b982-46ef-9df4-692f1e9dde83\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1771, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"OR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e15347dc-0b47-4091-ab11-22a2ee598890\\\", \\\"childbox\\\": \\\"96961fc9-dbec-4746-a1be-594b6dd414f4\\\", \\\"subtext\\\": \\\"421fabc0-6bde-4b95-9e3a-603bdabbecd8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1772, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Must agree to use contraception/barrier as detailed below\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"645db610-922a-4eef-b5a7-be2ddbd34ce3\\\", \\\"childbox\\\": \\\"be5083f7-9eb3-436b-9c10-da000479d6ec\\\", \\\"subtext\\\": \\\"cea57f29-5d4d-46b5-a5c8-e2186f59c9d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1773, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"645db610-922a-4eef-b5a7-be2ddbd34ce3\\\", \\\"childbox\\\": \\\"be5083f7-9eb3-436b-9c10-da000479d6ec\\\", \\\"subtext\\\": \\\"7aea3ad8-5229-4f94-99f9-310373d9f7fc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1774, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Agree to use a male condom AND female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year (as described in Section 10.4.2) when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"645db610-922a-4eef-b5a7-be2ddbd34ce3\\\", \\\"childbox\\\": \\\"be5083f7-9eb3-436b-9c10-da000479d6ec\\\", \\\"subtext\\\": \\\"01127392-831b-46c0-98a7-e10fea45d3be\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1775, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b. Female Participants:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f107bd4e-bbe5-448e-8681-200d150cf89c\\\", \\\"childbox\\\": \\\"bcb5aa69-02e5-4df3-a6d3-1cb65c53b3c6\\\", \\\"subtext\\\": \\\"fd545b1b-02a4-495f-8f11-3e4090b337ac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1776, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3ab39595-ec0f-4a56-af7b-1fd74f14410e\\\", \\\"childbox\\\": \\\"a6b003ba-51d2-47fa-b648-4c0ec540de64\\\", \\\"subtext\\\": \\\"3ca6992c-d8e6-449e-8d34-f09e258fec35\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1777, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o Is NOT a woman of childbearing potential (WOCBP) as defined in Section\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2f2926d2-d17f-44b9-afe1-66a00ebce260\\\", \\\"childbox\\\": \\\"eea2cc1d-53da-45bd-9a5d-0ae438f61301\\\", \\\"subtext\\\": \\\"77fad0ea-d3f7-415d-8996-d71cd3bca14d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1778, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.4.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5de70d7f-a9ec-4cc1-a34d-1a839df1cf17\\\", \\\"childbox\\\": \\\"cb26af98-8691-41a0-8521-7653e9e7adc9\\\", \\\"subtext\\\": \\\"0c525280-9511-4a14-92c8-3601e8a25096\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1779, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"OR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dec46cf6-787e-43e2-a0ca-003ff99c1586\\\", \\\"childbox\\\": \\\"c793be34-d657-4b1c-8051-98207198717b\\\", \\\"subtext\\\": \\\"9d02e1bf-169e-4569-9e7a-d2edc465d6ae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1780, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o Is a WOCBP and using two contraceptive methods that are highly effective\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"98a9ff3e-c89b-4b1d-997a-3c28608b75f4\\\", \\\"childbox\\\": \\\"219424ff-b4a7-40db-8d76-f88eb15a5848\\\", \\\"subtext\\\": \\\"8dd2a51e-096e-4783-b02b-9e02e74c085e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1781, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(with a failure rate of <1% per year), with low user dependency (see Section 10.4.2), for 30 days before the first dose of study intervention, during the intervention period and at least 12 weeks after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"236c96c9-beb2-4639-b58e-b1e15c0d13b0\\\", \\\"childbox\\\": \\\"177b3313-4ff5-476c-a402-7a2b7f521021\\\", \\\"subtext\\\": \\\"117a75d2-9ffc-46dc-b4ff-ddb4d762c11d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1782, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"236c96c9-beb2-4639-b58e-b1e15c0d13b0\\\", \\\"childbox\\\": \\\"b372c2ca-6b63-4184-aea7-6a315364798c\\\", \\\"subtext\\\": \\\"799b1e6d-d669-441d-998c-490a37f240a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1783, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 In addition to contraception requirements for study medication as outlined above, participants should follow csDMARD local labelling.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"405e8766-7f98-43eb-bab7-c34bed80baec\\\", \\\"childbox\\\": \\\"6d8ba4fc-7a17-4b14-8280-5df223d19f30\\\", \\\"subtext\\\": \\\"d9e25b84-791d-4d3d-9048-42a0f74cc191\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1784, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A WOCBP must have both:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ad52c699-9e1b-4477-b5fe-f8f8351d8a9e\\\", \\\"childbox\\\": \\\"a0435342-0fcc-44ba-944e-0f764548be14\\\", \\\"subtext\\\": \\\"a835f934-815f-4ba3-839c-53bf51913fc1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1785, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A confirmed menstrual period prior to the first dose of study intervention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6fac92be-cb7f-46df-95fe-4dd62b653b8f\\\", \\\"childbox\\\": \\\"46666e12-8631-4ccd-a5ea-b94c0607f4db\\\", \\\"subtext\\\": \\\"1972137a-b7e4-4e74-9125-eb45b736394b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1786, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AND\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f86a0802-34a7-434f-a6d0-e9af96d02d24\\\", \\\"childbox\\\": \\\"10c4234d-8681-46ad-a96e-30da37b36cc9\\\", \\\"subtext\\\": \\\"55d66ec0-aded-4e03-ab9c-c1b6fd4877cf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1787, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37eb3927-cfa4-4c3d-bc60-c34785ae5eb1\\\", \\\"childbox\\\": \\\"6950303f-5b89-46cc-b92f-3d00ff258076\\\", \\\"subtext\\\": \\\"222b2d99-0534-4125-974e-320748843b4a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1788, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"73f44632-7bd8-4bc3-b811-469ed6a70e78\\\", \\\"childbox\\\": \\\"307c5663-c687-4130-a5d2-e085a86ff65a\\\", \\\"subtext\\\": \\\"71a76532-1537-4b25-8c76-d9e1be12736b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1789, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"73f44632-7bd8-4bc3-b811-469ed6a70e78\\\", \\\"childbox\\\": \\\"27bd0533-8f57-4386-958b-b043df7b33e0\\\", \\\"subtext\\\": \\\"29ea9881-e9cb-48cd-9b91-772ce44e9634\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1790, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"37ca5ec6-eca0-4a7d-812f-302faa301982\\\", \\\"childbox\\\": \\\"450f9ed4-e6db-40c0-9abd-be9e97217f45\\\", \\\"subtext\\\": \\\"a86478ed-c75e-4570-8886-fc62bcdc2a42\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1791, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pregnancy tests for WOCBP are specified in the SoA (Section 1.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8fe981e2-821d-4814-8b56-3a365006ffc5\\\", \\\"childbox\\\": \\\"d2c570f8-fe28-4135-a88b-23ed66857c57\\\", \\\"subtext\\\": \\\"5cdd259c-3159-4ce8-96d6-5de39df037f2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1792, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8fe981e2-821d-4814-8b56-3a365006ffc5\\\", \\\"childbox\\\": \\\"5be0bd01-dd26-4fac-9bad-ac0b8ef9148f\\\", \\\"subtext\\\": \\\"f2449582-607a-4b0e-954f-b0f5054492f6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Contraception Eligibility Criteria for Female and Male Participants\\\", \\\"10.4.4.\\\", \\\"3\\\", 1793, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"header\\\", \\\"10.5. Appendix 5: Genetics\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4f3e8089-6026-4bba-9c73-b3310699db83\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1794, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"USE/ANALYSIS OF DNA\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4ef6e061-6af3-40fd-99be-b7eb416ee577\\\", \\\"childbox\\\": \\\"cfaba04c-3021-4d33-9469-7369e62306c2\\\", \\\"subtext\\\": \\\"cf9432ad-83a7-433c-b02a-2c9dab2a9f0a\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1795, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"\\\\u2022 Genetic variation may impact a participant\\\\u2019s response to study intervention, susceptibility, severity and progression of disease.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"38190201-d06f-4444-a536-e1a6fd29250d\\\", \\\"childbox\\\": \\\"e61e70ec-771e-4a28-9257-5be88f8a14bb\\\", \\\"subtext\\\": \\\"0f3ca61d-91c5-41f9-a412-430faf2cc3b5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1796, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"Variable response to study intervention may be due to genetic determinants that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of the drug; disease etiology; and/or molecular subtype of the disease being treated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"38190201-d06f-4444-a536-e1a6fd29250d\\\", \\\"childbox\\\": \\\"c81f2f0b-91ea-47a0-80e8-091b9ea7a225\\\", \\\"subtext\\\": \\\"c8688147-1a45-4dc3-b7ad-901152a97537\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1797, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"Therefore, where local regulations and IRB/IEC allow, a blood sample will be collected for DNA analysis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"38190201-d06f-4444-a536-e1a6fd29250d\\\", \\\"childbox\\\": \\\"74c96572-bafd-47f6-8aaf-4e8532a9558b\\\", \\\"subtext\\\": \\\"c9485c77-02a0-4211-ae37-7e91ab654565\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1798, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"\\\\u2022 DNA samples will be used for research related to GSK3196165 or RA and related diseases.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 51, \\\"end_idx\\\": 60, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"8c573c48-6107-4a86-971a-10b3d5afd5bc\\\", \\\"childbox\\\": \\\"6929cb6c-472f-44f9-9de3-a2d3a809f973\\\", \\\"subtext\\\": \\\"f2334883-9f64-4951-9ba4-05e2bffd86d9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1799, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"They may also be used to develop tests/assays (including diagnostic tests) related to GSK3196165, and RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 86, \\\"end_idx\\\": 95, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"8c573c48-6107-4a86-971a-10b3d5afd5bc\\\", \\\"childbox\\\": \\\"a4a1bf9c-1119-45d4-a36e-3ac285ef3f9d\\\", \\\"subtext\\\": \\\"f2334883-9f64-4951-9ba4-05e2bffd86d9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1800, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"Genetic research may consist of the analysis of one or more candidate genes or the analysis of genetic markers throughout the genome or analysis of the entire genome (as appropriate)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"8c573c48-6107-4a86-971a-10b3d5afd5bc\\\", \\\"childbox\\\": \\\"cd56cf52-8364-4849-b2c1-3583cdb82da6\\\", \\\"subtext\\\": \\\"ae0a7fd3-fbc0-4a24-a100-520ab690f09f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1801, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"\\\\u2022 DNA samples will be analysed if it is hypothesised that this may help further understand the clinical data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c056575f-5a02-4709-97af-3a42e450dc56\\\", \\\"childbox\\\": \\\"390161a7-deb3-4188-bc13-c89802bdcd61\\\", \\\"subtext\\\": \\\"b4261e51-96f9-4728-aee9-d7917a497a2b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1802, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"\\\\u2022 The samples may be analysed as part of a multi-study assessment of genetic factors involved in the response to GSK3196165 or study interventions of this class. The results of genetic analyses may be reported in the clinical study report or in a separate study summary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 113, \\\"end_idx\\\": 122, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"1a397a9b-1eeb-4417-be29-2b1bbb042562\\\", \\\"childbox\\\": \\\"924e196d-36cc-4a8d-b422-1461403182f1\\\", \\\"subtext\\\": \\\"0c439899-ac52-4ece-bb70-0965cb3367e5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1803, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"\\\\u2022 The sponsor will store the DNA samples in a secure storage space with adequate measures to protect confidentiality.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3c161029-6e31-4f7d-9eda-ebe4ef2b7cf0\\\", \\\"childbox\\\": \\\"eb132e97-4923-4224-9484-912a618bad53\\\", \\\"subtext\\\": \\\"f5430763-b210-41c1-838d-f89d0109454b\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1804, \\\"\\\"], [\\\"2\\\", \\\"Appendix 5: Genetics\\\", \\\"text\\\", \\\"\\\\u2022 The samples will be retained while research on GSK3196165 (or study interventions of this class) or RA continues but no longer than 15 years after the last participant last visit or other period as per local requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 49, \\\"end_idx\\\": 58, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4e4876b0-8ba8-45c9-b96f-b7149f12cde3\\\", \\\"childbox\\\": \\\"6a11582e-9bce-4a15-9ade-2de31191015f\\\", \\\"subtext\\\": \\\"dbca4ea6-d29b-453f-b691-c34bd92ba12a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 5: Genetics\\\", \\\"10.5.\\\", \\\"2\\\", 1805, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.6. Appendix 6: Liver chemistry stopping and monitoring criteria and required actions and follow up assessments (study specific for 202018)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e38db1f3-086a-4d29-b9ba-f0853d1088e5\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 6: Liver chemistry stopping and monitoring criteria and required actions and follow up assessments (study specific for 202018)\\\", \\\"10.6.\\\", \\\"2\\\", 1806, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Liver chemistry stopping and increased monitoring criteria\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7c80fcf0-e212-408c-b759-f6a58a5fd7b4\\\", \\\"childbox\\\": \\\"2c15fb3b-48fd-487a-9150-a06fcec34443\\\", \\\"subtext\\\": \\\"4b632d9a-5c18-440c-85d7-39d329e1c1fb\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 6: Liver chemistry stopping and monitoring criteria and required actions and follow up assessments (study specific for 202018)\\\", \\\"10.6.\\\", \\\"2\\\", 1807, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"have been designed to assure participant safety and evaluate liver event etiology\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"7c80fcf0-e212-408c-b759-f6a58a5fd7b4\\\", \\\"childbox\\\": \\\"2c15fb3b-48fd-487a-9150-a06fcec34443\\\", \\\"subtext\\\": \\\"a270ebd2-9ebe-44c9-b966-67b40865c2dc\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 6: Liver chemistry stopping and monitoring criteria and required actions and follow up assessments (study specific for 202018)\\\", \\\"10.6.\\\", \\\"2\\\", 1808, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.6.1. Liver chemistry stopping criteria and required follow up\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d70ecf54-3df9-4a2a-98d2-2ca80363d178\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1809, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"39945535-d42e-4173-8ce8-ecb86cb438c7\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1810, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e75af592-8f56-4dd6-b9f1-cb3609b550e2\\\", \\\"childbox\\\": \\\"f2e1e591-56a5-4bc5-abc7-62ac4dab7c13\\\", \\\"subtext\\\": \\\"4515431f-1c0a-4260-b1b4-611db26e2dd3\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1811, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Serum bilirubin fractionation should be performed if testing is available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"502c69e5-3c6a-4a7e-8e86-9598cd6e8874\\\", \\\"subtext\\\": \\\"c3d4fcd5-aa1c-4822-bd67-740ea8edca2c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1812, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If serum bilirubin fractionation is not immediately available, discontinue study intervention for that participant if ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"66c9a898-0a76-4dec-b144-c491510ae48d\\\", \\\"subtext\\\": \\\"c3d4fcd5-aa1c-4822-bd67-740ea8edca2c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1813, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"66c9a898-0a76-4dec-b144-c491510ae48d\\\", \\\"subtext\\\": \\\"d263a97b-fe0b-4cad-84ed-87149f7626bf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1814, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3xULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"66c9a898-0a76-4dec-b144-c491510ae48d\\\", \\\"subtext\\\": \\\"9986b50f-a068-4107-a68e-4c6299fc58fd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1815, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"66c9a898-0a76-4dec-b144-c491510ae48d\\\", \\\"subtext\\\": \\\"109aff39-1f9b-4e2d-ae0c-8704d77edf84\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1816, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"bilirubin\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"66c9a898-0a76-4dec-b144-c491510ae48d\\\", \\\"subtext\\\": \\\"7e56345b-0149-4018-9b92-52717547b021\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1817, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"66c9a898-0a76-4dec-b144-c491510ae48d\\\", \\\"subtext\\\": \\\"e2176d7e-bbfb-4366-889e-02219e59b6a4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1818, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2xULN.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"66c9a898-0a76-4dec-b144-c491510ae48d\\\", \\\"subtext\\\": \\\"48e367fc-b78a-4cf6-bd08-439062d81fc8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1819, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additionally, if serum bilirubin fractionation testing is unavailable,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"693b6d65-b485-4277-985f-62342c022fda\\\", \\\"subtext\\\": \\\"48e367fc-b78a-4cf6-bd08-439062d81fc8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1820, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"record presence of detectable urinary bilirubin on dipstick\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"693b6d65-b485-4277-985f-62342c022fda\\\", \\\"subtext\\\": \\\"8efb3ef9-629e-452a-b150-601c10c869c9\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1821, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"indicating direct bilirubin elevations and suggesting liver injury.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2afdff9d-c962-479b-a8bc-343a8b871aab\\\", \\\"childbox\\\": \\\"693b6d65-b485-4277-985f-62342c022fda\\\", \\\"subtext\\\": \\\"99401f11-15c6-4a92-b5fa-d17aaa06d049\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1822, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All events of ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"25da5056-cf8e-43e2-a3c8-a9951b0f1915\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1823, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"484c75c1-2460-4c75-96fc-966e584861e1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1824, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3xULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"cbb3aa2a-ac93-46c3-bcb1-281e915e5f42\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1825, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"0c41afce-609e-4b02-bcdb-318a21351d7e\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1826, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"bilirubin\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"ffa805c7-e966-4489-be1a-f1680b87f72a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1827, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"abb439e2-034d-4cba-a05e-06aecb23e721\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1828, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2xULN (>35% direct bilirubin) or ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"58757ce7-9a87-40f6-ae16-b42a359808d7\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1829, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"98c32e21-f776-440d-8d4e-6fecaf0d8f60\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1830, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3xULN\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"6fd7e5dc-7f8b-444b-8b14-778efc65383e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1831, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"62a9c45e-b4b7-4769-974c-634bf4691863\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1832, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"INR>1.5 which may indicate severe liver injury (possible \\\\u2018Hy\\\\u2019s Law\\\\u2019),\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"19f87dbb-2172-4204-806f-6316818150b0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1833, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"must be reported as an SAE (excluding studies of hepatic impairment or cirrhosis)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"a4dec5d4-1f10-49ec-b498-2275e58e5c0d\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1834, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"; the INR threshold value stated will not apply to participants receiving anticoagulants\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 74, \\\"end_idx\\\": 87, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"anticoagulants\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"418b3ed3-fd81-438a-a443-86f87f4e9169\\\", \\\"childbox\\\": \\\"cecb95ba-bd39-4e5c-b055-6c92513a3bde\\\", \\\"subtext\\\": \\\"057c61f1-2f0a-4cfd-b588-7e4520e88083\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1835, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or eosinophilia)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"aa6a9feb-b06c-4613-a439-ef619e194449\\\", \\\"childbox\\\": \\\"e25d9428-df0e-4ab5-9381-aaacbe4fc74a\\\", \\\"subtext\\\": \\\"30ac93c2-8be4-4466-ae6f-578fdb460434\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1836, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. Includes:Hepatitis A immunoglobulin M (IgM) antibody; Hepatitis B surface antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb); Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 86, \\\"end_idx\\\": 90, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"HBsAg\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"4dc5c6d6-8854-45a3-aa9a-4d50ccb22c97\\\", \\\"childbox\\\": \\\"46b8e13a-ce29-4c01-80e3-b36d14251dec\\\", \\\"subtext\\\": \\\"4833b65a-77ae-4dde-9f9d-0f5a3a01e1c8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1837, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5. PK sample may not be required for participants known to be receiving placebo or non-comparator interventions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d4e011c-50d8-48a2-a79d-a694ef7cf6b4\\\", \\\"childbox\\\": \\\"56607209-ed67-43a0-b2ee-6b350718cceb\\\", \\\"subtext\\\": \\\"38f204ce-7b43-4172-85d8-c7e99f02b75f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1838, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Record the date/time of the PK blood sample draw and the date/time of the last dose of study intervention prior to the PK blood sample draw on the CRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d4e011c-50d8-48a2-a79d-a694ef7cf6b4\\\", \\\"childbox\\\": \\\"d2d6cebf-4675-41be-b7cf-a8000e9a1022\\\", \\\"subtext\\\": \\\"38f204ce-7b43-4172-85d8-c7e99f02b75f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1839, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the date or time of the last dose is unclear, provide the participant\\\\u2019s best approximation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d4e011c-50d8-48a2-a79d-a694ef7cf6b4\\\", \\\"childbox\\\": \\\"3990b873-aa00-4597-be72-2369afc5e06d\\\", \\\"subtext\\\": \\\"036e605b-aa1c-481b-86cd-b4232801a911\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1840, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in the time period indicated above, do not obtain a PK sample.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d4e011c-50d8-48a2-a79d-a694ef7cf6b4\\\", \\\"childbox\\\": \\\"39a43991-c057-44e1-ab37-f4727e1de637\\\", \\\"subtext\\\": \\\"036e605b-aa1c-481b-86cd-b4232801a911\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1841, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Instructions for sample handling and shipping are in the Central Laboratory Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5d4e011c-50d8-48a2-a79d-a694ef7cf6b4\\\", \\\"childbox\\\": \\\"d654dc7a-5703-4be5-97d2-b320d2e9fc16\\\", \\\"subtext\\\": \\\"7c7ab29f-3d56-4d57-85c9-c5eb93423f18\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1842, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.6.2. Liver chemistry increased monitoring criteria with temporary\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c3d620ca-2d46-4c64-bd2d-10afcd6a9573\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1843, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"discontinuation of study intervention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"Heading4\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f9f6622c-3b38-43c1-b64a-e2ddf6507e08\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver chemistry stopping criteria and required follow up\\\", \\\"10.6.1.\\\", \\\"3\\\", 1844, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fe74d875-f4de-48a7-ac38-8236bbcb78fc\\\", \\\"childbox\\\": \\\"ddbff70d-88df-452b-b9bd-76a98c552ff2\\\", \\\"subtext\\\": \\\"4571fc67-791b-46ad-bc06-5ab15a35750c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1845, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"342876d6-c0d5-4464-a319-37af45ac7483\\\", \\\"childbox\\\": \\\"2f702ad6-2dd3-4c68-bbc3-f64a97f48e14\\\", \\\"subtext\\\": \\\"9f449843-bbc0-4add-ad6c-2409707bd0e9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1846, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"342876d6-c0d5-4464-a319-37af45ac7483\\\", \\\"childbox\\\": \\\"2f702ad6-2dd3-4c68-bbc3-f64a97f48e14\\\", \\\"subtext\\\": \\\"bda55aa2-56b9-4c91-8ae6-86b4dc6b1256\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1847, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3xULN, temporarily discontinue study intervention and monitor weekly for up to 4 weeks.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"342876d6-c0d5-4464-a319-37af45ac7483\\\", \\\"childbox\\\": \\\"2f702ad6-2dd3-4c68-bbc3-f64a97f48e14\\\", \\\"subtext\\\": \\\"89228c4c-b897-4d5b-84c3-892d4298d029\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1848, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If participant cannot be monitored, then permanently discontinue study intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"342876d6-c0d5-4464-a319-37af45ac7483\\\", \\\"childbox\\\": \\\"e230aa8d-5887-4d7a-a584-532641aa946f\\\", \\\"subtext\\\": \\\"89228c4c-b897-4d5b-84c3-892d4298d029\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1849, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After temporary discontinuation, study intervention may be restarted if ALT <1.5xULNwith additional monitoring.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"342876d6-c0d5-4464-a319-37af45ac7483\\\", \\\"childbox\\\": \\\"82b3e3b3-8580-4da7-9b38-a73c3612d6f7\\\", \\\"subtext\\\": \\\"89228c4c-b897-4d5b-84c3-892d4298d029\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1850, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"342876d6-c0d5-4464-a319-37af45ac7483\\\", \\\"childbox\\\": \\\"12942cf1-cd0a-4a0e-bdbe-3c687e3f382d\\\", \\\"subtext\\\": \\\"3461c982-e9ae-4cb7-9116-e16602cdd715\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1851, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f018f481-fa06-4048-aa3b-6d4607ce4208\\\", \\\"childbox\\\": \\\"e1246fa4-a821-4ba3-96a5-1954695cdb8b\\\", \\\"subtext\\\": \\\"652b6d94-6d84-4da1-8a9c-edbfc4ffa40d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1852, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3c8fb2ca-e0fa-4e17-9b51-0d0b2a7ade15\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1853, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"References\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ea43e230-6619-45ed-bbd6-e1b6a5d0ccdc\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1854, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee WM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 7, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"James LP\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ec318c2a-d53e-4823-ae1d-9e05860628b8\\\", \\\"childbox\\\": \\\"6f2b97ba-4e02-48c0-86dd-f942e3dcff33\\\", \\\"subtext\\\": \\\"1c56c18c-4080-4c11-9c1c-0c18aeb9e259\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1855, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen Overdose and Acute Liver Failure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 20, \\\"end_idx\\\": 39, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Acetaminophen-Adduct\\\"}, {\\\"start_idx\\\": 20, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Acetaminophen\\\"}, {\\\"start_idx\\\": 56, \\\"end_idx\\\": 68, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"Acetaminophen\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"ec318c2a-d53e-4823-ae1d-9e05860628b8\\\", \\\"childbox\\\": \\\"1a82c22b-11c8-40a5-8a0a-b98f558f8f59\\\", \\\"subtext\\\": \\\"16b85355-4a2b-4079-8f08-ae838e2888d8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1856, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Drug Metab Dispos 2009; 37:1779-1784.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ec318c2a-d53e-4823-ae1d-9e05860628b8\\\", \\\"childbox\\\": \\\"9ece89c8-e373-4be2-92bc-25489431116e\\\", \\\"subtext\\\": \\\"16b85355-4a2b-4079-8f08-ae838e2888d8\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Liver Chemistry Increased Monitoring Criteria \\\\u2013 Liver Monitoring Event with temporary discontinuation of study intervention\\\", \\\"10.6.2.\\\", \\\"3\\\", 1857, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.7. Appendix 7: Summary of composite endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bac0e6ae-67cf-449b-a874-dd57e2d9f5f9\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 7: Summary of composite endpoints\\\", \\\"10.7.\\\", \\\"2\\\", 1858, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These composite endpoints are calculated automatically by the ePRO and eCRF systems, using the data collected from assessments described in Section 8.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a5210e88-0571-425f-a1ed-75e95cbeda82\\\", \\\"childbox\\\": \\\"8c25a63b-917c-411f-bef4-a21b5bd5f390\\\", \\\"subtext\\\": \\\"4846ef38-6f43-43ae-b070-29fdb9889f85\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 7: Summary of composite endpoints\\\", \\\"10.7.\\\", \\\"2\\\", 1859, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.7.1. ACR\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1669ea23-55cf-4c15-9510-1780c0f518c1\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1860, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The American College of Rheumatology\\\\u2019s definition for calculating improvement in RA (ACR20) is calculated as a 20% improvement from baseline in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR-core set measures: patient and physician global assessments, pain, disability, and an acute-phase reactant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 4, \\\"end_idx\\\": 37, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"American College of Rheumatology\\\\u2019s\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"3ededf3f-4c13-467a-bbc7-68ecc88a1f43\\\", \\\"childbox\\\": \\\"7221791c-086e-4073-be6e-e4c7b2a7204f\\\", \\\"subtext\\\": \\\"1516dc27-9d17-40e0-a1a1-985baeebd93a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1861, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Similarly, ACR50 and ACR70 are calculated with the respective percent improvement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3ededf3f-4c13-467a-bbc7-68ecc88a1f43\\\", \\\"childbox\\\": \\\"9488c317-1d16-4739-b5ba-a6534d095076\\\", \\\"subtext\\\": \\\"d60cbed0-c50f-4add-aa30-38b5368f5183\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1862, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The specific components of the ACR Assessments that will be used in this study are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fae8642c-2d63-4b71-8cc2-eb029b4d4b55\\\", \\\"childbox\\\": \\\"f02ef5b6-9a95-4349-bb21-3046525d5e1b\\\", \\\"subtext\\\": \\\"1dc51347-26fe-428b-8486-1e02c367c211\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1863, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Tender/Painful Joint count (68).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cf6665de-e52e-4596-877d-632a8877578d\\\", \\\"childbox\\\": \\\"5f50a41b-37f9-4a77-89ad-0e6cc3e4cedf\\\", \\\"subtext\\\": \\\"c8e3a1d4-66ec-4fc9-836b-1c03bb2fd1ef\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1864, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Swollen Joint Count (66).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5250d7e2-6740-43d3-aa1f-fd6d98769715\\\", \\\"childbox\\\": \\\"7f002802-8765-4b36-831a-a6a626b3719c\\\", \\\"subtext\\\": \\\"0b2464b9-4df2-483f-b111-e9451bd174d5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1865, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Pain VAS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"53977d01-d1fd-4793-9438-a9529c9c573e\\\", \\\"childbox\\\": \\\"038a6b04-8d8b-4086-a7b2-fba6b5f19fde\\\", \\\"subtext\\\": \\\"43476f4e-0eb0-42a3-9e14-c8c4a9ceab77\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1866, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Patient\\\\u2019s Global Assessment of Arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6d536c2f-63ac-449b-888f-9b32ea6abe42\\\", \\\"childbox\\\": \\\"f0c7cdd6-f9de-4532-9506-7f66ac4cc5c5\\\", \\\"subtext\\\": \\\"e81889b5-3312-4945-8845-dbe83742737a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1867, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Physician\\\\u2019s Global Assessment of Arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ac2bb629-20fd-4ab6-b538-cb121e38c170\\\", \\\"childbox\\\": \\\"2ff140ba-c9c8-48c7-ac14-9420190181db\\\", \\\"subtext\\\": \\\"75145404-d793-4fca-8bf6-cdadb537c139\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1868, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Acute-phase reactant (hsCRP or ESR).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"26370baf-ad4d-4769-a37d-bb782a1c352a\\\", \\\"childbox\\\": \\\"7ca12fe7-6f21-4823-9b1e-0bcc1c3b2e4f\\\", \\\"subtext\\\": \\\"918a26d2-3bda-407a-af33-1b56028df6d1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1869, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Health Assessment Questionnaire \\\\u2013 Disability Index (HAQ-DI).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3535747f-42da-446a-b65f-dd81bcdd79e6\\\", \\\"childbox\\\": \\\"f73effb9-44fb-494b-8776-8b93a9ac19be\\\", \\\"subtext\\\": \\\"7645d242-244a-4fc4-9025-a97a87a2a779\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"ACR\\\", \\\"10.7.1.\\\", \\\"3\\\", 1870, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.7.2. Disease Activity Score\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b2104b3d-e5ba-48e4-ace0-9d266910acff\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1871, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Disease Activity Score (DAS) assessment is a derived measurement with differential weighting given to each component.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d1772b2a-8830-4add-bdc1-3952f75debb7\\\", \\\"childbox\\\": \\\"716de9ff-a219-4983-97f7-30de9e63098a\\\", \\\"subtext\\\": \\\"1a2c3350-9795-484d-80bf-b2dadadf3df2\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1872, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The DAS 28(CRP) or DAS 28(ESR) will be calculated at each assessment timepoint.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d1772b2a-8830-4add-bdc1-3952f75debb7\\\", \\\"childbox\\\": \\\"76dccb35-d97f-4dc1-8326-93155b1f8b3f\\\", \\\"subtext\\\": \\\"8b464dae-5e14-49de-becb-a8d58ece1829\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1873, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The components of the DAS 28 arthritis assessment include:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"088efac1-e4be-4575-a46e-30d8d3861b0e\\\", \\\"childbox\\\": \\\"ffb56802-c9a1-49fc-944b-0e532949920a\\\", \\\"subtext\\\": \\\"cad96b09-79b4-46df-9f2f-a32d5acd2a9f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1874, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Tender/Painful Joint Count (28).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6cb4b3a9-6d72-4380-bc5f-fa874d7ed63d\\\", \\\"childbox\\\": \\\"465caede-e035-45fb-8c7f-3196dbdc00a9\\\", \\\"subtext\\\": \\\"8a4f140f-c31a-4304-a5b3-e5fae7a47561\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1875, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Swollen Joint Count (28).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"950d08e2-db71-4357-a499-91b174a92d47\\\", \\\"childbox\\\": \\\"c3a69059-afa8-480d-a162-5778df7f8fba\\\", \\\"subtext\\\": \\\"01c64133-7132-4866-9edb-0585c28cefb0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1876, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 hsCRP or ESR.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"560e9821-8928-4dcd-ac69-d1bef84bece7\\\", \\\"childbox\\\": \\\"1e830723-5ecc-4cfc-bf26-65343d4e1d10\\\", \\\"subtext\\\": \\\"3cb8a4db-0247-42ec-be90-52e02c3ea489\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1877, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Patient\\\\u2019s Global Assessment of Arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f477aff1-e783-4c94-96e4-740e76bc5366\\\", \\\"childbox\\\": \\\"1b9726cf-29d3-411e-9022-4bec1fdfc91c\\\", \\\"subtext\\\": \\\"230583f0-debb-4754-afc8-51e9caad267d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Disease Activity Score\\\", \\\"10.7.2.\\\", \\\"3\\\", 1878, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.7.3. Clinical Disease Activity Index (CDAI)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"03e772a7-5746-440c-8bd4-5b3255a69d61\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1879, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The CDAI for rheumatoid arthritis is a clinical composite score to determine disease severity using only clinical data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"456df413-5557-4cfb-bc21-29e97bf3a07a\\\", \\\"childbox\\\": \\\"a3b46a55-aa20-4273-b6bf-af7f3f4dd172\\\", \\\"subtext\\\": \\\"1071ac00-2e89-45d0-85d4-4e686889fea5\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1880, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The CDAI score will be calculated at each assessment timepoint.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"456df413-5557-4cfb-bc21-29e97bf3a07a\\\", \\\"childbox\\\": \\\"b8ddde12-c6c9-4ec7-84f9-dca5debbb5dc\\\", \\\"subtext\\\": \\\"4a9d8172-8abc-4e7f-86a2-8dd50a5391ed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1881, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The components of the CDAI include:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"08fe1dca-fe43-4f23-acb6-50fc24d43c46\\\", \\\"childbox\\\": \\\"c1dd394b-79ab-4d2c-9e70-eef9f7fc68aa\\\", \\\"subtext\\\": \\\"f3070157-d2b6-4f0c-b2cd-6887b41ccd5d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1882, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Tender/Painful Joint Count (28).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"288e53d5-51cd-494c-866a-c1878f214e3a\\\", \\\"childbox\\\": \\\"0aeaa287-b276-4061-815e-9265e55f87eb\\\", \\\"subtext\\\": \\\"6ce97ef3-934e-41b6-80f2-3a3002912992\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1883, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Swollen Joint Count (28).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"50bade7a-478d-480d-8e86-e64162272657\\\", \\\"childbox\\\": \\\"2f5d245c-681b-48c3-b43d-e86d9164a882\\\", \\\"subtext\\\": \\\"f5b4cad7-43af-44b5-95de-18f00ed2aef1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1884, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Patient\\\\u2019s Global Assessment of Arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ec4692cb-0263-4aae-a145-a9cecd551d75\\\", \\\"childbox\\\": \\\"4633885d-704b-44a7-b663-3e9f066b3a5d\\\", \\\"subtext\\\": \\\"21b94f6d-3b14-419f-99d3-6567038aa9ac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1885, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Physician\\\\u2019s Global Assessment of Arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"13a8b81d-a91c-4d6b-a857-ef492d518228\\\", \\\"childbox\\\": \\\"bce32be2-45bc-414e-8b4e-00efd7940613\\\", \\\"subtext\\\": \\\"7dd7cc43-c035-4428-bbcc-b021ceff1e5f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1886, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"13a8b81d-a91c-4d6b-a857-ef492d518228\\\", \\\"childbox\\\": \\\"fa21ca83-81ee-4868-b527-10fed6af1f5e\\\", \\\"subtext\\\": \\\"31f2fcdd-7932-43ff-a510-994e0adeedd6\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Clinical Disease Activity Index (CDAI)\\\", \\\"10.7.3.\\\", \\\"3\\\", 1887, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.8. Appendix 8: Hierarchy Options to Demonstrate Superiority of Each Dose of GSK3196165 Versus Placebo or Sarilumab\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [{\\\"start_idx\\\": 79, \\\"end_idx\\\": 88, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"GSK3196165\\\"}, {\\\"start_idx\\\": 108, \\\"end_idx\\\": 116, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"Sarilumab\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"5f8f8d83-610f-4b34-b680-df4bbb4274a6\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 8: Hierarchy Options to Demonstrate Superiority of Each Dose of GSK3196165 Versus Placebo or Sarilumab\\\", \\\"10.8.\\\", \\\"2\\\", 1888, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"187e0188-13cf-458a-81a2-6b6838ace41a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 8: Hierarchy Options to Demonstrate Superiority of Each Dose of GSK3196165 Versus Placebo or Sarilumab\\\", \\\"10.8.\\\", \\\"2\\\", 1889, \\\"\\\"], [\\\"2\\\", \\\"Appendix 8: Country-specific Requirements\\\", \\\"header\\\", \\\"10.9. Appendix 9: Country-specific requirements\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"88b9440e-e71d-4e0f-90f9-790025196cf3\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 9: Country-specific requirements\\\", \\\"10.9.\\\", \\\"2\\\", 1890, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.10. Appendix 10: Abbreviations and Trademarks\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6a0f5494-3540-4e08-b1b0-80d7b765b295\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1891, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Abbreviations\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6814ccb3-c9ec-4ff3-bb41-f6d7f7adcc33\\\", \\\"childbox\\\": \\\"61de8731-9d6d-4520-9388-d7247a5e256d\\\", \\\"subtext\\\": \\\"839509ff-e004-4972-ab8b-e6d1ccd87640\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1892, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"d0baeeb6-002f-403c-a3e6-a442682cdc03\\\", \\\"childbox\\\": \\\"f8fa32ee-5bdc-40ca-be73-739d25eecfe7\\\", \\\"subtext\\\": \\\"b0a733ba-840a-4212-843e-33aa8a2a40cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1893, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5a64c27c-4701-4016-883c-8e7f00c92d3a\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1894, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3743506e-831a-4144-b131-c87c84322ec0\\\", \\\"childbox\\\": \\\"f60e4a47-11bf-488b-9f38-5a7e3e74e504\\\", \\\"subtext\\\": \\\"c60ffeaf-1a8c-4019-a352-e8318b63c65c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1895, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"bd048d4a-6944-4182-8fb2-af8799725358\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1896, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"fba84ed6-9d57-4dc8-a3c6-f70b019f52a2\\\", \\\"childbox\\\": \\\"fac81db0-3430-4244-927b-2b49c4822a80\\\", \\\"subtext\\\": \\\"4e562268-8be9-4a49-8138-6b8c40bd1745\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1897, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Trademark Information\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"79d84a4a-c234-4240-9487-b89de36b96e7\\\", \\\"childbox\\\": \\\"aca4c556-f571-40d7-bbef-782f394fc285\\\", \\\"subtext\\\": \\\"e6a1fba0-5b76-4ec4-a44b-2593fbeac1c8\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1898, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e82c4ce7-962d-4867-904f-a0f556d4d9f2\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1899, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 18, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline\\\"}, {\\\"start_idx\\\": 18, \\\"end_idx\\\": 32, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"42844642-118a-437e-afc7-292dfef7ace6\\\", \\\"childbox\\\": \\\"13359d7a-33bd-4bbb-b573-7bd2c96f26e0\\\", \\\"subtext\\\": \\\"52d0792b-358f-46c5-810e-2070e1038145\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1900, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b990dd3c-d4c9-4b01-8156-21b76eb65108\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1901, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"012014c9-3940-4837-8df0-a8fd5329a276\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1902, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 28, \\\"end_idx\\\": 42, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline\\\"}, {\\\"start_idx\\\": 28, \\\"end_idx\\\": 42, \\\"standard_entity_name\\\": \\\"Sponsor Name\\\", \\\"subcategory\\\": \\\"Sponsor Name\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"GlaxoSmithKline\\\"}], \\\"roi_id\\\": {\\\"para\\\": \\\"b8e94bcf-c51c-41a5-8486-bc5d8e3f6aae\\\", \\\"childbox\\\": \\\"cf91de6c-6637-45d4-ba91-23e310887f0e\\\", \\\"subtext\\\": \\\"9ec12e63-3e08-43c4-b785-3e5d10e3529c\\\"}, \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1903, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"22225d93-c020-43d3-8b57-ed1ffb6ad6e0\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1904, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9c61327c-3467-428a-a9ea-cf778ee89589\\\", \\\"childbox\\\": \\\"40024980-6de8-42c4-9e8b-94b630ee4b3c\\\", \\\"subtext\\\": \\\"86012c81-1555-4660-853c-f7b13e41b4e1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Supporting Documentation and Operational Considerations\\\", \\\"Appendix 10: Abbreviations and Trademarks\\\", \\\"10.10.\\\", \\\"2\\\", 1905, \\\"\\\"], [\\\"1\\\", \\\"References\\\", \\\"header\\\", \\\"11. REFERENCES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"137de644-d8c9-45b3-9730-e8277e002bda\\\", \\\"childbox\\\": \\\"\\\", \\\"subtext\\\": \\\"\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1906, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheumatoid arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e66a1f57-4857-41f4-ba30-b0c9f0901afa\\\", \\\"childbox\\\": \\\"8982b494-c398-4cd2-b8b8-f0e76f41770b\\\", \\\"subtext\\\": \\\"cb234e08-ab98-41af-89a5-923fab490876\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1907, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clin Exp Rheumatol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e66a1f57-4857-41f4-ba30-b0c9f0901afa\\\", \\\"childbox\\\": \\\"b17b0fc7-9e2c-4cb4-b1fb-6ff828ea59da\\\", \\\"subtext\\\": \\\"cb234e08-ab98-41af-89a5-923fab490876\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1908, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2016, 34(4 Suppl 98):39-44.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e66a1f57-4857-41f4-ba30-b0c9f0901afa\\\", \\\"childbox\\\": \\\"39c4892e-c9ff-407d-bc5a-c09ccb01d7d1\\\", \\\"subtext\\\": \\\"cb234e08-ab98-41af-89a5-923fab490876\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1909, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Behrens F, Tak PP, \\\\u00d8stergaard M, Stoilov R, Wiland P, Huizinga TW, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dc0f9941-fbf2-490d-b90d-8f0acac0bed4\\\", \\\"childbox\\\": \\\"bac91738-87c4-4bc5-9b5d-6ea338e3b98d\\\", \\\"subtext\\\": \\\"d4b354fd-3b77-41ab-9817-e3eb185697ac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1910, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dc0f9941-fbf2-490d-b90d-8f0acac0bed4\\\", \\\"childbox\\\": \\\"213ee0d4-ef24-400f-8f61-896819daf3dd\\\", \\\"subtext\\\": \\\"d4b354fd-3b77-41ab-9817-e3eb185697ac\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1911, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ann Rheum Dis 2015;74:1058-64.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"dc0f9941-fbf2-490d-b90d-8f0acac0bed4\\\", \\\"childbox\\\": \\\"e0b5b2f1-1881-4d60-bea5-d0599ea4bfe5\\\", \\\"subtext\\\": \\\"bc9240de-0932-40fe-95da-9edbbee55e00\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1912, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Bjorner JB, Rose M, Gandek B; Stone AA, Junghaenel DU, Ware Jr JE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2361c895-9a2f-4e36-bfd2-014b3c5d6950\\\", \\\"childbox\\\": \\\"cc5aef7a-6870-46ab-9c45-18efafebea43\\\", \\\"subtext\\\": \\\"a0989b14-dc74-4912-af00-512c5aa4f50d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1913, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Method of administration of PROMIS scales did not significantly impact score level, reliability, or validity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2361c895-9a2f-4e36-bfd2-014b3c5d6950\\\", \\\"childbox\\\": \\\"d66f5827-03dc-4156-876e-0b7f9510b570\\\", \\\"subtext\\\": \\\"a4bd29e1-7708-4205-9d84-bfd34a101baf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1914, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Journal of Clinical Epidemiology 2014;67:108-113.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"2361c895-9a2f-4e36-bfd2-014b3c5d6950\\\", \\\"childbox\\\": \\\"7f00a991-f0cf-4f50-b37a-7f7ed41860d7\\\", \\\"subtext\\\": \\\"a4bd29e1-7708-4205-9d84-bfd34a101baf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1915, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Burmester G, McInnes IB, Kremer JM, Miranda P, Korkosz M, Vencovsky J, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c89050b0-6555-40f1-8d7d-e1f17cb991d7\\\", \\\"childbox\\\": \\\"0c079010-b04c-449d-aae7-483352d2a236\\\", \\\"subtext\\\": \\\"ef2e963f-cffd-4c65-9b04-da36018111f1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1916, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c89050b0-6555-40f1-8d7d-e1f17cb991d7\\\", \\\"childbox\\\": \\\"33c61552-2954-49ae-9ae1-deeace9c2df7\\\", \\\"subtext\\\": \\\"aa7e24f1-086f-4323-a15b-058c87db6739\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1917, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ann Rheum Dis 2017;76:1020-30.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c89050b0-6555-40f1-8d7d-e1f17cb991d7\\\", \\\"childbox\\\": \\\"67bac291-359d-4d9d-8715-13479d34eece\\\", \\\"subtext\\\": \\\"aa7e24f1-086f-4323-a15b-058c87db6739\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1918, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovsk\\\\u00fd J, Godwood A, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b28592d3-032e-4a86-b182-f45bba50487b\\\", \\\"childbox\\\": \\\"9d3404b0-5184-4bc6-b160-cb3e19be7065\\\", \\\"subtext\\\": \\\"3e4d1999-6c55-4ec3-af99-08bb6fd9cb4c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1919, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"M.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"b28592d3-032e-4a86-b182-f45bba50487b\\\", \\\"childbox\\\": \\\"e9cc7a00-851b-40ac-998a-ce70bf65b77e\\\", \\\"subtext\\\": \\\"e07df03b-204a-47f9-817b-038889d2f59c\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1920, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor \\\\u03b1 Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5430484c-f551-408b-b8d5-0b638e77b492\\\", \\\"childbox\\\": \\\"5150e2ea-9dc4-448f-8264-049280e6c074\\\", \\\"subtext\\\": \\\"d2e8a61b-fa8b-4656-936b-d0d5a3a3b20a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1921, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Arthritis Rheumatol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5430484c-f551-408b-b8d5-0b638e77b492\\\", \\\"childbox\\\": \\\"62a19cb6-f535-40bb-934c-640dade9451c\\\", \\\"subtext\\\": \\\"d2e8a61b-fa8b-4656-936b-d0d5a3a3b20a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1922, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2018;70(5):679-689.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5430484c-f551-408b-b8d5-0b638e77b492\\\", \\\"childbox\\\": \\\"f8ceee70-ab82-45d2-a4db-5af38a9b53ca\\\", \\\"subtext\\\": \\\"d2e8a61b-fa8b-4656-936b-d0d5a3a3b20a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1923, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"81344d55-fd2c-4994-81a5-d348eba84644\\\", \\\"childbox\\\": \\\"edd3ee7e-4924-4e3d-b6e3-496a78a7e6d3\\\", \\\"subtext\\\": \\\"74a49f65-0f81-4688-a8a7-ca9a91274c9d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1924, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\\\\u20132008.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"81344d55-fd2c-4994-81a5-d348eba84644\\\", \\\"childbox\\\": \\\"b78a835a-6ed8-4e7f-8e3a-a2c1e6101ed8\\\", \\\"subtext\\\": \\\"b9dca77c-d337-4621-9cfc-2865bb2bea87\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1925, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Journal of clinical epidemiology 2010;63:1179-1194.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"81344d55-fd2c-4994-81a5-d348eba84644\\\", \\\"childbox\\\": \\\"bfac4704-88ed-43dd-80c9-623dfd29f393\\\", \\\"subtext\\\": \\\"b9dca77c-d337-4621-9cfc-2865bb2bea87\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1926, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbec75a4-8708-4132-943b-3e45c695de2d\\\", \\\"childbox\\\": \\\"759e3259-9f13-4c14-ad80-ed9514a52675\\\", \\\"subtext\\\": \\\"b2bcc025-bf77-46a4-9ed1-306483fb9bf0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1927, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blockade of collageninduced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbec75a4-8708-4132-943b-3e45c695de2d\\\", \\\"childbox\\\": \\\"223b31ef-d793-44bd-bfe7-4936b1878af3\\\", \\\"subtext\\\": \\\"b2bcc025-bf77-46a4-9ed1-306483fb9bf0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1928, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Arthritis Res 2001;3:293-8.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"cbec75a4-8708-4132-943b-3e45c695de2d\\\", \\\"childbox\\\": \\\"200e2d2a-5df8-4388-804b-b7604ce5e635\\\", \\\"subtext\\\": \\\"b2bcc025-bf77-46a4-9ed1-306483fb9bf0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1929, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cook AD, Pobjoy J, Steidl S, D\\\\u00fcrr M, Braine EL, Turner AL, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"920d72c4-118f-44db-92c1-fef64730a280\\\", \\\"childbox\\\": \\\"c7403c6e-4d41-4b3c-a83f-c5b063de727a\\\", \\\"subtext\\\": \\\"80f760d9-0c08-4107-98c1-16025fca8cc4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1930, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Granulocytemacrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"920d72c4-118f-44db-92c1-fef64730a280\\\", \\\"childbox\\\": \\\"f2c961e4-2fc0-4d68-9c96-6b995fce692c\\\", \\\"subtext\\\": \\\"80f760d9-0c08-4107-98c1-16025fca8cc4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1931, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Arthritis Res Ther 2012;14:R199.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"920d72c4-118f-44db-92c1-fef64730a280\\\", \\\"childbox\\\": \\\"4e640aa0-062e-4cdb-a180-9f1cf186e3ab\\\", \\\"subtext\\\": \\\"80f760d9-0c08-4107-98c1-16025fca8cc4\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1932, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cook AD, Pobjoy J, Sarros S, Steidl S, D\\\\u00fcrr M, Lacey DC, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ffb1a9e5-c3f6-45e2-945e-5ed0c4d26752\\\", \\\"childbox\\\": \\\"1c00ac8e-85fa-4d51-80b3-c1e4f1394bc2\\\", \\\"subtext\\\": \\\"1362c763-871c-4748-92d3-279672e61510\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1933, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Granulocytemacrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ffb1a9e5-c3f6-45e2-945e-5ed0c4d26752\\\", \\\"childbox\\\": \\\"0744e09f-a4df-47bd-a752-8d10b090dbad\\\", \\\"subtext\\\": \\\"9c8e98c0-163d-4925-b99e-af19a61915ce\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1934, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ann Rheum Dis. 2013, 72(2):265-70.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"ffb1a9e5-c3f6-45e2-945e-5ed0c4d26752\\\", \\\"childbox\\\": \\\"0797acb4-7db6-498a-af38-7fc0bb5893a2\\\", \\\"subtext\\\": \\\"9c8e98c0-163d-4925-b99e-af19a61915ce\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1935, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cook AD, Lee MC, Saleh R, Khiew HW, Christensen AD, Achuthan A, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6c94a786-4e69-4a19-aa34-983ab562f0fa\\\", \\\"childbox\\\": \\\"9b9d560d-6e94-4797-8353-e474d4191499\\\", \\\"subtext\\\": \\\"61c7fee0-8dba-466d-a229-e976ff36f610\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1936, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6c94a786-4e69-4a19-aa34-983ab562f0fa\\\", \\\"childbox\\\": \\\"96b40a81-61e2-4be3-b086-f2204f3c754c\\\", \\\"subtext\\\": \\\"61c7fee0-8dba-466d-a229-e976ff36f610\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1937, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"JCI Insight.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6c94a786-4e69-4a19-aa34-983ab562f0fa\\\", \\\"childbox\\\": \\\"9538122c-c4df-4ed1-b980-027fe59e2ed3\\\", \\\"subtext\\\": \\\"c0c9daed-222f-4863-b913-5d0352a16fae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1938, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2018a, 3(6).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6c94a786-4e69-4a19-aa34-983ab562f0fa\\\", \\\"childbox\\\": \\\"9f2cbb54-1832-465e-ad7e-ed25b928e9ba\\\", \\\"subtext\\\": \\\"c0c9daed-222f-4863-b913-5d0352a16fae\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1939, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cook AD, Hamilton JA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65a85a1f-f3ab-4fa5-8b76-d0e0442d3d90\\\", \\\"childbox\\\": \\\"8fd8b6e2-7433-497b-9100-02bbd4b4083e\\\", \\\"subtext\\\": \\\"684f6501-6285-4d23-829d-9ccba44d7e08\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1940, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-\\\\u03b1 in rheumatoid arthritis: focus on mavrilimumab.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65a85a1f-f3ab-4fa5-8b76-d0e0442d3d90\\\", \\\"childbox\\\": \\\"c25e65e3-baa0-4566-be6c-b1288f3a4adf\\\", \\\"subtext\\\": \\\"684f6501-6285-4d23-829d-9ccba44d7e08\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1941, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ther Adv Musculoskelet Dis. 2018b;10(2):29-38.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"65a85a1f-f3ab-4fa5-8b76-d0e0442d3d90\\\", \\\"childbox\\\": \\\"b35b2625-7e86-4b8d-907c-f21943d80720\\\", \\\"subtext\\\": \\\"dd0e8139-9c6a-49ea-ae4c-c8809244f227\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1942, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"FDA (Food and Drug Administration, 2014).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"835222be-94c0-45f8-8682-c7c0efe0999d\\\", \\\"childbox\\\": \\\"1cdcb595-34f4-4d74-99b7-45058baa0b8a\\\", \\\"subtext\\\": \\\"59c99bff-f956-44d3-9324-141d6bb73385\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1943, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"835222be-94c0-45f8-8682-c7c0efe0999d\\\", \\\"childbox\\\": \\\"33fcb4c1-e303-4a4c-a347-c62ef86af4af\\\", \\\"subtext\\\": \\\"59c99bff-f956-44d3-9324-141d6bb73385\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1944, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidanc es/ucm338856.pdf\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"835222be-94c0-45f8-8682-c7c0efe0999d\\\", \\\"childbox\\\": \\\"1087bf06-66b9-4dd0-ab0a-ec92c80a6168\\\", \\\"subtext\\\": \\\"59c99bff-f956-44d3-9324-141d6bb73385\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1945, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Fries JF, Spitz P, Kraines RG, Holman HR.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1a9890f7-299d-437c-ac15-b42a3a65687f\\\", \\\"childbox\\\": \\\"ea032d84-ba4d-4a07-8613-0a17bf970139\\\", \\\"subtext\\\": \\\"fb2b78d1-6254-4360-812f-6d098cc5f0eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1946, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Measurement of patient outcomes in arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1a9890f7-299d-437c-ac15-b42a3a65687f\\\", \\\"childbox\\\": \\\"3d7a8442-04b2-48b9-b147-074ddab8e5c4\\\", \\\"subtext\\\": \\\"fb2b78d1-6254-4360-812f-6d098cc5f0eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1947, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Arthritis Rheum 1980;23:137-45.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1a9890f7-299d-437c-ac15-b42a3a65687f\\\", \\\"childbox\\\": \\\"aee9a6dc-9371-4f14-9de9-1925a4f97ecf\\\", \\\"subtext\\\": \\\"fb2b78d1-6254-4360-812f-6d098cc5f0eb\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1948, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Gaujoux-Viala C, Nam J, Ramiro S, Landew\\\\u00e9 R, Buch MH, Smolen JS, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1cb0987e-0200-4e80-96c2-d0f85dbf07fe\\\", \\\"childbox\\\": \\\"01e1f665-9f5a-4a4a-b547-6b87dfc68b19\\\", \\\"subtext\\\": \\\"7dfde62f-0c4c-40ef-9a73-2768cbd621de\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1949, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1cb0987e-0200-4e80-96c2-d0f85dbf07fe\\\", \\\"childbox\\\": \\\"3b2b90fc-9206-44d3-9454-3e3d44655c05\\\", \\\"subtext\\\": \\\"7dfde62f-0c4c-40ef-9a73-2768cbd621de\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1950, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ann Rheum Dis 2014;73:5105.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"1cb0987e-0200-4e80-96c2-d0f85dbf07fe\\\", \\\"childbox\\\": \\\"e9897869-9cb7-4b2c-aaaa-c3e6430bc648\\\", \\\"subtext\\\": \\\"3eac0560-8f2a-4752-9043-0633c8f7ffad\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1951, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GSK Document Number 2017N353526_00.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f2e2a17f-ef83-4171-8270-87affe3dced4\\\", \\\"childbox\\\": \\\"d2893d41-c8ff-45dc-8ff0-af822592defd\\\", \\\"subtext\\\": \\\"46a0b38e-619a-4edb-8aaf-7ac97fc707a1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1952, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pharmacokinetic Study Analysis Report.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f2e2a17f-ef83-4171-8270-87affe3dced4\\\", \\\"childbox\\\": \\\"7ba680eb-57e0-4796-946d-4e18dd331ab2\\\", \\\"subtext\\\": \\\"46a0b38e-619a-4edb-8aaf-7ac97fc707a1\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1953, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Population Pharmacokinetic Analysis of GSK3196165 Following Intravenous and\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"546b6b45-9bfb-4949-9234-1e22d19f14d2\\\", \\\"childbox\\\": \\\"8b42690c-479c-45eb-96e2-f5d2a35523a0\\\", \\\"subtext\\\": \\\"3b40e628-83f2-4204-8816-42fea0a24af9\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1954, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subcutaneous Administration to Healthy Volunteers, and Subjects with Rheumatoid Arthritis and Multiple Sclerosis, Date: 07-Dec-2017\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"c0c06dea-a1f8-4133-9b25-707fb634428e\\\", \\\"childbox\\\": \\\"d1d88938-c7f8-418d-a924-258305f63f85\\\", \\\"subtext\\\": \\\"23ca59db-c60a-4ea1-8f03-38f21e73d3bd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1955, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GSK Document Number 2014N190256_02.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e69d8263-5cec-479e-a259-22b4213eb67d\\\", \\\"childbox\\\": \\\"a35d7936-7f6a-4917-880e-420f90b1b98f\\\", \\\"subtext\\\": \\\"3170b4b3-d5d9-4da0-98fc-7d6899f183cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1956, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GSK3196165 Investigator's Brochure Version 9 (2019).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"e69d8263-5cec-479e-a259-22b4213eb67d\\\", \\\"childbox\\\": \\\"c632c013-6090-4395-bbf9-0c02f4e23384\\\", \\\"subtext\\\": \\\"3170b4b3-d5d9-4da0-98fc-7d6899f183cd\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1957, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hamilton JA, Cook AD, Tak PP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a64b8583-1111-4b68-9a2c-b4c2223ccd72\\\", \\\"childbox\\\": \\\"0c869908-6ce4-4020-a89f-92387b0c72a6\\\", \\\"subtext\\\": \\\"15902e1f-4182-49b1-bde6-5b6a3952253a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1958, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a64b8583-1111-4b68-9a2c-b4c2223ccd72\\\", \\\"childbox\\\": \\\"d5a06d1f-10fb-4d56-8aa4-db09f32d40b1\\\", \\\"subtext\\\": \\\"15902e1f-4182-49b1-bde6-5b6a3952253a\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1959, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Nat Rev Drug Discov. 2016 29;16(1):53-70.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a64b8583-1111-4b68-9a2c-b4c2223ccd72\\\", \\\"childbox\\\": \\\"e86fdae1-b76f-410b-8141-4d0b48d136b9\\\", \\\"subtext\\\": \\\"da9efc21-11a6-4503-b92f-049058bbb48e\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1960, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"LeVine AM, Reed JA, Kurak KE, Cianciolo E, Whitsett JA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6f65a27a-d465-4107-8285-c6daff48c6c2\\\", \\\"childbox\\\": \\\"325cb2b0-9f9d-468c-b95c-adc994a61e61\\\", \\\"subtext\\\": \\\"a5a64fd0-1b75-4454-bd94-5b8f47da3282\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1961, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6f65a27a-d465-4107-8285-c6daff48c6c2\\\", \\\"childbox\\\": \\\"4ea41db1-23c1-42e9-ab3d-bc3dad79406e\\\", \\\"subtext\\\": \\\"a5a64fd0-1b75-4454-bd94-5b8f47da3282\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1962, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"J Clin Invest 1999;103:563-9.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"6f65a27a-d465-4107-8285-c6daff48c6c2\\\", \\\"childbox\\\": \\\"3bc97498-305a-49d9-a52b-52c9226849e2\\\", \\\"subtext\\\": \\\"a5a64fd0-1b75-4454-bd94-5b8f47da3282\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1963, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Martinez-Moczygemba M, Doan ML, Elidemir O, Fan LL, Cheung SW, Lei JT, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a46f5de7-664f-4f8a-a684-4185d13dfce2\\\", \\\"childbox\\\": \\\"006e2493-e990-4bbb-a258-2f0ede0c786e\\\", \\\"subtext\\\": \\\"768766e5-3950-47c7-adb4-baec6c07f3e0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1964, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pulmonary alveolar proteinosis caused by deletion of GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a46f5de7-664f-4f8a-a684-4185d13dfce2\\\", \\\"childbox\\\": \\\"41b8bb50-f7d9-4de9-a0d6-2bcf12773d47\\\", \\\"subtext\\\": \\\"768766e5-3950-47c7-adb4-baec6c07f3e0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1965, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"J Exp Med 2008;205:2711-6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"a46f5de7-664f-4f8a-a684-4185d13dfce2\\\", \\\"childbox\\\": \\\"ef77e97a-f096-4d63-b2d5-42bc555bbfda\\\", \\\"subtext\\\": \\\"4b8609b5-fb4c-4da8-b5f0-99358d159186\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1966, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5c8ea803-1e0f-4d3e-8b9d-4803827eddd5\\\", \\\"childbox\\\": \\\"bc7690e6-b0bd-474d-9e95-52d66ea9e605\\\", \\\"subtext\\\": \\\"d5cb1fe9-fb51-4658-863b-29583e9d594d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1967, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5c8ea803-1e0f-4d3e-8b9d-4803827eddd5\\\", \\\"childbox\\\": \\\"0dbb1216-0566-4982-ae35-5554527e9a52\\\", \\\"subtext\\\": \\\"d5cb1fe9-fb51-4658-863b-29583e9d594d\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1968, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ann Rheum Dis 2014;73:516-28.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"5c8ea803-1e0f-4d3e-8b9d-4803827eddd5\\\", \\\"childbox\\\": \\\"f336e00d-5ff8-4f3d-8b70-07401bf5dbd9\\\", \\\"subtext\\\": \\\"4daa15fb-2494-4ccd-9d00-a6a8221c6c70\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1969, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NCI. National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 NCI, NIH, DHHS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3d22f7d5-f451-47ce-9310-a01c391644b9\\\", \\\"childbox\\\": \\\"f1303380-e7c9-4bba-acbf-70183aebba6d\\\", \\\"subtext\\\": \\\"b95742c0-225d-46d0-ad91-c1a45aee1416\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1970, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"November 27th.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3d22f7d5-f451-47ce-9310-a01c391644b9\\\", \\\"childbox\\\": \\\"eccb9fef-dd28-4566-80ad-ffb8cb5683f4\\\", \\\"subtext\\\": \\\"44910b3d-e2af-465e-a936-e0be8deb9695\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1971, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2017.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"3d22f7d5-f451-47ce-9310-a01c391644b9\\\", \\\"childbox\\\": \\\"424797d7-0547-4924-8a5a-82130a57f5aa\\\", \\\"subtext\\\": \\\"44910b3d-e2af-465e-a936-e0be8deb9695\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1972, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Q uick_Reference_5x7.pdf\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"66b79c01-46bb-4552-904c-fea60fe66b92\\\", \\\"childbox\\\": \\\"8d3243cd-f771-41e3-80d3-59504f1680ac\\\", \\\"subtext\\\": \\\"711c74b8-bc4f-418c-a7bd-80d8ffe35f70\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1973, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Plater-Zyberk C, Joosten LAB, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"31911de4-402a-4857-bddf-6a7039f90d6b\\\", \\\"childbox\\\": \\\"d9bad2ee-bc99-4b29-bec1-e3e525c5ff8a\\\", \\\"subtext\\\": \\\"0960f0ee-4af1-4478-8cdc-343a4a330ddf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1974, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"31911de4-402a-4857-bddf-6a7039f90d6b\\\", \\\"childbox\\\": \\\"e362ba00-480b-463d-905c-3a8a9fd6a524\\\", \\\"subtext\\\": \\\"0960f0ee-4af1-4478-8cdc-343a4a330ddf\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1975, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ann Rheum Dis 2007;66:452-7.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"31911de4-402a-4857-bddf-6a7039f90d6b\\\", \\\"childbox\\\": \\\"b0675d02-fd8b-4e7a-bdf5-889e4b64f957\\\", \\\"subtext\\\": \\\"5e6a8909-31f0-4399-81cb-3bf2816de38f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1976, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"9c21c8ce-b6d3-4169-ba53-8f65df7ef71e\\\", \\\"childbox\\\": \\\"3f9b7191-11bd-4a58-b843-e56a90b85134\\\", \\\"subtext\\\": \\\"aa1c47bb-8d9d-47c3-8f6b-6a58de5da847\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1977, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f430a78e-5458-4cc2-9a3f-a8adc67b9d4b\\\", \\\"childbox\\\": \\\"882198b1-196d-4a63-89c9-befe4c9097a6\\\", \\\"subtext\\\": \\\"13f3563a-f23c-4205-98ae-df218d140942\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1978, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Proc Natl Acad Sci USA 1994;91:5592-6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"f430a78e-5458-4cc2-9a3f-a8adc67b9d4b\\\", \\\"childbox\\\": \\\"a02b6f86-9a44-4c98-84bf-95a1e92f10bd\\\", \\\"subtext\\\": \\\"00fb9394-2346-49ed-96da-e339601c5766\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1979, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Steidl S, Ratsch O, Brocks B, D\\\\u00fcrr M, Thomassen-Wolf E\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4b954e2a-4fe3-46a7-bbd9-0899b66d852b\\\", \\\"childbox\\\": \\\"588c7057-68d4-47d8-817b-1aff6e40710e\\\", \\\"subtext\\\": \\\"8cb92feb-e0be-4293-b5b1-64fbfc85d970\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1980, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4b954e2a-4fe3-46a7-bbd9-0899b66d852b\\\", \\\"childbox\\\": \\\"588c7057-68d4-47d8-817b-1aff6e40710e\\\", \\\"subtext\\\": \\\"7a084903-a458-44f8-a1c2-d3dc5df9eeed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1981, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In vitro\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4b954e2a-4fe3-46a7-bbd9-0899b66d852b\\\", \\\"childbox\\\": \\\"74dc7cef-790d-4f57-a803-fc88380c8bcf\\\", \\\"subtext\\\": \\\"7a084903-a458-44f8-a1c2-d3dc5df9eeed\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1982, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4b954e2a-4fe3-46a7-bbd9-0899b66d852b\\\", \\\"childbox\\\": \\\"74dc7cef-790d-4f57-a803-fc88380c8bcf\\\", \\\"subtext\\\": \\\"15e803da-8559-43bb-aa71-eaf420f14a84\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1983, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Mol Immunol 2008;46:13544.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"4b954e2a-4fe3-46a7-bbd9-0899b66d852b\\\", \\\"childbox\\\": \\\"29ebf397-9327-4ea4-b3fa-d7c40b544486\\\", \\\"subtext\\\": \\\"edbf502b-bd58-4b3d-8a38-719a4214d582\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1984, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17ca1dc2-2e39-42c2-9a84-7dbc61dd371f\\\", \\\"childbox\\\": \\\"917eeaa4-c209-4b30-9066-6d8b91e11b7c\\\", \\\"subtext\\\": \\\"f0d77fdc-822a-4fc8-baf6-3476e15aaae0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1985, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17ca1dc2-2e39-42c2-9a84-7dbc61dd371f\\\", \\\"childbox\\\": \\\"43781d4a-ac50-4715-8521-347d7f1061ff\\\", \\\"subtext\\\": \\\"f0d77fdc-822a-4fc8-baf6-3476e15aaae0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1986, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"J Exp Med 2008;205:2703-10.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"17ca1dc2-2e39-42c2-9a84-7dbc61dd371f\\\", \\\"childbox\\\": \\\"d7cc439a-d819-4a58-ac34-8c4ec9b70780\\\", \\\"subtext\\\": \\\"f0d77fdc-822a-4fc8-baf6-3476e15aaae0\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1987, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Wicks IP, Roberts AW.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"34ff840f-b0bb-4df7-a576-5a21b5c87b6c\\\", \\\"childbox\\\": \\\"40e62c05-8985-48ca-a358-eec47a0ee9ad\\\", \\\"subtext\\\": \\\"a58866f2-f707-4267-8edf-151a7b24e612\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1988, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Targeting GM-CSF in inflammatory diseases.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"34ff840f-b0bb-4df7-a576-5a21b5c87b6c\\\", \\\"childbox\\\": \\\"8b1ec9da-4229-42aa-940f-ba5c4486440d\\\", \\\"subtext\\\": \\\"a58866f2-f707-4267-8edf-151a7b24e612\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1989, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Nat Rev Rheumatol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"34ff840f-b0bb-4df7-a576-5a21b5c87b6c\\\", \\\"childbox\\\": \\\"6f1692c7-ad8e-4fed-89f2-b8ae0caf0426\\\", \\\"subtext\\\": \\\"0ccbbc17-9b82-4112-8dfc-bdc46e8a189f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1990, \\\"\\\"], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2016; 12(1):37-48.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"roi_id\\\": {\\\"para\\\": \\\"34ff840f-b0bb-4df7-a576-5a21b5c87b6c\\\", \\\"childbox\\\": \\\"f8a174a6-c20d-474f-934b-b65095027cdc\\\", \\\"subtext\\\": \\\"0ccbbc17-9b82-4112-8dfc-bdc46e8a189f\\\"}, \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"11.\\\", \\\"1\\\", 1991, \\\"\\\"]], \\\"metadata\\\": {\\\"protocol_title\\\": \\\"Protocol Title(Updated on 10/5 SSR 1):A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", \\\"protocol_title_short\\\": \\\"Efficacy and safety of GSK3196165 versus placebo and sarilumab in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", \\\"amendment_number\\\": \\\"\\\", \\\"is_amendment\\\": \\\"N\\\", \\\"trial_phase\\\": \\\"III\\\", \\\"sponsor\\\": \\\"GlaxoSmithKline Research & Development Limited\\\", \\\"sponsor_address\\\": \\\"\\\", \\\"drug\\\": \\\"\\\", \\\"approval_date\\\": \\\"20190306\\\", \\\"version_number\\\": \\\"1\\\", \\\"version_date\\\": \\\"\\\", \\\"blinded\\\": \\\"DOUBLE-BLIND\\\", \\\"compound_number\\\": \\\"\\\", \\\"control\\\": \\\"\\\", \\\"investigator\\\": \\\"\\\", \\\"study_id\\\": \\\"EudraCT\\\", \\\"number_of_subjects\\\": \\\"[1050, 1200]\\\", \\\"participant_age\\\": \\\"[0h, 16y)\\\", \\\"participant_sex\\\": \\\"FEMALE\\\", \\\"exclusion_criteria\\\": \\\"History of sensitivity to any of the study treatments, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.\\\", \\\"inclusion_criteria\\\": \\\"11. For participants on MTX: must be willing to continue or initiate treatment at screening, with oral folic acid (at least 5 mg/week) or equivalent and be treated during the entire study (mandatory co-medication for MTX treatment).\\\", \\\"indication\\\": \\\"rheumatoid arthritis\\\", \\\"objectives_section\\\": \\\"CSF = granulocyte-macrophage colony stimulating factor; ECM = extracellular matrix; RNA = ribonucleic acid; SF-36 = short form-36; FACIT = functional assessment of chronic illness therapy; RA = rheumatoid arthritis\\\", \\\"study_population\\\": \\\"\\\", \\\"entities_in_assessments\\\": \\\"\\\", \\\"soa_epochs\\\": \\\"\\\", \\\"assessment_footnote\\\": \\\"\\\", \\\"upload_date\\\": \\\"20210929090210\\\", \\\"protocol_number\\\": \\\"202018_SSR_REDACT_FB_0929_4\\\", \\\"study_status\\\": \\\"Phase 3\\\", \\\"molecule_device\\\": \\\"GSK3196165\\\", \\\"accuracy\\\": \\\"\\\", \\\"protocol_name\\\": \\\"\\\", \\\"primary_objectives\\\": \\\"CSF = granulocyte-macrophage colony stimulating factor; ECM = extracellular matrix; RNA = ribonucleic acid; SF-36 = short form-36; FACIT = functional assessment of chronic illness therapy; RA = rheumatoid arthritis\\\", \\\"secondary_objectives\\\": \\\"\\\", \\\"endpoints\\\": \\\"\\\", \\\"trial_type_randomized\\\": \\\"\\\"}}\"",
    "iqvdataSoa": "\"[[], 0]\"",
    "iqvdataSoaStd": "\"null\"",
    "iqvdataSummary": "\"{\\\"index\\\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30], \\\"columns\\\": [\\\"field_name\\\", \\\"field_value\\\", \\\"field_header\\\"], \\\"data\\\": [[\\\"protocol_name\\\", \\\"\\\", \\\"Protocol Name\\\"], [\\\"protocol_number\\\", \\\"202018_SSR_REDACT_FB_0929_4\\\", \\\"Protocol Number\\\"], [\\\"protocol_title\\\", \\\"Protocol Title(Updated on 10/5 SSR 1):A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing ~REDACTED~ with ~REDACTED~ and with ~REDACTED~, in combination with conventional synthetic DMARDs, in participants with moderately to severely active ~REDACTED~ who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", \\\"Protocol Title\\\"], [\\\"protocol_title_short\\\", \\\"Efficacy and safety of GSK3196165 versus placebo and sarilumab in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.\\\", \\\"Protocol Title Short\\\"], [\\\"is_amendment\\\", \\\"N\\\", \\\"Is Amendment\\\"], [\\\"amendment_number\\\", \\\"\\\", \\\"Amendment Number\\\"], [\\\"trial_phase\\\", \\\"~REDACTED~\\\", \\\"Trial Phase\\\"], [\\\"sponsor\\\", \\\"~REDACTED~\\\", \\\"Sponsor\\\"], [\\\"sponsor_address\\\", \\\"\\\", \\\"Sponsor Address\\\"], [\\\"drug\\\", \\\"\\\", \\\"Drug\\\"], [\\\"approval_date\\\", \\\"20190306\\\", \\\"Approval Date\\\"], [\\\"version_number\\\", \\\"1\\\", \\\"Version Number\\\"], [\\\"version_date\\\", \\\"\\\", \\\"Version Date\\\"], [\\\"blinded\\\", \\\"DOUBLE-BLIND\\\", \\\"Blinded\\\"], [\\\"compound_number\\\", \\\"\\\", \\\"Compound Number\\\"], [\\\"control\\\", \\\"\\\", \\\"Control\\\"], [\\\"investigator\\\", \\\"\\\", \\\"Investigator\\\"], [\\\"study_id\\\", \\\"EudraCT\\\", \\\"Study Id\\\"], [\\\"number_of_subjects\\\", \\\"[1050, 1200]\\\", \\\"Number Of Subjects\\\"], [\\\"participant_age\\\", \\\"[0h, 16y)\\\", \\\"Participant Age\\\"], [\\\"participant_sex\\\", \\\"FEMALE\\\", \\\"Participant Sex\\\"], [\\\"exclusion_criteria\\\", \\\"History of sensitivity to any of the study treatments, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.\\\", \\\"Exclusion Criteria\\\"], [\\\"inclusion_criteria\\\", \\\"11. For participants on MTX: must be willing to continue or initiate treatment at screening, with oral folic acid (at least 5 mg/week) or equivalent and be treated during the entire study (mandatory co-medication for MTX treatment).\\\", \\\"Inclusion Criteria\\\"], [\\\"indication\\\", \\\"rheumatoid arthritis\\\", \\\"Indication\\\"], [\\\"primary_objectives\\\", \\\"CSF = granulocyte-macrophage colony stimulating factor; ECM = extracellular matrix; RNA = ribonucleic acid; SF-36 = short form-36; FACIT = functional assessment of chronic illness therapy; RA = rheumatoid arthritis\\\", \\\"Primary Objectives\\\"], [\\\"secondary_objectives\\\", \\\"\\\", \\\"Secondary Objectives\\\"], [\\\"study_status\\\", \\\"Phase 3\\\", \\\"Study Status\\\"], [\\\"study_population\\\", \\\"\\\", \\\"Study Population\\\"], [\\\"endpoints\\\", \\\"\\\", \\\"Endpoints\\\"], [\\\"trial_type_randomized\\\", \\\"\\\", \\\"Trial Type Randomized\\\"], [\\\"molecule_device\\\", \\\"GSK3196165\\\", \\\"Molecule Device\\\"]], \\\"metadata\\\": {\\\"accuracy\\\": \\\"\\\"}}\"",
    "iqvdata": null,
    "isActive": false
}